
<html lang="en"     class="pb-page"  data-request-id="0786758d-3960-4898-9cf8-0db493d39f10"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b00343;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells" /></meta><meta name="dc.Creator" content="Sébastien  Fortin" /></meta><meta name="dc.Creator" content="Xavier  Charest-Morin" /></meta><meta name="dc.Creator" content="Vanessa  Turcotte" /></meta><meta name="dc.Creator" content="Coraline  Lauvaux" /></meta><meta name="dc.Creator" content="Jacques  Lacroix" /></meta><meta name="dc.Creator" content="Marie-France  Côté" /></meta><meta name="dc.Creator" content="Stéphane  Gobeil" /></meta><meta name="dc.Creator" content="René  C.-Gaudreault" /></meta><meta name="dc.Description" content="Prodrug-mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective release of potent anticancer products within cancer tissues is a promising approach in chemotherapy. We herein ..." /></meta><meta name="Description" content="Prodrug-mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective release of potent anticancer products within cancer tissues is a promising approach in chemotherapy. We herein ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 1, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00343" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00343" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00343" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00343" /></link>
        
    
    

<title>Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00343" /></meta><meta property="og:title" content="Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0009.jpeg" /></meta><meta property="og:description" content="Prodrug-mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective release of potent anticancer products within cancer tissues is a promising approach in chemotherapy. We herein report the rationale, preparation, biological evaluation, and mechanism of action of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs) that are antimicrotubule prodrugs activated by CYP1A1. Although PAIB-SOs are inert in most cells tested, they are highly cytocidal toward several human breast cancer cells, including hormone-independent and chemoresistant types. PAIB-SOs are N-dealkylated into cytotoxic phenyl 4-(2-oxo-3-imidazolidin-1-yl)benzenesulfonates (PIB-SOs) in CYP1A1-positive cancer cells, both in vitro and in vivo. In conclusion, PAIB-SOs are novel chemotherapeutic prodrugs with no equivalent among current antineoplastics and whose selective action toward breast cancer is tailored to the characteristic pattern of CYP1A1 expression observed in a large percentage of human breast tumors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00343"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00343">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00343&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00343&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00343&amp;href=/doi/10.1021/acs.jmedchem.7b00343" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 4963-4982</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00324" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00395" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=S%C3%A9bastien++Fortin">Sébastien Fortin</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-3374-2751" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xavier++Charest-Morin">Xavier Charest-Morin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vanessa++Turcotte">Vanessa Turcotte</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Coraline++Lauvaux">Coraline Lauvaux</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jacques++Lacroix">Jacques Lacroix</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marie-France++C%C3%B4t%C3%A9">Marie-France Côté</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=St%C3%A9phane++Gobeil">Stéphane Gobeil</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ren%C3%A9++C.-Gaudreault">René C.-Gaudreault</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">CHU de Québec Research Centre, Oncology Division, Hôpital Saint-François d’Assise, 10 rue de l’Espinay, Quebec City, Quebec, Canada G1L 3L5</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Faculty of Pharmacy, Université Laval, Quebec City, Quebec, Canada G1V 0A6</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">CHU de Québec Research Centre, Endocrinology and Nephrology Division, CHUL, 2705 Boulevard Laurier, Quebec City, Quebec, Canada G1V 4G2</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Department of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec City, Quebec, Canada G1V 0A6</span></div><div class="corresp-info"><strong>*</strong>For S.F.: phone, 418-525-4444 ext 52364; fax, 418-525-4372; E-mail, <a href="/cdn-cgi/l/email-protection#8dfee8efecfef9e4e8e3a3ebe2fff9e4e3cdfde5eca3f8e1ecfbece1a3eeec"><span class="__cf_email__" data-cfemail="5c2f393e3d2f28353932723a332e2835321c2c343d7229303d2a3d30723f3d">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For. R.C.-G.: phone, 418-525-4444 ext 52363; fax, 418-525-4372; E-mail <a href="/cdn-cgi/l/email-protection#196b7c777c377a347e786c7d6b7c786c756d597a6b6a7f78376c75786f7875377a78"><span class="__cf_email__" data-cfemail="83f1e6ede6ade0aee4e2f6e7f1e6e2f6eff7c3e0f1f0e5e2adf6efe2f5e2efade0e2">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00343&amp;href=/doi/10.1021%2Facs.jmedchem.7b00343" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 4963–4982</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 23, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 March 2017</li><li><span class="item_label"><b>Published</b> online</span>1 June 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 June 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00343" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00343</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4963%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DS%25C3%25A9bastien%2BFortin%252C%2BXavier%2BCharest-Morin%252C%2BVanessa%2BTurcotte%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D12%26contentID%3Dacs.jmedchem.7b00343%26title%3DActivation%2Bof%2BPhenyl%2B4-%25282-Oxo-3-alkylimidazolidin-1-yl%2529benzenesulfonates%2BProdrugs%2Bby%2BCYP1A1%2Bas%2BNew%2BAntimitotics%2BTargeting%2BBreast%2BCancer%2BCells%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4982%26publicationDate%3DJune%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00343"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1294</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00343" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sébastien&quot;,&quot;last_name&quot;:&quot;Fortin&quot;},{&quot;first_name&quot;:&quot;Xavier&quot;,&quot;last_name&quot;:&quot;Charest-Morin&quot;},{&quot;first_name&quot;:&quot;Vanessa&quot;,&quot;last_name&quot;:&quot;Turcotte&quot;},{&quot;first_name&quot;:&quot;Coraline&quot;,&quot;last_name&quot;:&quot;Lauvaux&quot;},{&quot;first_name&quot;:&quot;Jacques&quot;,&quot;last_name&quot;:&quot;Lacroix&quot;},{&quot;first_name&quot;:&quot;Marie-France&quot;,&quot;last_name&quot;:&quot;Côté&quot;},{&quot;first_name&quot;:&quot;Stéphane&quot;,&quot;last_name&quot;:&quot;Gobeil&quot;},{&quot;first_name&quot;:&quot;René&quot;,&quot;last_name&quot;:&quot;C.-Gaudreault&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;4963-4982&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00343&quot;},&quot;abstract&quot;:&quot;Prodrug-mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective release of potent anticancer products within cancer tissues is a promising approach in chemotherapy. We herein report the rationale, preparation, biological evaluation, and mechanism of action of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs) that are antimicrotubule prodrugs activated by CYP1A1. Although PAIB-SOs are inert in most cells tested, they are highly cytocidal toward several human breast cancer cells, including hormone-independent and chemoresistant types. PAIB-SOs are N-dealkylated into cytotoxic phenyl 4-(2-oxo-3-imidazolidin-1-yl)benzenesulfonates (PIB-SOs) in CYP1A1-positive cancer cells, both in vitro and in vivo. In conclusion, PAIB-SOs are novel chemotherapeutic prodrugs with no equivalent among current antineoplastics and whose selective action toward breast cancer is tailored to the characteristic pattern of CYP1A1 expression observed in a large percentage of human breast tumors.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00343&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00343" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00343&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00343" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00343&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00343" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00343&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00343&amp;href=/doi/10.1021/acs.jmedchem.7b00343" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00343" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00343" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00343%26sid%3Dliteratum%253Aachs%26pmid%3D28535350%26genre%3Darticle%26aulast%3DFortin%26date%3D2017%26atitle%3DActivation%2Bof%2BPhenyl%2B4-%25282-Oxo-3-alkylimidazolidin-1-yl%2529benzenesulfonates%2BProdrugs%2Bby%2BCYP1A1%2Bas%2BNew%2BAntimitotics%2BTargeting%2BBreast%2BCancer%2BCells%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D12%26spage%3D4963%26epage%3D4982%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/jmcmar.2017.60.issue-12/20170622/jmcmar.2017.60.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Prodrug-mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective release of potent anticancer products within cancer tissues is a promising approach in chemotherapy. We herein report the rationale, preparation, biological evaluation, and mechanism of action of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs) that are antimicrotubule prodrugs activated by CYP1A1. Although PAIB-SOs are inert in most cells tested, they are highly cytocidal toward several human breast cancer cells, including hormone-independent and chemoresistant types. PAIB-SOs are <i>N</i>-dealkylated into cytotoxic phenyl 4-(2-oxo-3-imidazolidin-1-yl)benzenesulfonates (PIB-SOs) in CYP1A1-positive cancer cells, both in vitro and in vivo. In conclusion, PAIB-SOs are novel chemotherapeutic prodrugs with no equivalent among current antineoplastics and whose selective action toward breast cancer is tailored to the characteristic pattern of CYP1A1 expression observed in a large percentage of human breast tumors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Breast cancer accounts for 25% of all female cancers, making it by far the most common cancer among women. It is estimated that 1.7 million new cases of breast cancers were diagnosed worldwide in 2012 and that they were responsible for over 520000 deaths.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> The five-year relative survival rate for women diagnosed with localized breast cancer is 98.6%; survival declines to 83.8% for regional stage and 23.3% for distant stage.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Therefore, breast cancer is among today’s most pressing health problems worldwide.</div><div class="NLM_p">Human cytochromes P450 (CYPs) are essential heme-containing enzymes comprising 57 individual types distributed into 18 families and 43 subfamilies. They catalyze >40 different redox reactions and are involved in the biosynthesis of various hormones and in the phase 1 elimination of various xenobiotics, including drugs and environmental pollutants. CYPs are ubiquitous but are mainly expressed in the liver and, to a lesser extent, in other organs and tissues.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> CYPs are of utmost importance in drug development strategies for optimizing bioavailability, tissue selectivity, and pharmacological responses to new drugs.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> In fact, these proteins are such critical determinants of drug interactions and adverse effects that the FDA now requires a full characterization of the induction and inhibition characteristics of the CYPs involved in the metabolism of every drug submitted for approval.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Although CYP-dependent metabolism is often perceived as a hindrance to drug development due to its effects on drug response, interactions, and adverse effects, CYPs are nonetheless essential shields against toxicity resulting from drug bioaccumulation.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> CYPs are widely used in drug design and in the development of prodrugs that can be converted into the active drug forms in vivo.<a onclick="showRef(event, 'ref8 ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10 ref11 ref12">(8-12)</a></div><div class="NLM_p">Prodrugs are designed so as to overcome issues of undesirable physicochemical, pharmacological, or pharmacodynamic properties.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> More recently, new promising prodrugs have been designed to exploit their bioactivation within tumors expressing specific CYPs, in keeping with the current principles of personalized medicine. In cancer chemotherapy, this approach aims at disseminating potent cancer drugs locally and selectively within sensitive tumors, thereby allowing maximum efficacy while reducing systemic toxicity. The underlying principle of the latter approach resides in the vast differences found in the expression level of the various CYP isoforms in tumors compared to other tissues. However, the development of tumor-specific, CYP-activatable prodrugs requires the selection of CYP isoforms expressed or inducible in the targeted tumor while being largely absent in adjacent normal tissues and distal organs. Many examples of such potentially targetable isoforms have been reported so far, including CYP1B1,<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> CYP2J2,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> CYP2S1, CYP2W1, and CYP1A1.<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22">(17-22)</a></div><div class="NLM_p">CYP1A1 is an extrahepatic isoform predominantly expressed in breast, lung, placenta, intestine, and skin.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Under physiological conditions, CYP1A1 expression is usually absent but is readily induced via the activation of the aryl hydrocarbon receptor (AhR) by several ligands such as halogenated dioxins (e.g., 2,3,7,8-tetrachlorodibenzo-<i>p</i>-dioxin, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) and polycyclic aromatic hydrocarbons (e.g., benzo[<i>a</i>]pyrene).<a onclick="showRef(event, 'ref19 ref24'); return false;" href="javascript:void(0);" class="ref ref19 ref24">(19, 24)</a> Catabolism of these environmental contaminants by CYP1A1 leads either to their detoxification or their conversion into genotoxic derivatives that may trigger carcinogenesis.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Several compounds, including drugs such as omeprazole and sunitinib, induce CYP1A1 expression via an AhR-independent or -dependent mechanism.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> Recent microarray and immunohistochemistry studies have shown that CYP1A1 is constitutively expressed in breast tumors, contrasting with its low expression in adjacent breast tissue.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28, 29)</a> Moreover, CYP1A1 expression correlates with breast cancer grade and progression and is inducible in various breast tumor cell lines (e.g., MCF7, MDA-MB-468, ZR-75-1, and T47D).<a onclick="showRef(event, 'ref19 ref29'); return false;" href="javascript:void(0);" class="ref ref19 ref29">(19, 29)</a> CYP1A1 and AhR contribute in a coordinated manner to carcinogenesis, proliferation, survival, and chemoresistance of cancer cells.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> In this regard, the induction of CYP1A1 in breast cancer cells, resulting in the local conversion of prodrugs into their active toxic form in situ, represents an innovative and promising strategy for breast cancer chemotherapy,<a onclick="showRef(event, 'ref31 ref32 ref33 ref34 ref35'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34 ref35">(31-35)</a> irrespective of the hormonal status of the tumor (positivity for estrogen receptor (ER), progesterone receptor (PR) and the HER2 (membrane-bound tyrosine kinase), i.e., the phenotype currently used clinically for selecting the appropriate therapeutic regimen.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of CYP1A1 inducers, including: 2,3,7,8-tetrachlorodibenzo-<i>p</i>-dioxin, benzo[<i>a</i>]pyrene, omeprazole, sunitinib, as well as two phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonate (PIB-SOs: <b>1</b> and <b>2</b>) derivatives acting as cytocidal antimicrotubules, as well as duocarmycin bioprecursor <b>3</b>, benzothiazole <b>4</b>, and aminoflavone <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We recently developed a subset of phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PIB-SOs, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) as highly potent microtubule-interfering agents exemplified by 3,4,5-trimethoxyphenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonate (CEU-602) and 3,5-dimethoxyphenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonate (CEU-699).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Briefly, PIB-SOs bind to the colchicine-binding site at the interface between α- and β-tubulins,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> exhibit antiproliferative activity at nanomolar concentrations in a wide range of tumor cell lines, and arrest cell cycle progression in G2/M. Their cytotoxic activity remains intact in cells resistant to paclitaxel and vinblastine and in cells overexpressing the P-glycoprotein. Moreover, the antitumoral activity of PIB-SOs is equivalent to that of cisplatin and combretastatin A-4 in human fibrosarcoma HT-1080 cells grafted onto the chorioallantoic membrane of developing chick embryos (or CAM assay), while displaying minor toxicity in the chick embryo.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> We now report the design, preparation, and biological evaluation of phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates (PAIB-SOs <b>6</b>–<b>68</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) as novel prodrugs bioactivated by CYP1A1 in human breast cancer cells.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i2" class="anchor-spacer"></div><h3 class="article-section__title" id="_i2"> Design of PAIB-SOs</h3><div class="NLM_p last">Microtubules play pivotal roles in major functions such as mitosis, cell, motility, and cytoplasmic transport.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> Antimicrotubule drugs are among the most potent in the cancer armamentarium, and particularly for breast cancer chemotherapy, and are thus prime candidates for the development of new cancer drugs.<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41-43)</a> However, microtubule-interfering agents have deleterious effects such as bone marrow suppression, hypersensitivity reactions, peripheral neuropathy, myalgia/arthralgia, as well as gastrointestinal and renal toxicity. We thus developed a tumor-specific drug delivery approach to circumvent these limitations while improving the pharmacological properties and tumor selectivity of antimicrotubule PIB-SOs. First, structure–activity relationship and molecular modeling studies showed that an unsubstituted amino group in the phenylimidazolidinone moiety is essential for the cytocidal activity of PIB-SOs. Moreover, various modifications, including the homologation of the imidazolidone moiety of PIB-SOs, dramatically decrease affinity for the colchicine-binding site, leading to inactive compounds.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> The rationale of our PAIB-SO prodrug design relied on the derivatization of the phenylimidazolidinone moiety with lower alkyl groups, thus eliminating the cytotoxic activity of the resulting PIB-SO precursors. With such a design, cytotoxicity can only be restored upon oxidative <i>N</i>-dealkylation by CYP1A1, which is frequently expressed and/or inducible in breast cancer tumors.</div></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83030" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83030" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> summarizes the synthesis of PAIB-SOs. First, 1-phenylimidazolidin-2-one was prepared quantitatively in two steps, as previously reported.<a onclick="showRef(event, 'ref37 ref44'); return false;" href="javascript:void(0);" class="ref ref37 ref44">(37, 44)</a> Then, NaH and the desired alkyl iodide were added to 1-phenylimidazolidin-2-one to yield 1-alkyl-3-phenylimidazolidin-2-ones <b>69</b>–<b>72</b> in good to very good yields. Moreover, we increased reaction yields to nearly quantitative levels by adding NaH and the alkyl iodide portionwise every 8 h until reaction completion. The 4-(3-alkyl-2-oxoimidazolidin-1-yl)benzenesulfonyl chlorides <b>73</b>–<b>76</b> were then obtained by reacting compounds <b>69</b>–<b>72</b> with 7.5 mol equiv of chlorosulfonic acid at 0 °C. Finally, the PAIB-SOs <b>6</b>–<b>68</b> were prepared by addition of the appropriate phenol and triethylamine to compounds <b>73</b>–<b>76</b> at room temperature.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0007.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaH, relevant alkyl iodide, THF; (ii) ClSO<sub>3</sub>H, CCl<sub>4</sub>; (iii) relevant phenol, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Antiproliferative Activity</h3><div class="NLM_p">Using several human cancer cell lines, we first studied the effects of the nature and position of aromatic ring B substituents and the homologation of the alkyl groups <i>N</i>-substituted on the phenylimidazolidinone moiety on the antiproliferative activity of the corresponding PAIB-SOs. The antiproliferative activity (IC<sub>50</sub>) of PAIB-SOs was first assessed in HT-29 colon carcinoma, M21 skin melanoma, and MCF7 estrogen-dependent breast carcinoma cells according to protocols recommended by the NCI/NIH Developmental Therapeutics Program<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). At first, the aromatic ring B of known PIB-SOs<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> substituted with either alkyl, methoxy, nitro, or halogen groups were converted into their corresponding PAIB-SOs <b>6</b>–<b>53</b> bearing a methyl-, ethyl-, and propyl-substituted phenylimidazolidinone moiety. <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> shows that with the exception in MCF7 cells of PAIB-SO <b>45</b>, <b>48</b>, and <b>49</b>, whose aromatic ring B is chloro- or methoxy-substituted at positions 3, 4, and/or 5, the antiproliferative activity of PAIB-SOs decreased upon lengthening of the alkyl chain. These results indicate that <i>N</i>-dealkylation does not occur with PAIB-SOs bearing either an <i>N</i>-methyl or <i>N</i>-ethyl group. Remarkably, however, <i>N</i>-propyl-substituted PAIB-SOs <b>45</b>, <b>48</b>, and <b>49</b> displayed an IC<sub>50</sub> value of 380, 270, and 49 nM, respectively, in MCF7 breast cancer cells, compared to a range of 3900 to 33000 nM in colon carcinoma and skin melanoma cells. Thus, a ∼2-log selectivity ratio [IC<sub>50</sub> (reference cell line)]/[IC<sub>50</sub> (sensitive cell line tested)] was observed that favored a selectivity of action of all active PAIB-SOs toward MCF7 breast cancer cells relative to M21 and HT-29 cells as well as all other nonmammary tumor cell lines tested so far. This marked selectivity strongly suggested the involvement of a selective enzymatic <i>N</i>-dealkylation of PAIB-SO <b>45</b>, <b>48</b>, and <b>49</b>, generating the highly cytocidal PIB-SO precursors in MCF7 cells to a much larger extent than in HT-29 and M21 cells. We next examined the effect of an <i>N</i>-substituted butyl group on the cytotoxicity of the resulting PAIB-SO prodrug toward breast cancer cells. As expected, substitution of the phenylimidazolidinone moiety of <b>1</b>, the most potent PIB-SO thus far identified, with a butyl group (compound <b>67</b>), induced strong and markedly selective cytotoxicity in MCF7 cells.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Cytotoxic Activity and Selectivity of PAIB-SO Derivatives toward MCF7 Breast Cancer Cells Compared to Non-Mammary (HT-29 and M21) Tumor Cell Lines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0008.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center">selectivity ratio<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center" char=".">HT-29</th><th class="colsep0 rowsep0" align="center" char=".">M21</th><th class="colsep0 rowsep0" align="center" char=".">MCF7</th><th class="colsep0 rowsep0" align="center">HT-29/MCF7</th><th class="colsep0 rowsep0" align="center">M21/MCF7</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2-Me</td><td class="colsep0 rowsep0" align="char" char=".">4800</td><td class="colsep0 rowsep0" align="char" char=".">2900</td><td class="colsep0 rowsep0" align="char" char=".">5600</td><td class="colsep0 rowsep0" align="center">0.9</td><td class="colsep0 rowsep0" align="center">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2-Et</td><td class="colsep0 rowsep0" align="char" char=".">4600</td><td class="colsep0 rowsep0" align="char" char=".">2300</td><td class="colsep0 rowsep0" align="char" char=".">26000</td><td class="colsep0 rowsep0" align="center">0.2</td><td class="colsep0 rowsep0" align="center">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2-OMe</td><td class="colsep0 rowsep0" align="char" char=".">26000</td><td class="colsep0 rowsep0" align="char" char=".">21000</td><td class="colsep0 rowsep0" align="char" char=".">26000</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2,4-Me</td><td class="colsep0 rowsep0" align="char" char=".">3000</td><td class="colsep0 rowsep0" align="char" char=".">1800</td><td class="colsep0 rowsep0" align="char" char=".">2500</td><td class="colsep0 rowsep0" align="center">1.2</td><td class="colsep0 rowsep0" align="center">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2,4,5-Cl</td><td class="colsep0 rowsep0" align="char" char=".">600</td><td class="colsep0 rowsep0" align="char" char=".">420</td><td class="colsep0 rowsep0" align="char" char=".">630</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2,4,6-Cl</td><td class="colsep0 rowsep0" align="char" char=".">2500</td><td class="colsep0 rowsep0" align="char" char=".">1700</td><td class="colsep0 rowsep0" align="char" char=".">2900</td><td class="colsep0 rowsep0" align="center">0.9</td><td class="colsep0 rowsep0" align="center">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3-Me</td><td class="colsep0 rowsep0" align="char" char=".">4300</td><td class="colsep0 rowsep0" align="char" char=".">2300</td><td class="colsep0 rowsep0" align="char" char=".">5100</td><td class="colsep0 rowsep0" align="center">0.9</td><td class="colsep0 rowsep0" align="center">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3-OMe</td><td class="colsep0 rowsep0" align="char" char=".">2500</td><td class="colsep0 rowsep0" align="char" char=".">1600</td><td class="colsep0 rowsep0" align="char" char=".">3000</td><td class="colsep0 rowsep0" align="center">0.8</td><td class="colsep0 rowsep0" align="center">0.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">5800</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="char" char=".">2100</td><td class="colsep0 rowsep0" align="char" char=".">1600</td><td class="colsep0 rowsep0" align="char" char=".">2200</td><td class="colsep0 rowsep0" align="center">0.9</td><td class="colsep0 rowsep0" align="center">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3-Br</td><td class="colsep0 rowsep0" align="char" char=".">1300</td><td class="colsep0 rowsep0" align="char" char=".">1300</td><td class="colsep0 rowsep0" align="char" char=".">1500</td><td class="colsep0 rowsep0" align="center">0.8</td><td class="colsep0 rowsep0" align="center">0.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3-I</td><td class="colsep0 rowsep0" align="char" char=".">590</td><td class="colsep0 rowsep0" align="char" char=".">400</td><td class="colsep0 rowsep0" align="char" char=".">560</td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">26000</td><td class="colsep0 rowsep0" align="char" char=".">23000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3,4-OMe</td><td class="colsep0 rowsep0" align="char" char=".">12000</td><td class="colsep0 rowsep0" align="char" char=".">8500</td><td class="colsep0 rowsep0" align="char" char=".">12000</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">0.72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3,5-OMe</td><td class="colsep0 rowsep0" align="char" char=".">190</td><td class="colsep0 rowsep0" align="char" char=".">82</td><td class="colsep0 rowsep0" align="char" char=".">230</td><td class="colsep0 rowsep0" align="center">0.9</td><td class="colsep0 rowsep0" align="center">0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3,4,5-OMe</td><td class="colsep0 rowsep0" align="char" char=".">62</td><td class="colsep0 rowsep0" align="char" char=".">54</td><td class="colsep0 rowsep0" align="char" char=".">120</td><td class="colsep0 rowsep0" align="center">0.5</td><td class="colsep0 rowsep0" align="center">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">4-Me</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">95000</td><td class="colsep0 rowsep0" align="center">>1.1</td><td class="colsep0 rowsep0" align="center">>1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="char" char=".">12000</td><td class="colsep0 rowsep0" align="char" char=".">43000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-OMe</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-OMe</td><td class="colsep0 rowsep0" align="char" char=".">22000</td><td class="colsep0 rowsep0" align="char" char=".">7000</td><td class="colsep0 rowsep0" align="char" char=".">14000</td><td class="colsep0 rowsep0" align="center">1,6</td><td class="colsep0 rowsep0" align="center">0,5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">11000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="char" char=".">6800</td><td class="colsep0 rowsep0" align="char" char=".">3900</td><td class="colsep0 rowsep0" align="char" char=".">5400</td><td class="colsep0 rowsep0" align="center">1,3</td><td class="colsep0 rowsep0" align="center">0,7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-Br</td><td class="colsep0 rowsep0" align="char" char=".">3800</td><td class="colsep0 rowsep0" align="char" char=".">3400</td><td class="colsep0 rowsep0" align="char" char=".">2500</td><td class="colsep0 rowsep0" align="center">1,5</td><td class="colsep0 rowsep0" align="center">1,4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-I</td><td class="colsep0 rowsep0" align="char" char=".">3100</td><td class="colsep0 rowsep0" align="char" char=".">2200</td><td class="colsep0 rowsep0" align="char" char=".">1900</td><td class="colsep0 rowsep0" align="center">1,7</td><td class="colsep0 rowsep0" align="center">1,2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3,4-OMe</td><td class="colsep0 rowsep0" align="char" char=".">37000</td><td class="colsep0 rowsep0" align="char" char=".">35000</td><td class="colsep0 rowsep0" align="char" char=".">39100</td><td class="colsep0 rowsep0" align="center">1,0</td><td class="colsep0 rowsep0" align="center">0,9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3,5-OMe</td><td class="colsep0 rowsep0" align="char" char=".">4300</td><td class="colsep0 rowsep0" align="char" char=".">4200</td><td class="colsep0 rowsep0" align="char" char=".">3500</td><td class="colsep0 rowsep0" align="center">1,2</td><td class="colsep0 rowsep0" align="center">1,2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3,4,5-OMe</td><td class="colsep0 rowsep0" align="char" char=".">640</td><td class="colsep0 rowsep0" align="char" char=".">870</td><td class="colsep0 rowsep0" align="char" char=".">700</td><td class="colsep0 rowsep0" align="center">0.9</td><td class="colsep0 rowsep0" align="center">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="char" char=".">60000</td><td class="colsep0 rowsep0" align="char" char=".">26000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">2-Me</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">2-Et</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>50000</td><td class="colsep0 rowsep0" align="char" char=".">2300</td><td class="colsep0 rowsep0" align="center">>43</td><td class="colsep0 rowsep0" align="center">>22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">2-OMe</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">13000</td><td class="colsep0 rowsep0" align="center">>7.7</td><td class="colsep0 rowsep0" align="center">>7.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">2,4-Me</td><td class="colsep0 rowsep0" align="char" char=".">26000</td><td class="colsep0 rowsep0" align="char" char=".">9700</td><td class="colsep0 rowsep0" align="char" char=".">1500</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center">6.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">2,4,5-Cl</td><td class="colsep0 rowsep0" align="char" char=".">19000</td><td class="colsep0 rowsep0" align="char" char=".">15000</td><td class="colsep0 rowsep0" align="char" char=".">13000</td><td class="colsep0 rowsep0" align="center">1.5</td><td class="colsep0 rowsep0" align="center">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">2,4,6-Cl</td><td class="colsep0 rowsep0" align="char" char=".">56000</td><td class="colsep0 rowsep0" align="char" char=".">56000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">N/A</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">3-Me</td><td class="colsep0 rowsep0" align="char" char=".">65000</td><td class="colsep0 rowsep0" align="char" char=".">28000</td><td class="colsep0 rowsep0" align="char" char=".">86000</td><td class="colsep0 rowsep0" align="center">0.8</td><td class="colsep0 rowsep0" align="center">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">3-OMe</td><td class="colsep0 rowsep0" align="char" char=".">25000</td><td class="colsep0 rowsep0" align="char" char=".">10000</td><td class="colsep0 rowsep0" align="char" char=".">6300</td><td class="colsep0 rowsep0" align="center">4.0</td><td class="colsep0 rowsep0" align="center">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="char" char=".">18000</td><td class="colsep0 rowsep0" align="char" char=".">12000</td><td class="colsep0 rowsep0" align="char" char=".">24000</td><td class="colsep0 rowsep0" align="center">0.8</td><td class="colsep0 rowsep0" align="center">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="char" char=".">13000</td><td class="colsep0 rowsep0" align="char" char=".">8600</td><td class="colsep0 rowsep0" align="char" char=".">380</td><td class="colsep0 rowsep0" align="center">34</td><td class="colsep0 rowsep0" align="center">23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">38000</td><td class="colsep0 rowsep0" align="char" char=".">19000</td><td class="colsep0 rowsep0" align="center">>5.3</td><td class="colsep0 rowsep0" align="center">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">3,4-OMe</td><td class="colsep0 rowsep0" align="char" char=".">14000</td><td class="colsep0 rowsep0" align="char" char=".">28000</td><td class="colsep0 rowsep0" align="char" char=".">6800</td><td class="colsep0 rowsep0" align="center">2.0</td><td class="colsep0 rowsep0" align="center">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">3,5-OMe</td><td class="colsep0 rowsep0" align="char" char=".">16000</td><td class="colsep0 rowsep0" align="char" char=".">33000</td><td class="colsep0 rowsep0" align="char" char=".">270</td><td class="colsep0 rowsep0" align="center">59</td><td class="colsep0 rowsep0" align="center">120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">3,4,5-OMe</td><td class="colsep0 rowsep0" align="char" char=".">5600</td><td class="colsep0 rowsep0" align="char" char=".">3900</td><td class="colsep0 rowsep0" align="char" char=".">49</td><td class="colsep0 rowsep0" align="center">110</td><td class="colsep0 rowsep0" align="center">80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">4-Me</td><td class="colsep0 rowsep0" align="char" char=".">25000</td><td class="colsep0 rowsep0" align="char" char=".">28000</td><td class="colsep0 rowsep0" align="char" char=".">64000</td><td class="colsep0 rowsep0" align="center">0.4</td><td class="colsep0 rowsep0" align="center">0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="char" char=".">16000</td><td class="colsep0 rowsep0" align="char" char=".">23000</td><td class="colsep0 rowsep0" align="char" char=".">20000</td><td class="colsep0 rowsep0" align="center">0.8</td><td class="colsep0 rowsep0" align="center">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="char" char=".">23000</td><td class="colsep0 rowsep0" align="char" char=".">14000</td><td class="colsep0 rowsep0" align="char" char=".">33000</td><td class="colsep0 rowsep0" align="center">0.7</td><td class="colsep0 rowsep0" align="center">0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">Prop</td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="char" char=".">15000</td><td class="colsep0 rowsep0" align="char" char=".">34000</td><td class="colsep0 rowsep0" align="char" char=".">18000</td><td class="colsep0 rowsep0" align="center">0.8</td><td class="colsep0 rowsep0" align="center">1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">8800</td><td class="colsep0 rowsep0" align="center">>11</td><td class="colsep0 rowsep0" align="center">>11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">2-OMe</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">3800</td><td class="colsep0 rowsep0" align="center">>26</td><td class="colsep0 rowsep0" align="center">>26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3-OMe</td><td class="colsep0 rowsep0" align="char" char=".">13000</td><td class="colsep0 rowsep0" align="char" char=".">30000</td><td class="colsep0 rowsep0" align="char" char=".">490</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center">61</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="char" char=".">76000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">310</td><td class="colsep0 rowsep0" align="center">250</td><td class="colsep0 rowsep0" align="center">>320</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="char" char=".">21000</td><td class="colsep0 rowsep0" align="char" char=".">90000</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="center">190</td><td class="colsep0 rowsep0" align="center">820</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3-Br</td><td class="colsep0 rowsep0" align="char" char=".">16000</td><td class="colsep0 rowsep0" align="char" char=".">35000</td><td class="colsep0 rowsep0" align="char" char=".">85</td><td class="colsep0 rowsep0" align="center">190</td><td class="colsep0 rowsep0" align="center">410</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3-I</td><td class="colsep0 rowsep0" align="char" char=".">9600</td><td class="colsep0 rowsep0" align="char" char=".">23000</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="center">170</td><td class="colsep0 rowsep0" align="center">400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3,4-OMe</td><td class="colsep0 rowsep0" align="char" char=".">21000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">340</td><td class="colsep0 rowsep0" align="center">61</td><td class="colsep0 rowsep0" align="center">>300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3,4-F</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">760</td><td class="colsep0 rowsep0" align="center">>130</td><td class="colsep0 rowsep0" align="center">>130</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3,5-OMe</td><td class="colsep0 rowsep0" align="char" char=".">36000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="center">1900</td><td class="colsep0 rowsep0" align="center">>5300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3,5-F</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">400</td><td class="colsep0 rowsep0" align="center">>250</td><td class="colsep0 rowsep0" align="center">>250</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3,5-Cl</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">58000</td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="center">>1700</td><td class="colsep0 rowsep0" align="center">970</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3,5-Br</td><td class="colsep0 rowsep0" align="char" char=".">43000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">58</td><td class="colsep0 rowsep0" align="center">740</td><td class="colsep0 rowsep0" align="center">>1700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">3,4,5-OMe</td><td class="colsep0 rowsep0" align="char" char=".">3600</td><td class="colsep0 rowsep0" align="char" char=".">3800</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="center">360</td><td class="colsep0 rowsep0" align="center">380</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left">But</td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="char" char=".">35000</td><td class="colsep0 rowsep0" align="char" char=".">>100000</td><td class="colsep0 rowsep0" align="char" char=".">2500</td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="center">>39</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">IC<sub>50</sub> represents the concentration of drug inhibiting cell growth by 50% after 48 h of treatment.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">The selectivity ratio is calculated as the ratio of the IC<sub>50</sub> value of each compound toward the comparatively insensitive HT-29 or M21 cell lines, to that measured for MCF7 breast cancer cells.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">N/A: not applicable.</p></div></div></div><div class="NLM_p">Finally, permutation of halogen and methoxy groups between positions 3, 4, and/or 5 of ring B and substitution of the 2-imidazolidone moiety with an <i>N</i>-<i>n</i>-butyl group led to PAIB-SOs <b>55</b>–<b>68</b>. With the exception of PAIB-SO <b>55</b>, <b>56</b>, and <b>68</b>, the latter series exhibited IC<sub>50</sub> values in the nanomolar range and selectivity ratio values in favor of MCF7 cells ranging from 61 to >5.3 × 10<sup>3</sup>. Furthermore, di- or trisubstituted PAIB-SOs (<b>61</b>–<b>67</b>) were more cytocidal and exhibited better breast cancer cell selectivity than their respective monosubstituted counterparts (<b>55</b>–<b>60</b>). Of note, compounds <b>63</b> and <b>65</b>, which bear a 3,5-OMe and 3,5-Cl group, respectively, on ring B, and whose phenylimidazolidinone moiety was <i>N</i>-substituted with an <i>n</i>-butyl group, exhibited IC<sub>50</sub> values ≤60 nM and selectivity ratios >1 × 10<sup>3</sup> with respect to MCF7 cells. In addition, PAIB-SO <b>67</b> was the most potent, with an IC<sub>50</sub> value of 10 nM toward MCF7 cells, whereas compound <b>63</b> exhibited the highest selectivity against MCF7 cells (>5.3 × 10<sup>3</sup>).</div><div class="NLM_p">The latter results suggested that at least some of the PAIB-SOs synthesized might exhibit a remarkably more selective cytocidal activity toward breast tumor cells than in human cancer cells of different histological origin. To further assess this hypothesis, compounds <b>49</b>, <b>63</b>, and <b>67</b> were evaluated using an array of breast cancer cell lines expressing various phenotypes of clinical interest, including so-called triple-negative types (ER-, PR- and HER2-negative, i.e., ER<sup>–</sup>/PR<sup>–</sup>/HER2<sup>–</sup>; MDA-MB-231 and MDA-MB-468 cells), ER<sup>+</sup>/PR<sup>+</sup>/HER2<sup>low</sup> (T47D cells) and ER<sup>–</sup>/PR<sup>–</sup>/HER2<sup>high</sup> (SK-BR-3 cells).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> With the exception of MDA-MB-231 cells, which are insensitive to all PAIB-SOs tested, all breast cancer cell lines evaluated so far were remarkably sensitive to the selected PAIB-SOs (with SK-BR-3 > MDA-MB-468 > T47D cells, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), with IC<sub>50</sub> values in the 10<sup>–9</sup>–10<sup>–7</sup> M range (2.0–240 nM) and selectivity ratios of 0.13–3.0 × 10<sup>3</sup> (relative to insensitive MDA-MB-231 cells), according to the cell line and/or PAIB-SO considered. Of note, we assessed the effect of phenol red in culture medium on the activity of PAIB-SO <b>67</b> on MDA-MB-231, MDA-MB-468, T47D, SK-BR-3, and MCF7 cell lines and phenol red does not impact significantly the antiproliferative activity of <b>67</b> in all cancer cell lines tested.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferative Activity and Selectivity Ratio of a Selected Panel of PAIB-SO Derivatives in MDA-MB-468, T47D, SK-BR-3, and MCF7 Human Breast Cancer Cells, As Compared with Insensitive MDA-MB-231 Cells, Along with Apparent Substrate Affinity (As Estimated by the <i>K</i><sub>i</sub> Value) toward CYP1A1 and Ratio of CYP1A1-Mediated Conversion into the Parent PIB-SO</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="4" align="center">selectivity ratio<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">MDA-MB-231<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">MDA-MB-468<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="±">T47D<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="±">SK-BR-3<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char="±">MCF7</th><th class="colsep0 rowsep0" align="center">MDA-MB-231/MDA-MB-468</th><th class="colsep0 rowsep0" align="center">MDA-MB-231/T47D</th><th class="colsep0 rowsep0" align="center">MDA-MB-231/SK-BR-3</th><th class="colsep0 rowsep0" align="center">MDA-MB-231/MCF7</th><th class="colsep0 rowsep0" align="center">PAIB-SOs conversion by CYP1A1 (min)<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a></th><th class="colsep0 rowsep0" align="center">affinity (<i>K</i><sub>i</sub>, 10<sup>–7</sup>)<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">6.4 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">4.6 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">6.2 ± 3.0</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">3.1 ± 0.5</td><td class="colsep0 rowsep0" align="center">1.4</td><td class="colsep0 rowsep0" align="center">1.0</td><td class="colsep0 rowsep0" align="center">2.1</td><td class="colsep0 rowsep0" align="center">2.1</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="center">6000 ± 3000</td><td class="colsep0 rowsep0" align="char" char="±">26 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">49 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">5.0 ± 3.0</td><td class="colsep0 rowsep0" align="char" char="±">18 ± 2</td><td class="colsep0 rowsep0" align="center">240</td><td class="colsep0 rowsep0" align="center">130</td><td class="colsep0 rowsep0" align="center">1300</td><td class="colsep0 rowsep0" align="center">340</td><td class="colsep0 rowsep0" align="center">++ (15)</td><td class="colsep0 rowsep0" align="center">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="center">6000 ± 3000</td><td class="colsep0 rowsep0" align="char" char="±">10 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">20 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">2.0 ± 1.5</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 2.0</td><td class="colsep0 rowsep0" align="center">590</td><td class="colsep0 rowsep0" align="center">300</td><td class="colsep0 rowsep0" align="center">3000</td><td class="colsep0 rowsep0" align="center">1100</td><td class="colsep0 rowsep0" align="center">++ (30)</td><td class="colsep0 rowsep0" align="center">5.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="center">10 ± 1</td><td class="colsep0 rowsep0" align="char" char="±">6.5 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">8.7 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 1.0</td><td class="colsep0 rowsep0" align="char" char="±">4.0 ± 0.1</td><td class="colsep0 rowsep0" align="center">1.5</td><td class="colsep0 rowsep0" align="center">1.1</td><td class="colsep0 rowsep0" align="center">1.8</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">–</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="center">>100000</td><td class="colsep0 rowsep0" align="char" char="±">160 ± 90</td><td class="colsep0 rowsep0" align="char" char="±">240 ± 100</td><td class="colsep0 rowsep0" align="char" char="±">52 ± 5</td><td class="colsep0 rowsep0" align="char" char="±">35 ± 1.5</td><td class="colsep0 rowsep0" align="center">>630</td><td class="colsep0 rowsep0" align="center">>420</td><td class="colsep0 rowsep0" align="center">>1900</td><td class="colsep0 rowsep0" align="center">>2900</td><td class="colsep0 rowsep0" align="center">+ (15)</td><td class="colsep0 rowsep0" align="center">4.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">IC<sub>50</sub> is expressed as the concentration of drug inhibiting cell proliferation by 50% after 72 h of treatment.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">MDA-MB-231 and MDA-MB-468 cells are triple-negative breast cancer cells (ER<sup>–</sup>/PR<sup>–</sup>/HER2<sup>–</sup>).</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">T47D cells exhibit an ER<sup>+</sup>/PR<sup>+</sup>/HER2<sup>low</sup> phenotype.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">SK-BR-3 cells express an ER<sup>–</sup>/PR<sup>–</sup>/HER2<sup>high</sup> phenotype.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">Selectivity ratio is expressed as the ratio of the IC<sub>50</sub> value found in insensitive cells (MDA-MB-231) to that measured in sensitive cells (MDA-MB-468, T47D, SK-BR-3, and MCF7).</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">N/A, not applicable; +, low; ++, moderate; +++, good.</p></div><div class="footnote" id="t2fn7"><sup>g</sup><p class="last">–, no affinity. The IC<sub>50</sub> values found for the parent PIB-SOs <b>1</b> and <b>2</b> that are cytotoxic in all cell types are provided for comparison.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Determination of the Mechanism of Action</h3><div class="NLM_p">To confirm that the <i>N</i>-dealkylation of PAIB-SOs into PIB-SOs occurs in a enzymatically mediated fashion, we assessed the effect of PAIB-SO <b>67</b> on cell cycle progression and microtubule integrity in PAIB-SO-sensitive MDA-MB-468 and MCF7 cell lines in comparison to insensitive MDA-MB-231 cells. <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> shows that PAIB-SO <b>67</b> blocks cell cycle progression in the G2/M phase and disrupts the microtubule network of sensitive tumor cells (MDA-MB-468 and MCF7) in a manner similar to that observed with an equimolar concentration of <b>1</b> while having no detectable effect in insensitive MDA-MB-231 cells tested in parallel.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PAIB-SO <b>67</b> has an antimicrotubule effect in sensitive MDA-MB-468 and MCF7 cells and are inactive in MDA-MB-231 cells. Effect of PAIB-SO <b>67</b> [50 nM, (c,f,i)] and its parental drug <b>1</b> [8 nM, (b,e,h)] on cytoskeletal integrity and cell cycle progression in sensitive MDA-MB-468 (a–c) and MCF7 (d–f) and insensitive MDA-MB-231 cells (g–i). Control groups (a, d, g) were incubated with vehicle only (0.5% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To identify the tumor-specific CYP isoform responsible for the <i>N</i>-dealkylation of PAIB-SOs in breast cancer cells, sensitive MDA-MB-468 cells were coincubated with PAIB-SO <b>67</b> and subtoxic concentrations of various CYP inhibitors (α-naphthoflavone, resveratrol, ketoconazole, quercetin, tacrine, capsaicin, aniline, curcumin, mefipristone, pentachlorophenol, and salicylamide). As shown in <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>, a 72 h incubation with either α-naphthoflavone, resveratrol, ketoconazole, quercetin, tacrine, and capsaicin dramatically reduced the cytocidal activity of PAIB-SO <b>67</b> toward MDA-MB-468 cells, while neither aniline, curcumin, mefipristone, pentachlorophenol nor salicylamide affected the antiproliferative activity of the PAIB-SO. Interestingly, the inhibitors that reduced the antiproliferative activity of PAIB-SO <b>67</b> are known nonselective inhibitors of several CYPs, including CYP1A1, whereas the subset of compounds that did not interfere with the cytocidal effect of <b>67</b> do not inhibit the CYP1A1 isoform.<a onclick="showRef(event, 'ref47 ref48 ref49 ref50 ref51 ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref49 ref50 ref51 ref52 ref53">(47-53)</a></div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of subtoxic concentrations of known CYP1A1 inhibitors [(a) α-naphthoflavone, (b) resveratrol, (c) ketoconazole, (d) quercetin, (e) tacrine, and (f) capsaicin] and known CYP inhibitors devoid of anti-CYP1A1 activity [(g) aniline, (h) curcumin, (i) mefipristone, (j) pentachlorophenol, and (k) salicylamide] on the cytocidal activity of PAIB-SO <b>67</b> in sensitive MDA-MB-468 cells. The experiments were conducted in triplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The evidence gathered so led us to determine the affinity of the most potent PAIB-SOs for CYP1A1, along with their intracellular activation to the corresponding PIB-SO. As shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> and in <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>, CYP1A1 readily oxidizes all PAIB-SOs thus evaluated. Moreover, CYP1A1 <i>N</i>-dealkylates PAIB-SOs with various velocities, yielding the corresponding hydroxylated intermediates. In addition, the ethoxyresorufin-<i>O</i>-deethylase assay for CYP1A1 activity showed that all PAIB-SOs studied inhibit the CYP1A1-mediated oxidation of 7-ethoxyresorufin to fluorescent resorufin while PIB-SOs do not inhibit the latter reaction. These results showed that all PAIB-SOs studied are competitive CYP1A1 inhibitors, with <i>K</i><sub>i</sub> values ranging from 2.4 × 10<sup>–7</sup> to 5.4 × 10<sup>–7</sup> M. Importantly, <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a> shows that a 4-h incubation (maximum incubation time) of PAIB-SO <b>67</b> with CYP1A2, -1B1, and -3A4 did not yield detectable amounts of the parent PIB-SO <b>1</b>; longer incubation times were not assessed because enzymes instability may occur.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54, 55)</a> Nonetheless, the incubation of PAIB-SO with CYP1A2 leads to a oxidized intermediate. The results shown above thus confirm that the activation of PAIB-SOs observed in breast cancer cells is related to CYP1A1 expression. However, several other experiments should be conducted to study the activation and identify others CYPs involved in the metabolization pathway of PAIB-SOs. Interestingly, incubation of <b>67</b> with human liver microsomes pooled from several donors showed that after 60 min, approximately 25% of the intact PAIB-SO and only 3.3% of the parent PIB-SO <b>1</b> were found. These results confirmed that hepatic enzymes have the ability to metabolize PAIB-SOs into several oxidized intermediates and only a small amount of PIB-SOs is generated suggesting a relative resistance of PAIB-SOs to hepatic metabolism. Further experiments are required to study the antineoplastic activity and the potential hepatotoxicity of PAIB-SOs on animal models of human breast cancers.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Conversion of inactive PAIB-SOs into potent PIB-SOs by CYP1A1. Oxidation of PAIB-SOs (a) <b>49</b>, (b) <b>67</b>, and (c) <b>63</b> to their parent PIB-SOs (<b>1</b> and <b>2</b>) by CYP1A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Stability of PAIB-SO toward various CYPs. HPLC analysis of a control mixture containing (a) PAIB-SO <b>67</b> and its parent PIB-SO drug <b>1</b>, and the supernatant obtained after incubation of PAIB-SO <b>67</b> with (b) CYP1A2, (c) CYP1B1, (d) CYP3A4, and (e) human liver microsomes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further confirm that CYP1A1 is involved in the activation of PAIB-SOs in sensitive breast cancer cells, we determined the effect of compound <b>67</b> on <i>CYP1A1</i> mRNA expression in MCF7 and MDA-MB-231 cells. Indeed, PAIB-SO <b>67</b> did not significantly increase the <i>CYP1A1</i> mRNA levels after 18 and 24 h of treatment in insensitive MDA-MB-231 cells while it led to a 2-fold increase in <i>CYP1A1</i> mRNA levels in sensitive MCF7 cells after an 18 h incubation, an effect which was transient, as seen with the eventual decline in the mRNA level in the following 6 h interval (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00343/suppl_file/jm7b00343_si_001.pdf" class="ext-link">Figure S1</a> in Supporting Information). Next, we found that PAIB-SOs are inactive both on wild-type human fibrosarcoma HT-1080 cells and HT-1080 cells transfected with the empty vector pCMV6-AC_Empty (HT-1080<sup>empty</sup>) that do not express CYP1A1 enzyme with a cytocidal activity in the micromolar range (IC<sub>50</sub> value of 5.5–82 μM). However, when HT-1080 cells are stably transfected with pCMV6-AC_CYP1A1 plasmid (HT-1080<sup><i>CYP1A1</i></sup>), they become sensitive to PAIB-SOs <b>49</b>, <b>67</b>, and <b>63</b> with a cytocidal activity in the low nanomolar range (IC<sub>50</sub> value of 13–31 nM) and a selectivity ratio ranging from 2600 to 5100 relative to HT-1080<sup>empty</sup> (i.e., IC<sub>50</sub> (HT-1080<sup>empty</sup>)/IC<sub>50</sub> (HT-1080<sup><i>CYP1A1</i></sup>), <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). On one hand, in the chick CAM assay, <b>1</b> used as positive control inhibited the growth of HT-1080 tumor cells tumors by 51% while reducing the growth of HT-1080<sup><i>CYP1A1</i></sup> and HT-1080<sup>empty</sup> by 32% and 21%, respectively. On the other hand, PAIB-SOs <b>67</b> inhibited the growth of HT-1080<sup><i>CYP1A1</i></sup> tumors by 49% while reducing the growth of wild-type HT-1080 tumor only by 15% and does not reduce the growth of HT-1080<sup>empty</sup> cells. Therefore, PAIB-SO <b>67</b> showed in vivo selectivity toward HT-1080<sup><i>CYP1A1</i></sup> cells in the chick CAM assay while exhibiting no or only marginal toxicity toward chick embryos. The weak antitumor activity of PAIB-SO <b>67</b> on wild-type HT-1080 cells tumors could also involve another CYP or enzyme capable of bioactivating PAIB-SO not identified yet. It could be due also to the inhibition of various processes in the formation and growth of tumors in this model other than the bioactivation of PAIB-SO into antimicrotubule agents. Finally, PAIB-SO <b>67</b> seemed unaffected by potential resistance profile of HT-1080 cells because it reached approximatively the maximum antitumor value observed using that model.<a onclick="showRef(event, 'ref37 ref44 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref37 ref44 ref56 ref57">(37, 44, 56, 57)</a></div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vitro and in vivo selectivity of PAIB-SOs toward human fibrosarcoma HT-1080 cells stably transfected with pCMV6-AC_Empty (HT-1080<sup>empty</sup>) and pCMV6-AC_CYP1A1 (HT-1080<sup><i>CYP1A1</i></sup>) plasmids. (a) Antiproliferative activity and selectivity ratios (HT-1080<sup>empty</sup>/HT-1080<sup><i>CYP1A1</i></sup>) of <b>1</b>, <b>2</b>, and the selected <b>49</b>, <b>67</b>, and <b>63</b> derivatives in HT-1080 wild-type, HT-1080<sup>empty</sup>, and HT-1080<sup><i>CYP1A1</i></sup> cells. (b) CYP1A1 expression in HT-1080, HT-1080<sup>empty</sup>, and HT-1080<sup><i>CYP1A1</i></sup> cells. (c) Effect of PAIB-SO <b>67</b> and <b>1</b> on HT-1080, HT-1080<sup>empty</sup>, and HT-1080<sup><i>CYP1A1</i></sup> tumor growth using the CAM assay, with the assessment of drug toxicity in the chick embryos. The <i>blue</i> bars represent the percentage of tumor-specific wet weight in tumor grafts treated with and without excipient. The <i>red</i> bars indicate the percentage of chick embryo mortality.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27508" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27508" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pharmacological strategies based on the CYP enzyme family represent a relevant and promising approach for the development of new and highly selective tumor-targeting drugs exploiting CYP-dependent bioactivation of prodrugs.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Such finely designed strategies might in principle improve treatment regimens and efficacy while reducing the deleterious effects associated with nontarget drug action. However, this concept has been notoriously difficult to implement because its therapeutic success depends on several prerequisites.<a onclick="showRef(event, 'ref13 ref58'); return false;" href="javascript:void(0);" class="ref ref13 ref58">(13, 58)</a> First, the CYP isoform selected for activating the prodrug must be overexpressed or inducible in the tumor while remaining expressed at negligible levels in off-target tissues. Second, the design of the prodrug must aim at optimal physicochemical and pharmacokinetic properties to allow its efficient diffusion into the tumors, while its oxidation must release a cytocidal metabolite locally. Third, such a prodrug should exhibit a high affinity and selectivity toward a specific CYP isoform, and the parent drug released upon enzymatic activation must bind its target(s) selectively and readily, with minimal entry into the general circulation. Finally, the prodrug should not or only partially be a substrate for other CYP isoenzymes to maximally reduce potential off-target toxicity.</div><div class="NLM_p">CYP1A1 was identified as one of the most promising isoforms for the development of new cancer prodrugs for the specific treatment of human breast carcinomas.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Indeed, CYP1A1 is an extrahepatic enzyme that is constitutively expressed in several breast cancer tumors but largely absent in healthy adjacent tissues.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> It is also involved in carcinogenesis, in tumor aggressiveness, and in the induction of cancer cell defense mechanisms. Over the past decade, three families of antitumor prodrugs, namely precursors of duocarmycin, benzothiazoles, and aminoflavones, have been developed based on the concept of CYP1A1 bioactivation. Aminoflavones and benzothiazoles prodrugs induce CYP1A1 expression while duocarmycin bioprecursors do not. They are converted into potent alkylating metabolites that covalently bind to DNA and/or other macromolecules.<a onclick="showRef(event, 'ref21 ref31 ref59'); return false;" href="javascript:void(0);" class="ref ref21 ref31 ref59">(21, 31, 59)</a> While duocarmycin bioprecursors (1-(chloromethyl)-1,6-dihydropyrrolo[3,2-<i>e</i>]indol-3(2<i>H</i>)-yl)(5-methoxy-1<i>H</i>-indol-2-yl)methanone (<b>3</b>, ICT2700) are still undergoing preclinical studies,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> extensive structure–activity relationship studies of aminoflavones and benzothiazoles have singled out two lead compounds exhibiting high activity and selectivity toward human breast cancer cells both in vitro and in vivo for subsequent clinical studies.<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59, 60)</a> The lysyl benzothiazole 2-[4-amino-3-methylphenyl]-5-fluorobenzothiazole lysylamide dihydrochloride (<b>4</b>, NSC710305, Phortress) and the lysyl aminoflavone (2<i>S</i>)-2,6-diamino-<i>N</i>-[4-(5-amino-6,8-difluoro-7-methyl-4-oxochromen-2-yl)-2-fluorophenyl]hexanamide (<b>5</b>, NSC710464) have been assessed as prodrugs in clinical trials (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Compound <b>5</b> is now in phase II studies to assess its efficacy in triple-negative and ER<sup>+</sup> breast carcinomas and is currently in preclinical evaluation for kidney and ovarian cancers.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Of note, dosage limitation was observed in phase I with <b>5</b> due to pulmonary toxicity. On the other hand, the clinical evaluation of <b>4</b> has been discontinued, as phase I studies failed to determine a maximal tolerated dose and displayed lung and liver toxicity.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">The preclinical results obtained for <b>3</b>, <b>4</b>, and <b>5</b> as well as the phase II evaluation of <b>5</b> have shown that a CYP-activated prodrug approach holds much promise for the development of innovative, highly selective cancer therapies. This prompted us to develop PAIB-SOs as a new class of cancer prodrugs relying on a CYP-based activation strategy. This study supports our hypothesis that PAIB-SOs are potent anticancer prodrugs with a high selectivity toward a subset of established breast tumor cells. A subset of these prodrugs induce <i>CYP1A1</i> mRNA expression to a moderate and significant extent in sensitive cells and exhibit a high affinity and selectivity for activation via this CYP isoform. The other CYP isoenzymes examined so far did not release the expected PIB-SO parent drug. The design of PAIB-SOs relies on a genuine molecular scaffold that can be easily prepared, purified, and modified and whose synthesis can be scaled up at low cost. Moreover, because their core molecular structure is unrelated to aminoflavone, benzothiazole, and duocarmycin prodrugs, PAIB-SOs exhibit distinctive physicochemical and biopharmaceutical properties that might circumvent the clinical limitations of <b>4</b> and <b>5</b>. The CYP1A1-dependent antimicrotubule action of PAIB-SOs, which is unique to this class of CYP-activated prodrugs to the best of our knowledge, might present advantages over the other prodrugs mentioned above. Indeed, microtubule-disrupting agents such as paclitaxel and vinblastine have been used successfully for breast cancer therapy without the pulmonary toxicity that impaired the use of the other CYP1A1-dependent prodrugs in clinical trials. Furthermore, the off-target toxicity of the PAIB-SOs might be expected to be lower than with other CYP1A1-activatable drugs that potentially affect a wider spectrum of biological targets due to their reactive character. Indeed, cytoskeleton-disrupting drugs such as nocodazole are known to progressively downregulate <i>CYP1A1</i> expression.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Unlike nocodazole, which acts indirectly by disrupting the microtubule transport system that is responsible for <i>CYP1A1</i> induction by polycyclic aromatic hydrocarbons via the AhR,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> PAIB-SOs, the prodrug form of PIB-SOs, might affect <i>CYP1A1</i> expression via a two-pronged mechanism. Thus, PAIB-SOs likely upregulate <i>CYP1A1</i> expression via the microtubule transport system and the AhR, a process that sustains itself via a self-amplified induction loop in the case of polycyclic aromatic hydrocarbons that interact with the AhR but are inactive toward the microtubule transport system.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> However, <i>CYP1A1</i> upregulation by PAIB-SOs is expected to be short-lived, unlike with other inducers, as it is allosterically inhibited by the direct inactivation of microtubules by PIB-SOs.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In turn, the retroinhibitory action of PIB-SOs on the <i>CYP1A1</i> induction loop initially afforded by PAIB-SOs progressively suppresses further release of PIB-SOs, thereby leading to an autoregulatory mechanism of action for the PAIB-SO prodrug.</div><div class="NLM_p">In vitro studies have shown that <i>CYP1A1</i> is a striking example of strictly ligand-dependent transcriptional control. Whereas <i>CYP1A1</i> expression is virtually negligible in cells unexposed to inducing agents, it is strikingly induced upon ligand-dependent activation of the AhR by a number of pollutants or pharmaceuticals.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Ligand-bound AhR is translocated to the nucleus via microtubules and other cytoskeletal elements,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> where it heterodimerizes with the aryl hydrocarbon nuclear translocator.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The latter heterodimer then interacts with xenobiotic DNA response elements present within the <i>CYP1A1</i> promoter, thereby activating <i>CYP1A1</i> transcription and expression. An intriguing hypothesis for the suppression of <i>CYP1A1</i> induction observed in MCF7 cells incubated with compound <b>67</b> for intervals >18 h might be an allosteric interference with AhR nuclear translocation by the steady release and accumulation of the active PIB-SO parent drug upon sustained <i>CYP1A1</i> induction due to disruption of the microtubule bundles.</div><div class="NLM_p">The cytocidal activity of PAIB-SOs was found to be independent from the hormone receptor status of target breast cancer cells. Our previous studies have also shown that PIB-SOs released upon CYP1A1 activation exhibit intact cytocidal activity in cancer cells resistant to colchicine, paclitaxel, and vinblastine or overexpressing the P-glycoprotein.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> These observations suggest that PAIB-SOs might be useful as a second-line breast cancer therapy after failure of endocrine therapy, or for the chemotherapy of the more aggressive triple-negative tumors, which have a poorer prognosis. In addition to their potential as a first-line therapy, PAIB-SOs might also be considered as an alternative strategy against tumors that have become resistant to current microtubule-disrupting drugs.</div><div class="NLM_p last">Thus, in contrast with prodrugs of alkylating agents,<a onclick="showRef(event, 'ref21 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref21 ref59 ref60">(21, 59, 60)</a> despite PAIB-SOs being potential ligands of the AhR, their action is self-limited by the AhR/microtubule-dependent system of <i>CYP1A1</i> induction by retroinhibition via an autoregulatory inactivation of the latter system. Therefore, as a new class of CYP1A1-dependent prodrugs, PAIB-SOs present the advantages of acting selectively in tissues displaying a basal level of CYP1A1 expression, and via the disruption of microtubules in a specific and self-contained manner. These features suggest that such drugs may offer especially attractive pharmacological properties due to the highly localized and selective character of their mechanism of action.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34350" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34350" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, we developed new and promising antimicrotubule prodrugs that are highly selective and cytocidal in the low nanomolar range toward several breast cancer cell lines representative of the cancer tumors diagnosed in clinic. Their mechanism of action is not dependent on the hormone receptor status and is based on their <i>N</i>-dealkylation by CYP1A1 into highly potent microtubule-disrupting agents. Moreover, PAIB-SO <b>67</b> showed also selectivity toward HT-1080 cells stably transfected with <i>CYP1A1</i> in the CAM assay, with only minimal toxicity toward chick embryos. PAIB-SOs thus represent a promising and innovative approach for a high-quality oncological new drug target for the treatments of breast cancers that become unresponsive to currently used chemotherapy. Finally, this work opens the door for the design of new antimitotic and antineoplastic prodrugs targeting CYP1A1 and is paving the way to the identification of other cancer tissues in which CYP1A1 is overexpressed or induced and the development of new prodrugs using this strategic approach.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54124" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54124" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Biological Methods and Cell Culture</h3><div class="NLM_p last">HT-29 human colon carcinoma, MCF7 human breast carcinoma, MDA-MB-231 human breast carcinoma, MDA-MB-468 human breast adenocarcinoma, T47D human breast ductal carcinoma, SK-BR-3 human breast adenocarcinoma, and HT-1080 human fibrosarcoma cells were purchased from the American Type Culture Collection (Manassas, VA). M21 human skin melanoma cells were kindly provided by Dr. David Cheresh (University of California, San Diego School of Medicine). All cell lines were maintained in DMEM containing NaHCO<sub>3</sub>, high glucose concentration, glutamine, phenol red (or not), and sodium pyruvate (Hyclone, Logan, UT) supplemented with 5% calf serum (Life Technologies). Cultures of HT-1080 cells stably transfected with CYP1A1 (HT-1080<sup><i>CYP1A1</i></sup>) were maintained in the presence of the selective agent (1% G418). All cells were grown at 37 °C in a 5% CO<sub>2</sub>, moisture-saturated atmosphere.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Antiproliferative Activity Assay</h3><div class="NLM_p last">The antiproliferative activity of PAIB-SOs was assessed using the procedure described by the National Cancer Institute for its drug screening program, with slight modifications.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The 96-well microtiter plates were seeded with 75 μL of tumor cell suspension (for HT-29, 5.0 × 10<sup>3</sup> cells; M21, 3.5 × 10<sup>3</sup> cells; MCF7, 7.5 × 10<sup>3</sup> cells; HT-1080, 3.0 × 10<sup>3</sup> cells; HT-1080<sup><i>CYP1A1</i></sup>, 3.0 × 10<sup>3</sup> cells; MDA-MB-231, 3.0 × 10<sup>3</sup> cells; MDA-MB-468, 5.0 × 10<sup>3</sup> cells; T47D, 3.0 × 10<sup>3</sup> cells; SK-BR-3, 3.0 × 10<sup>3</sup> cells) in the appropriate medium. Plates were incubated for 24 h. Drugs freshly solubilized in DMSO were added in fresh medium, and 75 μL aliquots containing a range of concentrations (from 0.75 to 1.0 × 10<sup>5</sup> nM) of the drug were then added to the plates and cells incubated for the indicated time period (48 or 72 h). Cells were then stained with sulforhodamine B to determine the number of viable cells. Briefly, cells were fixed by addition of cold trichloroacetic acid to the wells (10% (w/v) final concentration) for 30 min at 4 °C. Plates were washed five times with tap water and dried. Then 50 μL of a sulforhodamine B solution (0.1% (w/v) in 1% acetic acid) were added to each well, and the plates were incubated for 15 min at room temperature. Unbound dye was removed by washing the cell plates five times with 1% acetic acid. Bonded dye was solubilized in 10 mM Tris base, and the absorbance was then determined using a μQuant Universal microplate spectrophotometer (Biotek, Winooski, VT) using an optimal wavelength (530–565 nm), according to color intensity. Experiments were performed at least twice with triplicate cultures. The IC<sub>50</sub> assay was considered valid when the relative standard deviation was <10%.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Cell Cycle Progression</h3><div class="NLM_p last">After incubating MCF7, MDA-MB-468, and MDA-MB-231 cells (2.5 × 10<sup>5</sup>) with the drugs at a 1-, 2-, and 5-fold equivalent of the respective IC<sub>50</sub> value for 24 h, cells were trypsinized, washed with PBS, resuspended in 250 μL of PBS, fixed by the addition of 750 μL of ice-cold EtOH under agitation, and stored at −20 °C until analysis. Prior to FACS analysis, cells were washed with PBS and resuspended in 500 μL of PBS containing 2 μg/mL 4′,6′-diamidino-2-phenylindole (DAPI). Cell cycle distribution of fixed cell suspensions was analyzed using an LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Fluorescence Microscopy</h3><div class="NLM_p last">MDA-MB-468, MCF7, and MDA-MB-231 cells were seeded at 1 × 10<sup>5</sup> cells per well in six-well plates containing 22 μm glass coverslips coated with fibronectin (10 μg/mL) and incubated for 24 h. Tumor cells were incubated either with PAIB-SO <b>67</b> and its PIB-SO counterpart <b>1</b> at 2- and 5-fold equivalents of their respective IC<sub>50</sub> value or with (0.5% DMSO) for 24 h. Cells were then washed twice with PBS and fixed with 3.7% formaldehyde in PBS for 10 min. After two washes with PBS, the cells were permeabilized with saponin (0.1% in PBS) and blocked with 3% (w/v) BSA in PBS for 45 min at 37 °C. The cells were then incubated for 2 h at room temperature with an anti-β-tubulin monoclonal antibody (clone TUB 2.1, 1:200) in a solution containing 0.1% saponin and 3% BSA in PBS. The cells were washed twice with PBS containing 0.05% Tween 20 and nuclei were then stained using antimouse IgG Alexa Fluor 488 (Molecular Probes, Eugene, OR; 1:1000) and DAPI (1.25 ng/mL final concentration) in blocking buffer for 1 h at 37 °C. Cells were then mounted on a microscope slide overnight with slow fade reagent (DakoCytomation, Carpinteria, CA) before analysis under an Olympus BX51 microscope. Images were acquired as 8 bit-tagged image format files with a Q imaging RETIGA EXI digital camera using the Image Pro Express software.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Stable Transfection of CYP1A1 in HT-1080 Cells</h3><div class="NLM_p last">The pCMV6-AC_CYP1A1 and pCMV6-AC_Empty plasmids (Origene, Rockville, MD) were stably transfected in HT-1080 cells using the antibiotic G418 (Geneticin, Thermo Scientific, MA) as selection agent and Effectene (Qiagen) as transfection reagent. Briefly, HT-1080 cells were seeded (1 × 10<sup>6</sup>) in 100 mm dishes containing DMEM (plus 5% calf serum) and incubated for 24 h at 37 °C and 5% CO<sub>2</sub>. Cells were then transfected with 2000 ng of plasmid using Effectene according to the manufacturer’s protocol and incubated for 24 h. Culture media was then renewed and G418 added at 1000 μg/mL (optimal concentration determined experimentally) until cells were selected. Positive clones were harvested and stored at −180 °C until needed.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Western Blot Analysis of CYP1A1</h3><div class="NLM_p last">HT-1080, HT-1080<sup>empty</sup>, and HT-1080<sup><i>CYP1A1</i></sup> cells were washed in ice-cold PBS and harvested in Laemmli 1× buffer (4.6% SDS, 20% glycerol, 125 mM Tris pH 6.8, and 5% β-mercaptoethanol). The protein concentration was determined using the Lowry method.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Then 20 μg of total protein were subjected to electrophoresis in 10% bis(acrylamide) gels. Proteins were then transferred onto nitrocellulose membranes and incubated with 5% nonfat dry milk and TBST (TBS, pH 7.4 containing 0.1% Tween 20) for 1 h at room temperature, followed by the rabbit anti-CYP1A1 polyclonal antibody (sc-20772, Santa Cruz Biotechnology, CA) for 16 h at room temperature (1:500). Membranes were washed with TBST and incubated with peroxidase-conjugated immunoglobulins (1:5000) in TBST for 1 h at room temperature. After washing the membranes with TBST, immunoblotted proteins were detected using an enhanced chemiluminescence detection reagent kit. Anti-β-actin-HRP (1:10 000) (Santa Cruz Biotechnology, CA) was used to normalize the amount of protein per sample analyzed in each well.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Determination of the Relative Affinity of PAIB-SOs for CYP1A1</h3><div class="NLM_p last">The <i>K</i><sub>i</sub> value was determined using the ethoxyresorufin-<i>O</i>-deethylase (EROD) assay, which measures the inhibition of the conversion of 7-ethoxyresorufin (7-ER, Sigma-Aldrich, Oakville, ON, Canada) into fluorescent resorufin. Potassium phosphate buffer, human CYP1A1 supersomes containing reductase, and NADPH-regenerating system solutions A and B were supplied by Corning Discovery Labware (Mississauga, ON, Canada). Briefly, drugs and 7-ER freshly solubilized in DMSO were diluted in potassium phosphate buffer to final concentrations from 32 to 31600 nM and from 94 to 3000 nM for drugs and 7-ER, respectively. The final concentration of DMSO was kept constant at 0.35% (49 mM). Then, 50 μL of drug solution and 50 μL of 7-ER were added successively in 96-well microtiter plates and incubated at 37 °C for 5 min. The enzymatic reaction was next initiated by adding 50 μL of NADPH-regenerating system solution A (3%), NADPH regenerating system solution B (0.6%), and 0.15 pmol of CYP1A1 supersomes in a final volume of 150 μL. The enzymatic transformation of 7-ER into resorufin was monitored every minute for a 15 min interval at 37 °C using a Fluoroskan Ascent plate reader (LabSystems, ThermoFisher Scientific; λ<sub>exc</sub> = 544 nm, λ<sub>em</sub> = 590 nm). The initial velocity (<i>V</i><sub>0</sub>) was calculated for each condition using the linear portion of the curve (1–5 min). Then, the maximal velocity (<i>V</i><sub>max</sub>) of the reaction and the Michaelis–Menten constant (<i>K</i><sub>m</sub>) were calculated using a Lineweaver–Burk plot. The <i>K</i><sub>i</sub> value was derived from the Michaelis–Menten equation in the form:<span class="NLM_disp-formula" id="ueq1"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/jm-2017-00343u_m001.gif" alt="" /></img></span></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Oxidation of PAIB-SOs by Various CYPs</h3><div class="NLM_p last">Human supersomes CYP1A1, CYP1A2, CYP1B1, CYP3A4 (including B5), and human liver S9 fraction microsome pools from human liver donors (20 mg/mL) including NADPH CYP reductase, potassium phosphate (0.5 M), and NADPH-regenerating system solutions A and B, were supplied by BD Biosciences (Mississauga, ON, Canada). Briefly, drugs freshly solubilized at 10 mM in DMSO were further diluted to 1 mM in acetonitrile. Then, 710 μL of purified water, 200 μL of potassium phosphate buffer, 50 μL of NADPH-regenerating system solution A, 10 μL of NADPH-regenerating system solution B, and 10 μL of the substrate (in acetonitrile) were mixed and warmed to 37 °C for 5 min. The enzymatic reaction was next initiated by adding 20 μL of freshly thawed human supersomes (1 nmol/mL) to the mixture. At 0, 15, 30, 60, 120, and 240 min, 100 μL of the mixture were withdrawn, to which 100 μL of acetonitrile were added, and the sample was mixed and kept on ice until HPLC analysis. Samples removed at the end of the experimental period (240 min) were further analyzed by HPLC-MS using internal standards of PAIB-SOs and PIB-SOs. HPLC analysis was performed using a Prominence LCMS-2020 system with binary solvent equipped with a UV/visible photodiode array and an APCI probe (Shimadzu, Columbia, MD). All the MS spectra were recorded in positive ionization mode. All compounds were eluted within 25 min using an MeOH/H<sub>2</sub>O linear gradient (1.0 mL/min) on a Zorbax SB-C18 reversed-phase column (5 μm, 4.6 mm × 250 mm) equipped with a Zorbax XDB C18 precolumn (5 μm, 4 mm × 4 mm).</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Quantitative PCR Analysis of <i>CYP1A1</i> mRNA</h3><div class="NLM_p last">MCF-7 and MDA-MB-231 cells were treated with 10 nM of PAIB-SO <b>67</b>, and <i>CYP1A1</i> expression was determined at 18 and 24 h. Total RNA was extracted with TriReagent (Sigma) following the manufacturer’s instructions. Reverse transcription was performed with M-MuLV reverse transcriptase (NEB), random hexamers and oligo(dT). Four ng of cDNA were analyzed in quadruplicate for each data point using iTAQ Universal Sybr Green Supermix (BioRad). The following cycling program was performed using a CFX384 RealTimeSystem (BioRad): 95 °C for 30 s and 40 cycles at 95 °C for 5 s, followed by 60 °C for 30 s. Relative expression was determined with the 2<sup>–ΔΔ<i>Ct</i></sup> method,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> with <i>ACTB</i> and <i>B2M</i> as control genes for normalization. The primers used were: (ACTB), F-TCAAGATCATTGCTCCTCCTGAG and R-ACATCTGCTGGAAGGTGGAGA; (B2M), F-ACTGAATTCACCCCCACTGA and R-CCTCCATGATGCTGCTTACA; and (CYP1A1), F-CCCAACCCTTCCCTGAATG and R-TTCTCCTGACAGTGCTCAATC.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> CAM Tumor Assay</h3><div class="NLM_p last">CYP1A1-transfected (HT-1080<sup><i>CYP1A1</i></sup>) and wild-type human HT-1080 fibrosarcoma cells were used to assess the antitumor activity of PAIB-SO <b>67</b> and <b>1</b> in the CAM assay. Briefly, fertilized chicken eggs purchased from Couvoirs Victoriaville (Victoriaville, QC, Canada) were incubated for 10 d in a Pro-FI egg incubator (Lyon Electric, Chula Vista, San Diego, CA) fitted with an automatic egg turner before being transferred to a Roll-X static incubator for the rest of the incubation time. The eggs were kept at 37 °C in a 60% relative humidity atmosphere for the entire incubation period. On day 10, using a hobby drill (Dremel, Racine, WI), a hole was drilled on the side of the egg and a negative pressure was applied to create a new air sac. A window was opened on this new air sac and was covered with transparent adhesive tape to prevent contamination. A freshly prepared suspension (40 μL) of HT-1080 human fibrosarcoma or HT-1080<sup><i>CYP1A1</i></sup> (3.5 × 10<sup>5</sup> cells/egg) cells was applied directly onto the freshly exposed CAM tissue through the window. On day 11, the drugs dissolved in DMSO (40 mM) were extemporaneously diluted in the excipient (cremophor/99% EtOH/PBS, 6.25/6.25/87.5 v/v). The concentration of DMSO in the excipient was kept below 0.5% to minimize toxicity and osmotic stress. The drug dissolved in 100 μL of excipient was injected intravenously into 10<b>-</b>12 eggs. The eggs were incubated until day 17, at which time the embryos were euthanized at 4 °C, followed by decapitation. Tumors were collected, and the tumor wet weight was recorded. Drugs were assessed twice in two independent experiments (total of 20–24 eggs). The number of dead embryos and signs of toxicity from the different groups were recorded.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Chemical Procedures</h3><div class="NLM_p last">Proton NMR spectra were recorded on a Bruker AM-300 spectrometer (Bruker, Germany). Chemical shifts (δ) are reported in parts per million. IR spectra were recorded on a Magna FT-IR spectrometer (Nicolet Instrument Corporation, Madison, WI). Uncorrected melting points were determined using an Electrothermal melting point apparatus. HPLC analysis was performed using a Prominence LCMS-2020 system with binary solvent equipped with a UV/visible photodiode array and an APCI probe (Shimadzu, Columbia, MD). All the MS spectra were recorded in positive ionization mode. Compounds were eluted within 10 min on an Alltech Alltima C18 reversed-phase column (5 μm, 250 mm × 4.6 mm) equipped with an Alltech Alltima C18 precolumn (5 μm, 7.5 mm × 4.6 mm) with an MeOH/H<sub>2</sub>O linear gradient (1.0 mL/min). The purity of the final compounds synthesized was >95%. All reactions were performed under a dried Ar atmosphere. All chemicals were supplied by Aldrich Chemicals (Milwaukee, WI) or VWR International (Mont-Royal, QC, Canada) and used as received unless specified otherwise. Liquid flash chromatography was performed on silica gel F60 (60 Å, 40<b>-</b>63 μm) supplied by Silicycle (Québec, Canada) using an FPX flash purification system (Biotage, Charlottesville, VA) and the indicated solvent mixture (expressed as v/v ratios). Solvents and reagents were used without prior purification unless specified otherwise. The progress of all reactions was monitored by TLC using precoated 60 F254 silica gel plates (VWR International). The chromatograms were viewed under UV light at 254 and/or 275 nm.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Preparation of Compounds <b>6</b>–<b>68</b></h3><div class="NLM_p">The appropriate sulfonyl chloride derivative (8.00 mmol, compounds <b>73</b>–<b>76</b>) was suspended in dry CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and the selected phenol (8.00 mmol) and then triethylamine (8.00 mmol) were successively added dropwise. The mixture was stirred at room temperature for 48 h and then acidified with 1 N HCl (10 mL) and extracted three times with CH<sub>2</sub>Cl<sub>2</sub> (10 mL). The combined CH<sub>2</sub>Cl<sub>2</sub> extracts were washed successively with 1 N NaOH (20 mL) and brine (20 mL), dried over sodium sulfate, filtered, and the filtrate dried under vacuum. The residue was purified by flash chromatography on silica gel.</div><div id="sec5_12_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 2-Tolyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>6</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 93%; white solid; mp 157–158 °C. IR ν: 2928 (Ar), 1701 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.74–7.66 (m, 4H, Ar), 7.12–7.07 (m, 3H, Ar), 6.98–6.95 (m, 1H, Ar), 3.82–3.77 (m, 2H, CH<sub>2</sub>), 3.53–3.48 (m, 2H, CH<sub>2</sub>), 2.89 (s, 3H, CH<sub>3</sub>), 2.05 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.1, 148.4, 145.8, 131.6, 129.5, 127.7, 126.9, 126.9, 122.3, 116.1, 43.5, 42.0, 31.0, 16.3. MS (APSI+) <i>m</i>/<i>z</i> found 347.1; C<sub>17</sub>H<sub>19</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 347.1.</div></div><div id="sec5_12_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 2-Ethylphenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>7</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 92%; white solid; mp 126–128 °C. IR ν: 2878 (Ar), 1703 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.76–7.67 (m, 4H, Ar), 7.19–7.05 (m, 3H, Ar), 6.98–6.96 (m, 1H, Ar), 3.81–3.76 (m, 2H, CH<sub>2</sub>), 3.52–3.47 (m, 2H, CH<sub>2</sub>), 2.88 (s, 3H, CH<sub>3</sub>), 2.48 (q, 2H, <i>J</i> = 7.6 Hz, CH<sub>2</sub>), 1.08 (t, 3H, <i>J</i> = 7.6 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.1, 147.9, 145.8, 137.3, 129.8, 129.5, 127.8, 127.1, 126.8, 122.1, 116.1, 43.5, 42.0, 31.0, 22.8, 14.1. MS (APSI+) <i>m</i>/<i>z</i> found 361.1; C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 361.1.</div></div><div id="sec5_12_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-Methoxyphenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>8</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 61%; white solid; mp 134–136 °C. IR ν: 2897 (Ar), 1707 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.76–7.63 (m, 4H, Ar), 7.19–7.09 (m, 2H, Ar), 6.87–6.79 (m, 2H, Ar), 3.82–3.77 (m, 2H, CH<sub>2</sub>), 3.54–3.48 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 2,89 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.1, 151.8, 145.6, 138.5, 129.7, 128.0, 127.9, 124.0, 120.6, 115.8, 112.7, 55.6, 43.6, 42.0, 31.0. MS (APSI+) <i>m</i>/<i>z</i> found 363.1; C<sub>17</sub>H<sub>19</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 363.1.</div></div><div id="sec5_12_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 2,4-Dimethylphenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>9</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 51%; white solid; mp 159–161 °C. IR ν: 2899 (Ar), 1706 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.72–7.64 (m, 4H, Ar), 6.90–6.79 (m, 3H, Ar), 3.81–3.76 (m, 2H, CH<sub>2</sub>), 3.52–3.46 (m, 2H, CH<sub>2</sub>), 2.87 (s, 3H, CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 1.99 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.1, 146.2, 145.8, 136.7, 132.2, 131.1, 129.5, 127.7, 127.4, 122.0, 116.1, 43.5, 42.0, 30.9, 20.8, 16.2. MS (APSI+) <i>m</i>/<i>z</i> found 361.1; C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 361.1.</div></div><div id="sec5_12_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2,4,5-Trichlorophenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>10</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 84%; white solid; mp 181–183 °C. IR ν: 2937 (Ar), 1711 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub> and MeOD): δ 7.76–7.65 (m, 4H, Ar), 7.41–7.38 (m, 2H, Ar), 3.84–3.78 (m, 2H, CH<sub>2</sub>), 3.53–3.48 (m, 2H, CH<sub>2</sub>), 2.86 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub> and MeOD): δ 157.1, 146.3, 144.2, 131.6, 131.5, 131.3, 129.9, 126.8, 126.4, 125.7, 116.3, 43.5, 42.0, 30.8. MS (APSI+) <i>m</i>/<i>z</i> found 435.0; C<sub>16</sub>H<sub>14</sub>Cl<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 435.0.</div></div><div id="sec5_12_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2,4,6-Trichlorophenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>11</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 73%; white solid; mp 185–187 °C. IR ν: 3707 (Ar), 1715 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub> and MeOD): δ 7.83–7.80 (m, 2H, Ar), 7.68–7.65 (m, 2H, Ar), 7.26 (s, 2H, Ar), 3.82–3.77 (m, 2H, CH<sub>2</sub>), 3.51–3.46 (m, 2H, CH<sub>2</sub>), 2.83 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub> and MeOD): δ 157.2, 146.1, 142.3, 132.7, 130.8, 129.7, 129.1, 128.3, 116.2, 43.5, 42.0, 30.8. MS (APSI+) <i>m</i>/<i>z</i> found 435.0; C<sub>16</sub>H<sub>14</sub>Cl<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 435.0.</div></div><div id="sec5_12_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3-Tolyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>12</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 99%; white solid; mp 123–125 °C. IR ν: 2926 (Ar), 1694 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71–7.64 (m, 4H, Ar), 7.12–6.99 (m, 2H, Ar), 6.82 (s, 1H, Ar), 6.69–6.67 (m, 1H, Ar), 3.80–3.75 (m, 2H, CH<sub>2</sub>), 3.51–3.46 (m, 2H, CH<sub>2</sub>), 2.87 (s, 3H, CH<sub>3</sub>), 2.25 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.1, 149.6, 145.8, 140.0, 129.6, 129.2, 127.8, 127.1, 123.0, 119.1, 116.0, 43.5, 41.9, 31.0, 21.2. MS (APSI+) <i>m</i>/<i>z</i> found 347.1; C<sub>17</sub>H<sub>19</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 347.1.</div></div><div id="sec5_12_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-Methoxyphenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>13</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 92%; white solid; mp 111–113 °C. IR ν: 2897 (Ar), 1713 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71–7.63 (m, 4H, Ar), 7.13–7.08 (m, 1H, Ar), 6.75–6.71 (m, 1H, Ar), 6.54–6.48 (m, 2H, Ar), 3.78–3.74 (m, 2H, CH<sub>2</sub>), 3.67 (s, 3H, CH<sub>3</sub>), 3.51–3.45 (m, 2H, CH<sub>2</sub>), 2.87 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 160.4, 157.0, 150.5, 145.9, 129.9, 129.6, 126.9, 116.1, 114.3, 112.9, 108.4, 55.5, 43.5, 41.9, 31.0. MS (APSI+) <i>m</i>/<i>z</i> found, 363.1; C<sub>17</sub>H<sub>19</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 363.1.</div></div><div id="sec5_12_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 3-Fluorophenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>14</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 99%; white solid; mp 175–177 °C. IR ν: 2902 (Ar), 1697 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub> and MeOD): δ 7.65–7.58 (m, 4H, Ar), 7.18–7.11 (m, 1H, Ar), 6.89–6.83 (m, 1H, Ar), 6.68–6.64 (m, 2H, Ar), 3.79–3.74 (m, 2H, CH<sub>2</sub>), 3.49–3.44 (m, 2H, CH<sub>2</sub>), 2.81 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub> and MeOD): δ 164.2, 160.9, 157.3, 150.2, 150.0, 145.9, 130.4, 130.3, 129.6, 126.5, 118.1, 118.1, 116.2, 114.3, 114.1, 110.5, 110.2, 43.5, 42.0, 30.7. MS (APSI+) <i>m</i>/<i>z</i> found 351.1; C<sub>16</sub>H<sub>16</sub>FN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 351.1.</div></div><div id="sec5_12_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 3-Chlorophenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>15</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 81%; white solid; mp 105–106 °C. IR ν: 2900 (Ar), 1705 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.67 (s, 4H, Ar), 7.19–7.15 (m, 2H, Ar), 7.02 (s, 1H, Ar), 6.83–6.79 (m, 1H, Ar), 3.81–3.75 (m, 2H, CH<sub>2</sub>), 3.52–3.47 (m, 2H, CH<sub>2</sub>), 2.87 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.0, 150.0, 146.1, 134.8, 130.4, 129.6, 127.4, 126.3, 123.0, 120.7, 116.1, 43.5, 41.9, 31.0. MS (APSI+) <i>m</i>/<i>z</i> found, 367.1; C<sub>16</sub>H<sub>16</sub>ClN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 367.1.</div></div><div id="sec5_12_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 3-Bromophenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>16</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 70%; white solid; mp 102–104 °C. IR ν: 2892 (Ar), 1706 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.74–7.67 (m, 4H, Ar), 7.37–7.34 (m, 1H, Ar), 7.20–7.10 (m, 2H, Ar), 6.90–6.87 (m, 1H, Ar), 3.85–3.80 (m, 2H, CH<sub>2</sub>), 3.55–3.50 (m, 2H, CH<sub>2</sub>), 2.91 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.0, 150.0, 146.0, 130.6, 130.3, 129.7, 126.5, 125.9, 122.4, 121.2, 116.2, 43.5, 42.0, 31.0. MS (APSI+) <i>m</i>/<i>z</i> found, 411.1; C<sub>16</sub>H<sub>16</sub>BrN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 411.0.</div></div><div id="sec5_12_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 3-Iodophenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>17</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 72%; white solid; mp 118–120 °C. IR ν: 2892 (Ar), 1688 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.70 (s, 4H, Ar), 7.56–7.53 (m, 1H, Ar), 7.37 (s, 1H, Ar), 7.00–6.88 (m, 2H, Ar), 3.84–3.79 (m, 2H, CH<sub>2</sub>), 3.55–3.50 (m, 2H, CH<sub>2</sub>), 2.90 (m, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.0, 149.7, 146.1, 136.2, 131.6, 130.9, 129.7, 126.5, 121.8, 116.2, 93.5, 43.5, 42.0, 31.0. MS (APSI+) <i>m</i>/<i>z</i> found, 459.0; C<sub>16</sub>H<sub>16</sub>IN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 459.0.</div></div><div id="sec5_12_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 3-Nitrophenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>18</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 82%; white solid; mp 167–169 °C. IR ν: 2901 (Ar), 1699 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub> and MeOD): δ 8.04–8.02 (m, 1H, Ar), 7.74–7.73 (m, 1H, Ar), 7.68–7.61 (m, 4H, Ar), 7.45–7.39 (m, 1H, Ar), 7.30–7.26 (m, 1H, Ar), 3.81–3.75 (m, 2H, CH<sub>2</sub>), 3.51–3.45 (m, 2H, CH<sub>2</sub>), 2.82 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub> and MeOD): δ 157.2, 149.7, 148.6, 146.2, 130.4, 129.6, 128.7, 125.9, 121.9, 117.9, 116.4, 43.4, 42.0, 30.7. MS (APSI+) <i>m</i>/<i>z</i> found, 378.1; C<sub>16</sub>H<sub>16</sub>N<sub>3</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 378.1.</div></div><div id="sec5_12_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 3,4-Dimethoxyphenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>19</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 68%; white solid; mp 158–160 °C. IR ν: 2936 (Ar), 1707 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71–7.64 (m, 4H, Ar), 6.67–6.64 (m, 1H, Ar), 6.53–6.53 (m, 1H, Ar), 6.44–6.40 (m, 1H, Ar), 3.82- 3.77 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 3.72 (s, 3H, CH<sub>3</sub>), 3.53–3.48 (m, 2H, CH<sub>2</sub>), 2.89 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.1, 149.3, 147.8, 145.8, 143.2, 129.8, 126.9, 116.0, 113.9, 110.8, 106.6, 56.1, 43.5, 42.0, 31.0. MS (APSI+) <i>m</i>/<i>z</i> found, 393.1; C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 393.1.</div></div><div id="sec5_12_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 3,5-Dimethoxyphenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>20</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 54%; white solid; mp 97–99 °C. IR ν: 2905 (Ar), 1705 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.77–7.67 (m, 4H, Ar), 6.29 (s, 1H, Ar), 6.15–6.14 (m, 2H, Ar), 3.83–3.77 (m, 2H, CH<sub>2</sub>), 3.67 (s, 6H, 2 × CH<sub>3</sub>), 3.54–3.49 (m, 2H, CH<sub>2</sub>), 2.90 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 161.0, 157.1, 151.1, 145.8, 129.7, 127.1, 116.1, 100.8, 99.3, 55.5, 43.6, 42.0, 31.0. MS (APSI+) <i>m</i>/<i>z</i> found, 393.1; C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 393.1.</div></div><div id="sec5_12_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 3,4,5-Trimethoxyphenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>21</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 87%; white solid; mp 160–162 °C. IR ν: 2938 (Ar), 1712 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.74–7.66 (m, 4H, Ar), 6.18 (s, 2H, Ar), 3.81–3.76 (m, 2H, CH<sub>2</sub>), 3.75 (s, 3H, CH<sub>3</sub>), 3.67 (s, 6H, 2 × CH<sub>3</sub>), 3.53–3.47 (m, 2H, CH<sub>2</sub>), 2.88 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.0, 153.3, 145.9, 145.5, 136.8, 129.8, 126.9, 116.1, 100.0, 60.9, 56.2, 43.5, 42.0, 31.0. MS (APSI+) <i>m</i>/<i>z</i> found 423.2; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>7</sub>S (M<sup>+</sup> + H) expected, 423.1.</div></div><div id="sec5_12_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 4-Tolyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>22</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 93%; white solid; mp 155–157 °C. IR ν: 2896 (Ar), 1709 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.65 (s, 4H, Ar), 7.00 (d, 2H, <i>J</i> = 8.3 Hz, Ar), 6.79 (d, 2H, <i>J</i> = 8.3 Hz, Ar), 3.78–3.73 (m, 2H, CH<sub>2</sub>), 3.50–3.45 (m, 2H, CH<sub>2</sub>), 2.86 (s, 3H, CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.1, 147.5, 145.8, 136.9, 130.1, 129.6, 126.9, 122.1, 116.0, 43.5, 41.9, 30.9, 20.9. MS (APSI+) <i>m</i>/<i>z</i> found 347.1; C<sub>17</sub>H<sub>19</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 347.1.</div></div><div id="sec5_12_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 4-Methoxyphenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>23</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 80%; white solid; mp 183–185 °C. IR ν: 2919 (Ar), 1706 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub> and MeOD): δ 7.69–7.62 (m, 4H, Ar), 6.84–6.80 (m, 2H, Ar), 6.74–6.70 (m, 2H, Ar), 3.84–3.78 (m, 2H, CH<sub>2</sub>), 3.72 (s, 3H, CH<sub>3</sub>), 3.54–3.48 (m, 2H, CH<sub>2</sub>), 2.88 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub> and MeOD): δ 158.1, 157.3, 145.6, 143.1, 129.7, 127.0, 123.4, 116.1, 114.5, 55.5, 43.6, 42.0, 30.9. MS (APSI+) <i>m</i>/<i>z</i> found 363.1; C<sub>17</sub>H<sub>19</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 363.1.</div></div><div id="sec5_12_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 4-Fluorophenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>24</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 89%; white solid; mp 170–172 °C. IR ν: 2918 (Ar), 1702 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub> and MeOD): δ 7.63 (s, 4H, Ar), 6.92–6.87 (m, 4H, Ar), 3.81–3.76 (m, 2H, CH<sub>2</sub>), 3.52–3.46 (m, 2H, CH<sub>2</sub>), 2.85 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub> and MeOD): δ 162.6, 159.3, 157.2, 145.9, 145.4, 145.4, 129.6, 126.4, 124.1, 124.0, 116.4, 116.2, 116.1, 43.5, 42.0, 30.8. MS (APSI+) <i>m</i>/<i>z</i> found, 351.1; C<sub>16</sub>H<sub>16</sub>FN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 351.1.</div></div><div id="sec5_12_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-Chlorophenyl 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>25</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 92%; white solid; mp 165–168 °C. IR ν: 2901 (Ar), 1705 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub> and MeOD): δ 7.64 (s, 4H, Ar), 7.19–7.15 (m, 2H, Ar), 6.86–6.83 (m, 2H, Ar), 3.80–3.75 (m, 2H, CH<sub>2</sub>), 3.51–3.46 (m, 2H, CH<sub>2</sub>), 2.85 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub> and MeOD): δ 157.2, 148.0, 145.9, 132.7, 129.7, 129.6, 126.4, 123.8, 116.2, 43.5, 42.0, 30.9. MS (APSI+) <i>m</i>/<i>z</i> found, 367.1; C<sub>16</sub>H<sub>16</sub>ClN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 367.1.</div></div><div id="sec5_12_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 2-Methoxyphenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>26</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 57%; white solid; mp 131–134 °C. IR ν: 2846 (Ar), 1696 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.76–7.64 (m, 4H, Ar), 7.18–7.09 (m, 2H, Ar), 6.87–6.79 (m, 2H, Ar), 3.84–3.79 (m, 2H, CH<sub>2</sub>), 3.55–3.50 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 3.36 (q, 2H, <i>J</i> = 7.2 Hz, CH<sub>2</sub>), 1.17 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.7, 151.9, 145.6, 138.5, 129.8, 128.0, 127.9, 124.0, 120.6, 115.9, 112.8, 55.7, 42.1, 40.7, 38.6, 12.5. MS (APSI+) <i>m</i>/<i>z</i> found, 377.1; C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 377.1.</div></div><div id="sec5_12_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 3-Methoxyphenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>27</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 32%; white solid; mp 95–97 °C. IR ν: 2981 (Ar), 1694 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.76–7.67 (m, 4H, Ar), 7.16–7.11 (m, 1H, Ar), 6.78–6.74 (m, 1H, Ar), 6.58–6.50 (m, 2H, Ar), 3.86–3.81 (m, 2H, CH<sub>2</sub>), 3.72 (s, 3H, CH<sub>3</sub>), 3.56–3.41 (m, 2H, CH<sub>2</sub>), 3.37 (q, 2H, <i>J</i> = 7.3 Hz, CH<sub>2</sub>), 1.18 (t, 3H, J ═ 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 160.4, 156.6, 150.6, 145.8, 129.9, 129.7, 127.1, 116.1, 114.3, 113.0, 108.4, 55.5, 42.1, 40.7, 38.6, 12.5. MS (APSI+) <i>m</i>/<i>z</i> found, 377.1; C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 377.1.</div></div><div id="sec5_12_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-Fluorophenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>28</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 80%; white solid; mp 112–114 °C. IR ν: 2874 (Ar), 1693 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.75–7.69 (m, 4H, Ar), 7.27–7.19 (m, 1H, Ar), 6.98–6.92 (m, 1H, Ar), 6.79–6.73 (m, 2H, Ar), 3.88–3.82 (m, 2H, CH<sub>2</sub>), 3.58–3.53 (m, 2H, CH<sub>2</sub>), 3.38 (q, 2H, <i>J</i> = 7.2 Hz, CH<sub>2</sub>), 1.19 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 164.3, 161.0, 156.5, 150.2, 146.1, 130.4, 130.3, 129.7, 126.6, 118.3, 118.2, 116.2, 114.4, 114.1, 110.7, 110.4, 42.1, 40.7, 38.6, 12.5. MS (APSI+) <i>m</i>/<i>z</i> found, 365.1; C<sub>17</sub>H<sub>18</sub>FN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 365.1.</div></div><div id="sec5_12_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 3-Chlorophenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>29</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 66%; white solid; mp 73–75 °C. IR ν: 2975 (Ar), 1693 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.76–7.70 (m, 4H, Ar), 7.24–7.16 (m, 2H, Ar), 7.05 (s, 1H, Ar), 6.88–6.84 (m, 1H, Ar), 3.88–3.82 (m, 2H, CH<sub>2</sub>), 3.58–3.53 (m, 2H, CH<sub>2</sub>), 3.38 (q, 2H, <i>J</i> = 7.3 Hz, CH<sub>2</sub>), 1.19 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.6, 150.0, 146.1, 134.8, 130.3, 129.7, 127.4, 126.6, 123.1, 120.7, 116.2, 42.1, 40.7, 38.6, 12.5. MS (APSI+) <i>m</i>/<i>z</i> found 381.1; C<sub>17</sub>H<sub>18</sub>ClN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 381.1.</div></div><div id="sec5_12_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-Bromophenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>30</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 69%; white solid; mp 81–83 °C. IR ν: 2964 (Ar), 1710 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.75−7.68 (m, 4H, Ar), 7.37–7.35 (m, 1H, Ar), 7.20–7.10, (m, 2H, Ar), 6.90–6.87 (m, 1H, Ar), 3.86–3.81 (m, 2H, CH<sub>2</sub>), 3.57–3.52 (m, 2H, CH<sub>2</sub>), 3.37 (q, 2H, <i>J</i> = 7.3 Hz, CH<sub>2</sub>), 1.18 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.5, 150.0, 146.1, 130.6, 130.3, 129.7, 126.5, 125.9, 122.4, 121.2, 116.2, 42.1, 40.7, 38.6, 12.5. MS (APSI+) <i>m</i>/<i>z</i> found, 425.0; C<sub>17</sub>H<sub>18</sub>BrN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 425.0.</div></div><div id="sec5_12_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-Iodophenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>31</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 64%; white sticky solid. IR ν: 2926 (Ar), 1702 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.76–7.69 (m, 4H, Ar), 7.58–7.55 (m, 1H, Ar), 7.40–7.39 (m, 1H, Ar), 7.02–6.91 (m, 2H, Ar), 3.88–3.83 (m, 2H, CH<sub>2</sub>), 3.58–3.53 (m, 2H, CH<sub>2</sub>), 3.38 (q, 2H, <i>J</i> = 7.2 Hz, CH<sub>2</sub>), 1.19 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.5, 149.8, 146.1, 136.2, 131.6, 130.8, 129.7, 126.6, 121.8, 116.2, 93.5, 42.1, 40.7, 38.6, 12.5. MS (APSI+) <i>m</i>/<i>z</i> found, 473.0; C<sub>17</sub>H<sub>18</sub>IN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 473.0.</div></div><div id="sec5_12_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 3,4-Dimethoxyphenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>32</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 70%; white solid; mp 116–118 °C. IR ν: 2968 (Ar), 1703 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71–7.64 (m, 4H, Ar), 6.66–6.63 (m, 1H, Ar), 6.54–6.53 (m, 1H, Ar), 6.43–6.39 (m, 1H, Ar), 3.83–3.78 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 3.72 (s, 3H, CH<sub>3</sub>), 3.54–3.49 (m, 2H, CH<sub>2</sub>), 3.35 (q, 2H, <i>J</i> = 7.3 Hz, CH<sub>2</sub>), 1.15 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.6, 149.3, 147.8, 145.8, 143.2, 129.7, 126.8, 116.1, 113.9, 110.8, 106.6, 56.1, 42.1, 40.7, 38.5, 12.5. MS (APSI+) <i>m</i>/<i>z</i> found, 407.2; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 407.1.</div></div><div id="sec5_12_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 3,5-Dimethoxyphenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>33</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 72%; white solid; mp 132–134 °C. IR ν: 2965 (Ar), 1701 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.77–7.67 (m, 4H, Ar), 6.30–629 (m, 1H, Ar), 6.15–6.14 (m, 2H, Ar), 3.84–3.79 (m, 2H, CH<sub>2</sub>), 3.67 (s, 6H, 2 × CH<sub>3</sub>), 3.55–3.50 (m, 2H, CH<sub>2</sub>), 3.36 (q, 2H, <i>J</i> = 7.2 Hz, CH<sub>2</sub>), 1.17 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 161.0, 156.6, 151.1, 145.9, 129.7, 126.9, 116.1, 100.8, 99.2, 55.5, 42.1, 40.7, 38.5, 12.5. MS (APSI+) <i>m</i>/<i>z</i> found, 407.1; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 407.1.</div></div><div id="sec5_12_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 3,4,5-Trimethoxyphenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>34</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 73%; white solid; mp 139–141 °C. IR ν: 2937 (Ar), 1707 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.73–7.65 (m, 4H, Ar), 6.18 (s, 2H, Ar), 3.81–3.74 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 3.66 (s, 6H, 2 × CH<sub>3</sub>), 3.53–3.48 (m, 2H, CH<sub>2</sub>), 3.33 (q, 2H, <i>J</i> = 7.2 Hz, CH<sub>2</sub>), 1.14 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.5, 153.3, 145.9, 145.6, 136.8, 129.7, 126.8, 116.1, 100.0, 60.9, 56.2, 42.1, 40.6, 38.5, 12.5. MS (APSI+) <i>m</i>/<i>z</i> found 437.2; C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>7</sub>S (M<sup>+</sup> + H) expected, 437.1.</div></div><div id="sec5_12_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 4-Methoxyphenyl 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>35</b>)</h4><div class="NLM_p last">Flash chromatography (hexanes to hexanes/EtOAc (5:5)). Yield, 78%; white solid; mp 138–140 °C. IR ν: 2972 (Ar), 1702 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub> and MeOD): δ 7.61–7.58 (m, 4H, Ar), 6.80–6.77 (m, 2H, Ar), 6.70–6.66 (m, 2H, Ar), 3.81–3.75 (m, 2H, CH<sub>2</sub>), 3.67 (s, 3H, CH<sub>3</sub>), 3.51–3.46 (m, 2H, CH<sub>2</sub>), 3.29 (q, 2H, <i>J</i> = 7.2 Hz, CH<sub>2</sub>), 1.11 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub> and MeOD): δ 158.1, 156.8, 145.7, 143.0, 129.6, 126.7, 123.3, 116.2, 114.4, 55.5, 42.1, 40.7, 38.5, 12.3. MS (APSI+) <i>m</i>/<i>z</i> found, 377.1; C<sub>18</sub>H<sub>21</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 377.1.</div></div><div id="sec5_12_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-Tolyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>36</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 86%; white solid; mp 139–141 °C. IR ν: 2968 (Ar), 1698 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.73–7.66 (m, 4H, Ar), 7.11–7.04 (m, 3H, Ar), 6.96–6.93 (m, 1H, Ar), 3.83–3.78 (m, 2H, CH<sub>2</sub>), 3.53–3.48 (m, 2H, CH<sub>2</sub>), 3.27–3.22 (m, 2H, CH<sub>2</sub>), 2.05 (s, 3H, CH<sub>3</sub>), 1.63–1.51 (m, 2H, CH<sub>2</sub>), 0.92 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.9, 148.4, 145.9, 131.6, 129.5, 127.6, 126.9, 126.9, 122.3, 116.1, 45.6, 42.1, 41.3, 20.6, 16.3, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 375.2; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 375.1.</div></div><div id="sec5_12_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-Ethylphenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>37</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 86%; white solid; mp 103–105 °C. IR ν: 2970 (Ar), 1697 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.74–7.66 (m, 4H, Ar), 7.18–7.04 (m, 3H, Ar), 6.97–6.94 (m, 1H, Ar), 3.82–3.76 (m, 2H, CH<sub>2</sub>), 3.52–3.47 (m, 2H, CH<sub>2</sub>), 3.26–3.21 (m, 2H, CH<sub>2</sub>), 2.48 (q, 2H, <i>J</i> = 7.5 Hz, CH<sub>2</sub>), 1.60–1.53 (m, 2H, CH<sub>2</sub>), 1.08 (t, 3H, <i>J</i> = 7.5 Hz, CH<sub>3</sub>), 0.92 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.9, 147.9, 145.9, 137.3, 129.8, 129.4, 127.6, 127.1, 126.8, 122.0, 116.2, 45.6, 42.1, 41.3, 22.8, 20.6, 14.1, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 389.2; C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 389.2.</div></div><div id="sec5_12_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 2-Methoxyphenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>38</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 81%; white solid; mp 136–138 °C. IR ν: 2965 (Ar), 1697 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.75–7.64 (m, 4H, Ar), 7.18–7.08 (m, 2H, Ar), 6.87–6.79 (m, 2H, Ar), 3.84–3.79 (m, 2H, CH<sub>2</sub>), 3.55–3.49 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 3.27–3.23 (m, 2H, CH<sub>2</sub>), 1.64–1.52 (m, 2H, CH<sub>2</sub>), 0.93 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.9, 151.9, 145.7, 138.5, 129.7, 128.0, 127.8, 124.0, 120.6, 115.9, 112.8, 55.7, 45.6, 42.1, 41.3, 20.6, 11.3. MS (APSI+) <i>m</i>/<i>z</i> found, 391.1; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 391.1.</div></div><div id="sec5_12_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2,4-Dimethylphenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>39</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 86%; white solid; mp 85–87 °C. IR ν: 2930 (Ar), 1699 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.75–7.67 (m, 4H, Ar), 6.92–6.80 (m, 3H, Ar), 3.85–3.80 (m, 2H, CH<sub>2</sub>), 3.55–3.49 (m, 2H, CH<sub>2</sub>), 3.29–3.24 (m, 2H, CH<sub>2</sub>), 2.25 (s, 3H, CH<sub>3</sub>), 2.02 (s, 3H, CH<sub>3</sub>), 1.65–1.53 (m, 2H, CH<sub>2</sub>), 0.94 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.9, 146.2, 145.8, 136.7, 132.2, 131.1, 129.5, 127.8, 127.4, 122.0, 116.1, 45.6, 42.1, 41.3, 20.8, 20.6, 16.3, 11.3. MS (APSI+) <i>m</i>/<i>z</i> found, 389.2; C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 389.2.</div></div><div id="sec5_12_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 2,4,5-Trichlorophenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>40</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 87%; white solid; mp 125–127 °C. IR ν: 2932 (Ar), 1699 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.79–7.70 (m, 4H, Ar), 7.45 (s, 1H, Ar), 7.41 (s, 1H, Ar), 3.87–3.81 (m, 2H, CH<sub>2</sub>), 3.56–3.51 (m, 2H, CH<sub>2</sub>), 3.29–3.24 (m, 2H, CH<sub>2</sub>), 1.65–1.52 (m, 2H, CH<sub>2</sub>), 0.93 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.7, 146.5, 144.3, 131.6, 131.5, 131.3, 129.9, 126.8, 126.2, 125.7, 116.2, 45.6, 42.1, 41.3, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 463.0; C<sub>18</sub>H<sub>18</sub>Cl<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 463.0.</div></div><div id="sec5_12_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2,4,6-Trichlorophenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>41</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 73%; white solid; mp 109–111 °C. IR ν: 2929 (Ar), 1700 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.88–7.85 (m, 2H, Ar), 7.75–7.72 (m, 2H, Ar), 7.30 (s, 2H, Ar), 3.87–3.82 (m, 2H, CH<sub>2</sub>), 3.55–3.50 (m, 2H, CH<sub>2</sub>), 3.28–3.23 (m, 2H, CH<sub>2</sub>), 1.64–1.52 (m, 2H, CH<sub>2</sub>), 0.93 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 146.4, 142.4, 132.7, 130.9, 129.8, 129.1, 128.2, 116.1, 45.6, 42.1, 41.3, 20.6, 11.3. MS (APSI+) <i>m</i>/<i>z</i> found, 463.1; C<sub>18</sub>H<sub>18</sub>Cl<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 463.0.</div></div><div id="sec5_12_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 3-Tolyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>42</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 77%; white solid; mp 76–78 °C. IR ν: 2932 (Ar), 1700 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71–7.68 (m, 4H, Ar), 7.12–6.98 (m, 2H, Ar), 6.83 (s, 1H, Ar), 6.68–6.66 (m, 1H, Ar), 3.83–3.77 (m, 2H, CH<sub>2</sub>), 3.53–3.48 (m, 2H, CH<sub>2</sub>), 3.27–3.22 (m, 2H, CH<sub>2</sub>), 2.25 (s, 3H, CH<sub>3</sub>), 1.63–1.51 (m, 2H, CH<sub>2</sub>), 0.92 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.9, 149.6, 145.8, 140.0, 129.6, 129.2, 127.8, 127.0, 123.0, 119.1, 116.1, 45.6, 42.1, 41.3, 21.2, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 375.2; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 375.1.</div></div><div id="sec5_12_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 3-Methoxyphenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>43</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 79%; white solid; mp 64–66 °C. IR ν: 2966 (Ar), 1695 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.70–7.67 (m, 4H, Ar), 7.12–7.07 (m, 1H, Ar), 6.74–6.70 (m, 1H, Ar), 6.53–6.47 (m, 2H, Ar), 3.81–3.75 (m, 2H, CH<sub>2</sub>), 3.67 (s, 3H, CH<sub>3</sub>), 3.50–3.46 (m, 2H, CH<sub>2</sub>), 3.25–3.20 (m, 2H, CH<sub>2</sub>), 1.62–1.50 (m, 2H, CH<sub>2</sub>), 0.91 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 160.4, 156.8, 150.5, 145.9, 129.9, 129.6, 126.8, 116.1, 114.3, 112.9, 108.4, 55.5, 45.5, 42.1, 41.3, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 391.1; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 391.1.</div></div><div id="sec5_12_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 3-Fluorophenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>44</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 74%; white solid; mp 89–91 °C. IR ν: 2666 (Ar), 1701 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.73–7.64 (m, 4H, Ar), 7.23–7.15 (m, 1H, Ar), 6.93–6.88 (m, 1H, Ar), 6.73–6.70 (m, 2H, Ar), 3.82–3.80 (m, 2H, CH<sub>2</sub>), 3.53–3.47 (m, 2H, CH<sub>2</sub>), 3.25–3.21 (m, 2H, CH<sub>2</sub>), 1.62–1.49 (m, 2H, CH<sub>2</sub>), 0.90 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 164.2, 160.9, 156.8, 150.3, 150.2, 146.2, 130.5, 130.3, 129.6, 126.2, 118.2, 118.2, 116.2, 114.4, 114.1, 110.7, 110.3, 45.5, 42.1, 41.2, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 379.1; C<sub>18</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 379.1.</div></div><div id="sec5_12_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 3-Chlorophenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>45</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 55%; white solid; mp 76–78 °C. IR ν: 2933 (Ar), 1703 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71 (s, 4H, Ar), 7.20–7.17 (m, 2H, Ar), 7.04 (s, 1H, Ar), 6.85–6.82 (m, 1H, Ar), 3.86–3.80 (m, 2H, CH<sub>2</sub>), 3.56–3.50 (m, 2H, CH<sub>2</sub>), 3.29–3.24 (m, 2H, CH<sub>2</sub>), 1.65–1.53 (m, 2H, CH<sub>2</sub>), 0.94 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 150.0, 146.1, 134.8, 130.3, 129.7, 127.4, 126.4, 123.1, 120.7, 116.2, 45.6, 42.1, 41.3, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 395.1; C<sub>18</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 395.1.</div></div><div id="sec5_12_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 3-Nitrophenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>46</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 79%; white solid; mp 116–118 °C. IR ν: 2958 (Ar), 1711 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 8.09–8.06 (m, 1H, Ar), 7.82–7.81 (m, 1H, Ar), 7.73–7.67 (m, 4H, Ar), 7.49–7.43 (m, 1H, Ar), 7.33–7.30 (m, 1H, Ar), 3.86–3.80 (m, 2H, CH<sub>2</sub>), 3.56–3.50 (m, 2H, CH<sub>2</sub>), 3.27–3.22 (m, 2H, CH<sub>2</sub>), 1.63–1.51 (m, 2H, CH<sub>2</sub>), 0.91 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.7, 149.8, 148.7, 146.5, 130.4, 129.7, 128.8, 125.7, 121.9, 118.1, 116.3, 45.6, 42.1, 41.2, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found 406.1; C<sub>18</sub>H<sub>20</sub>N<sub>3</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 406.1.</div></div><div id="sec5_12_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 3,4-Dimethoxyphenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>47</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 82%; white solid; mp 139–141 °C. IR ν: 2932 (Ar), 1705 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.68–7.62 (m, 4H, Ar), 6.65–6.62 (m, 1H, Ar), 6.52–6.51 (m, 1H, Ar), 6.41–6.38 (m, 1H, Ar), 3.81–3.77 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 3.70 (s, 3H, CH<sub>3</sub>), 3.51–3.46 (m, 2H, CH<sub>2</sub>), 3.25–3.20 (m, 2H, CH<sub>2</sub>), 1.61–1.49 (m, 2H, CH<sub>2</sub>), 0.90 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 149.2, 147.8, 145.9, 143.2, 129.7, 126.7, 116.1, 113.8, 110.8, 106.6, 56.0, 45.5, 42.1, 41.3, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 421.2; C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 421.1.</div></div><div id="sec5_12_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3,5-Dimethoxyphenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>48</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (80:20)). Yield, 54%; white solid; mp 104–105 °C. IR ν: 2956 (Ar), 1699 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.76–7.66 (m, 4H, Ar), 6.29–6.28 (m, 1H, Ar), 6.14–6.13 (m, 2H, Ar), 3.83–3.78 (m, 2H, CH<sub>2</sub>), 3.66 (s, 6H, 2 × CH<sub>3</sub>), 3.54–3.49 (m, 2H, CH<sub>2</sub>), 3.28–3.23 (m, 2H, CH<sub>2</sub>), 1.64–1.52 (m, 2H, CH<sub>2</sub>), 0.93 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 161.0, 156.8, 151.1, 145.9, 129.6, 127.0, 116.1, 100.8, 99.2, 55.5, 45.6, 42.1, 41.3, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 421.2; C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 421.1.</div></div><div id="sec5_12_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 3,4,5-Trimethoxyphenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>49</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 64%; white solid; mp 133–134 °C. IR ν: 2935 (Ar), 1701 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.72–7.64 (m, 4H, Ar), 6.17 (s, 2H, Ar), 3.81–3.75 (m, 2H, CH<sub>2</sub>), 3.73 (s, 3H, CH<sub>3</sub>), 3.65 (s, 6H, 2 × CH<sub>3</sub>), 3.51–3.46 (m, 2H, CH<sub>2</sub>), 3.24–3.19 (m, 2H, CH<sub>2</sub>), 1.61–1.49 (m, 2H, CH<sub>2</sub>), 0.89 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 153.3, 146.0, 145.5, 136.7, 129.7, 126.7, 116.1, 100.0, 60.9, 56.2, 45.5, 42.1, 41.2, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 451.2; C<sub>21</sub>H<sub>27</sub>N<sub>2</sub>O<sub>7</sub>S (M<sup>+</sup> + H) expected, 451.2.</div></div><div id="sec5_12_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 4-Tolyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>50</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 84%; white solid; mp 86–88 °C. IR ν: 2964 (Ar), 1697 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.66 (s, 4H, Ar), 7.02–6.99 (m, 2H, Ar), 6.81–6.78 (m, 2H, Ar), 3.82–3.77 (m, 2H, CH<sub>2</sub>), 3.52–3.47 (m, 2H, CH<sub>2</sub>), 3.26–3.21 (m, 2H, CH<sub>2</sub>), 2.25 (s, 3H, CH<sub>3</sub>), 1.62–1.51 (m, 2H, CH<sub>2</sub>), 0.92 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.9, 147.5, 145.8, 136.9, 130.1, 129.6, 126.8, 122.1, 116.1, 45.6, 42.1, 41.3, 20.9, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 375.2; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 375.1.</div></div><div id="sec5_12_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 4-Methoxyphenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>51</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 99%; white solid; mp 105–107 °C. IR ν: 2967 (Ar), 1696 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.68 (s, 4H, Ar), 6.87–6.72 (m, 4H, Ar), 3.85–3.80 (m, 2H, CH<sub>2</sub>), 3.74 (s, 3H, CH<sub>3</sub>), 3.55–3.50 (m, 2H, CH<sub>2</sub>), 3.29–3.24 (m, 2H, CH<sub>2</sub>), 1.65–1.53 (m, 2H, CH<sub>2</sub>), 0.92 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 158.2, 156.9, 145.8, 143.1, 129.7, 126.9, 123.4, 116.1, 114.5, 55.5, 45.6, 42.1, 41.3, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 391.1; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 391.1.</div></div><div id="sec5_12_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 4-Fluorophenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>52</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 81%; white solid; mp 126–127 °C. IR ν: 2967 (Ar), 1690 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.70–7.63 (m, 4H, Ar), 6.95–6.89 (m, 4H, Ar), 3.84–3.78 (m, 2H, CH<sub>2</sub>), 3.54–3.48 (m, 2H, CH<sub>2</sub>), 3.27–3.22 (m, 2H, CH<sub>2</sub>), 1.63–1.51 (m, 2H, CH<sub>2</sub>), 0.92 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 162.6, 159.3, 156.8, 146.1, 145.5, 145.5, 129.7, 126.3, 124.1, 124.0, 116.5, 116.1, 45.6, 42.1, 41.3, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 379.1; C<sub>18</sub>H<sub>20</sub>FN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 379.1.</div></div><div id="sec5_12_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 4-Chlorophenyl 4-(2-Oxo-3-propylimidazolidin-1-yl)benzenesulfonate (<b>53</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 72%; white solid; mp 96–98 °C. IR ν: 2966 (Ar), 1691 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.70–7.64 (m, 4H, Ar), 7.22–7.18 (m, 2H, Ar), 6.89–6.85 (m, 2H, Ar), 3.83–3.78 (m, 2H, CH<sub>2</sub>), 3.53–3.48 (m, 2H, CH<sub>2</sub>), 3.27–3.22 (m, 2H, CH<sub>2</sub>), 1.63–1.51 (m, 2H, CH<sub>2</sub>), 0.91 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 148.1, 146.1, 132.7, 129.7, 129.7, 126.3, 123.8, 116.2, 45.6, 42.1, 41.3, 20.6, 11.2. MS (APSI+) <i>m</i>/<i>z</i> found, 395.1; C<sub>18</sub>H<sub>20</sub>ClN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 395.1.</div></div><div id="sec5_12_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Phenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>54</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 78%; white solid; mp 96–98 °C. IR ν: 2925 (Ar), 1699 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.72–7.66 (m, 4H, Ar), 7.28–7.21 (m, 3H, Ar), 6.97–6.94 (m, 2H, Ar), 3.85–3.80 (m, 2H, CH<sub>2</sub>), 3.55–3.50 (m, 2H, CH<sub>2</sub>), 3.33–3.28 (m, 2H, CH<sub>2</sub>), 1.59–1.50 (m, 2H, CH<sub>2</sub>), 1.42–1.30 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 149.7, 145.9, 129.7, 129.6, 127.0, 126.9, 122.5, 116.1, 43.6, 42.1, 41.3, 29.4, 20.0, 13.8. MS (APSI+) <i>m</i>/<i>z</i> found, 375.1; C<sub>19</sub>H<sub>23</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 375.1.</div></div><div id="sec5_12_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 2-Methoxyphenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>55</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 61%; white solid; mp 113–115 °C. IR ν: 2922 (Ar), 1711 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.78–7.65 (m, 4H, Ar), 7.20–7.10 (m, 2H, Ar), 6.88–6.81 (m, 2H, Ar), 3.85–3.80 (m, 2H, CH<sub>2</sub>), 3.57–3.50 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 3.33–3.28 (m, 2H, CH<sub>2</sub>), 1.60–1.50 (m, 2H, CH<sub>2</sub>), 1.42–1.30 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.9, 151.9, 145.6, 138.5, 129.8, 128.0, 124.0, 120.6, 115.9, 112.8, 55.7, 43.7, 42.2, 41.3, 29.4, 20.0, 13.8. MS (APSI+) <i>m</i>/<i>z</i> found, 405.2; C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 405.1.</div></div><div id="sec5_12_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 3-Methoxyphenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>56</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 90%; white solid; mp 55–57 °C. IR ν: 2932 (Ar), 1701 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.75–7.67 (m, 4H, Ar), 7.16–7.11 (m, 1H, Ar), 6.78–6.74 (m, 1H, Ar), 6.58–6.50 (m, 2H, Ar), 3.85–3.80 (m, 2H, CH<sub>2</sub>), 3.71 (s, 3H, CH<sub>3</sub>), 3.56–3.50 (m, 2H, CH<sub>2</sub>), 3.33–3.28 (m, 2H, CH<sub>2</sub>), 1.60–1.50 (m, 2H, CH<sub>2</sub>), 1.40–1.32 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 160.4, 156.8, 150.6, 145.9, 129.9, 129.7, 127.0, 116.1, 114.3, 113.0, 108.4, 55.5, 43.7, 42.1, 41.3, 29.4, 20.0, 13.8. MS (APSI+) <i>m</i>/<i>z</i> found, 405.2; C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 405.1.</div></div><div id="sec5_12_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 3-Fluorophenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>57</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 55%; white solid; mp 76–78 °C. IR ν: 2925 (Ar), 1701 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.76–7.69 (m, 4H, Ar), 7.27–7.19 (m, 1H, Ar), 6.98–6.92 (m, 1H, Ar), 6.79–6.73 (m, 2H, Ar), 3.87–3.82 (m, 2H, CH<sub>2</sub>), 3.57–3.52 (m, 2H, CH<sub>2</sub>), 3.34–3.29 (m, 2H, CH<sub>2</sub>), 1.61–1.51 (m, 2H, CH<sub>2</sub>), 1.43–1.31 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 164.3, 161.0, 156.8, 150.4, 150.2, 146.1, 130.4, 130.3, 129.7, 126.5, 118.3, 118.2, 116.2, 114.3, 114.1, 110.7, 110.4, 43.7, 42.1, 41.3, 29.4, 20.0, 13.8. MS (APSI+) <i>m</i>/<i>z</i> found, 393.1; C<sub>19</sub>H<sub>22</sub>FN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 393.1.</div></div><div id="sec5_12_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 3-Chlorophenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>58</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (97:3)). Yield, 69%; white solid; mp 74–76 °C. IR ν: 2930 (Ar), 1710 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.70 (brs, 4H, Ar), 7.19–7.14 (m, 2H, Ar), 7.04 (s, 1H, Ar), 6.84–6.81 (m, 1H, Ar), 3.85–3.80 (m, 2H, CH<sub>2</sub>), 3.55–3.50 (m, 2H, CH<sub>2</sub>), 3.32–3.27 (m, 2H, CH<sub>2</sub>), 1.59–1.49 (m, 2H, CH<sub>2</sub>), 1.41–1.31 (m, 2H, CH<sub>2</sub>), 0.94 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 150.0, 146.2, 134.8, 130.3, 129.6, 127.4, 126.4, 123.1, 120.7, 116.2, 43.6, 42.1, 41.3, 29.4, 20.0, 13.8. MS (APSI+) <i>m</i>/<i>z</i> found, 409.1; C<sub>19</sub>H<sub>22</sub>ClN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 409.1.</div></div><div id="sec5_12_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 3-Bromophenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>59</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 72%; white solid; mp 81–83 °C. IR ν: 2959 (Ar), 1711 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71–7.68 (m, 4H, Ar), 7.37–7.35 (m, 1H, Ar), 7.21–7.10 (m, 2H, Ar), 6.90–6.87 (m, 1H, Ar), 3.86–3.81 (m, 2H, CH<sub>2</sub>), 3.56–3.51 (m, 2H, CH<sub>2</sub>), 3.33–3.28 (m, 2H, CH<sub>2</sub>), 1.60–1.50 (m, 2H, CH<sub>2</sub>), 1.42–1.30 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 150.0, 146.1, 130.6, 130.3, 129.7, 126.5, 125.9, 122.4, 121.2, 116.2, 43.7, 42.1, 41.3, 29.4, 20.0, 13.8. MS (APSI+) <i>m</i>/<i>z</i> found, 453.1; C<sub>19</sub>H<sub>22</sub>BrN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 453.0.</div></div><div id="sec5_12_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 3-Iodophenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>60</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 71%; white solid; mp 96–98 °C. IR ν: 2872 (Ar), 1713 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.74–7.68 (m, 4H, Ar), 7.57–7.55 (m, 1H, Ar), 7.39–7.38 (m, 1H, Ar), 7.01–6.89 (m, 2H, Ar), 3.87–3.82 (m, 2H, CH<sub>2</sub>), 3.57–3.51 (m, 2H, CH<sub>2</sub>), 3.33–3.29 (m, 2H, CH<sub>2</sub>), 1.60–1.50 (m, 2H, CH<sub>2</sub>), 1.43–1.30 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 149.7, 146.1, 136.2, 131.6, 130.9, 129.7, 126.5, 121.8, 116.2, 93.5, 43.7, 42.1, 41.3, 29.4, 20.0, 13.8. MS (APSI+) <i>m</i>/<i>z</i> found, 501.1; C<sub>19</sub>H<sub>22</sub>IN<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 501.0.</div></div><div id="sec5_12_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 3,4-Dimethoxyphenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>61</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 62%; colorless oil. IR ν: 2931 (Ar), 1705 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.72–7.65 (m, 4H, Ar), 6.67–6.64 (m, 1H, Ar), 6.55–6.54 (m, 1H, Ar), 6.44–6.40 (m, 1H, Ar), 3.84–3.79 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 3.73 (s, 3H, CH<sub>3</sub>), 3.54–3.49 (m, 2H, CH<sub>2</sub>), 3.31–3.27 (m, 2H, CH<sub>2</sub>), 1.58–1.48 (m, 2H, CH<sub>2</sub>), 1.41–1.29 (m, 2H, CH<sub>2</sub>), 0.93 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 149.3, 147.8, 145.8, 143.2, 129.7, 126.8, 116.1, 113.9, 110.8, 106.6, 56.1, 43.6, 42.1, 41.3, 29.4, 19.9, 13.7. MS (APSI+) <i>m</i>/<i>z</i> found, 435.2; C<sub>21</sub>H<sub>27</sub>N<sub>2</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 435.2.</div></div><div id="sec5_12_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 3,4-Difluorophenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>62</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 70%; white solid; mp 99–101 °C. IR ν: 2929 (Ar), 1712 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.71 (brs, 4H, Ar), 7.09–7.00 (m, 1H, Ar), 6.91–6.84 (m, 1H, Ar), 6.74–6.68 (m, 1H, Ar), 3.87–3.82 (m, 2H, CH<sub>2</sub>), 3.57–3.52 (m, 2H, CH<sub>2</sub>), 3.34–3.29 (m, 2H, CH<sub>2</sub>), 1.60–1.50 (m, 2H, CH<sub>2</sub>), 1.43–1.30 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.7, 151.7, 151.5, 150.9, 150.8, 148.4, 148.2, 147.6, 147.5, 146.2, 145.1, 145.1, 145.0, 145.0, 129.7, 126.1, 118.8, 118.7, 118.7, 118.6, 117.6, 117.3, 116.2, 112.7, 112.5, 43.7, 42.1, 41.3, 29.4, 20.0, 13.7. MS (APSI+) <i>m</i>/<i>z</i> found, 411.2; C<sub>19</sub>H<sub>21</sub>F<sub>2</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 411.1.</div></div><div id="sec5_12_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 3,5-Dimethoxyphenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>63</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 80%; white solid; mp 112–113 °C. IR ν: 2957 (Ar), 1708 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.75–7.66 (m, 4H, Ar), 6.29–6.27 (m, 1H, Ar), 6.14–6.13 (m, 2H, Ar), 3.82–3.77 (m, 2H, CH<sub>2</sub>), 3.65 (s, 6H, 2 × CH<sub>3</sub>), 3.53–3.48 (m, 2H, CH<sub>2</sub>), 3.30–3.26 (m, 2H, CH<sub>2</sub>), 1.58–1.48 (m, 2H, CH<sub>2</sub>), 1.40–1.28 (m, 2H, CH<sub>2</sub>), 0.93 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 161.0, 156.8, 151.1, 145.9, 129.6, 126.9, 116.1, 100.8, 99.2, 55.5, 43.6, 42.1, 41.3, 29.4, 19.9, 13.7. MS (APSI+) <i>m</i>/<i>z</i> found, 435.2; C<sub>21</sub>H<sub>27</sub>N<sub>2</sub>O<sub>6</sub>S (M<sup>+</sup> + H) expected, 435.2.</div></div><div id="sec5_12_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 3,5-Difluorophenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>64</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 46%; white solid; mp 119–121 °C. IR ν: 2929 (Ar), 1712 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.77–7.71 (m, 4H, Ar), 6.74–6.67 (m, 1H, Ar), 6.61–6.56 (m, 2H, Ar), 3.88–3.83 (m, 2H, CH<sub>2</sub>), 3.58–3.52 (m, 2H, CH<sub>2</sub>), 3.34–3.29 (m, 2H, CH<sub>2</sub>), 1.64–1.51 (m, 2H, CH<sub>2</sub>), 1.43–1.31 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 164.5, 164.3, 161.2, 161.0, 156.7, 150.9, 150.7, 150.5, 146.3, 129.7, 126.1, 116.2, 106.9, 106.8, 106.7, 106.6, 106.5, 106.5, 103.3, 103.0, 102.6, 43.7, 42.1, 41.3, 29.4, 20.0, 13.7. MS (APSI+) <i>m</i>/<i>z</i> found, 411.2; C<sub>19</sub>H<sub>21</sub>F<sub>2</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 411.1.</div></div><div id="sec5_12_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 3,5-Dichlorophenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>65</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 54%; white solid; mp 147–149 °C. IR ν: 2879 (Ar), 1708 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.74 (brs, 4H, Ar), 7.24–7.23 (m, 1H, Ar), 6.95–6.94 (m, 2H, Ar), 3.88–3.82 (m, 2H, CH<sub>2</sub>), 3.57–3.52 (m, 2H, CH<sub>2</sub>), 3.34–3.29 (m, 2H, CH<sub>2</sub>), 1.60–1.50 (m, 2H, CH<sub>2</sub>), 1.43–1.30 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.7, 150.1, 146.3, 135.4, 129.7, 127.5, 126.1, 121.5, 116.3, 43.7, 42.1, 41.3, 29.4, 20.0, 13.7. MS (APSI+) <i>m</i>/<i>z</i> found, 443.1; C<sub>19</sub>H<sub>21</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 443.1.</div></div><div id="sec5_12_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 3,5-Dibromophenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>66</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 86%; white solid; mp 159–161 °C. IR ν: 2874 (Ar), 1708 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.74 (brs, 4H, Ar), 7.54 (s, 1H, Ar), 7.13–7.13 (m, 2H, Ar), 3.87–3.82 (m, 2H, CH<sub>2</sub>), 3.57–3.52 (m, 2H, CH<sub>2</sub>), 3.34–3.29 (m, 2H, CH<sub>2</sub>), 1.60–1.50 (m, 2H, CH<sub>2</sub>), 1.43–1.30 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.7, 150.1, 146.4, 132.9, 129.7, 126.0, 124.7, 122.9, 116.3, 43.7, 42.1, 41.3, 29.4, 20.0, 13.8. MS (APSI+) <i>m</i>/<i>z</i> found, 531.0; C<sub>19</sub>H<sub>21</sub>Br<sub>2</sub>N<sub>2</sub>O<sub>4</sub>S (M<sup>+</sup> + H) expected, 531.0.</div></div><div id="sec5_12_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 3,4,5-Trimethoxyphenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>67</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1) and hexanes to hexanes/EtOAc (5:5)). Yield, 80%; white solid; mp 116–118 °C. IR ν: 2938 (Ar), 1701 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.78–7.69 (m, 4H, Ar), 6.21 (s, 2H, Ar), 3.85–3.77 (m, 5H, CH<sub>2</sub> and CH<sub>3</sub>), 3.70 (s, 6H, 2 × CH<sub>3</sub>), 3.56–3.51 (m, 2H, CH<sub>2</sub>), 3.33–3.28 (m, 2H, CH<sub>2</sub>), 1.59–1.50 (m, 2H, CH<sub>2</sub>), 1.41–1.32 (m, 2H, CH<sub>2</sub>), 0.94 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.8, 153.3, 145.9, 145.6, 136.8, 129.8, 126.9, 116.1, 100.0, 60.9, 56.2, 43.7, 42.1, 41.3, 29.4, 20.0, 13.7. MS (APSI+) <i>m</i>/<i>z</i> found, 465.2; C<sub>22</sub>H<sub>29</sub>N<sub>2</sub>O<sub>7</sub>S (M<sup>+</sup> + H) expected, 465.2.</div></div><div id="sec5_12_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 4-Methoxyphenyl 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzenesulfonate (<b>68</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 63%; white solid; mp 66–68 °C. IR ν: 2949 (Ar), 1704 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.68 (brs, 4H, Ar), 6.87–6.82 (m, 2H, Ar), 6.76–6.72 (m, 2H, Ar), 3.85–3.80 (m, 2H, CH<sub>2</sub>), 3.74 (s, 3H, CH<sub>3</sub>), 3.55–3.50 (m, 2H, CH<sub>2</sub>), 3.32–3.27 (m, 2H, CH<sub>2</sub>), 1.59–1.49 (m, 2H, CH<sub>2</sub>), 1.42–1.30 (m, 2H, CH<sub>2</sub>), 0.94 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 158.2, 156.8, 145.8, 143.1, 129.7, 126.8, 123.4, 116.1, 114.5, 55.5, 43.6, 42.1, 41.3, 29.4, 20.0, 13.8. MS (APSI+) <i>m</i>/<i>z</i> found, 405.2; C<sub>20</sub>H<sub>25</sub>N<sub>2</sub>O<sub>5</sub>S (M<sup>+</sup> + H) expected, 405.1.</div></div><div id="sec5_12_63_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Preparation of 1-Phenylimidazolidin-2-one</h4><div class="NLM_p last">The synthesis and characterization of 1-phenylimidazolidin-2-one have been previously reported.<a onclick="showRef(event, 'ref37 ref44'); return false;" href="javascript:void(0);" class="ref ref37 ref44">(37, 44)</a> Briefly, 2-chloroethylisocyanate (105 mmol) was added dropwise to solution of aniline (100 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The reaction mixture was stirred at room temperature for 20 h. After completion of the reaction, the solvent was evaporated under reduced pressure to give an off-white quantitative solid, which was recrystallized from CH<sub>2</sub>Cl<sub>2</sub>/hexane (1:5). 1-Phenylimidazolidin-2-one was obtained by cyclization of 1-(2-chloroethyl)-3-phenylurea. Briefly, <i>N</i>-phenyl <i>N</i>-(2-chloroethyl)urea (20 mmol) was added slowly to a suspension of sodium hydride 60% (44 mmol) in tetrahydrofuran at 0 °C. The reaction was stirred at room temperature for 5 h and quenched with ice–water and diluted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated in vacuo to provide the crude title compound, which was tritured from hexane.</div></div></div><div id="sec5_12_63_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Preparation of Compounds <b>69</b>–<b>72</b></h3><div class="NLM_p">Sodium hydride (60% stock; 33 mmol) was added slowly to a cold solution of 1-phenylimidazolidin-2-one (30 mmol) in dry tetrahydrofuran. The ice bath was next removed after 30 min, the appropriate alkyl iodide (36 mmol) then added slowly, and the reaction mixture was stirred at room temperature for 20 h. The reaction was quenched at 0 °C, and the mixture then diluted with EtOAc. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by flash chromatography.</div><div id="sec5_12_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 1-Methyl-3-phenylimidazolidin-2-one (<b>69</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (85:15)). Yield, 73%; yellow solid; mp 96–97 °C. IR ν: 2926 (Ar), 1687 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.53–7.50 (m, 2H, Ar), 7.31–7.26 (m, 2H, Ar), 7.01–6.96 (m, 1H, Ar), 3.70–3.65 (m, 2H, CH<sub>2</sub>), 3.37–3.31 (m, 2H, CH<sub>2</sub>), 2.80 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 158.0, 140.8, 128.7, 122.0, 117.0, 43.9, 42.1, 31.1.</div></div><div id="sec5_12_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 1-Ethyl-3-phenylimidazolidin-2-one (<b>70</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 54%; white solid; mp 68–70 °C. IR ν: 2972 (Ar), 1687 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.54–7.52 (m, 2H, Ar), 7.32–2.26 (m, 2H, Ar), 7.01–6.96 (m, 1H, Ar), 3.74–3.68 (m, 2H, CH<sub>2</sub>), 3.41–3.27 (m, 4H, 2 × CH<sub>2</sub>), 1.14 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.7, 140.8, 128.7, 122.1, 117.2, 42.4, 41.1, 38.6, 12.6.</div></div><div id="sec5_12_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 1-Phenyl 3-Propylimidazolidin-2-one (<b>71</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (85:15)). Yield, 69%; yellow solid; mp 61–63 °C. IR ν: 2925 (Ar), 1684 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.56–7.53 (m, 2H, Ar), 7.33–7.27 (m, 2H, Ar), 7.02–6.97 (m, 1H, Ar), 3.77–3.72 (m, 2H, CH<sub>2</sub>), 3.44–3.39 (m, 2H, CH<sub>2</sub>), 3.23 (t, 2H, <i>J</i> = 7.4 Hz, CH<sub>2</sub>), 1.63–1.51 (m, 2H, CH<sub>2</sub>), 0.93 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.9, 140.8, 128.7, 122.1, 117.2, 45.7, 42.4, 41.7, 20.8, 11.3.</div></div><div id="sec5_12_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 1-Butyl-3-phenylimidazolidin-2-one (<b>72</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (9:1)). Yield, 72%; white solid; mp 43–44 °C. IR ν: 2954 (Ar), 1689 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.56–7.54 (m, 2H, Ar), 7.33–7.28 (m, 2H, Ar), 7.03–6.98 (m, 1H, Ar), 3.78–3.73 (m, 2H, CH<sub>2</sub>), 3.45–3.40 (m, 2H, CH<sub>2</sub>), 3.27 (t, 2H, <i>J</i> = 7.3 Hz, CH<sub>2</sub>), 1.58–1.49 (m, 2H, CH<sub>2</sub>), 1.42–1.30 (m, 2H, CH<sub>2</sub>), 0.95 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 157.9, 140.8, 128.7, 122.1, 117.2, 43.7, 42.4, 41.7, 29.6, 20.0, 13.8.</div></div></div><div id="sec5_12_67_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> Preparation of Compounds <b>73</b>–<b>76</b></h3><div class="NLM_p">The appropriate compound in the <b>69</b>–<b>72</b> series (3.1 mmol) was added slowly to chlorosulfonic acid (23.1 mmol) in CCl<sub>4</sub> (5 mL) at 0 °C. The reaction was essentially completed after 2 h at 0 °C. The reaction mixture was poured slowly into ice–water and then filtered to collect the solid thus formed. The latter solid was dried overnight under vacuum. The filtrate was extracted three times with CH<sub>2</sub>Cl<sub>2</sub>. The combined CH<sub>2</sub>Cl<sub>2</sub> extracts were washed with brine (20 mL), dried over sodium sulfate, filtered, and evaporated to dryness under vacuum.</div><div id="sec5_12_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 4-(3-Methyl-2-oxoimidazolidin-1-yl)benzene-1-sulfonyl chloride (<b>73</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 76%; white solid; mp 147–149 °C. IR ν: 2905 (Ar), 1702 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.98–7.95 (m, 2H, Ar), 7.81–7.78 (m, 2H, Ar), 3.91–3.86 (m, 2H, CH<sub>2</sub>), 3.60–3.55 (m, 2H, CH<sub>2</sub>), 2.95 (s, 3H, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.9, 146.7, 136.4, 128.5, 116.4, 43.5, 42.0, 31.0.</div></div><div id="sec5_12_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 4-(3-Ethyl-2-oxoimidazolidin-1-yl)benzene-1-sulfonyl chloride (<b>74</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 91%; white solid; mp 182–184 °C. IR ν: 1704 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.54 (brs, 4H, Ar), 3.82–3.77 (m, 2H, CH<sub>2</sub>), 3.48–3.43 (m, 2H, CH<sub>2</sub>), 3.23 (q, 2H, <i>J</i> = 7.1 Hz, CH<sub>2</sub>), 1.09 (t, 3H, <i>J</i> = 7.2 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 156.8, 141.2, 140.7, 126.1, 115.6, 41.9, 40.4, 38.0, 12.4.</div></div><div id="sec5_12_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 4-(2-Oxo-3-propylimidazolidin-1-yl)benzene-1-sulfonyl chloride (<b>75</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 88%; white solid; mp 141–143 °C. IR ν: 2961 (Ar), 1700 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 7.98–7.95 (m, 2H, Ar), 7.81–7.78 (m, 2H, Ar), 3.92–3.87 (m, 2H, CH<sub>2</sub>), 3.60–3.55 (m, 2H, CH<sub>2</sub>), 3.30 (t, 2H, <i>J</i> = 7.4 Hz, CH<sub>2</sub>), 1.68–1.56 (m, 2H, CH<sub>2</sub>), 0.96 (t, 3H, <i>J</i> = 7.4 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (CDCl<sub>3</sub>): δ 156.6, 146.7, 136.3, 128.5, 116.4, 45.6, 42.2, 41.3, 20.6, 11.2.</div></div><div id="sec5_12_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 4-(3-Butyl-2-oxoimidazolidin-1-yl)benzene-1-sulfonyl chloride (<b>76</b>)</h4><div class="NLM_p last">Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (95:5)). Yield, 89%; white solid; mp 148–150 °C. IR ν: 2955 (Ar), 1701 (C═O) cm<sup>–1</sup>. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>): δ 7.54–7.51 (m, 4H, Ar), 3.83–3.77 (m, 2H, CH<sub>2</sub>), 3.48–3.43 (m, 2H, CH<sub>2</sub>), 3.19 (t, 2H, <i>J</i> = 7.1 Hz, CH<sub>2</sub>), 1.54–1.44 (m, 2H, CH<sub>2</sub>), 1.37–1.24 (m, 2H, CH<sub>2</sub>), 0.92 (t, 3H, <i>J</i> = 7.3 Hz, CH<sub>3</sub>). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 157.0, 141.2, 140.8, 126.1, 115.6, 42.9, 41.9, 41.0, 28.9, 19.5, 13.7.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i98"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00343">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00343" class="ext-link">10.1021/acs.jmedchem.7b00343</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Induction of CYP1A1 by PAIB-SO <b>67</b> in MCF7 and MDA-MB-231 cells (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00343/suppl_file/jm7b00343_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00343/suppl_file/jm7b00343_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00343/suppl_file/jm7b00343_si_001.pdf">jm7b00343_si_001.pdf (147.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00343/suppl_file/jm7b00343_si_002.csv">jm7b00343_si_002.csv (4.86 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.7b00343" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68544" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68544" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sébastien Fortin</span> - <span class="hlFld-Affiliation affiliation">CHU
de Québec Research Centre, Oncology Division, Hôpital Saint-François d’Assise, 10 rue de l’Espinay, Quebec City, Quebec, Canada G1L 3L5</span>; 
    <span class="hlFld-Affiliation affiliation">Faculty
of Pharmacy, Université Laval, Quebec City, Quebec, Canada G1V 0A6</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3374-2751" title="Orcid link">http://orcid.org/0000-0002-3374-2751</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#245741464557504d414a0a424b56504d4a64544c450a5148455245480a4745"><span class="__cf_email__" data-cfemail="bfccdadddecccbd6dad191d9d0cdcbd6d1ffcfd7de91cad3dec9ded391dcde">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">René C.-Gaudreault</span> - <span class="hlFld-Affiliation affiliation">CHU
de Québec Research Centre, Oncology Division, Hôpital Saint-François d’Assise, 10 rue de l’Espinay, Quebec City, Quebec, Canada G1L 3L5</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec
City, Quebec, Canada G1V 0A6</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bac8dfd4df94d997dddbcfdec8dfdbcfd6cefad9c8c9dcdb94cfd6dbccdbd694d9db"><span class="__cf_email__" data-cfemail="c1b3a4afa4efa2eca6a0b4a5b3a4a0b4adb581a2b3b2a7a0efb4ada0b7a0adefa2a0">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xavier Charest-Morin</span> - <span class="hlFld-Affiliation affiliation">CHU
de Québec Research Centre, Oncology Division, Hôpital Saint-François d’Assise, 10 rue de l’Espinay, Quebec City, Quebec, Canada G1L 3L5</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vanessa Turcotte</span> - <span class="hlFld-Affiliation affiliation">CHU
de Québec Research Centre, Oncology Division, Hôpital Saint-François d’Assise, 10 rue de l’Espinay, Quebec City, Quebec, Canada G1L 3L5</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Coraline Lauvaux</span> - <span class="hlFld-Affiliation affiliation">CHU
de Québec Research Centre, Endocrinology and Nephrology Division, CHUL, 2705 Boulevard Laurier, Quebec City, Quebec, Canada G1V 4G2</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jacques Lacroix</span> - <span class="hlFld-Affiliation affiliation">CHU
de Québec Research Centre, Oncology Division, Hôpital Saint-François d’Assise, 10 rue de l’Espinay, Quebec City, Quebec, Canada G1L 3L5</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marie-France Côté</span> - <span class="hlFld-Affiliation affiliation">CHU
de Québec Research Centre, Oncology Division, Hôpital Saint-François d’Assise, 10 rue de l’Espinay, Quebec City, Quebec, Canada G1L 3L5</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stéphane Gobeil</span> - <span class="hlFld-Affiliation affiliation">CHU
de Québec Research Centre, Endocrinology and Nephrology Division, CHUL, 2705 Boulevard Laurier, Quebec City, Quebec, Canada G1V 4G2</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec
City, Quebec, Canada G1V 0A6</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d160e9292-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i99">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86008" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86008" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We acknowledge the Canadian Institutes of Health Research (R.C.-G., grant MOP-79334 and grant MOP-89707) for funding. S.F. is a recipient of a studentship from the Canadian Institutes of Health Research (grant CGD-83623). We sincerely thank Dr. Richard Poulin for his helpful comments and expert editing of this manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i100" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i100"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i101" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i101"> Abbreviations Used</h2><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">PAIB-SOs</td><td class="NLM_def"><p class="first last">phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates</p></td></tr><tr><td class="NLM_term">PIB-SOs</td><td class="NLM_def"><p class="first last">phenyl 4-(2-oxo-3-imidazolidin-1-yl)benzenesulfonates</p></td></tr><tr><td class="NLM_term">AhR</td><td class="NLM_def"><p class="first last">aryl hydrocarbon receptor</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">CAM</td><td class="NLM_def"><p class="first last">chick chorioallantoic membrane</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70151" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70151" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 67 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Torre, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferlay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lortet-Tieulent, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Global cancer statistics, 2012</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.3322/caac.21262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.3322%2Fcaac.21262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=25651787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=87-108&author=L.+A.+Torreauthor=F.+Brayauthor=R.+L.+Siegelauthor=J.+Ferlayauthor=J.+Lortet-Tieulentauthor=A.+Jemal&title=Global+cancer+statistics%2C+2012&doi=10.3322%2Fcaac.21262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics, 2012</span></div><div class="casAuthors">Torre Lindsey A; Bray Freddie; Siegel Rebecca L; Ferlay Jacques; Lortet-Tieulent Joannie; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer constitutes an enormous burden on society in more and less economically developed countries alike.  The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development.  Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide.  Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide.  Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries.  Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males.  In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death.  Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries.  This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment.  Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer).  A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93OidvnAA79ts4TFFB11gfW6udTcc2eZUGXVcPa8Q67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D&md5=f008b208320b129e10c7c383193ff772</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21262%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DLortet-Tieulent%26aufirst%3DJ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2015%26volume%3D65%26spage%3D87%26epage%3D108%26doi%3D10.3322%2Fcaac.21262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Torre, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Global cancer incidence and mortality rates and trends-an update</span> <span class="citation_source-journal">Cancer Epidemiol., Biomarkers Prev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1158/1055-9965.EPI-15-0578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1158%2F1055-9965.EPI-15-0578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=26667886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC28vpvVOlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=16-27&author=L.+A.+Torreauthor=R.+L.+Siegelauthor=E.+M.+Wardauthor=A.+Jemal&title=Global+cancer+incidence+and+mortality+rates+and+trends-an+update&doi=10.1158%2F1055-9965.EPI-15-0578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Global Cancer Incidence and Mortality Rates and Trends--An Update</span></div><div class="casAuthors">Torre Lindsey A; Siegel Rebecca L; Jemal Ahmedin; Ward Elizabeth M</div><div class="citationInfo"><span class="NLM_cas:title">Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There are limited published data on recent cancer incidence and mortality trends worldwide.  We used the International Agency for Research on Cancer's CANCERMondial clearinghouse to present age-standardized cancer incidence and death rates for 2003-2007.  We also present trends in incidence through 2007 and mortality through 2012 for select countries from five continents.  High-income countries (HIC) continue to have the highest incidence rates for all sites, as well as for lung, colorectal, breast, and prostate cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates.  Mortality rates from these cancers are declining in many HICs while they are increasing in LMICs.  LMICs have the highest rates of stomach, liver, esophageal, and cervical cancer.  Although rates remain high in HICs, they are plateauing or decreasing for the most common cancers due to decreases in known risk factors, screening and early detection, and improved treatment (mortality only).  In contrast, rates in several LMICs are increasing for these cancers due to increases in smoking, excess body weight, and physical inactivity.  LMICs also have a disproportionate burden of infection-related cancers.  Applied cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTTu2rxqNRkftos8R3JUhXfW6udTcc2eZUGXVcPa8Q67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vpvVOlsw%253D%253D&md5=a700298a7a2bc2d381bb33ed9279df5b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F1055-9965.EPI-15-0578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1055-9965.EPI-15-0578%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DWard%26aufirst%3DE.%2BM.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520incidence%2520and%2520mortality%2520rates%2520and%2520trends-an%2520update%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2016%26volume%3D25%26spage%3D16%26epage%3D27%26doi%3D10.1158%2F1055-9965.EPI-15-0578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSantis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virgo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariotto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gansler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedewa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannady, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scoppa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hachey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, E.</span><span> </span><span class="NLM_article-title">Cancer treatment and survivorship statistics, 2012</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.3322/caac.21149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.3322%2Fcaac.21149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22700443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC38jhvFGrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=220-241&author=R.+Siegelauthor=C.+DeSantisauthor=K.+Virgoauthor=K.+Steinauthor=A.+Mariottoauthor=T.+Smithauthor=D.+Cooperauthor=T.+Ganslerauthor=C.+Lerroauthor=S.+Fedewaauthor=C.+Linauthor=C.+Leachauthor=R.+S.+Cannadyauthor=H.+Choauthor=S.+Scoppaauthor=M.+Hacheyauthor=R.+Kirchauthor=A.+Jemalauthor=E.+Ward&title=Cancer+treatment+and+survivorship+statistics%2C+2012&doi=10.3322%2Fcaac.21149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer treatment and survivorship statistics, 2012</span></div><div class="casAuthors">Siegel Rebecca; DeSantis Carol; Virgo Katherine; Stein Kevin; Mariotto Angela; Smith Tenbroeck; Cooper Dexter; Gansler Ted; Lerro Catherine; Fedewa Stacey; Lin Chunchieh; Leach Corinne; Cannady Rachel Spillers; Cho Hyunsoon; Scoppa Steve; Hachey Mark; Kirch Rebecca; Jemal Ahmedin; Ward Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">220-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although there has been considerable progress in reducing cancer incidence in the United States, the number of cancer survivors continues to increase due to the aging and growth of the population and improvements in survival rates.  As a result, it is increasingly important to understand the unique medical and psychosocial needs of survivors and be aware of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship.  To highlight the challenges and opportunities to serve these survivors, the American Cancer Society and the National Cancer Institute estimated the prevalence of cancer survivors on January 1, 2012 and January 1, 2022, by cancer site.  Data from Surveillance, Epidemiology, and End Results (SEER) registries were used to describe median age and stage at diagnosis and survival; data from the National Cancer Data Base and the SEER-Medicare Database were used to describe patterns of cancer treatment.  An estimated 13.7 million Americans with a history of cancer were alive on January 1, 2012, and by January 1, 2022, that number will increase to nearly 18 million.  The 3 most prevalent cancers among males are prostate (43%), colorectal (9%), and melanoma of the skin (7%), and those among females are breast (41%), uterine corpus (8%), and colorectal (8%).  This article summarizes common cancer treatments, survival rates, and posttreatment concerns and introduces the new National Cancer Survivorship Resource Center, which has engaged more than 100 volunteer survivorship experts nationwide to develop tools for cancer survivors, caregivers, health care professionals, advocates, and policy makers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiAZAFyHc8fwWRJ3OJdH_qfW6udTcc2eaT6gS50-ALZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jhvFGrtw%253D%253D&md5=2aeac577b945bdbf9c9248fae48b1df6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21149%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DDeSantis%26aufirst%3DC.%26aulast%3DVirgo%26aufirst%3DK.%26aulast%3DStein%26aufirst%3DK.%26aulast%3DMariotto%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DCooper%26aufirst%3DD.%26aulast%3DGansler%26aufirst%3DT.%26aulast%3DLerro%26aufirst%3DC.%26aulast%3DFedewa%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DLeach%26aufirst%3DC.%26aulast%3DCannady%26aufirst%3DR.%2BS.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DScoppa%26aufirst%3DS.%26aulast%3DHachey%26aufirst%3DM.%26aulast%3DKirch%26aufirst%3DR.%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DE.%26atitle%3DCancer%2520treatment%2520and%2520survivorship%2520statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2012%26volume%3D62%26spage%3D220%26epage%3D241%26doi%3D10.3322%2Fcaac.21149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Zanger, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, M.</span><span> </span><span class="NLM_article-title">Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2012.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.pharmthera.2012.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23333322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislykt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2013&pages=103-141&author=U.+M.+Zangerauthor=M.+Schwab&title=Cytochrome+P450+enzymes+in+drug+metabolism%3A+regulation+of+gene+expression%2C+enzyme+activities%2C+and+impact+of+genetic+variation&doi=10.1016%2Fj.pharmthera.2012.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation</span></div><div class="casAuthors">Zanger, Ulrich M.; Schwab, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-141</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cytochromes P 450 (CYP) are a major source of variability in drug pharmacokinetics and response.  Of 57 putatively functional human CYPs only about a dozen enzymes, belonging to the CYP1, 2, and 3 families, are responsible for the biotransformation of most foreign substances including 70-80% of all drugs in clin. use.  The highest expressed forms in liver are CYPs 3A4, 2C9, 2C8, 2E1, and 1A2, while 2A6, 2D6, 2B6, 2C19 and 3A5 are less abundant and CYPs 2J2, 1A1, and 1B1 are mainly expressed extrahepatically.  Expression of each CYP is influenced by a unique combination of mechanisms and factors including genetic polymorphisms, induction by xenobiotics, regulation by cytokines, hormones and during disease states, as well as sex, age, and others.  Multiallelic genetic polymorphisms, which strongly depend on ethnicity, play a major role for the function of CYPs 2D6, 2C19, 2C9, 2B6, 3A5 and 2A6, and lead to distinct pharmacogenetic phenotypes termed as poor, intermediate, extensive, and ultrarapid metabolizers.  For these CYPs, the evidence for clin. significance regarding adverse drug reactions (ADRs), drug efficacy and dose requirement is rapidly growing.  Polymorphisms in CYPs 1A1, 1A2, 2C8, 2E1, 2J2, and 3A4 are generally less predictive, but new data on CYP3A4 show that predictive variants exist and that addnl. variants in regulatory genes or in NADPH:cytochrome P 450 oxidoreductase (POR) can have an influence.  Here we review the recent progress on drug metab. activity profiles, interindividual variability and regulation of expression, and the functional and clin. impact of genetic variation in drug metabolizing P450s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyfuepoWIAkLVg90H21EOLACvtfcHk0lgcNIYCRwwseQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislykt7w%253D&md5=474dd89d1aae3c9d57ff2d33f176602e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2012.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2012.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DZanger%26aufirst%3DU.%2BM.%26aulast%3DSchwab%26aufirst%3DM.%26atitle%3DCytochrome%2520P450%2520enzymes%2520in%2520drug%2520metabolism%253A%2520regulation%2520of%2520gene%2520expression%252C%2520enzyme%2520activities%252C%2520and%2520impact%2520of%2520genetic%2520variation%26jtitle%3DPharmacol.%2520Ther.%26date%3D2013%26volume%3D138%26spage%3D103%26epage%3D141%26doi%3D10.1016%2Fj.pharmthera.2012.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Guengerich, F. P.</span><span> </span><span class="NLM_article-title">Cytochrome P450 enzymes in the generation of commercial products</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span><span class="refDoi"> DOI: 10.1038/nrd792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnrd792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=12120411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFSitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=359-366&author=F.+P.+Guengerich&title=Cytochrome+P450+enzymes+in+the+generation+of+commercial+products&doi=10.1038%2Fnrd792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 enzymes in the generation of commercial products</span></div><div class="casAuthors">Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">359-366</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 enzymes are remarkably diverse oxygenation catalysts that are found throughout nature.  Although most of the interest in the pharmaceutical industry has focused on the role of cytochrome P450s in drug development, these enzymes also offer potential in the discovery not only of drugs, but also of other useful chems.  Potential applications range from the use of cytochrome P450s as drug targets, to the use of randomly generated mutants of cytochrome P450s to produce libraries of new chems. and drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMc-V9Gis5WLVg90H21EOLACvtfcHk0lgcNIYCRwwseQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFSitbg%253D&md5=c39a8f0d7e43510ade7f2400766f4701</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd792%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DCytochrome%2520P450%2520enzymes%2520in%2520the%2520generation%2520of%2520commercial%2520products%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D359%26epage%3D366%26doi%3D10.1038%2Fnrd792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roychowdhury, A.</span><span> </span><span class="NLM_article-title">Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3605</span><span class="NLM_x">–</span> <span class="NLM_lpage">3621</span><span class="refDoi"> DOI: 10.2174/092986712801323180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F092986712801323180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22680629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2itbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3605-3621&author=S.+Kumarauthor=R.+Sharmaauthor=A.+Roychowdhury&title=Modulation+of+cytochrome-P450+inhibition+%28CYP%29+in+drug+discovery%3A+a+medicinal+chemistry+perspective&doi=10.2174%2F092986712801323180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective</span></div><div class="casAuthors">Kumar, Sanjay; Sharma, Rajiv; Roychowdhury, Abhijit</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3605-3621</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP450) has widely been implicated for drug-drug interactions (DDI) in the pharmaceutical industry.  Inhibition or induction of this enzyme family has led to withdrawal of multiple drugs from the market leading to major time and financial losses for the pharmaceutical industry.  CYP450 plays a prevailing role in the biotransformation of a large no. of structurally diverse drugs.  Few isoenzymes of the CYP enzyme family (CYP3A4, 2D6 and 2C9 family) are mainly involved in metab. of most of the drugs.  To avoid such interactions and potentially minimize DDI, major pharmaceutical organizations prefer to incorporate CYP enzyme screening at an early stage of their discovery program.  While this has been a prevalent practice in the pharmaceutical industry lately, there is very limited literature available reviewing the relationship between chemotypes and CYP isoforms.  This review will collate literature pertaining to CYP-inhibition modulation through physicochem. parameters and chem. modification and thus bring to focus commonly used trends by medicinal chemists world-wide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVIogYUZJywLVg90H21EOLACvtfcHk0lioOFHRuNugpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2itbrF&md5=1f675ef0f7cd31a254b82d8b2eaac44b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F092986712801323180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801323180%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DRoychowdhury%26aufirst%3DA.%26atitle%3DModulation%2520of%2520cytochrome-P450%2520inhibition%2520%2528CYP%2529%2520in%2520drug%2520discovery%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D3605%26epage%3D3621%26doi%3D10.2174%2F092986712801323180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Lynch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, A.</span><span> </span><span class="NLM_article-title">The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects</span> <span class="citation_source-journal">Am. Fam. Physician</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=17708140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BD2svovFGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=391-396&author=T.+Lynchauthor=A.+Price&title=The+effect+of+cytochrome+P450+metabolism+on+drug+response%2C+interactions%2C+and+adverse+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects</span></div><div class="casAuthors">Lynch Tom; Price Amy</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">391-6</span>
        ISSN:<span class="NLM_cas:issn">0002-838X</span>.
    </div><div class="casAbstract">Cytochrome P450 enzymes are essential for the metabolism of many medications.  Although this class has more than 50 enzymes, six of them metabolize 90 percent of drugs, with the two most significant enzymes being CYP3A4 and CYP2D6.  Genetic variability (polymorphism) in these enzymes may influence a patient's response to commonly prescribed drug classes, including beta blockers and antidepressants.  Cytochrome P450 enzymes can be inhibited or induced by drugs, resulting in clinically significant drug-drug interactions that can cause unanticipated adverse reactions or therapeutic failures.  Interactions with warfarin, antidepressants, antiepileptic drugs, and statins often involve the cytochrome P450 enzymes.  Knowledge of the most important drugs metabolized by cytochrome P450 enzymes, as well as the most potent inhibiting and inducing drugs, can help minimize the possibility of adverse drug reactions and interactions.  Although genotype tests can determine if a patient has a specific enzyme polymorphism, it has not been determined if routine use of these tests will improve outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQE6VB-Pf2cThe4jJGKT5N0fW6udTcc2eYeaf2SOp2Jp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svovFGhtQ%253D%253D&md5=68832276c56c8fb5f2818fc25bcc637f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%26aulast%3DPrice%26aufirst%3DA.%26atitle%3DThe%2520effect%2520of%2520cytochrome%2520P450%2520metabolism%2520on%2520drug%2520response%252C%2520interactions%252C%2520and%2520adverse%2520effects%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2007%26volume%3D76%26spage%3D391%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Huttunen, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahonen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raunio, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rautio, J.</span><span> </span><span class="NLM_article-title">Cytochrome P450-activated prodrugs: targeted drug delivery</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2346</span><span class="NLM_x">–</span> <span class="NLM_lpage">2365</span><span class="refDoi"> DOI: 10.2174/092986708785909120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F092986708785909120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18855665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCqsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2346-2365&author=K.+M.+Huttunenauthor=N.+Mahonenauthor=H.+Raunioauthor=J.+Rautio&title=Cytochrome+P450-activated+prodrugs%3A+targeted+drug+delivery&doi=10.2174%2F092986708785909120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450-activated prodrugs: targeted drug delivery</span></div><div class="casAuthors">Huttunen, Kristiina M.; Mahonen, Niina; Raunio, Hannu; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2346-2365</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP) enzymes are a superfamily of heme contg. proteins that catalyze xenobiotic metab. phase I reactions.  Oxidn. reactions are the most common CYP-catalyzed reactions for both endogenous substrates and exogenous compds., including drugs, although CYP enzymes are capable also to catalyze redn. reactions.  Whereas the majority of clin. used drugs are inactivated by CYPs, several prodrugs are bioconverted to their active species by these enzymes.  Therefore, this mechanism could be exploited to a greater extend, e.g. by taking advantage of the different CYP enzymes to achieve targeted drug delivery, to improve efficacy or to decrease the unwanted adverse effects of existing and novel drug mols.  This review describes the potential of CYP enzymes in prodrug design and summarizes a wide variety of CYP-activated prodrug structures, which are on the market or under the development.  The bioactivation mechanisms of each CYP-activated prodrug structure are described and the specificity for the different forms of CYP enzymes is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqPjpymFFv2LVg90H21EOLACvtfcHk0lioOFHRuNugpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCqsb%252FO&md5=9e8392539ebdf2cb44b080129fbc5e6e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F092986708785909120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785909120%26sid%3Dliteratum%253Aachs%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DMahonen%26aufirst%3DN.%26aulast%3DRaunio%26aufirst%3DH.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DCytochrome%2520P450-activated%2520prodrugs%253A%2520targeted%2520drug%2520delivery%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2346%26epage%3D2365%26doi%3D10.2174%2F092986708785909120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Stella, V. J.</span><span> </span><span class="NLM_article-title">Prodrugs as therapeutics</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1517/13543776.14.3.277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1517%2F13543776.14.3.277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslGiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=277-280&author=V.+J.+Stella&title=Prodrugs+as+therapeutics&doi=10.1517%2F13543776.14.3.277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs as therapeutics</span></div><div class="casAuthors">Stella, Valentino J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-280</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review and discussion.  Prodrugs are bioreversible derivs. of drug mols. used to overcome some barriers to the utility of the parent drug mol.  These barriers include, but are not limited to, soly., permeability, stability, presystemic metab. and targeting limitations.  The patent literature shows a dramatic increase in nos. of prodrug patents (>2000% increase in 2002 compared to 1993), with claims for cancer treatment comprising 37% of these.  This increase is largely due to the rise from North American-based multinationals and some smaller drug delivery companies mirroring the overall trend.  In 2001 and 2002, 14% of all new approved chem. drugs were prodrugs.  It appears that prodrugs to overcome barriers to the delivery of problematic drug candidates are becoming an integral part of the drug discovery paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMwmFxtC_ygLVg90H21EOLACvtfcHk0lioOFHRuNugpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslGiur4%253D&md5=904bd948cc7c772097eac32cec40170a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F13543776.14.3.277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.14.3.277%26sid%3Dliteratum%253Aachs%26aulast%3DStella%26aufirst%3DV.%2BJ.%26atitle%3DProdrugs%2520as%2520therapeutics%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2004%26volume%3D14%26spage%3D277%26epage%3D280%26doi%3D10.1517%2F13543776.14.3.277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Stella, V. J.; Borchardt, R. T.; Hageman, M. J.; Oliyai, R.; Maag, H.; Tilley, J.</span> <span class="citation_source-book">Prodrugs: Challenges and Rewards (Parts 1 and 2)</span>; <span class="NLM_publisher-name">AAPS Press</span>: <span class="NLM_publisher-loc">Arlington, VA</span>; <span class="NLM_publisher-name">Springer Science</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1007%2F978-0-387-49785-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=V.+J.+Stella&author=R.+T.+Borchardt&author=M.+J.+Hageman&author=R.+Oliyai&author=H.+Maag&author=J.+Tilley&title=Prodrugs%3A+Challenges+and+Rewards+%28Parts+1+and+2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-49785-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-49785-3%26sid%3Dliteratum%253Aachs%26aulast%3DStella%26aufirst%3DV.%2BJ.%26btitle%3DProdrugs%253A%2520Challenges%2520and%2520Rewards%2520%2528Parts%25201%2520and%25202%2529%26pub%3DAAPS%2520Press%26pub%3DSpringer%2520Science%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Guise, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mowday, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashoorzadeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia</span> <span class="citation_source-journal">Aizheng</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.5732/cjc.012.10285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.5732%2Fcjc.012.10285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23845143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFaiu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=80-86&author=C.+P.+Guiseauthor=A.+M.+Mowdayauthor=A.+Ashoorzadehauthor=R.+Yuanauthor=W.+H.+Linauthor=D.+H.+Wuauthor=J.+B.+Smaillauthor=A.+V.+Pattersonauthor=K.+Ding&title=Bioreductive+prodrugs+as+cancer+therapeutics%3A+targeting+tumor+hypoxia&doi=10.5732%2Fcjc.012.10285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia</span></div><div class="casAuthors">Guise, Christopher P.; Mowday, Alexandra M.; Amir, Ashoorzadeh; Yuan, Ran; Lin, Wan-hua; Wu, Dong-hai; Smaill, Jeff B.; Patterson, Adam V.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-86</span>CODEN:
                <span class="NLM_cas:coden">CJCHDJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sun Yat-sen University Cancer Center</span>)
        </div><div class="casAbstract">A review.  Hypoxia, a state of low oxygen, is a common feature of solid tumors and is assocd. with disease progression as well as resistance to radiotherapy and certain chemotherapeutic drugs.  Hypoxic regions in tumors, therefore, represent attractive targets for cancer therapy.  To date, five distinct classes of bioreactive prodrugs have been developed to target hypoxic cells in solid tumors.  These hypoxia-activated prodrugs, including nitro compds., N-oxides, quinones and metal complexes, generally share a common mechanism of activation whereby they are reduced by intracellular oxidoreductases in an oxygen-sensitive manner to form cytotoxins.  Several examples including PR-104, TH-302, and EO9 are currently undergoing phase II and phase III clin. evaluation.  In this review, we discuss the nature of tumor hypoxia as a therapeutic target, focusing on the development of bioreductive prodrugs.  We also describe the current knowledge of how each prodrug class is activated and detail the clin. progress of leading examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnm_C8IXOkcLVg90H21EOLACvtfcHk0libMFqgVFcNSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFaiu7%252FM&md5=68b99104d2f73798fb5878437760cd06</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.5732%2Fcjc.012.10285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5732%252Fcjc.012.10285%26sid%3Dliteratum%253Aachs%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DMowday%26aufirst%3DA.%2BM.%26aulast%3DAshoorzadeh%26aufirst%3DA.%26aulast%3DYuan%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DWu%26aufirst%3DD.%2BH.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DBioreductive%2520prodrugs%2520as%2520cancer%2520therapeutics%253A%2520targeting%2520tumor%2520hypoxia%26jtitle%3DAizheng%26date%3D2014%26volume%3D33%26spage%3D80%26epage%3D86%26doi%3D10.5732%2Fcjc.012.10285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Rautio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpulainen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliyai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savolainen, J.</span><span> </span><span class="NLM_article-title">Prodrugs: design and clinical applications</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nrd2468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnrd2468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18219308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=255-270&author=J.+Rautioauthor=H.+Kumpulainenauthor=T.+Heimbachauthor=R.+Oliyaiauthor=D.+Ohauthor=T.+Jarvinenauthor=J.+Savolainen&title=Prodrugs%3A+design+and+clinical+applications&doi=10.1038%2Fnrd2468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs: design and clinical applications</span></div><div class="casAuthors">Rautio, Jarkko; Kumpulainen, Hanna; Heimbach, Tycho; Oliyai, Reza; Oh, Dooman; Jaervinen, Tomi; Savolainen, Jouko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-270</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Prodrugs are bioreversible derivs. of drug mols. that undergo an enzymic and/or chem. transformation in vivo to release the active parent drug, which can then exert the desired pharmacol. effect.  In both drug discovery and development, prodrugs have become an established tool for improving physicochem., biopharmaceutical or pharmacokinetic properties of pharmacol. active agents.  About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend.  To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxnlEXYMLCVbVg90H21EOLACvtfcHk0libMFqgVFcNSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D&md5=481a088ad2ee4da062779b5b28a33cbb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd2468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2468%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DKumpulainen%26aufirst%3DH.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DOliyai%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DD.%26aulast%3DJarvinen%26aufirst%3DT.%26aulast%3DSavolainen%26aufirst%3DJ.%26atitle%3DProdrugs%253A%2520design%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D255%26epage%3D270%26doi%3D10.1038%2Fnrd2468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Huttunen, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raunio, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rautio, J.</span><span> </span><span class="NLM_article-title">Prodrugs-from serendipity to rational design</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">750</span><span class="NLM_x">–</span> <span class="NLM_lpage">771</span><span class="refDoi"> DOI: 10.1124/pr.110.003459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1124%2Fpr.110.003459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=21737530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=750-771&author=K.+M.+Huttunenauthor=H.+Raunioauthor=J.+Rautio&title=Prodrugs-from+serendipity+to+rational+design&doi=10.1124%2Fpr.110.003459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs - from serendipity to rational design</span></div><div class="casAuthors">Huttunen, Kristiina M.; Raunio, Hannu; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-771</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The prodrug concept has been used to improve undesirable properties of drugs since the late 19th century, although it was only at the end of the 1950s that the actual term prodrug was introduced for the first time.  Prodrugs are inactive, bioreversible derivs. of active drug mols. that must undergo an enzymic and/or chem. transformation in vivo to release the active parent drug, which can then elicit its desired pharmacol. effect in the body.  In most cases, prodrugs are simple chem. derivs. that are only one or two chem. or enzymic steps away from the active parent drug.  However, some prodrugs lack an obvious carrier or promoiety but instead result from a mol. modification of the prodrug it- self, which generates a new active compd.  Numerous prodrugs designed to overcome formulation, delivery, and toxicity barriers to drug utilization have reached the market.  In fact, approx. 20% of all small mol. drugs approved during the period 2000 to 2008 were prodrugs.  Although the development of a prodrug can be very challenging, the prodrug approach represents a feasible way to improve the erratic properties of investigational drugs or drugs already on the market.  This review introduces in depth the rationale behind the use of the prodrug approach from past to present, and also considers the possible problems that can arise from inadequate activation of prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrULDT77jec3bVg90H21EOLACvtfcHk0lhL5BdfM_xxKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtbrO&md5=5eafb63a714ed05cf60407ca588aa01a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.003459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.003459%26sid%3Dliteratum%253Aachs%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DRaunio%26aufirst%3DH.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DProdrugs-from%2520serendipity%2520to%2520rational%2520design%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D750%26epage%3D771%26doi%3D10.1124%2Fpr.110.003459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">McFadyen, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, G. I.</span><span> </span><span class="NLM_article-title">Cytochrome P450 1B1: a novel anticancer therapeutic target</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1517/14796694.1.2.259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1517%2F14796694.1.2.259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16555997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlOmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=259-263&author=M.+C.+McFadyenauthor=G.+I.+Murray&title=Cytochrome+P450+1B1%3A+a+novel+anticancer+therapeutic+target&doi=10.1517%2F14796694.1.2.259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 1B1: a novel anticancer therapeutic target</span></div><div class="casAuthors">McFadyen, Morag; Murray, Graeme I.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-263</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP)1B1 is overexpressed in tumor cells and is also recognized as a biomarker of the tumor phenotype.  This review highlights the tremendous potential of this enzyme as a novel cancer therapeutic target.  The range of therapeutic strategies including immunotherapeutics, CYP1B1-activated prodrugs and CYP1B1 inhibitors, that are currently being developed to exploit the presence and activity of CYP1B1 in tumor cells is outlined.  The therapeutic strategy, which is at the most advanced stage of development, is a CYP1B1-based vaccine which has already successfully completed a Phase I clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9cwEq9as3qrVg90H21EOLACvtfcHk0lhL5BdfM_xxKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlOmtbk%253D&md5=d600899104592d118ae8f73cc9f42b93</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F14796694.1.2.259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14796694.1.2.259%26sid%3Dliteratum%253Aachs%26aulast%3DMcFadyen%26aufirst%3DM.%2BC.%26aulast%3DMurray%26aufirst%3DG.%2BI.%26atitle%3DCytochrome%2520P450%25201B1%253A%2520a%2520novel%2520anticancer%2520therapeutic%2520target%26jtitle%3DFuture%2520Oncol.%26date%3D2005%26volume%3D1%26spage%3D259%26epage%3D263%26doi%3D10.1517%2F14796694.1.2.259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Potter, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruparelia, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ijaz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilsher, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanogho, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoang, T. T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, M. D.</span><span> </span><span class="NLM_article-title">DMU-212: A novel CYP1B1 activated anticancer prodrug</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">S117</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2002&pages=S117&author=G.+A.+Potterauthor=P.+C.+Butlerauthor=K.+C.+Rupareliaauthor=T.+Ijazauthor=N.+E.+Wilsherauthor=E.+Wanoghoauthor=H.+L.+Tanauthor=T.+T.+V.+Hoangauthor=L.+A.+Stanleyauthor=M.+D.+Burke&title=DMU-212%3A+A+novel+CYP1B1+activated+anticancer+prodrug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPotter%26aufirst%3DG.%2BA.%26aulast%3DButler%26aufirst%3DP.%2BC.%26aulast%3DRuparelia%26aufirst%3DK.%2BC.%26aulast%3DIjaz%26aufirst%3DT.%26aulast%3DWilsher%26aufirst%3DN.%2BE.%26aulast%3DWanogho%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DH.%2BL.%26aulast%3DHoang%26aufirst%3DT.%2BT.%2BV.%26aulast%3DStanley%26aufirst%3DL.%2BA.%26aulast%3DBurke%26aufirst%3DM.%2BD.%26atitle%3DDMU-212%253A%2520A%2520novel%2520CYP1B1%2520activated%2520anticancer%2520prodrug%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D86%26spage%3DS117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. W.</span><span> </span><span class="NLM_article-title">CYP epoxygenase derived EETs: from cardiovascular protection to human cancer therapy</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1454</span><span class="NLM_x">–</span> <span class="NLM_lpage">1469</span><span class="refDoi"> DOI: 10.2174/1568026611313120007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F1568026611313120007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23688135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WntrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1454-1469&author=C.+Chenauthor=D.+W.+Wang&title=CYP+epoxygenase+derived+EETs%3A+from+cardiovascular+protection+to+human+cancer+therapy&doi=10.2174%2F1568026611313120007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy</span></div><div class="casAuthors">Chen, Chen; Wang, Dao Wen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1454-1469</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Arachidonic acids are converted to eicosanoid mediators by the distinct enzyme systems: cyclooxygenase, lipoxygenase and cytochrome P 450 (CYP) monooxygenase pathways ( ω/ω-1-hydroxylases and epoxygenases).  CYP2J2, CYP2C8 and CYP2C9 are the predominant epoxygenase isoforms abundantly expressed in the endothelium, myocardium, and kidney in human.  The primary epoxidn. products by epoxygenases are four regioisomers of cisepoxyeicosatrienoic acids (EETs): 5,6-, 8,9-, 11,12-, and 14,15-EETs.  Numerous studies demonstrated that the cardiovascular protective effects of CYP epoxygenases and EETs range from vasodilation, anti-hypertension, pro-angiogenesis, anti-atherosclerosis, and anti-inflammation to anti-injury caused by ischemia-reperfusion.  The roles of arachidonic acids and its metabolites in cancer biol. have recently attracted great attentions.  However, CYP epoxygenase derived EETs and cancer has received little attention.  It was demonstrated that CYP epoxygenases and EETs are significantly upregulated in human tumors and promote tumor progression and metastasis.  Addnl., specific inhibitors of CYP2J2, derived from terfenadine, exhibit strong anti-tumor activity in vitro and in vivo.  It is implicated that CYP2J2 may be a therapeutic target for treating human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkBhXAIWmmAbVg90H21EOLACvtfcHk0lhL5BdfM_xxKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WntrrL&md5=cc1b4be6547a8632d3ea5a49cba53d0a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F1568026611313120007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313120007%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%2BW.%26atitle%3DCYP%2520epoxygenase%2520derived%2520EETs%253A%2520from%2520cardiovascular%2520protection%2520to%2520human%2520cancer%2520therapy%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1454%26epage%3D1469%26doi%3D10.2174%2F1568026611313120007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span> </span><span class="NLM_article-title">Cytochrome P450-activated prodrugs</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span><span class="refDoi"> DOI: 10.4155/fmc.12.197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.4155%2Ffmc.12.197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23360144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=213-228&author=P.+R.+Ortiz+de+Montellano&title=Cytochrome+P450-activated+prodrugs&doi=10.4155%2Ffmc.12.197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450-activated prodrugs</span></div><div class="casAuthors">Ortiz de Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-228</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  A prodrug is a compd. that has negligible, or lower, activity against a specified pharmacol. target than one of its major metabolites.  Prodrugs can be used to improve drug delivery or pharmacokinetics, to decrease toxicity, or to target the drug to specific cells or tissues.  Ester and phosphate hydrolysis are widely used in prodrug design because of their simplicity, but such approaches are relatively ineffective for targeting drugs to specific sites.  The activation of prodrugs by the cytochrome P 450 system provides a highly versatile approach to prodrug design that is particularly adaptable for targeting drug activation to the liver, to tumors or to hypoxic tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGS2TH9y2VLVg90H21EOLACvtfcHk0lhfTEyFfd9row"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aiurk%253D&md5=dbb23db4fb8703d63dc8aa1f1d0d9dc1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.197%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DCytochrome%2520P450-activated%2520prodrugs%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D213%26epage%3D228%26doi%3D10.4155%2Ffmc.12.197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Nishida, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Montellano, P. R.</span><span> </span><span class="NLM_article-title">Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1124/mol.110.065045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1124%2Fmol.110.065045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20566689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFersbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=497-502&author=C.+R.+Nishidaauthor=M.+Leeauthor=P.+R.+de+Montellano&title=Efficient+hypoxic+activation+of+the+anticancer+agent+AQ4N+by+CYP2S1+and+CYP2W1&doi=10.1124%2Fmol.110.065045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1</span></div><div class="casAuthors">Nishida, Clinton R.; Lee, Melody; Ortiz de Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">497-502</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">AQ4N [1,4-bis{[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione], a prodrug with two dimethylamino N-oxide groups, is converted to the topoisomerase II inhibitor AQ4 [1,4-bis{[2-(dimethylamino)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione] by redn. of the N-oxides to dimethylamino substituents.  Earlier studies showed that several drug-metabolizing cytochrome P 450 enzymes can catalyze this reductive reaction under hypoxic conditions comparable with those in solid tumors.  CYP2S1 and CYP2W1, two extrahepatic P 450 enzymes identified from the human genome whose functions are unknown, are expressed in hypoxic tumor cells at much higher levels than in normal tissue.  Here, we demonstrate that CYP2S1, contrary to a published report (Mol Pharmacol 76:1031-1043, 2009), is efficiently reduced by NADPH-P 450 reductase.  Most importantly, both CYP2S1 and CYP2W1 are better catalysts for the reductive activation of AQ4N to AQ4 than all previously examd. P 450 enzymes.  The overexpression of CYP2S1 and CYP2W1 in tumor tissues, together with their high catalytic activities for AQ4N activation, suggests that they may be exploited for the localized activation of anticancer prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4p-3yzvt6bVg90H21EOLACvtfcHk0lhfTEyFfd9row"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFersbjO&md5=537f933a472173bc88f656f68593a0c5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.065045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.065045%26sid%3Dliteratum%253Aachs%26aulast%3DNishida%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DM.%26aulast%3Dde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DEfficient%2520hypoxic%2520activation%2520of%2520the%2520anticancer%2520agent%2520AQ4N%2520by%2520CYP2S1%2520and%2520CYP2W1%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D78%26spage%3D497%26epage%3D502%26doi%3D10.1124%2Fmol.110.065045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rodriguez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, D. A.</span><span> </span><span class="NLM_article-title">CYP1A1 regulates breast cancer proliferation and survival</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-12-0675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1158%2F1541-7786.MCR-12-0675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23576571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFenu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=780-792&author=M.+Rodriguezauthor=D.+A.+Potter&title=CYP1A1+regulates+breast+cancer+proliferation+and+survival&doi=10.1158%2F1541-7786.MCR-12-0675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CYP1A1 Regulates Breast Cancer Proliferation and Survival</span></div><div class="casAuthors">Rodriguez, Mariangellys; Potter, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">780-792</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cytochrome P 450-1A1 (CYP1A1) is an extrahepatic phase I metabolizing enzyme whose expression is suppressed under physiol. conditions but can be induced by substrates via the aryl hydrocarbon receptor (AhR).  Recent studies have shown that the majority of breast cancer tumors constitutively express CYP1A1.  These findings led us to test the hypothesis that CYP1A1 promotes breast cancer progression by evaluating the effects of CYP1A1 knockdown on the proliferation and survival of the MCF7 and MDA-MB-231 lines.  Independently of estrogen receptor status, CYP1A1 knockdown decreased colony formation, decreased cell proliferation, blocked the cell cycle at G0-G1 assocd. with redn. of cyclin D1, and increased apoptosis assocd. with redn. of survivin.  CYP1A1 knockdown markedly increased phosphorylation of AMP-activated protein kinase (AMPK) and decreased phosphorylation of AKT, extracellular signal-regulated kinases 1 and 2 (ERK1/2), and 70-kDa ribosomal protein S6 kinase (P70S6K).  AMPK inhibition by compd. C partially abrogated the proapoptotic effects of CYP1A1 knockdown, suggesting that effects of CYP1A1 knockdown are mediated in part through AMPK signaling.  Consistent with CYP1A1 knockdown, pharmacol. redn. of CYP1A1 levels by the phytopolyphenol carnosol also correlated with impaired proliferation and induced AMPK phosphorylation.  These results indicate that redn. of basal CYP1A1 expression is crit. for inhibition of proliferation, which is not affected by α-naphthoflavone-mediated inhibition of CYP1A1 activity nor modulated by AhR silencing.  This study supports the notion that CYP1A1 promotes breast cancer proliferation and survival, at least in part, through suppression of AMPK signaling and that redn. of CYP1A1 levels is a potential strategy for breast cancer therapeutics.  Mol Cancer Res; 11(7); 780-92. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnj6PvXHmqh7Vg90H21EOLACvtfcHk0lhfTEyFfd9row"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFenu7zF&md5=44d8766ab0ad65a500180527b814a832</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-12-0675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-12-0675%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DPotter%26aufirst%3DD.%2BA.%26atitle%3DCYP1A1%2520regulates%2520breast%2520cancer%2520proliferation%2520and%2520survival%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2013%26volume%3D11%26spage%3D780%26epage%3D792%26doi%3D10.1158%2F1541-7786.MCR-12-0675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Pors, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiakos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searcey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, L. H.</span><span> </span><span class="NLM_article-title">Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">12062</span><span class="NLM_x">–</span> <span class="NLM_lpage">12064</span><span class="refDoi"> DOI: 10.1039/c1cc15638a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1039%2Fc1cc15638a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22002321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=12062-12064&author=K.+Porsauthor=P.+M.+Loadmanauthor=S.+D.+Shnyderauthor=M.+Sutherlandauthor=H.+M.+Sheldrakeauthor=M.+Guinoauthor=K.+Kiakosauthor=J.+A.+Hartleyauthor=M.+Searceyauthor=L.+H.+Patterson&title=Modification+of+the+duocarmycin+pharmacophore+enables+CYP1A1+targeting+for+biological+activity&doi=10.1039%2Fc1cc15638a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity</span></div><div class="casAuthors">Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark; Sheldrake, Helen M.; Guino, Meritxell; Kiakos, Konstantinos; Hartley, John A.; Searcey, Mark; Patterson, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">12062-12064</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The identification of an agent that is selectively activated by a cytochrome P 450 (CYP) has the potential for tissue specific dose intensification as a means of significantly improving its therapeutic value.  Towards this goal, we disclose evidence for the pathway of activation of a duocarmycin analog, ICT2700, which targets CYP1A1 for biol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7hViB3S6PnbVg90H21EOLACvtfcHk0lhfTEyFfd9row"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntb7P&md5=85cf95f8b0edca5d63e0e22ea584b7c9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc1cc15638a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cc15638a%26sid%3Dliteratum%253Aachs%26aulast%3DPors%26aufirst%3DK.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DSutherland%26aufirst%3DM.%26aulast%3DSheldrake%26aufirst%3DH.%2BM.%26aulast%3DGuino%26aufirst%3DM.%26aulast%3DKiakos%26aufirst%3DK.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DSearcey%26aufirst%3DM.%26aulast%3DPatterson%26aufirst%3DL.%2BH.%26atitle%3DModification%2520of%2520the%2520duocarmycin%2520pharmacophore%2520enables%2520CYP1A1%2520targeting%2520for%2520biological%2520activity%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2011%26volume%3D47%26spage%3D12062%26epage%3D12064%26doi%3D10.1039%2Fc1cc15638a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Sheldrake, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travica, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsalem, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illingworth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cresswell, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuillon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mkrtchian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searcey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingelman-Sundberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pors, K.</span><span> </span><span class="NLM_article-title">Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6273</span><span class="NLM_x">–</span> <span class="NLM_lpage">6277</span><span class="refDoi"> DOI: 10.1021/jm4000209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4000209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6273-6277&author=H.+M.+Sheldrakeauthor=S.+Travicaauthor=I.+Johanssonauthor=P.+M.+Loadmanauthor=M.+Sutherlandauthor=L.+Elsalemauthor=N.+Illingworthauthor=A.+J.+Cresswellauthor=T.+Reuillonauthor=S.+D.+Shnyderauthor=S.+Mkrtchianauthor=M.+Searceyauthor=M.+Ingelman-Sundbergauthor=L.+H.+Pattersonauthor=K.+Pors&title=Re-engineering+of+the+duocarmycin+structural+architecture+enables+bioprecursor+development+targeting+CYP1A1+and+CYP2W1+for+biological+activity&doi=10.1021%2Fjm4000209"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm4000209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4000209%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrake%26aufirst%3DH.%2BM.%26aulast%3DTravica%26aufirst%3DS.%26aulast%3DJohansson%26aufirst%3DI.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DSutherland%26aufirst%3DM.%26aulast%3DElsalem%26aufirst%3DL.%26aulast%3DIllingworth%26aufirst%3DN.%26aulast%3DCresswell%26aufirst%3DA.%2BJ.%26aulast%3DReuillon%26aufirst%3DT.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DMkrtchian%26aufirst%3DS.%26aulast%3DSearcey%26aufirst%3DM.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DPatterson%26aufirst%3DL.%2BH.%26aulast%3DPors%26aufirst%3DK.%26atitle%3DRe-engineering%2520of%2520the%2520duocarmycin%2520structural%2520architecture%2520enables%2520bioprecursor%2520development%2520targeting%2520CYP1A1%2520and%2520CYP2W1%2520for%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6273%26epage%3D6277%26doi%3D10.1021%2Fjm4000209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Sutherland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laye, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illingworth, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alandas, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searcey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pors, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, L. H.</span><span> </span><span class="NLM_article-title">Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1158%2F1535-7163.MCT-12-0405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23033491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntValug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=27-37&author=M.+Sutherlandauthor=J.+H.+Gillauthor=P.+M.+Loadmanauthor=J.+P.+Layeauthor=H.+M.+Sheldrakeauthor=N.+A.+Illingworthauthor=M.+N.+Alandasauthor=P.+A.+Cooperauthor=M.+Searceyauthor=K.+Porsauthor=S.+D.+Shnyderauthor=L.+H.+Patterson&title=Antitumor+activity+of+a+duocarmycin+analogue+rationalized+to+be+metabolically+activated+by+cytochrome+P450+1A1+in+human+transitional+cell+carcinoma+of+the+bladder&doi=10.1158%2F1535-7163.MCT-12-0405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder</span></div><div class="casAuthors">Sutherland, Mark; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, Mark; Pors, Klaus; Shnyder, Steve D.; Patterson, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We identify cytochrome P 450 1A1 (CYP1A1) as a target for tumor-selective drug development in bladder cancer and describe the characterization of ICT2700, designed to be metabolized from a prodrug to a potent cytotoxin selectively by CYP1A1.  Elevated CYP1A1 expression was shown in human bladder cancer relative to normal human tissues.  RT112 bladder cancer cells, endogenously expressing CYP1A1, were selectively chemosensitive to ICT2700, whereas EJ138 bladder cells that do not express CYP1A1 were significantly less responsive.  Introduction of CYP1A1 into EJ138 cells resulted in 75-fold increased chemosensitivity to ICT2700 relative to wild-type EJ138.  Negligible chemosensitivity was obsd. in ICT2700 in EJ138 cells expressing CYP1A2 or with exposure of EJ138 cells to CYP1B1- or CYP3A4-generated metabolites of ICT2700.  Chemosensitivity to ICT2700 was also negated in EJ138-CYP1A1 cells by the CYP1 inhibitor α-naphthoflavone.  Furthermore, ICT2700 did not induce expression of the AhR-regulated CYP1 family, indicating that constitutive CYP1A1 expression is sufficient for activation of ICT2700.  Consistent with the selective activity by CYP1A1 was a time and concn.-dependent increase in γ-H2AX protein expression, indicative of DNA damage, assocd. with the activation of ICT2700 in RT112 but not EJ138 cells.  In mice-bearing CYP1A1-pos. and neg. isogenic tumors, ICT2700 administration resulted in an antitumor response only in the CYP1A1-expressing tumor model.  This antitumor response was assocd. with detection of the CYP1A1-activated metabolite in tumors but not in the liver.  Our findings support the further development of ICT2700 as a tumor-selective treatment for human bladder cancers.  Mol Cancer Ther; 12(1); 27-37. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYjJoCLDNXLVg90H21EOLACvtfcHk0lj3xQyp33QHvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntValug%253D%253D&md5=37b3d9b31e93f01da485bca19fe2a48e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0405%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DM.%26aulast%3DGill%26aufirst%3DJ.%2BH.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DLaye%26aufirst%3DJ.%2BP.%26aulast%3DSheldrake%26aufirst%3DH.%2BM.%26aulast%3DIllingworth%26aufirst%3DN.%2BA.%26aulast%3DAlandas%26aufirst%3DM.%2BN.%26aulast%3DCooper%26aufirst%3DP.%2BA.%26aulast%3DSearcey%26aufirst%3DM.%26aulast%3DPors%26aufirst%3DK.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DPatterson%26aufirst%3DL.%2BH.%26atitle%3DAntitumor%2520activity%2520of%2520a%2520duocarmycin%2520analogue%2520rationalized%2520to%2520be%2520metabolically%2520activated%2520by%2520cytochrome%2520P450%25201A1%2520in%2520human%2520transitional%2520cell%2520carcinoma%2520of%2520the%2520bladder%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D27%26epage%3D37%26doi%3D10.1158%2F1535-7163.MCT-12-0405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Androutsopoulos, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsatsakis, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spandidos, D. A.</span><span> </span><span class="NLM_article-title">Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="refDoi"> DOI: 10.1186/1471-2407-9-187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1186%2F1471-2407-9-187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=19531241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvlt1SjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=187&author=V.+P.+Androutsopoulosauthor=A.+M.+Tsatsakisauthor=D.+A.+Spandidos&title=Cytochrome+P450+CYP1A1%3A+wider+roles+in+cancer+progression+and+prevention&doi=10.1186%2F1471-2407-9-187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention</span></div><div class="casAuthors">Androutsopoulos Vasilis P; Tsatsakis Aristidis M; Spandidos Demetrios A</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CYP1A1 is one of the main cytochrome P450 enzymes, examined extensively for its capacity to activate compounds with carcinogenic properties.  Continuous exposure to inhalation chemicals and environmental carcinogens is thought to increase the level of CYP1A1 expression in extrahepatic tissues, through the aryl hydrocarbon receptor (AhR).  Although the latter has long been recognized as a ligand-induced transcription factor, which is responsible for the xenobiotic activating pathway of several phase I and phase II metabolizing enzymes, recent evidence suggests that the AhR is involved in various cell signaling pathways critical to cell cycle regulation and normal homeostasis.  Disregulation of these pathways is implicated in tumor progression.  In addition, it is becoming increasingly evident that CYP1A1 plays an important role in the detoxication of environmental carcinogens, as well as in the metabolic activation of dietary compounds with cancer preventative activity.  Ultimately the contribution of CYP1A1 to cancer progression or prevention may depend on the balance of procarcinogen activation/detoxication and dietary natural product extrahepatic metabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_xKAnLQ_73VMGsG_HTXYFfW6udTcc2ebGtu6mgFTcF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvlt1SjtA%253D%253D&md5=4ce7773732301c4d620307dc2ce8f441</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-9-187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-9-187%26sid%3Dliteratum%253Aachs%26aulast%3DAndroutsopoulos%26aufirst%3DV.%2BP.%26aulast%3DTsatsakis%26aufirst%3DA.%2BM.%26aulast%3DSpandidos%26aufirst%3DD.%2BA.%26atitle%3DCytochrome%2520P450%2520CYP1A1%253A%2520wider%2520roles%2520in%2520cancer%2520progression%2520and%2520prevention%26jtitle%3DBMC%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D187%26doi%3D10.1186%2F1471-2407-9-187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Nguyen, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradfield, C. A.</span><span> </span><span class="NLM_article-title">The search for endogenous activators of the aryl hydrocarbon receptor</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1021/tx7001965</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7001965" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=102-116&author=L.+P.+Nguyenauthor=C.+A.+Bradfield&title=The+search+for+endogenous+activators+of+the+aryl+hydrocarbon+receptor&doi=10.1021%2Ftx7001965"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Ftx7001965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7001965%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%2BP.%26aulast%3DBradfield%26aufirst%3DC.%2BA.%26atitle%3DThe%2520search%2520for%2520endogenous%2520activators%2520of%2520the%2520aryl%2520hydrocarbon%2520receptor%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D102%26epage%3D116%26doi%3D10.1021%2Ftx7001965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Shimada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii-Kuriyama, Y.</span><span> </span><span class="NLM_article-title">Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2004.tb03162.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1111%2Fj.1349-7006.2004.tb03162.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=14720319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFOrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=1-6&author=T.+Shimadaauthor=Y.+Fujii-Kuriyama&title=Metabolic+activation+of+polycyclic+aromatic+hydrocarbons+to+carcinogens+by+cytochromes+P450+1A1+and+1B1&doi=10.1111%2Fj.1349-7006.2004.tb03162.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1</span></div><div class="casAuthors">Shimada, Tsutomu; Fujii-Kuriyama, Yoshiaki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">A review.  Polycyclic arom. hydrocarbons (PAHs) are ubiquitously distributed environmental chems.  PAHs acquire carcinogenicity only after they were activated by xenobiotic-metabolizing enzymes to highly reactive metabolites capable of attacking cellular DNA.  Cytochrome P 450 (CYP) enzymes are central to the metabolic activation of these PAHs to epoxide intermediates, which are converted with the aid of epoxide hydrolase to the ultimate carcinogens, diol-epoxides.  Historically, CYP1A1 was believed to be the only enzyme that catalyzes activation of these procarcinogenic PAHs.  However, recent studies have established that CYP1B1, a newly identified member of the CYP1 family, plays a very important role in the metabolic activation of PAHs.  In CYP1B1 gene-knockout mice treated with 7,12-dimethylbenz[a]anthracene and dibenzo[a,l]pyrene, decreased rates of tumor formation were obsd., when compared to wild-type mice.  Significantly, gene expression of CYP1A1 and 1B1 is induced by PAHs and polyhalogenated hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin through the arylhydrocarbon receptor.  Differences in the susceptibility of individuals to the adverse action of PAHs may, in part, be due to differences in the levels of expression of CYP1A1 and 1B1 and to genetic variations in the CYP1A1 and 1B1 genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNa2KB5QQ18rVg90H21EOLACvtfcHk0lhUfEUjKP3gMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFOrtL8%253D&md5=b71f6b453d43b5aceaf8ea7c76d085b0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2004.tb03162.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2004.tb03162.x%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DFujii-Kuriyama%26aufirst%3DY.%26atitle%3DMetabolic%2520activation%2520of%2520polycyclic%2520aromatic%2520hydrocarbons%2520to%2520carcinogens%2520by%2520cytochromes%2520P450%25201A1%2520and%25201B1%26jtitle%3DCancer%2520Sci.%26date%3D2004%26volume%3D95%26spage%3D1%26epage%3D6%26doi%3D10.1111%2Fj.1349-7006.2004.tb03162.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Altmann, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gertsch, J.</span><span> </span><span class="NLM_article-title">Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span><span class="refDoi"> DOI: 10.1039/B515619J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1039%2FB515619J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=17390000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Oqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2007&pages=327-357&author=K.+H.+Altmannauthor=J.+Gertsch&title=Anticancer+drugs+from+nature-natural+products+as+a+unique+source+of+new+microtubule-stabilizing+agents&doi=10.1039%2FB515619J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents</span></div><div class="casAuthors">Altmann, Karl-Heinz; Gertsch, Jurg</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-357</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review on the current state of research in the area of microtubule-stabilizing agents from natural sources, with a primary focus on the biochem., biol., and pharmacol. assocd. with these compds.  A variety of natural products have been discovered over the last decade to inhibit human cancer cell proliferation through a taxol-like mechanism.  These compds. represent a whole new range of structurally diverse lead structures for anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcQVNENM_PALVg90H21EOLACvtfcHk0lhUfEUjKP3gMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Oqsro%253D&md5=4da4dab103a7fd80567920b602bdb8c2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FB515619J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB515619J%26sid%3Dliteratum%253Aachs%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DGertsch%26aufirst%3DJ.%26atitle%3DAnticancer%2520drugs%2520from%2520nature-natural%2520products%2520as%2520a%2520unique%2520source%2520of%2520new%2520microtubule-stabilizing%2520agents%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2007%26volume%3D24%26spage%3D327%26epage%3D357%26doi%3D10.1039%2FB515619J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Maayah, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Gendy, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kadi, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korashy, H. M.</span><span> </span><span class="NLM_article-title">Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation</span> <span class="citation_source-journal">Arch. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">856</span><span class="refDoi"> DOI: 10.1007/s00204-012-0996-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1007%2Fs00204-012-0996-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23288144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVGmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=847-856&author=Z.+H.+Maayahauthor=M.+A.+El+Gendyauthor=A.+O.+El-Kadiauthor=H.+M.+Korashy&title=Sunitinib%2C+a+tyrosine+kinase+inhibitor%2C+induces+cytochrome+P450+1A1+gene+in+human+breast+cancer+MCF7+cells+through+ligand-independent+aryl+hydrocarbon+receptor+activation&doi=10.1007%2Fs00204-012-0996-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation</span></div><div class="casAuthors">Maayah, Zaid H.; El Gendy, Mohamed A. M.; El-Kadi, Ayman O.; Korashy, Hesham M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">847-856</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Sunitinib (SUN) is a new multi-targeted oral tyrosine kinase inhibitor that has both anti-angiogenic and anti-tumor activities.  However, information reported in the literature on the effects of SUN on the constitutive expression of cytochrome P 450 1A1 (CYP1A1) gene in cells from mammalian species remains unclear.  Therefore, the main objectives of the current work were to investigate the potentiality of SUN to induce CYP1A1 gene expression in human breast cancer MCF7 cells and to explore the mol. mechanisms involved.  Our results showed that SUN induced the CYP1A1 mRNA, protein, and activity levels in a concn.-dependent manner in MCF7 cells.  The increase in CYP1A1 mRNA by SUN was completely blocked by the transcriptional inhibitor, actinomycin D; implying that SUN increased de novo RNA synthesis.  Furthermore, the ability of SUN to increase luciferase reporter gene expression suggests an aryl hydrocarbon receptor (AhR)-dependent transcriptional control and excludes the possibility of any posttranscriptional mechanisms.  In addn., blocking of AhR activation by resveratrol, a well-known AhR antagonist, prevented the SUN-induced CYP1A1 gene expression, further confirms the involvement of AhR.  Interestingly, this was assocd. with the inability of SUN to directly bind to and induce transformation of cytosolic AhR to its DNA-binding form in vitro, suggesting that the effect of SUN does not involve direct binding to AhR.  The current manuscript provides the first evidence for the ability of SUN to induce CYP1A1 gene expression in MCF7 cells through AhR ligand-independent mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc-m-DDKDjYrVg90H21EOLACvtfcHk0lhUfEUjKP3gMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVGmsg%253D%253D&md5=cedd024c06f1b8e01094d27e7d5b2ed2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00204-012-0996-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-012-0996-y%26sid%3Dliteratum%253Aachs%26aulast%3DMaayah%26aufirst%3DZ.%2BH.%26aulast%3DEl%2BGendy%26aufirst%3DM.%2BA.%26aulast%3DEl-Kadi%26aufirst%3DA.%2BO.%26aulast%3DKorashy%26aufirst%3DH.%2BM.%26atitle%3DSunitinib%252C%2520a%2520tyrosine%2520kinase%2520inhibitor%252C%2520induces%2520cytochrome%2520P450%25201A1%2520gene%2520in%2520human%2520breast%2520cancer%2520MCF7%2520cells%2520through%2520ligand-independent%2520aryl%2520hydrocarbon%2520receptor%2520activation%26jtitle%3DArch.%2520Toxicol.%26date%3D2013%26volume%3D87%26spage%3D847%26epage%3D856%26doi%3D10.1007%2Fs00204-012-0996-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Murray, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patimalla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heys, S. D.</span><span> </span><span class="NLM_article-title">Profiling the expression of cytochrome P450 in breast cancer</span> <span class="citation_source-journal">Histopathology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1111/j.1365-2559.2010.03606.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1111%2Fj.1365-2559.2010.03606.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20716162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC3cjlsFGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2010&pages=202-211&author=G.+I.+Murrayauthor=S.+Patimallaauthor=K.+N.+Stewartauthor=I.+D.+Millerauthor=S.+D.+Heys&title=Profiling+the+expression+of+cytochrome+P450+in+breast+cancer&doi=10.1111%2Fj.1365-2559.2010.03606.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling the expression of cytochrome P450 in breast cancer</span></div><div class="casAuthors">Murray Graeme I; Patimalla Siva; Stewart Keith N; Miller Iain D; Heys Steven D</div><div class="citationInfo"><span class="NLM_cas:title">Histopathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">202-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  The cytochrome P450s (P450) are key oxidative enzymes that metabolize many carcinogens and anticancer drugs.  Thus, these enzymes influence tumour development, tumour response to therapy and are putative tumour biomarkers.  The aim was to define the P450 expression profile in breast cancer and establish the significance of P450 expression in this tumour type.  METHODS AND RESULTS:  A tissue microarray containing 170 breast cancers of no special type was immunostained for a panel of 21 P450s.  The highest percentage of strong immunopositivity in breast cancers was seen for CYP4X1 (50.8%), CYP2S1 (37.5%) and CYP2U1 (32.2%), while CYP2J (98.6%) and CYP3A43 (70.7%) were the P450s that most frequently displayed no immunoreactivity.  CYP4V2 (P = 0.01), CYP4X1 (P = 0.01) and CYP4Z1 (P = 0.01) showed correlations with tumour grade.  CYP1B1 (P = 0.001), CYP3A5 (P = 0.001) and CYP51 (P = 0.005) showed the most significant correlations with oestrogen receptor status.  Correlations with survival were identified for CYP2S1 (P = 0.03), CYP3A4 (P = 0.025), CYP4V2 (P = 0.026) and CYP26A1 (P = 0.03), although none of these P450s was an independent marker of prognosis.  CONCLUSIONS:  This study has defined the expression profile of cytochrome P450s in breast cancer and may offer their potential application as biomarkers to aid decisions regarding optimal adjuvant hormonal therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0ZpvUgyuFaDAyhZbj3lKdfW6udTcc2eYOSh0sydtKrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjlsFGnsg%253D%253D&md5=96f08d44d30348e8511e91145b731b75</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2559.2010.03606.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2559.2010.03606.x%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DG.%2BI.%26aulast%3DPatimalla%26aufirst%3DS.%26aulast%3DStewart%26aufirst%3DK.%2BN.%26aulast%3DMiller%26aufirst%3DI.%2BD.%26aulast%3DHeys%26aufirst%3DS.%2BD.%26atitle%3DProfiling%2520the%2520expression%2520of%2520cytochrome%2520P450%2520in%2520breast%2520cancer%26jtitle%3DHistopathology%26date%3D2010%26volume%3D57%26spage%3D202%26epage%3D211%26doi%3D10.1111%2Fj.1365-2559.2010.03606.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Vinothini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagini, S.</span><span> </span><span class="NLM_article-title">Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NFkappaB signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast</span> <span class="citation_source-journal">Clin. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">411</span><span class="NLM_x">, </span> <span class="NLM_fpage">368</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.1016/j.cca.2009.11.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.cca.2009.11.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=19995559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2010&pages=368-374&author=G.+Vinothiniauthor=S.+Nagini&title=Correlation+of+xenobiotic-metabolizing+enzymes%2C+oxidative+stress+and+NFkappaB+signaling+with+histological+grade+and+menopausal+status+in+patients+with+adenocarcinoma+of+the+breast&doi=10.1016%2Fj.cca.2009.11.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NFκB signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast</span></div><div class="casAuthors">Vinothini, Govindarajah; Nagini, Siddavaram</div><div class="citationInfo"><span class="NLM_cas:title">Clinica Chimica Acta</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">411</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">368-374</span>CODEN:
                <span class="NLM_cas:coden">CCATAR</span>;
        ISSN:<span class="NLM_cas:issn">0009-8981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Adenocarcinoma of the breast is the most common cancer worldwide and accounts for the highest morbidity and mortality.  The increasing global incidence of breast cancer emphasizes the need to understand the mol. mechanisms of breast tumorigenesis.  The present study was designed to correlate changes in xenobiotic-metabolizing enzymes (XME), oxidative stress and NFκB signaling with histol. grading and menopausal status in breast cancer patients.  Sixty breast cancer patients histol. categorized as grades I, II and III, and as pre- and postmenopausal were chosen for the study.  We analyzed phase I and phase II XME activities as well as the expression of the CYP isoforms CYP1A1 and CYP1B1, oxidative stress markers, and the expression of NFκB family members in tumor and adjacent tissues by immunohistochem. localization and Western blot analyses.  The breast tumors analyzed in the present study were characterized by increased activities of xenobiotic-metabolizing enzymes and enhanced oxidative damage to lipids, proteins, and DNA assocd. with variations in the expression of NFκB family members.  The magnitude of the changes was however more pronounced in premenopausal patients and in grade III breast tumors.  The present study delineates the correlation between XME-mediated oxidative stress and NFκB signaling that leads to the development of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkxCVRl-2LHrVg90H21EOLACvtfcHk0lhIpMH2JbLqtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCmsLw%253D&md5=a77c7062bb92b91ac51109a2ec80220f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.cca.2009.11.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cca.2009.11.034%26sid%3Dliteratum%253Aachs%26aulast%3DVinothini%26aufirst%3DG.%26aulast%3DNagini%26aufirst%3DS.%26atitle%3DCorrelation%2520of%2520xenobiotic-metabolizing%2520enzymes%252C%2520oxidative%2520stress%2520and%2520NFkappaB%2520signaling%2520with%2520histological%2520grade%2520and%2520menopausal%2520status%2520in%2520patients%2520with%2520adenocarcinoma%2520of%2520the%2520breast%26jtitle%3DClin.%2520Chim.%2520Acta%26date%3D2010%26volume%3D411%26spage%3D368%26epage%3D374%26doi%3D10.1016%2Fj.cca.2009.11.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">McLean, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soto, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brantley, E.</span><span> </span><span class="NLM_article-title">Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1665</span><span class="NLM_x">–</span> <span class="NLM_lpage">1674</span><span class="refDoi"> DOI: 10.1002/ijc.23244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1002%2Fijc.23244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18059023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVahsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=1665-1674&author=L.+McLeanauthor=U.+Sotoauthor=K.+Agamaauthor=J.+Francisauthor=R.+Jimenezauthor=Y.+Pommierauthor=L.+Sowersauthor=E.+Brantley&title=Aminoflavone+induces+oxidative+DNA+damage+and+reactive+oxidative+species-mediated+apoptosis+in+breast+cancer+cells&doi=10.1002%2Fijc.23244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells</span></div><div class="casAuthors">McLean, Lancelot; Soto, Ubaldo; Agama, Keli; Francis, Jawad; Jimenez, Randi; Pommier, Yves; Sowers, Lawrence; Brantley, Eileen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1665-1674</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Aminoflavone (5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methylchromen-4-one; AF; NSC 686288), a novel anticancer candidate agent, is undergoing clin. evaluation.  AF induces DNA-protein cross-links (DPCs), γ-H2AX phosphorylation, aryl hydrocarbon receptor (AhR) signaling, apoptosis and its own metab. via cytochrome P 4501A1 and 1A2 (CYP1A1/1A2) activation in sensitive estrogen receptor pos. (ER+) MCF7 breast cancer cells.  Estrogen receptor neg. (ER-) breast cancer is typically more aggressive with a poorer prognosis.  In this investigation, we evaluated the ability of AF to induce reactive oxygen species (ROS) formation, oxidative DNA damage and apoptosis in ER- MDA-MB-468 breast cancer cells.  The antioxidant, N-acetyl-L-cysteine (NAC), attenuated the cytotoxic effects of AF in MDA-MB-468 cells; an effect is also obsd. in ER+ T47D breast cancer cells.  Nonmalignant MCF10A breast epithelial cells were resistant to the cytotoxic effects of AF.  AF increased intracellular ROS, an effect blocked by NAC and the CYP1A1/1A2 inhibitor, α-Naphthoflavone (α-NF).  AF induced oxidative DNA damage as evidenced by increased 8-oxo-7,8-dihydroguanine (8-oxodG) levels and DPC formation in these cells.  AF caused S-phase arrest corresponding to an increase in p21(waf1/cip1) protein expression.  AF induced caspase 3, 8 and 9 activation, caspase-dependent apoptotic body formation and poly [ADP-ribose] polymerase (PARP) cleavage.  Pretreatment with the pan-caspase inhibitor, benzyloxy-carbonyl-Val-Ala-DL-Asp(OMe)-fluoromethylketone inhibited apoptosis and partially inhibited ROS formation and oxidative DNA damage.  Pretreatment with NAC attenuated AF-induced apoptotic body formation and caspase 3 activation.  These studies suggest AF inhibits the growth of breast cancer cells in part, by inducing ROS prodn., oxidative DNA damage and apoptosis and has the potential to treat hormone-independent breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNPnwbDX4L-rVg90H21EOLACvtfcHk0lhIpMH2JbLqtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVahsLk%253D&md5=cd4aa5fadc5db6d67df076100c7be329</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fijc.23244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23244%26sid%3Dliteratum%253Aachs%26aulast%3DMcLean%26aufirst%3DL.%26aulast%3DSoto%26aufirst%3DU.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DJimenez%26aufirst%3DR.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DSowers%26aufirst%3DL.%26aulast%3DBrantley%26aufirst%3DE.%26atitle%3DAminoflavone%2520induces%2520oxidative%2520DNA%2520damage%2520and%2520reactive%2520oxidative%2520species-mediated%2520apoptosis%2520in%2520breast%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D1665%26epage%3D1674%26doi%3D10.1002%2Fijc.23244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Hose, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollingshead, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monks, A.</span><span> </span><span class="NLM_article-title">Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1265</span><span class="NLM_x">–</span> <span class="NLM_lpage">1272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=14707267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFSk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=1265-1272&author=C.+D.+Hoseauthor=M.+Hollingsheadauthor=E.+A.+Sausvilleauthor=A.+Monks&title=Induction+of+CYP1A1+in+tumor+cells+by+the+antitumor+agent+2-%5B4-amino-3-methylphenyl%5D-5-fluoro-benzothiazole%3A+a+potential+surrogate+marker+for+patient+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: A potential surrogate marker for patient sensitivity</span></div><div class="casAuthors">Hose, Curtis D.; Hollingshead, Melinda; Sausville, Edward A.; Monks, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1265-1272</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A candidate antitumor agent, 2-(4-amino-3-methylphenyl)-5-fluoro-benzothiazole (5F-203), like its non-fluorinated parent compd. (DF-203), has a unique cytotoxicity pattern in the National Cancer Institute in vitro anticancer drug screen.  These compds. show selective toxicity for a subset of cell types including estrogen receptor pos. breast cancer and certain renal and ovarian cancer cell lines.  Metabolic activation of these benzothiazoles seems to be mediated through the CYP1 family of cytochrome P450s.  In an effort to characterize the involvement of CYP1A1 and CYP1B1 in the unique toxicity response of 5F-203, constitutive and 5F-203-induced gene expression patterns were measured in 60 cell lines of the National Cancer Institute drug screen using TaqMan real-time PCR.  The patterns of CYP1A1 and CYP1B1 gene expression in the 60 cell lines were correlated with the toxicity pattern of 5F-203 and DF-203.  There was significant correlation between drug sensitivity and induced CYP1A1 (R = 0.752, P < 0.001), but not constitutive CYP1A1 mRNA expression.  CYP1A1 protein expression was found to mirror the corresponding gene expression, indicating that gene expression changes were concordant with function.  Treatment of sensitive cell lines with 10 μM resveratrol, an inhibitor of CYP1A1 induction, in combination with either 1 or 10 μM 5F-203 showed an ablation of the obsd. CYP1A1, but not CYP1B1 mRNA induction in parallel with a decreased sensitivity to 5F-203.  Fine needle aspirates were obtained from a variety of human tumor xenografts, and treated ex vivo with 1 μM 5F-203 for 24 h.  In these samples, induction of CYP1A1 by 5F-203 correlated with in vitro sensitivity (R = 0.711, P < 0.05), and corresponded to in vivo sensitivity in human tumor xenografts.  These data are concordant with the idea that toxicity of 5F-203 requires activation by CYP1A1, and therefore induction of CYP1A1 mRNA in response to 5F-203 treatments ex vivo may provide a possible surrogate marker for detn. of drug-sensitive tumors in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Bm6TZpLeRrVg90H21EOLACvtfcHk0ljumdSzoAN0Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFSk&md5=e868510342b8124a7da2b73f00ce6de9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHose%26aufirst%3DC.%2BD.%26aulast%3DHollingshead%26aufirst%3DM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DMonks%26aufirst%3DA.%26atitle%3DInduction%2520of%2520CYP1A1%2520in%2520tumor%2520cells%2520by%2520the%2520antitumor%2520agent%25202-%255B4-amino-3-methylphenyl%255D-5-fluoro-benzothiazole%253A%2520a%2520potential%2520surrogate%2520marker%2520for%2520patient%2520sensitivity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D1265%26epage%3D1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwell, A. D.</span><span> </span><span class="NLM_article-title">The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.2174/0929867013373714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F0929867013373714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=11172675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVSgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=203-210&author=T.+D.+Bradshawauthor=M.+F.+Stevensauthor=A.+D.+Westwell&title=The+discovery+of+the+potent+and+selective+antitumour+agent+2-%284-amino-3-methylphenyl%29benzothiazole+%28DF+203%29+and+related+compounds&doi=10.2174%2F0929867013373714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds</span></div><div class="casAuthors">Bradshaw, T. D.; Stevens, M. F. G.; Westwell, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-210</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 14 refs.  The development of a series of potent and selective antitumor agents, the 2-(4-aminophenyl)benzothiazoles, is described.  The original lead compd. in this series, CJM 126, exhibits nanomolar in vitro activity against certain human breast cancer cell lines.  Structure-activity relation studies within this simple antitumor benzothiazole pharmacophore revealed that 2-(4-aminophenyl) benzothiazoles bearing a 3'- Me, 3'-bromo, 3'-iodo or 3'-chloro substituent are esp. potent, extending the spectrum of in vitro antitumor activity to ovarian, lung, renal and colon carcinoma cell lines with a remarkable selectivity profile (NCI anal.).  Other interesting features of this series include the highly unusual transient biphasic dose response relation and possible unique mechanism of action (NCI COMPARE anal.).  2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) has been selected as the lead compd. in this series on the basis of superior in vivo results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx9w0zxmLgGbVg90H21EOLACvtfcHk0ljumdSzoAN0Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVSgtrc%253D&md5=cb79d5da405114a2367cf50c26417fcc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F0929867013373714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867013373714%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DStevens%26aufirst%3DM.%2BF.%26aulast%3DWestwell%26aufirst%3DA.%2BD.%26atitle%3DThe%2520discovery%2520of%2520the%2520potent%2520and%2520selective%2520antitumour%2520agent%25202-%25284-amino-3-methylphenyl%2529benzothiazole%2520%2528DF%2520203%2529%2520and%2520related%2520compounds%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2001%26volume%3D8%26spage%3D203%26epage%3D210%26doi%3D10.2174%2F0929867013373714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwell, A. D.</span><span> </span><span class="NLM_article-title">The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1009</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.2174/0929867043455530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F0929867043455530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=15078163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFGjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=1009-1021&author=T.+D.+Bradshawauthor=A.+D.+Westwell&title=The+development+of+the+antitumour+benzothiazole+prodrug%2C+Phortress%2C+as+a+clinical+candidate&doi=10.2174%2F0929867043455530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The development of the antitumour benzothiazole prodrug, phortress, as a clinical candidate</span></div><div class="casAuthors">Bradshaw, T. D.; Westwell, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1009-1021</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review traces the development of a series of potent and selective antitumor benzothiazoles from the discovery of the initial lead compd., 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) in 1995 to the identification of a clin. candidate, Phortress, scheduled to enter Phase 1 trials in Q1 2004 under the auspices of Cancer Research U.K.  Advances in the authors' understanding of the mechanism of action of this unique series of agents are described and can be summarized as follows: selective uptake into sensitive cells followed by Arylhydrocarbon Receptor (AhR) binding and translocation into the nucleus, induction of the cytochrome P 450 isoform (CYP) 1A1, conversion of the drug into an electrophilic reactive intermediate and formation of extensive DNA adducts resulting in cell death.  The authors' understanding of this mechanistic scenario has played a crucial role in the drug development process, most notably in the synthesis of fluorinated DF 203 analogs to thwart deactivating oxidative metab. (5F 203) and water-sol. prodrug design for parenteral administration.  Aspects of mechanism of action studies, in vitro and in vivo screening, synthetic chem. and pharmacokinetics are reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdjQPzfUjzIbVg90H21EOLACvtfcHk0ljumdSzoAN0Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFGjs7o%253D&md5=6e9498925bf7d40abbdb3aa6f0774eaf</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2174%2F0929867043455530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867043455530%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DWestwell%26aufirst%3DA.%2BD.%26atitle%3DThe%2520development%2520of%2520the%2520antitumour%2520benzothiazole%2520prodrug%252C%2520Phortress%252C%2520as%2520a%2520clinical%2520candidate%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2004%26volume%3D11%26spage%3D1009%26epage%3D1021%26doi%3D10.2174%2F0929867043455530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Inhibitors and prodrugs targeting CYP1: a novel approach in cancer prevention and therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.2174/09298673113206660277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F09298673113206660277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=24083611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFyis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=519-552&author=J.+Cuiauthor=S.+Li&title=Inhibitors+and+prodrugs+targeting+CYP1%3A+a+novel+approach+in+cancer+prevention+and+therapy&doi=10.2174%2F09298673113206660277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors and Prodrugs Targeting CYP1: A Novel Approach in Cancer Prevention and Therapy</span></div><div class="casAuthors">Cui, Jiahua; Li, Shaoshun</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-552</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since Human CYP1 enzymes catalyze the metabolic activation of procarcinogens and deactivation of certain anticancer drugs, the inhibition of these enzymes has been considered as an effective approach for chemoprevention and treatment of CYP1-mediated drug resistance.  Recent knowledge relating to the enhanced expression of CYP1B1 in tumors also provided certain advantages in cancer therapy by the activation of prodrugs only in tumor cells.  This review concs. on the characterized CYP1 inhibitors and CYP1-activated anticancer prodrugs.  The mechanism for enzyme inhibition and activation of prodrugs, the cancer preventive/therapeutic potential of these chems. and their related SARs are highlighted.  According to their structural features, CYP1 inhibitors are divided into the following categories: flavonoids, trans-stilbenes, coumarins, terpenoids, alkaloids, quinones, isothiocyanates and synthetic aroms.  In the same way, CYP1-activated prodrugs are categorized into four groups: benzothiazoles, flavonoids, stilbenes and alkylating agents.  Almost all of these inhibitors and prodrugs are planar mols. with one arom. ring and some have similarity with identified CYP1 substrates.  CYP1 inhibitors could effectively block the procarcinogen-induced tumor initiation in animal models and benefit us with chemoprevention.  The advent of Phortress and aminoflavone as clin. candidates shows promising perspectives in developing CYP1-mediated prodrugs as chemotherapeutic drugs that are specifically activated in tumors.  All of these preclin. and clin. studies indicate that inhibitors and prodrugs target CYP1 are promising anticancer strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNaK3qEukohrVg90H21EOLACvtfcHk0ljumdSzoAN0Ag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFyis7g%253D&md5=d8f45c83c1c3f1d69b5d54856f4b9ceb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F09298673113206660277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113206660277%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DInhibitors%2520and%2520prodrugs%2520targeting%2520CYP1%253A%2520a%2520novel%2520approach%2520in%2520cancer%2520prevention%2520and%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D519%26epage%3D552%26doi%3D10.2174%2F09298673113206660277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Kuffel, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pobst, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span> </span><span class="NLM_article-title">Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1124/mol.62.1.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1124%2Fmol.62.1.143" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=143-153&author=M.+J.+Kuffelauthor=J.+C.+Schroederauthor=L.+J.+Pobstauthor=S.+Naylorauthor=J.+M.+Reidauthor=S.+H.+Kaufmannauthor=M.+M.+Ames&title=Activation+of+the+antitumor+agent+aminoflavone+%28NSC+686288%29+is+mediated+by+induction+of+tumor+cell+cytochrome+P450+1A1%2F1A2&doi=10.1124%2Fmol.62.1.143"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fmol.62.1.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.62.1.143%26sid%3Dliteratum%253Aachs%26aulast%3DKuffel%26aufirst%3DM.%2BJ.%26aulast%3DSchroeder%26aufirst%3DJ.%2BC.%26aulast%3DPobst%26aufirst%3DL.%2BJ.%26aulast%3DNaylor%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26atitle%3DActivation%2520of%2520the%2520antitumor%2520agent%2520aminoflavone%2520%2528NSC%2520686288%2529%2520is%2520mediated%2520by%2520induction%2520of%2520tumor%2520cell%2520cytochrome%2520P450%25201A1%252F1A2%26jtitle%3DMol.%2520Pharmacol.%26date%3D2002%26volume%3D62%26spage%3D143%26epage%3D153%26doi%3D10.1124%2Fmol.62.1.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Haas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harth, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruning, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justenhoven, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brauch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. P.</span><span> </span><span class="NLM_article-title">Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">1785</span><span class="NLM_x">–</span> <span class="NLM_lpage">1791</span><span class="refDoi"> DOI: 10.1002/ijc.21915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1002%2Fijc.21915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16721811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Sns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=1785-1791&author=S.+Haasauthor=C.+Pierlauthor=V.+Harthauthor=B.+Peschauthor=S.+Rabsteinauthor=T.+Bruningauthor=Y.+Koauthor=U.+Hamannauthor=C.+Justenhovenauthor=H.+Brauchauthor=H.+P.+Fischer&title=Expression+of+xenobiotic+and+steroid+hormone+metabolizing+enzymes+in+human+breast+carcinomas&doi=10.1002%2Fijc.21915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas</span></div><div class="casAuthors">Haas, Susanne; Pierl, Christiane; Harth, Volker; Pesch, Beate; Rabstein, Sylvia; Bruening, Thomas; Ko, Yon; Hamann, Ute; Justenhoven, Christina; Brauch, Hiltrud; Fischer, Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1785-1791</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The potential to metabolize endogenous and exogenous substances may influence breast cancer development and tumor growth.  Therefore, the authors investigated the protein expression of Glutathione S-transferase (GST) isoforms and cytochrome P 450 (CYP) known to be involved in the metab. of steroid hormones and endogenous as well as exogenous carcinogens in breast cancer tissue to obtain new information on their possible role in tumor progression.  Expression of GST pi, mu, alpha and CYP1A1/2, 1A2, 3A4/5, 1B1, 2E1 was assessed by immunohisto-chem. for primary breast carcinomas of 393 patients from the German GENICA breast cancer collection.  The percentages of pos. tumors were 50.1 and 44.5% for GST mu and CYP2E1, and ranged from 13 to 24.7% for CYP1A2, GST pi, CYP1A1/2, CYP3A4/5, CYP1B1.  GST alpha was expressed in 1.8% of tumors.  The authors obsd. the following assocns. between strong protein expression and histopathol. characteristics: GST expression was assocd. with a better tumor differentiation (GST mu, p = 0.018) and with reduced lymph node metastasis (GST pi, p = 0.02).  In addn., GST mu expression was assocd. with a pos. estrogen receptor and progesterone receptor status (p < 0.001).  CYP3A4/5 expression was assocd. with a pos. nodal status (p = 0.018).  Expression of CYP1B1 was assocd. with poor tumor differentiation (p = 0.049).  Our results demonstrate that the majority of breast carcinomas expressed xenobiotic and drug metabolizing enzymes.  They particularly suggest that GST mu and pi expression may indicate a better prognosis and that strong CYP3A4/5 and CYP1B1 expression may be key features of non-favorable prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRo025xvmHJbVg90H21EOLACvtfcHk0li15xBbWZin7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Sns70%253D&md5=263d70c71205fd9b43a8c77566e1a7d4</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fijc.21915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21915%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DS.%26aulast%3DPierl%26aufirst%3DC.%26aulast%3DHarth%26aufirst%3DV.%26aulast%3DPesch%26aufirst%3DB.%26aulast%3DRabstein%26aufirst%3DS.%26aulast%3DBruning%26aufirst%3DT.%26aulast%3DKo%26aufirst%3DY.%26aulast%3DHamann%26aufirst%3DU.%26aulast%3DJustenhoven%26aufirst%3DC.%26aulast%3DBrauch%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DH.%2BP.%26atitle%3DExpression%2520of%2520xenobiotic%2520and%2520steroid%2520hormone%2520metabolizing%2520enzymes%2520in%2520human%2520breast%2520carcinomas%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D119%26spage%3D1785%26epage%3D1791%26doi%3D10.1002%2Fijc.21915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petitclerc, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotra, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C.-Gaudreault, R.</span><span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4559</span><span class="NLM_x">–</span> <span class="NLM_lpage">4580</span><span class="refDoi"> DOI: 10.1021/jm200488a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200488a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVSjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4559-4580&author=S.+Fortinauthor=L.+Weiauthor=E.+Moreauauthor=J.+Lacroixauthor=M.-F.+C%C3%B4t%C3%A9author=E.+Petitclercauthor=L.+P.+Kotraauthor=R.+C.-Gaudreault&title=Design%2C+synthesis%2C+biological+evaluation%2C+and+structure-activity+relationships+of+substituted+phenyl+4-%282-oxoimidazolidin-1-yl%29benzenesulfonates+as+new+tubulin+inhibitors+mimicking+combretastatin+A-4&doi=10.1021%2Fjm200488a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Biological Evaluation, and Structure-Activity Relationships of Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl)benzenesulfonates as New Tubulin Inhibitors Mimicking Combretastatin A-4</span></div><div class="casAuthors">Fortin, Sebastien; Wei, Lianhu; Moreau, Emmanuel; Lacroix, Jacques; Cote, Marie-France; Petitclerc, Eric; Kotra, Lakshmi P.; C.-Gaudreault, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4559-4580</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sixty-one Ph 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PIB-SOs), e.g. I [R = 4-Me2N; 2-Et; 3-Cl; 3,5-(MeO)2; 3,4,5-(MeO)3; 3-Me-4-H2N; 4-I], and 13 of their tetrahydro-2-oxopyrimidin-1(2H)-yl analogs (PPB-SOs), e.g. II [R = 2-Et, 3,4,5-(MeO)3], were prepd. and biol. evaluated.  The antiproliferative activities of PIB-SOs on 16 cancer cell lines are in the nanomolar range and unaffected in cancer cells resistant to colchicine, paclitaxel, and vinblastine or overexpressing the P-glycoprotein.  None of the PPB-SOs exhibit significant antiproliferative activity.  PIB-SOs block the cell cycle progression in the G2/M phase and bind to the colchicine-binding site on β-tubulin leading to cytoskeleton disruption and cell death.  Chick chorioallantoic membrane tumor assays show that compds. I [R = 3-Cl; 3,5-(MeO)2; 3,4,5-(MeO)3], efficiently block angiogenesis and tumor growth at least at similar levels as combretastatin A-4 (CA-4) and exhibit low to very low toxicity on the chick embryos.  PIB-SOs were subjected to CoMFA and CoMSIA analyses to establish quant. structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGdFVEICwzpbVg90H21EOLACvtfcHk0li15xBbWZin7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVSjs7c%253D&md5=8de94a7636a14fcfac8c339e906cdac4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm200488a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200488a%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DLacroix%26aufirst%3DJ.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DM.-F.%26aulast%3DPetitclerc%26aufirst%3DE.%26aulast%3DKotra%26aufirst%3DL.%2BP.%26aulast%3DC.-Gaudreault%26aufirst%3DR.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520structure-activity%2520relationships%2520of%2520substituted%2520phenyl%25204-%25282-oxoimidazolidin-1-yl%2529benzenesulfonates%2520as%2520new%2520tubulin%2520inhibitors%2520mimicking%2520combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4559%26epage%3D4580%26doi%3D10.1021%2Fjm200488a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotra, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C.-Gaudreault, R.</span><span> </span><span class="NLM_article-title">Novel cytocidal substituted phenyl 4-(2-oxoimidazolidin-1-yl) benzenesulfonates and benzenesulfonamides with affinity to the colchicine-binding site: is the phenyl 2-imidazolidinone moiety a new haptophore for the design of new antimitotics?</span> <span class="citation_source-journal">Open J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.4236/ojmc.2015.51002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.4236%2Fojmc.2015.51002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFymtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=9-22&author=S.+Fortinauthor=L.+Weiauthor=L.+P.+Kotraauthor=R.+C.-Gaudreault&title=Novel+cytocidal+substituted+phenyl+4-%282-oxoimidazolidin-1-yl%29+benzenesulfonates+and+benzenesulfonamides+with+affinity+to+the+colchicine-binding+site%3A+is+the+phenyl+2-imidazolidinone+moiety+a+new+haptophore+for+the+design+of+new+antimitotics%3F&doi=10.4236%2Fojmc.2015.51002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel cytocidal substituted phenyl 4-(2-oxoimidazolidin-1-yl) benzenesulfonates and benzenesulfonamides with affinity to the colchicine-binding site: is the phenyl 2-imidazolidinone moiety a new haptophore for the design of new antimitotics?</span></div><div class="casAuthors">Fortin, Sebastien; Wei, Lianhu; Kotra, Lakshmi P.; C.-Gaudreault, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Open Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">OJMCAD</span>;
        ISSN:<span class="NLM_cas:issn">2164-313X</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">Ph 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PIB-SOs) and Ph 4-(2-oxoimidazolidin- 1-yl)benzenesulfonamides (PIB-SAs) are new, potent combretastatin A-4 (CA-4) analogs designed on the basis of their common Ph 2-imidazolidone moiety.  This Ph 2-imidazolidone group is a bioisosteric equiv. of the trimethoxyphenyl group also found in colchicine, podophyllotoxin and several other ligands of the colchicine-binding site (C-BS).  In this study, we investigate the interactions involved in the binding of PIB-SO and PIB-SA into the C-BS.  We describe three distinct pockets (I, II, and III) as key structural elements involved in the interactions between the C-BS and PIB-SOs as well as PIB-SAs.  We show that PIB-SOs and PIB-SAs adopt 4 and 3 distinct binding conformations, resp., within the C-BS.  The binding conformations I and IV are common to most PIB-SOs and PIB-SAs exhibiting high affinity for the C-BS and high cytocidal potency.  In addn., binding conformation I is the main conformation adopted by PIB-SOs, PIB-SAs, T138067, ABT-751, colchicine and CA-4.  We also observe that the sulfonate and the sulfonamide moieties of PIB-SOs and PIB-SAs are bioisosteric equiv.  Interestingly, we further find that a large portion of the Ph 2-imidazolidinone moiety in these analogs does not bind to pocket I unlike the trimethoxyphenyl moiety found in several antimicrotubule agents such as colchicine, CA-4 and podophyllotoxin, suggesting that the Ph 2-imidazolidinone group may represent a new haptophoric moiety useful for the design of new C-BS inhibitors mimicking the tropolone and the methoxylated phenolic moieties of colchicine and CA-4, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDIdN43sCtdLVg90H21EOLACvtfcHk0lg2tke9u6nTAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFymtrvN&md5=e8d3c850fa6c892b4c204c3e643b753d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.4236%2Fojmc.2015.51002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fojmc.2015.51002%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DKotra%26aufirst%3DL.%2BP.%26aulast%3DC.-Gaudreault%26aufirst%3DR.%26atitle%3DNovel%2520cytocidal%2520substituted%2520phenyl%25204-%25282-oxoimidazolidin-1-yl%2529%2520benzenesulfonates%2520and%2520benzenesulfonamides%2520with%2520affinity%2520to%2520the%2520colchicine-binding%2520site%253A%2520is%2520the%2520phenyl%25202-imidazolidinone%2520moiety%2520a%2520new%2520haptophore%2520for%2520the%2520design%2520of%2520new%2520antimitotics%253F%26jtitle%3DOpen%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D5%26spage%3D9%26epage%3D22%26doi%3D10.4236%2Fojmc.2015.51002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Fletcher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullins, R. D.</span><span> </span><span class="NLM_article-title">Cell mechanics and the cytoskeleton</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">463</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">492</span><span class="refDoi"> DOI: 10.1038/nature08908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnature08908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20110992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Slu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=485-492&author=D.+A.+Fletcherauthor=R.+D.+Mullins&title=Cell+mechanics+and+the+cytoskeleton&doi=10.1038%2Fnature08908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cell mechanics and the cytoskeleton</span></div><div class="casAuthors">Fletcher, Daniel A.; Mullins, R. Dyche</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7280</span>),
    <span class="NLM_cas:pages">485-492</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ability of a eukaryotic cell to resist deformation, to transport intracellular cargo and to change shape during movement depends on the cytoskeleton, an interconnected network of filamentous polymers and regulatory proteins.  Recent work has demonstrated that both internal and external phys. forces can act through the cytoskeleton to affect local mech. properties and cellular behavior.  Attention is now focused on how cytoskeletal networks generate, transmit and respond to mech. signals over both short and long timescales.  An important insight emerging from this work is that long-lived cytoskeletal structures may act as epigenetic determinants of cell shape, function and fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9ixndytG2bLVg90H21EOLACvtfcHk0lg2tke9u6nTAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Slu7o%253D&md5=aa99ea3ac26664afad09ac8ba4963080</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnature08908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08908%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DD.%2BA.%26aulast%3DMullins%26aufirst%3DR.%2BD.%26atitle%3DCell%2520mechanics%2520and%2520the%2520cytoskeleton%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D485%26epage%3D492%26doi%3D10.1038%2Fnature08908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Hall, A.</span><span> </span><span class="NLM_article-title">The cytoskeleton and cancer</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1007/s10555-008-9166-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1007%2Fs10555-008-9166-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=19153674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BD1M3hslSntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=5-14&author=A.+Hall&title=The+cytoskeleton+and+cancer&doi=10.1007%2Fs10555-008-9166-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The cytoskeleton and cancer</span></div><div class="casAuthors">Hall Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer metastasis reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">5-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer is a disease in which many of the characteristics of normal cell behavior are lost or perturbed.  Uncontrolled cell proliferation and inappropriate cell survival are common features of all cancers, but in addition defects in cellular morphogenesis that lead to tissue disruption, the acquisition of inappropriate migratory and invasive characteristics and the generation of genomic instability through defects in mitosis also accompany progression of the disease.  This volume is focused on the actin and microtubule cytoskeletons, key players that underpin these cellular processes.  Actin and tubulin form highly versatile, dynamic polymers that are capable of organizing cytoplasmic organelles and intracellular compartments, defining cell polarity and generating both pushing and contractile forces.  In the cell cycle, these two cytoskeletal structures drive chromosomal separation and cell division.  During morphogenesis, they determine cell shape and polarity, and promote stable cell-cell and cell-matrix adhesions through their interactions with cadherins and integrins, respectively.  Finally, during cell migration they generate protrusive forces at the front and retraction forces at the rear.  These are all aspects of cell behavior than often go awry in cancer.  This volume brings together those interested in understanding the contribution of the actin and microtubule cytoskeletons to the cell biology of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgWNHWmc0hKNTiMd2aNQVUfW6udTcc2eb8m9Gs9MLPfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3hslSntw%253D%253D&md5=3cf3fa56373a36e883fee0812d3cc0cc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9166-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9166-3%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%26atitle%3DThe%2520cytoskeleton%2520and%2520cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2009%26volume%3D28%26spage%3D5%26epage%3D14%26doi%3D10.1007%2Fs10555-008-9166-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannakakou, P.</span><span> </span><span class="NLM_article-title">Targeting microtubules for cancer chemotherapy</span> <span class="citation_source-journal">Curr. Med. Chem.: Anti-Cancer Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.2174/1568011053352569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F1568011053352569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=15720262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-71&author=J.+Zhouauthor=P.+Giannakakou&title=Targeting+microtubules+for+cancer+chemotherapy&doi=10.2174%2F1568011053352569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting microtubules for cancer chemotherapy</span></div><div class="casAuthors">Zhou, Jun; Giannakakou, Paraskevi</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chem. compds. that interfere with microtubules such as the vinca alkaloids and taxanes are important chemotherapeutic agents for the treatment of cancer.  As knowledge of microtubule-targeting drugs increases, the mechanism underlying the anticancer activity of these agents may mainly lie in their inhibitory effects on spindle microtubule dynamics, rather than in their effects on microtubule polymer mass.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell cycle progression at mitosis and eventually leading to apoptotic cell death.  The effectiveness of microtubule-targeting drugs for cancer therapy has been impaired by various side effects, notably neurol. and hematol. toxicities.  Drug resistance is another notorious factor that thwarts the effectiveness of these agents, as with many other cancer chemotherapeutics.  Several new microtubule-targeting agents have shown potent activity against the proliferation of various cancer cells, including cells that display resistance to the existing microtubule-targeting drugs.  Continued investigation of the mechanisms of action of microtubule-targeting drugs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance may provide more effective therapeutic options for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI0IucAUr4V7Vg90H21EOLACvtfcHk0lg2tke9u6nTAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D&md5=e5d34ca2c4d4adf0e6975989da8aaee8</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2174%2F1568011053352569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011053352569%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGiannakakou%26aufirst%3DP.%26atitle%3DTargeting%2520microtubules%2520for%2520cancer%2520chemotherapy%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D71%26doi%3D10.2174%2F1568011053352569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, M. A.</span><span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0ljRvCjkvKtADw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span><span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0ljRvCjkvKtADw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petitclerc, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotra, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C.-Gaudreault, R.</span><span> </span><span class="NLM_article-title">Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5327</span><span class="NLM_x">–</span> <span class="NLM_lpage">5342</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2011.08.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.ejmech.2011.08.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=5327-5342&author=S.+Fortinauthor=L.+Weiauthor=E.+Moreauauthor=J.+Lacroixauthor=M.+F.+Coteauthor=E.+Petitclercauthor=L.+P.+Kotraauthor=R.+C.-Gaudreault&title=Substituted+phenyl+4-%282-oxoimidazolidin-1-yl%29benzenesulfonamides+as+antimitotics.+Antiproliferative%2C+antiangiogenic+and+antitumoral+activity%2C+and+quantitative+structure-activity+relationships&doi=10.1016%2Fj.ejmech.2011.08.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.08.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.08.034%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DLacroix%26aufirst%3DJ.%26aulast%3DCote%26aufirst%3DM.%2BF.%26aulast%3DPetitclerc%26aufirst%3DE.%26aulast%3DKotra%26aufirst%3DL.%2BP.%26aulast%3DC.-Gaudreault%26aufirst%3DR.%26atitle%3DSubstituted%2520phenyl%25204-%25282-oxoimidazolidin-1-yl%2529benzenesulfonamides%2520as%2520antimitotics.%2520Antiproliferative%252C%2520antiangiogenic%2520and%2520antitumoral%2520activity%252C%2520and%2520quantitative%2520structure-activity%2520relationships%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D5327%26epage%3D5342%26doi%3D10.1016%2Fj.ejmech.2011.08.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span>NCI-60 Human Tumor Cell Line Screen, <span class="NLM_publisher-name">Developmental Therapeutics Program, National Cancer Institute (NCI/NIH)</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, Aug 26,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://dtp.cancer.gov/discovery_development/nci-60/default.htm" class="extLink">https://dtp.cancer.gov/discovery_development/nci-60/default.htm</a> (accessed February 17, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NCI-60+Human+Tumor+Cell+Line+Screen%2C+Developmental+Therapeutics+Program%2C+National+Cancer+Institute+%28NCI%2FNIH%29%3A+Bethesda%2C+MD%2C+Aug+26%2C+2015%3B+https%3A%2F%2Fdtp.cancer.gov%2Fdiscovery_development%2Fnci-60%2Fdefault.htm+%28accessed+February+17%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCI-60%2520Human%2520Tumor%2520Cell%2520Line%2520Screen%26pub%3DDevelopmental%2520Therapeutics%2520Program%252C%2520National%2520Cancer%2520Institute%2520%2528NCI%252FNIH%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Subik, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strzepek, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonfiglio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, P.</span><span> </span><span class="NLM_article-title">The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines</span> <span class="citation_source-journal">Breast Cancer (Auckl)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1177%2F117822341000400004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20697531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC3cjjs1Wguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=35-41&author=K.+Subikauthor=J.+F.+Leeauthor=L.+Baxterauthor=T.+Strzepekauthor=D.+Costelloauthor=P.+Crowleyauthor=L.+Xingauthor=M.+C.+Hungauthor=T.+Bonfiglioauthor=D.+G.+Hicksauthor=P.+Tang&title=The+expression+patterns+of+ER%2C+PR%2C+HER2%2C+CK5%2F6%2C+EGFR%2C+Ki-67+and+AR+by+immunohistochemical+analysis+in+breast+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines</span></div><div class="casAuthors">Subik Kristina; Lee Jin-Feng; Baxter Laurie; Strzepek Tamera; Costello Dawn; Crowley Patti; Xing Lianping; Hung Mien-Chie; Bonfiglio Thomas; Hicks David G; Tang Ping</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer : basic and clinical research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The molecular classification for breast carcinomas has been used in clinical studies with a simple surrogate panel of immunohistochemistry (IHC) markers.  The objective of this current project was to study the molecular classification of commonly used breast cancer cell lines by IHC analysis.  Seventeen breast cancer cell lines were harvested, fixed in formalin and made into cell blocks.  IHC analyses were performed on each cell block with antibodies to estrogen receptor (ER), progesterone receptor (PR), HER2, EGFR, CK5/6, Ki-67 and androgen receptor (AR).  Among the 17 cell lines, MCF-7 and ZR-75-1 fell to Luminal A subtype; BT-474 to Luminal B subtype; SKBR-3, MDA-MD-435 and AU 565 to HER2 over-expression subtype; MDA-MB-231, MCF-12A, HBL 101, HS 598 T, MCF-10A, MCF-10F, BT-20, 468 and BT-483 to basal subtype.  MDA-MB-453 belonged to Unclassified subtype.  Since each subtype defined by this IHC-based molecular classification does show a distinct clinical outcome, attention should be paid when choosing a cell line for any study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYiuOaYnyGMPh3YQQtAhNufW6udTcc2eYHgl46wFoRWLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjjs1Wguw%253D%253D&md5=d443eb5bfd9c90667fefd356b1c1a191</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1177%2F117822341000400004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F117822341000400004%26sid%3Dliteratum%253Aachs%26aulast%3DSubik%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DJ.%2BF.%26aulast%3DBaxter%26aufirst%3DL.%26aulast%3DStrzepek%26aufirst%3DT.%26aulast%3DCostello%26aufirst%3DD.%26aulast%3DCrowley%26aufirst%3DP.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DBonfiglio%26aufirst%3DT.%26aulast%3DHicks%26aufirst%3DD.%2BG.%26aulast%3DTang%26aufirst%3DP.%26atitle%3DThe%2520expression%2520patterns%2520of%2520ER%252C%2520PR%252C%2520HER2%252C%2520CK5%252F6%252C%2520EGFR%252C%2520Ki-67%2520and%2520AR%2520by%2520immunohistochemical%2520analysis%2520in%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DBreast%2520Cancer%2520%2528Auckl%2529%26date%3D2010%26volume%3D4%26spage%3D35%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Elsherbiny, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kadi, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brocks, D. R.</span><span> </span><span class="NLM_article-title">The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole</span> <span class="citation_source-journal">J. Pharm. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.18433/J3SG66</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.18433%2FJ3SG66" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18445370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ClsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=147-159&author=M.+E.+Elsherbinyauthor=A.+O.+El-Kadiauthor=D.+R.+Brocks&title=The+metabolism+of+amiodarone+by+various+CYP+isoenzymes+of+human+and+rat%2C+and+the+inhibitory+influence+of+ketoconazole&doi=10.18433%2FJ3SG66"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole</span></div><div class="casAuthors">Elsherbiny, Marwa E.; El-Kadi, Ayman O. S.; Brocks, Dion R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy & Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-159</span>CODEN:
                <span class="NLM_cas:coden">JPPSFY</span>;
        ISSN:<span class="NLM_cas:issn">1482-1826</span>.
    
            (<span class="NLM_cas:orgname">Canadian Society for Pharmaceutical Sciences</span>)
        </div><div class="casAbstract">To evaluate the metab. of amiodarone (AM) to desethylamiodarone (DEA) by selected human and rat cytochrome P 450, and the inhibitory effect of ketoconazole (KTZ).  Some important CYP isoenzymes (rat CYP1A1, 1A2, 2C6, 2C11, 2D1, 2D2, and 3A1 and human CYP1A1, 1A2, 2D6 and 3A4) were spiked with various concns. of AM to det. the relative kinetic parameters for formation of DEA in the presence and absence of various concns. of KTZ.  The formation of DEA was obsd. when AM was exposed to each of the CYP tested, although the rates were varied.  Human CYP1A1 followed by 3A4 had the highest intrinsic clearance (CLint) for DEA formation whereas in rat, CYP2D1 followed by CYP2C11 had the highest CLint.  Human and rat CYP1A2 seemed to have the lowest CLint.  At high concns. of AM and KTZ, near those expected in vivo, significant inhibition of all isoforms except for rat CYP1A2 was obsd.  At lower concn. ranges of both drugs, the inhibitory const. was detd.  At these levels, KTZ was found to potently inhibit human CYP1A1 and 3A4 and rat 2D2 and 1A1.  Human CYP1A1 and 3A4 and rat CYP2D1 and 2C11 were most efficient in converting AM to DEA.  For DEA formation, the in vivo administration of KTZ could inhibit other CYP isoforms besides CYP3A in human and rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolP7FYnhCLl7Vg90H21EOLACvtfcHk0lgIezWcQLR8rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ClsLnE&md5=03c5e4e247ccde0e30d818bc0e6ad379</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.18433%2FJ3SG66&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18433%252FJ3SG66%26sid%3Dliteratum%253Aachs%26aulast%3DElsherbiny%26aufirst%3DM.%2BE.%26aulast%3DEl-Kadi%26aufirst%3DA.%2BO.%26aulast%3DBrocks%26aufirst%3DD.%2BR.%26atitle%3DThe%2520metabolism%2520of%2520amiodarone%2520by%2520various%2520CYP%2520isoenzymes%2520of%2520human%2520and%2520rat%252C%2520and%2520the%2520inhibitory%2520influence%2520of%2520ketoconazole%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D11%26spage%3D147%26epage%3D159%26doi%3D10.18433%2FJ3SG66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Beedanagari, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebenek, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hankinson, O.</span><span> </span><span class="NLM_article-title">Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1093/toxsci/kfp079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1093%2Ftoxsci%2Fkfp079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=19376845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFKktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2009&pages=61-67&author=S.+R.+Beedanagariauthor=I.+Bebenekauthor=P.+Buiauthor=O.+Hankinson&title=Resveratrol+inhibits+dioxin-induced+expression+of+human+CYP1A1+and+CYP1B1+by+inhibiting+recruitment+of+the+aryl+hydrocarbon+receptor+complex+and+RNA+polymerase+II+to+the+regulatory+regions+of+the+corresponding+genes&doi=10.1093%2Ftoxsci%2Fkfp079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol Inhibits Dioxin-Induced Expression of Human CYP1A1 and CYP1B1 by Inhibiting Recruitment of the Aryl Hydrocarbon Receptor Complex and RNA Polymerase II to the Regulatory Regions of the Corresponding Genes</span></div><div class="casAuthors">Beedanagari, Sudheer R.; Bebenek, Ilona; Bui, Peter; Hankinson, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-67</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The CYP1A family of cytochrome P450s (CYPs), comprising CYP1A1, CYP1A2, and CYP1B1, plays a role in bioactivation of several procarcinogens to carcinogenic derivs., and also in detoxification of several xenobiotic compds.  Resveratrol (3,4,5-trihydroxystelbine) is a naturally occurring compd. that has been shown in a no. of studies to inhibit the induction of CYP1A1 and CYP1B1 by dioxin (2,3,7,8-tetrachloro-dibenzo-p-dioxin), but the mechanism(s) of resveratrol inhibition is controversial.  In the current study, 100nM dioxin treatment for 24, 48, and 72 h induced CYP1A1, CYP1A2, and CYP1B1 mRNA levels in the human breast cancer cell line MCF-7, and CYP1A1 and CYP1A2 mRNA levels in the human hepatocellular carcinoma cell line, HepG2.  Simultaneous treatment with 10μM resveratrol significantly inhibited dioxin-induced mRNA expression levels of these genes in both cell lines.  Our studies are novel in that we used the chromatin immunopptn. assay to assay dioxin-induced recruitment of the aryl hydrocarbon receptor (AHR), and aryl hydrocarbon nuclear translocator (ARNT) to the enhancer regions and recruitment of RNA polymerase II to the promoter regions, of the CYP1A1 and CYP1B1 genes in their natural chromosomal settings.  These recruitments were significantly inhibited in cells cotreated with resveratrol.  Our studies thus indicate that resveratrol inhibits dioxin induction of the CYP1 family members either by directly or indirectly inhibiting the recruitment of the transcription factors AHR and ARNT to the xenobiotic response elements of the corresponding genes.  The reduced transcriptional factor binding at their enhancers then results in reduced pol II recruitment at the promoters of these genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33EQ9RtRUK7Vg90H21EOLACvtfcHk0lgIezWcQLR8rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFKktLk%253D&md5=cc33d83dc51a512103fbed6ce38b3224</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfp079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfp079%26sid%3Dliteratum%253Aachs%26aulast%3DBeedanagari%26aufirst%3DS.%2BR.%26aulast%3DBebenek%26aufirst%3DI.%26aulast%3DBui%26aufirst%3DP.%26aulast%3DHankinson%26aufirst%3DO.%26atitle%3DResveratrol%2520inhibits%2520dioxin-induced%2520expression%2520of%2520human%2520CYP1A1%2520and%2520CYP1B1%2520by%2520inhibiting%2520recruitment%2520of%2520the%2520aryl%2520hydrocarbon%2520receptor%2520complex%2520and%2520RNA%2520polymerase%2520II%2520to%2520the%2520regulatory%2520regions%2520of%2520the%2520corresponding%2520genes%26jtitle%3DToxicol.%2520Sci.%26date%3D2009%26volume%3D110%26spage%3D61%26epage%3D67%26doi%3D10.1093%2Ftoxsci%2Fkfp079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Chen, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurh, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Na, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surh, Y. J.</span><span> </span><span class="NLM_article-title">Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2013</span><span class="refDoi"> DOI: 10.1093/carcin/bgh183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1093%2Fcarcin%2Fbgh183" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=2005-2013&author=Z.+H.+Chenauthor=Y.+J.+Hurhauthor=H.+K.+Naauthor=J.+H.+Kimauthor=Y.+J.+Chunauthor=D.+H.+Kimauthor=K.+S.+Kangauthor=M.+H.+Choauthor=Y.+J.+Surh&title=Resveratrol+inhibits+TCDD-induced+expression+of+CYP1A1+and+CYP1B1+and+catechol+estrogen-mediated+oxidative+DNA+damage+in+cultured+human+mammary+epithelial+cells&doi=10.1093%2Fcarcin%2Fbgh183"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgh183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgh183%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%2BH.%26aulast%3DHurh%26aufirst%3DY.%2BJ.%26aulast%3DNa%26aufirst%3DH.%2BK.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DChun%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DKang%26aufirst%3DK.%2BS.%26aulast%3DCho%26aufirst%3DM.%2BH.%26aulast%3DSurh%26aufirst%3DY.%2BJ.%26atitle%3DResveratrol%2520inhibits%2520TCDD-induced%2520expression%2520of%2520CYP1A1%2520and%2520CYP1B1%2520and%2520catechol%2520estrogen-mediated%2520oxidative%2520DNA%2520damage%2520in%2520cultured%2520human%2520mammary%2520epithelial%2520cells%26jtitle%3DCarcinogenesis%26date%3D2004%26volume%3D25%26spage%3D2005%26epage%3D2013%26doi%3D10.1093%2Fcarcin%2Fbgh183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Pelkonen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turpeinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakkola, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honkakoski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hukkanen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raunio, H.</span><span> </span><span class="NLM_article-title">Inhibition and induction of human cytochrome P450 enzymes: current status</span> <span class="citation_source-journal">Arch. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span><span class="refDoi"> DOI: 10.1007/s00204-008-0332-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1007%2Fs00204-008-0332-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18618097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ehtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=667-715&author=O.+Pelkonenauthor=M.+Turpeinenauthor=J.+Hakkolaauthor=P.+Honkakoskiauthor=J.+Hukkanenauthor=H.+Raunio&title=Inhibition+and+induction+of+human+cytochrome+P450+enzymes%3A+current+status&doi=10.1007%2Fs00204-008-0332-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and induction of human cytochrome P450 enzymes: current status</span></div><div class="casAuthors">Pelkonen, Olavi; Turpeinen, Miia; Hakkola, Jukka; Honkakoshi, Paavo; Hukkanen, Janne; Raunio, Hannu</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">667-715</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The variability of drug metab., esp. that of the most important phase I enzymes or cytochrome P 450 (CYP) enzymes, is an important complicating factor in many areas of pharmacol. and toxicol., in drug development, preclin. toxicity studies, clin. trials, drug therapy, environmental exposures, and risk assessment.  With these frequently enormous consequences in mind, predictive and pre-emption measures have been a top priority in both pharmacol. and toxicol.  This means the development of predictive in vitro approaches.  Sound prediction is always based on a firm background of basic research on the phenomena of inhibition and induction and their underlying mechanisms; consequently, the description of these aspects is the purpose of this review.  Here, the authors cover both inhibition and induction of CYP isoforms, always keeping in mind the basic mechanisms on which to build predictive and preventive in vitro approaches.  Just because validation is an essential part of any in vitro/in vivo extrapolation scenario, the authors also cover necessary in vivo research and findings in order to provide a proper view to justify in vitro approaches and observations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRVX_0TMOx8rVg90H21EOLACvtfcHk0lhcTRzC7aja1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ehtLfL&md5=d5e7527e1dfd964e3d5be002a0fe0273</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs00204-008-0332-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-008-0332-8%26sid%3Dliteratum%253Aachs%26aulast%3DPelkonen%26aufirst%3DO.%26aulast%3DTurpeinen%26aufirst%3DM.%26aulast%3DHakkola%26aufirst%3DJ.%26aulast%3DHonkakoski%26aufirst%3DP.%26aulast%3DHukkanen%26aufirst%3DJ.%26aulast%3DRaunio%26aufirst%3DH.%26atitle%3DInhibition%2520and%2520induction%2520of%2520human%2520cytochrome%2520P450%2520enzymes%253A%2520current%2520status%26jtitle%3DArch.%2520Toxicol.%26date%3D2008%26volume%3D82%26spage%3D667%26epage%3D715%26doi%3D10.1007%2Fs00204-008-0332-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Ciolino, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daschner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, G. C.</span><span> </span><span class="NLM_article-title">Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span><span class="refDoi"> DOI: 10.1016/S0006-2952(98)00143-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2FS0006-2952%2898%2900143-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1998&pages=197-206&author=H.+P.+Ciolinoauthor=P.+J.+Daschnerauthor=T.+T.+Wangauthor=G.+C.+Yeh&title=Effect+of+curcumin+on+the+aryl+hydrocarbon+receptor+and+cytochrome+P450+1A1+in+MCF-7+human+breast+carcinoma+cells&doi=10.1016%2FS0006-2952%2898%2900143-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2898%2900143-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252898%252900143-9%26sid%3Dliteratum%253Aachs%26aulast%3DCiolino%26aufirst%3DH.%2BP.%26aulast%3DDaschner%26aufirst%3DP.%2BJ.%26aulast%3DWang%26aufirst%3DT.%2BT.%26aulast%3DYeh%26aufirst%3DG.%2BC.%26atitle%3DEffect%2520of%2520curcumin%2520on%2520the%2520aryl%2520hydrocarbon%2520receptor%2520and%2520cytochrome%2520P450%25201A1%2520in%2520MCF-7%2520human%2520breast%2520carcinoma%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1998%26volume%3D56%26spage%3D197%26epage%3D206%26doi%3D10.1016%2FS0006-2952%2898%2900143-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Navas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herradon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segner, H.</span><span> </span><span class="NLM_article-title">Induction of cytochrome P4501A (CYP1A) by clotrimazole, a non-planar aromatic compound. Computational studies on structural features of clotrimazole and related imidazole derivatives</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span><span class="refDoi"> DOI: 10.1016/j.lfs.2004.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.lfs.2004.09.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=699-714&author=J.+M.+Navasauthor=A.+Chanaauthor=B.+Herradonauthor=H.+Segner&title=Induction+of+cytochrome+P4501A+%28CYP1A%29+by+clotrimazole%2C+a+non-planar+aromatic+compound.+Computational+studies+on+structural+features+of+clotrimazole+and+related+imidazole+derivatives&doi=10.1016%2Fj.lfs.2004.09.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2004.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2004.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DNavas%26aufirst%3DJ.%2BM.%26aulast%3DChana%26aufirst%3DA.%26aulast%3DHerradon%26aufirst%3DB.%26aulast%3DSegner%26aufirst%3DH.%26atitle%3DInduction%2520of%2520cytochrome%2520P4501A%2520%2528CYP1A%2529%2520by%2520clotrimazole%252C%2520a%2520non-planar%2520aromatic%2520compound.%2520Computational%2520studies%2520on%2520structural%2520features%2520of%2520clotrimazole%2520and%2520related%2520imidazole%2520derivatives%26jtitle%3DLife%2520Sci.%26date%3D2004%26volume%3D76%26spage%3D699%26epage%3D714%26doi%3D10.1016%2Fj.lfs.2004.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Casper, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quesne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirota, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolivet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milgrom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savouret, J. F.</span><span> </span><span class="NLM_article-title">Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=784-790&author=R.+F.+Casperauthor=M.+Quesneauthor=I.+M.+Rogersauthor=T.+Shirotaauthor=A.+Jolivetauthor=E.+Milgromauthor=J.+F.+Savouret&title=Resveratrol+has+antagonist+activity+on+the+aryl+hydrocarbon+receptor%3A+implications+for+prevention+of+dioxin+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasper%26aufirst%3DR.%2BF.%26aulast%3DQuesne%26aufirst%3DM.%26aulast%3DRogers%26aufirst%3DI.%2BM.%26aulast%3DShirota%26aufirst%3DT.%26aulast%3DJolivet%26aufirst%3DA.%26aulast%3DMilgrom%26aufirst%3DE.%26aulast%3DSavouret%26aufirst%3DJ.%2BF.%26atitle%3DResveratrol%2520has%2520antagonist%2520activity%2520on%2520the%2520aryl%2520hydrocarbon%2520receptor%253A%2520implications%2520for%2520prevention%2520of%2520dioxin%2520toxicity%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26spage%3D784%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Bjornsson, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einolf, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snikeris, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span> </span><span class="NLM_article-title">The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">815</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1124/dmd.31.7.815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1124%2Fdmd.31.7.815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=12814957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltFalu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=815-832&author=T.+D.+Bjornssonauthor=J.+T.+Callaghanauthor=H.+J.+Einolfauthor=V.+Fischerauthor=L.+Ganauthor=S.+Grimmauthor=J.+Kaoauthor=S.+P.+Kingauthor=G.+Miwaauthor=L.+Niauthor=G.+Kumarauthor=J.+McLeodauthor=R.+S.+Obachauthor=S.+Robertsauthor=A.+Roeauthor=A.+Shahauthor=F.+Snikerisauthor=J.+T.+Sullivanauthor=D.+Tweedieauthor=J.+M.+Vegaauthor=J.+Walshauthor=S.+A.+Wrighton&title=The+conduct+of+in+vitro+and+in+vivo+drug-drug+interaction+studies%3A+a+Pharmaceutical+Research+and+Manufacturers+of+America+%28PhRMA%29+perspective&doi=10.1124%2Fdmd.31.7.815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective</span></div><div class="casAuthors">Bjornsson, Thorir D.; Callaghan, John T.; Einolf, Heidi J.; Fischer, Volker; Gan, Lawrence; Grimm, Scott; Kao, John; King, S. Peter; Miwa, Gerald; Ni, Lan; Kumar, Gondi; McLeod, James; Obach, R. Scott; Roberts, Stanley; Roe, Amy; Shah, Anita; Snikeris, Fred; Sullivan, John T.; Tweedie, Donald; Vega, Jose M.; Walsh, John; Wrighton, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">815-832</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies.  There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs.  There is also a growing consensus for the standardization of cytochrome P 450 (P 450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients.  While existing guidances cover mainly P 450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed.  This article was prepd. by the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metab. and Clin. Pharmacol. Tech. Working Groups and represents the current industry position.  The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compd. registration dossiers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogi0LDV4FgLVg90H21EOLACvtfcHk0lhcTRzC7aja1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltFalu70%253D&md5=2a41b5f54f65504448656ac7f7409aea</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.7.815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.7.815%26sid%3Dliteratum%253Aachs%26aulast%3DBjornsson%26aufirst%3DT.%2BD.%26aulast%3DCallaghan%26aufirst%3DJ.%2BT.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DGan%26aufirst%3DL.%26aulast%3DGrimm%26aufirst%3DS.%26aulast%3DKao%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DS.%2BP.%26aulast%3DMiwa%26aufirst%3DG.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMcLeod%26aufirst%3DJ.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DRoe%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DSnikeris%26aufirst%3DF.%26aulast%3DSullivan%26aufirst%3DJ.%2BT.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DVega%26aufirst%3DJ.%2BM.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26atitle%3DThe%2520conduct%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520drug-drug%2520interaction%2520studies%253A%2520a%2520Pharmaceutical%2520Research%2520and%2520Manufacturers%2520of%2520America%2520%2528PhRMA%2529%2520perspective%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D815%26epage%3D832%26doi%3D10.1124%2Fdmd.31.7.815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span> </span><span class="NLM_article-title">The conduct of drug metabolism studies considered good practice (II): in vitro experiments</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">822</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span><span class="refDoi"> DOI: 10.2174/138920007782798207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F138920007782798207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18220563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVahtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=822-829&author=L.+Jiaauthor=X.+Liu&title=The+conduct+of+drug+metabolism+studies+considered+good+practice+%28II%29%3A+in+vitro+experiments&doi=10.2174%2F138920007782798207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The conduct of drug metabolism studies considered good practice (II): in vitro experiments</span></div><div class="casAuthors">Jia, Lee; Liu, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">822-829</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In vitro drug metab. studies, which are inexpensive and readily carried out, serve as an adequate screening mechanism to characterize drug metabolites, elucidate their pathways, and make suggestions for further in vivo testing.  This publication is a sequel to part I in a series and aims at providing a general framework to guide designs and protocols of the in vitro drug metab. studies considered good practice in an efficient manner such that it would help researchers avoid common pitfalls and misleading results.  The in vitro models include hepatic and non-hepatic microsomes, cDNA-expressed recombinant human CYPs expressed in insect cells or human B lymphoblastoid, chem. P 450 inhibitors, S9 fraction, hepatocytes and liver slices.  Important conditions for conducting the in vitro drug metab. studies using these models are stated, including relevant concns. of enzymes, co-factors, inhibitors and test drugs; time of incubation and sampling in order to establish kinetics of reactions; appropriate control settings, buffer selection and method validation.  Sep. in vitro data should be logically integrated to explain results from animal and human studies and to provide insights into the nature and consequences of in vivo drug metab.  This article offers tech. information and data and addresses scientific rationales and practical skills related to in vitro evaluation of drug metab. to meet regulatory requirements for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGoXIA8orbI7Vg90H21EOLACvtfcHk0lhMEwQEt7MJNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVahtrrP&md5=d4d3c90782386a82d8978b7a71bf78b1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F138920007782798207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007782798207%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DThe%2520conduct%2520of%2520drug%2520metabolism%2520studies%2520considered%2520good%2520practice%2520%2528II%2529%253A%2520in%2520vitro%2520experiments%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D822%26epage%3D829%26doi%3D10.2174%2F138920007782798207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasseur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselin, É.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bérubé, G.</span><span> </span><span class="NLM_article-title">New platinum(II) complexes conjugate at position 7α of 17β-acetyl-testosterone as new combi-molecules against prostate cancer: Design, synthesis, structure-activity relationships and biological evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.ejmech.2013.08.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=433-443&author=S.+Fortinauthor=K.+Brasseurauthor=N.+Morinauthor=%C3%89.+Asselinauthor=G.+B%C3%A9rub%C3%A9&title=New+platinum%28II%29+complexes+conjugate+at+position+7%CE%B1+of+17%CE%B2-acetyl-testosterone+as+new+combi-molecules+against+prostate+cancer%3A+Design%2C+synthesis%2C+structure-activity+relationships+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2013.08.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DBrasseur%26aufirst%3DK.%26aulast%3DMorin%26aufirst%3DN.%26aulast%3DAsselin%26aufirst%3D%25C3%2589.%26aulast%3DB%25C3%25A9rub%25C3%25A9%26aufirst%3DG.%26atitle%3DNew%2520platinum%2528II%2529%2520complexes%2520conjugate%2520at%2520position%25207%25CE%25B1%2520of%252017%25CE%25B2-acetyl-testosterone%2520as%2520new%2520combi-molecules%2520against%2520prostate%2520cancer%253A%2520Design%252C%2520synthesis%252C%2520structure-activity%2520relationships%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D433%26epage%3D443%26doi%3D10.1016%2Fj.ejmech.2013.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Pauty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortin, S.</span><span> </span><span class="NLM_article-title">Investigation of the DNA damage response to SFOM-0046, a new small-molecule drug inducing DNA double-strand breaks</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">23302</span><span class="refDoi"> DOI: 10.1038/srep23302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fsrep23302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=27001483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVersrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=23302&author=J.+Pautyauthor=M.-F.+C%C3%B4t%C3%A9author=A.+Rodrigueauthor=D.+Velicauthor=J.-Y.+Massonauthor=S.+Fortin&title=Investigation+of+the+DNA+damage+response+to+SFOM-0046%2C+a+new+small-molecule+drug+inducing+DNA+double-strand+breaks&doi=10.1038%2Fsrep23302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the DNA damage response to SFOM-0046, a new small-molecule drug inducing DNA double-strand breaks</span></div><div class="casAuthors">Pauty, Joris; Cote, Marie-France; Rodrigue, Amelie; Velic, Denis; Masson, Jean-Yves; Fortin, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23302</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">2-Ethylphenyl 4-(3-ethylureido)benzenesulfonate (SFOM-0046) is a novel anticancer agent that arrests cell cycle in S-phase and causes DNA replication stress leading to the phosphorylation of H2AX into γ-H2AX.  First, using the M21, HT29, HT-1080 and HeLa cell lines, we confirmed that S-phase cell cycle arrest and γ-H2AX foci induction by SFOM-0046 is a general mechanism occurring in diverse cancer cell lines.  In addn. to γ-H2AX, SFOM-0046 activates preferentially ATR-Chk1 in M21 and HT29 cells while both ATR-Chk1 and ATM-Chk2 pathways are activated in HCT116 cells.  Co-localization of SFOM-0046-induced 53BP1 foci with γ-H2AX foci validates that the DNA damage generated corresponds to double-strand-breaks (DSBs).  Consistent with an S-phase arrest, SFOM-0046 treatment induces RAD51 foci formation but not DNA-PKcs foci, confirming that homologous recombination is the major DSB repair pathway targeted by the drug.  Furthermore, using isogenic HCT116 p53+/+ and HCT116 p53-/- cells, we showed that p53 plays a key role in the survival mechanism to SFOM-0046.  Finally, SFOM-0046 exhibits a dose-dependent antitumor activity on human fibrosarcoma HT-1080 tumors grafted onto chick chorioallantoic membranes without showing embryo toxicity even at high doses.  Altogether, our results highlight SFOM-0046 as a very promising drug that induces a replication stress response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKEPZ_bC4lubVg90H21EOLACvtfcHk0lhMEwQEt7MJNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVersrg%253D&md5=0c8c76bf9f1480d3dc4343ea21184401</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsrep23302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep23302%26sid%3Dliteratum%253Aachs%26aulast%3DPauty%26aufirst%3DJ.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DM.-F.%26aulast%3DRodrigue%26aufirst%3DA.%26aulast%3DVelic%26aufirst%3DD.%26aulast%3DMasson%26aufirst%3DJ.-Y.%26aulast%3DFortin%26aufirst%3DS.%26atitle%3DInvestigation%2520of%2520the%2520DNA%2520damage%2520response%2520to%2520SFOM-0046%252C%2520a%2520new%2520small-molecule%2520drug%2520inducing%2520DNA%2520double-strand%2520breaks%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D23302%26doi%3D10.1038%2Fsrep23302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Mahato, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span> </span><span class="NLM_article-title">Prodrugs for improving tumor targetability and efficiency</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1016/j.addr.2011.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.addr.2011.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=21333700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslalurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=659-670&author=R.+Mahatoauthor=W.+Taiauthor=K.+Cheng&title=Prodrugs+for+improving+tumor+targetability+and+efficiency&doi=10.1016%2Fj.addr.2011.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs for improving tumor targetability and efficiency</span></div><div class="casAuthors">Mahato, Rubi; Tai, Wanyi; Cheng, Kun</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">659-670</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As the mainstay in the treatment of various cancers for several decades, chemotherapy is successful but still faces challenges including non-selectivity and high toxicity.  Improving the selectivity is therefore a crit. step to improve the therapeutic efficacy of chemotherapy.  Prodrug is one of the most promising approaches to increase the selectivity and efficacy of a chemotherapy drug.  The classical prodrug approach is to improve the pharmaceutical properties (soly., stability, permeability, irritation, distribution, etc.) via a simple chem. modification.  This review will focus on various targeted prodrug designs that were developed to increase the selectivity of chemotherapy drugs.  Various tumor-targeting ligands, transporter-assocd. ligands, and polymers can be incorporated in a prodrug to enhance the tumor uptake.  Prodrugs can also be activated by enzymes that are specifically expressed at a higher level in tumors, leading to a selective anti-tumor effect.  This can be achieved by conjugating the enzyme to a tumor-specific antibody, or delivering a vector expressing the enzyme into tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHPTqCpofgqrVg90H21EOLACvtfcHk0lhMEwQEt7MJNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslalurg%253D&md5=4ab69987ce95c6ab2ecb1601f8a3e17c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2011.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2011.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DMahato%26aufirst%3DR.%26aulast%3DTai%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DK.%26atitle%3DProdrugs%2520for%2520improving%2520tumor%2520targetability%2520and%2520efficiency%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D659%26epage%3D670%26doi%3D10.1016%2Fj.addr.2011.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Loaiza-Perez, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boswell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollingshead, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hose, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciolino, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistica, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span> </span><span class="NLM_article-title">Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=15210858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVajs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=715-725&author=A.+I.+Loaiza-Perezauthor=S.+Kenneyauthor=J.+Boswellauthor=M.+Hollingsheadauthor=M.+C.+Alleyauthor=C.+Hoseauthor=H.+P.+Ciolinoauthor=G.+C.+Yehauthor=J.+B.+Trepelauthor=D.+T.+Visticaauthor=E.+A.+Sausville&title=Aryl+hydrocarbon+receptor+activation+of+an+antitumor+aminoflavone%3A+basis+of+selective+toxicity+for+MCF-7+breast+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells</span></div><div class="casAuthors">Loaiza-Perez, Andrea I.; Kenney, Susan; Boswell, Jamie; Hollingshead, Melinda; Alley, Michael C.; Hose, Curtis; Ciolino, Henry P.; Yeh, Grace C.; Trepel, Jane B.; Vistica, David T.; Sausville, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">715-725</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aminoflavone (4H-1-benzopyran-4-one, 5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl; NSC 686288) demonstrates differential antiproliferative activity in the National Cancer Institute's anticancer drug screen.  We demonstrate here that MCF-7 human breast cancer cells are sensitive to aminoflavone both in vitro and when grown in vivo as xenografts in athymic mice.  As previous work has indicated that aminoflavone requires metabolic activation by cytochrome P 450 1A1 (CYP1A1), we investigated the effect of aminoflavone on CYP1A1 expression and on the aryl hydrocarbon receptor (AhR), a transcriptional regulator of CYP1A1.  In aminoflavone-sensitive but not aminoflavone-resistant cells, the drug caused a 100-fold induction of CYP1A1 mRNA and a corresponding increase in ethoxyresorufin-O-deethylase activity.  An AhR-deficient variant of the MCF-7 breast carcinoma, AHR100, with diminished CYP1A1 inducibility, exhibits cellular resistance to aminoflavone and is refractory to CYP1A1 mRNA induction by the drug.  The increase in CYP1A1 mRNA in the aminoflavone-sensitive MCF-7 breast tumor cell results from transcriptional activation of xenobiotic-responsive element (XRE)-controlled transcription.  Aminoflavone treatment causes a translocation of the AhR from the cytoplasm to the nucleus with subsequent formation of AhR-XRE protein DNA complexes.  In contrast to the aminoflavone-sensitive MCF-7 cells, the resistant cell lines (MDA-MB-435, PC-3, and AHR100) demonstrated constitutive nuclear localization of AhR.  Addnl., aminoflavone failed to induce ethoxyresorufin-O-deethylase activity, CYP1A1 transcription, AhR-XRE complex formation, and apoptosis in aminoflavone-resistant cells.  These results suggest that the cytotoxicity of aminoflavone in a sensitive breast tumor cell line is the result of the engagement of AhR-mediated signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBxtJjXbIVRLVg90H21EOLACvtfcHk0liTiDSdmahMRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVajs7Y%253D&md5=14a3ca764db9af562945d2d305630d69</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoaiza-Perez%26aufirst%3DA.%2BI.%26aulast%3DKenney%26aufirst%3DS.%26aulast%3DBoswell%26aufirst%3DJ.%26aulast%3DHollingshead%26aufirst%3DM.%26aulast%3DAlley%26aufirst%3DM.%2BC.%26aulast%3DHose%26aufirst%3DC.%26aulast%3DCiolino%26aufirst%3DH.%2BP.%26aulast%3DYeh%26aufirst%3DG.%2BC.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DVistica%26aufirst%3DD.%2BT.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26atitle%3DAryl%2520hydrocarbon%2520receptor%2520activation%2520of%2520an%2520antitumor%2520aminoflavone%253A%2520basis%2520of%2520selective%2520toxicity%2520for%2520MCF-7%2520breast%2520tumor%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D715%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Leong, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heydon, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Double, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, M. F.</span><span> </span><span class="NLM_article-title">Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6600719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fsj.bjc.6600719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=12569393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=470-477&author=C.+O.+Leongauthor=M.+Gaskellauthor=E.+A.+Martinauthor=R.+T.+Heydonauthor=P.+B.+Farmerauthor=M.+C.+Bibbyauthor=P.+A.+Cooperauthor=J.+A.+Doubleauthor=T.+D.+Bradshawauthor=M.+F.+Stevens&title=Antitumour+2-%284-aminophenyl%29benzothiazoles+generate+DNA+adducts+in+sensitive+tumour+cells+in+vitro+and+in+vivo&doi=10.1038%2Fsj.bjc.6600719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo</span></div><div class="casAuthors">Leong, C-O.; Gaskell, M.; Martin, E. A.; Heydon, R. T.; Farmer, P. B.; Bibby, M. C.; Cooper, P. A.; Double, J. A.; Bradshaw, T. D.; Stevens, M. F. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">470-477</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">2-(4-Aminophenyl)benzothiazoles represent a potent and highly selective class of antitumor agent.  In vitro, sensitive carcinoma cells deplete 2-(4-aminophenyl)benzothiazoles from nutrient media; cytochrome P 450 1A1 activity, crit. for execution of antitumor activity, and protein expression are powerfully induced. 2-(4-Amino-3-methylphenyl)benzothiazole-derived covalent binding to cytochrome P 450 1A1 is reduced by glutathione, suggesting 1A1-dependent prodn. of a reactive electrophilic species.  In vitro, 2-(4-aminophenyl)benzothiazole-generated DNA adducts form in sensitive tumor cells only.  At concns. >100 nM, adducts were detected in DNA of MCF-7 cells treated with 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203).  5F 203 (1 μM) led to the formation of one major and a no. of minor adducts.  However, treatment of cells with 10 μM 5F 203 resulted in the emergence of a new dominant adduct.  Adducts accumulated steadily within DNA of MCF-7 cells exposed to 1 μM 5F 203 between 2 and 24 h.  Concns. of the lysylamide prodrug of 5F 203 (Phortress) ≥100 nM generated adducts in the DNA of sensitive MCF-7 and IGROV-1 ovarian cells.  At 1 μM, one major Phortress-derived DNA adduct was detected in these two sensitive phenotypes; 10 μM Phortress led to the emergence of an addnl. major adduct detected in the DNA of MCF-7 cells.  Inherently resistant MDA-MB-435 breast carcinoma cells incurred no DNA damage upon exposure to Phortress (≤10 μM, 24 h).  In vivo, DNA adducts accumulated within sensitive ovarian IGROV-1 and breast MCF-7 xenografts 24 h after treatment of mice with Phortress (20 mg kg-1).  Moreover, Phortress-derived DNA adduct generation distinguished sensitive MCF-7 tumors from inherently resistant MDA-MB-435 xenografts implanted in opposite flanks of the same mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQQ-QrsA4eBLVg90H21EOLACvtfcHk0liTiDSdmahMRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKmuw%253D%253D&md5=b24f741cf9b0ea7ce29055c4a437cf19</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600719%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DC.%2BO.%26aulast%3DGaskell%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DE.%2BA.%26aulast%3DHeydon%26aufirst%3DR.%2BT.%26aulast%3DFarmer%26aufirst%3DP.%2BB.%26aulast%3DBibby%26aufirst%3DM.%2BC.%26aulast%3DCooper%26aufirst%3DP.%2BA.%26aulast%3DDouble%26aufirst%3DJ.%2BA.%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DStevens%26aufirst%3DM.%2BF.%26atitle%3DAntitumour%25202-%25284-aminophenyl%2529benzothiazoles%2520generate%2520DNA%2520adducts%2520in%2520sensitive%2520tumour%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D470%26epage%3D477%26doi%3D10.1038%2Fsj.bjc.6600719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Callero, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loaiza-Perez, A. I.</span><span> </span><span class="NLM_article-title">The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone</span> <span class="citation_source-journal">Int. J. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">923250</span><span class="refDoi"> DOI: 10.4061/2011/923250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.4061%2F2011%2F923250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22295239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC387ptlymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=923250&author=M.+A.+Calleroauthor=A.+I.+Loaiza-Perez&title=The+role+of+aryl+hydrocarbon+receptor+and+crosstalk+with+estrogen+receptor+in+response+of+breast+cancer+cells+to+the+novel+antitumor+agents+benzothiazoles+and+aminoflavone&doi=10.4061%2F2011%2F923250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone</span></div><div class="casAuthors">Callero Mariana A; Loaiza-Perez Andrea I</div><div class="citationInfo"><span class="NLM_cas:title">International journal of breast cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">923250</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many estrogen-receptor- (ER-) expressing breast cancers become refractory to ER-based therapies.  New antitumor drugs like aminoflavone (AF) and benzothiazoles (Bzs) have been developed and have exquisite antitumor activity in ER+MCF-7 and T47D cells and in a MCF-7 nude mouse model.  ER(-) breast cancer cells like MDA-MB-231 are less susceptible.  We previously found in MCF-7 cells that these drugs activate the aryl hydrocarbon receptor (AhR) via translocation to the nucleus, induction of AhR-specific DNA binding activity, and expression of CYP1A1, whose transcription is controlled by the AhR-ARNT transcription factor.  CYP1A1 metabolizes AF and Bz to a species which directly or after further metabolism damages DNA.  In contrast an AhR-deficient variant of MCF-7 or cells with predominantly nuclear AhR expression, such as MDA-MB 231, are resistant.  Thus, these drugs, unlike other neoplastic agents, require AhR-mediated signaling to cause DNA damage.  This is a new treatment strategy for breast cancers with intact AhR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQY89M2DydDN7mQt-ICR3qNfW6udTcc2ebF7vyB6YtgK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387ptlymtQ%253D%253D&md5=276bba155eb5d7c0324860b614c8592c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.4061%2F2011%2F923250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4061%252F2011%252F923250%26sid%3Dliteratum%253Aachs%26aulast%3DCallero%26aufirst%3DM.%2BA.%26aulast%3DLoaiza-Perez%26aufirst%3DA.%2BI.%26atitle%3DThe%2520role%2520of%2520aryl%2520hydrocarbon%2520receptor%2520and%2520crosstalk%2520with%2520estrogen%2520receptor%2520in%2520response%2520of%2520breast%2520cancer%2520cells%2520to%2520the%2520novel%2520antitumor%2520agents%2520benzothiazoles%2520and%2520aminoflavone%26jtitle%3DInt.%2520J.%2520Breast%2520Cancer%26date%3D2011%26volume%3D2011%26spage%3D923250%26doi%3D10.4061%2F2011%2F923250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Callero, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loaiza-Perez, A. I.</span><span> </span><span class="NLM_article-title">Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.3892/ijo.2012.1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.3892%2Fijo.2012.1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22485252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC38Xptl2lsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=125-134&author=M.+A.+Calleroauthor=G.+V.+Suarezauthor=G.+Luzzaniauthor=B.+Itkinauthor=B.+Nguyenauthor=A.+I.+Loaiza-Perez&title=Aryl+hydrocarbon+receptor+activation+by+aminoflavone%3A+new+molecular+target+for+renal+cancer+treatment&doi=10.3892%2Fijo.2012.1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment</span></div><div class="casAuthors">Callero, Mariana A.; Suarez, Guadalupe V.; Luzzani, Gabriela; Itkin, Boris; Nguyen, Binh; Loaiza-Perez, Andrea I.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Aminoflavone (AF; NSC 686288, AFP464, NSC710464) is a new anticancer drug that has recently entered phase II clin. trials.  It has demonstrated antiproliferative effects in MCF-7 human breast cancer cells mediated by the aryl hydrocarbon receptor (AhR).  AF also exhibits noteworthy evidence of antitumor activity in vitro and in vivo against neoplastic cells of renal origin.  AF treatment of sensitive renal cells, in contrast to resistant cells, promotes the induction of CYP1A1, the covalent binding of AF-reactive intermediates and apoptosis.  Based on this evidence, the aim of this study was to evaluate the role of AhR, the main transcriptional regulator of CYP1A1, in the antiproliferative effects of AF in human renal cancer cells.  AF-cytoxicity in human renal cell lines and a renal cancer cell strain was assessed by MTS assay in the presence or absence of an Ahr inhibitor.  Drug-induced AhR nuclear translocation was evaluated by western blotting of AhR in cytosolic and nuclear fractions and by measuring xenobiotic response element-driven luciferase activity.  Apoptosis induced by the drug was evaluated by 4,6-diamidino-2-phenylindole and acridine orange/ethidium bromide staining and by measuring phosphorylated P53 (p-P53) and P21 levels, caspase 3 activation and poly(ADP-ribose) polymerase cleavage.  AF inhibited cell growth in a dose-dependent manner in TK-10, Caki-1, SN12-C and A498 human renal cells but not in ACHN cells.  The antiproliferative effect of AF was abrogated by pre-incubation of TK-10, Caki-1 and SN12-C cells with the AhR antagonist, α-naphthoflavone.  AF treatment also induced apoptosis in TK-10, Caki-1 and SN12-C cells, which was not obsd. in ACHN cells.  AF induced time-dependent AhR nuclear translocation and AhR transcriptional activity in sensitive renal cancer cell lines.  A renal cell strain derived from a human papillary tumor also showed sensitivity to AF, as well as AhR pathway activation and drug-induced apoptosis.  AhR translocation could be included as a marker of sensitivity to AF in sensitive renal tumor cells of different histol. origin, in ongoing phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6EVkR9xO0nLVg90H21EOLACvtfcHk0ljbebMTSHJM6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xptl2lsLk%253D&md5=4e855f044c41cbd081a2091db7afefde</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3892%2Fijo.2012.1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2012.1427%26sid%3Dliteratum%253Aachs%26aulast%3DCallero%26aufirst%3DM.%2BA.%26aulast%3DSuarez%26aufirst%3DG.%2BV.%26aulast%3DLuzzani%26aufirst%3DG.%26aulast%3DItkin%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DLoaiza-Perez%26aufirst%3DA.%2BI.%26atitle%3DAryl%2520hydrocarbon%2520receptor%2520activation%2520by%2520aminoflavone%253A%2520new%2520molecular%2520target%2520for%2520renal%2520cancer%2520treatment%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2012%26volume%3D41%26spage%3D125%26epage%3D134%26doi%3D10.3892%2Fijo.2012.1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Seckl, M.; Cresti, N.; Boddy, A.; Phillips, R.; Chapman, F.; Schmid, P.; Calvert, H.; Robson, L.; Plummer, R.</span><span> </span><span class="NLM_article-title">A Cancer Research UK phase I trial of Phortress (novel antitumour benzothiazole) given intravenously in consecutive 21 day cycles with treatment on day 1 of each cycle</span>. 8th NCRI Cancer Conference, November 4–7, 2013, BT Convention Center, Liverpool,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><div class="note"><p class="first last">Poster Session B, Diagnosis and Therapy</p></div>,  <a href="http://conference.ncri.org.uk/abstracts/2012/abstracts/LB79.html" class="extLink">http://conference.ncri.org.uk/abstracts/2012/abstracts/LB79.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Seckl&author=N.+Cresti&author=A.+Boddy&author=R.+Phillips&author=F.+Chapman&author=P.+Schmid&author=H.+Calvert&author=L.+Robson&author=R.+Plummer&title=A+Cancer+Research+UK+phase+I+trial+of+Phortress+%28novel+antitumour+benzothiazole%29+given+intravenously+in+consecutive+21+day+cycles+with+treatment+on+day+1+of+each+cycle"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSeckl%26aufirst%3DM.%26atitle%3DA%2520Cancer%2520Research%2520UK%2520phase%2520I%2520trial%2520of%2520Phortress%2520%2528novel%2520antitumour%2520benzothiazole%2529%2520given%2520intravenously%2520in%2520consecutive%252021%2520day%2520cycles%2520with%2520treatment%2520on%2520day%25201%2520of%2520each%2520cycle%26jtitle%3D8th%2520NCRI%2520Cancer%2520Conference%252C%2520November%25204%25E2%2580%25937%252C%25202013%252C%2520BT%2520Convention%2520Center%252C%2520Liverpool%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Dvorak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrichova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modriansky, M.</span><span> </span><span class="NLM_article-title">Role of microtubules network in CYP genes expression</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.2174/138920005774832623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F138920005774832623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16379668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1GrurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=545-552&author=Z.+Dvorakauthor=J.+Ulrichovaauthor=M.+Modriansky&title=Role+of+microtubules+network+in+CYP+genes+expression&doi=10.2174%2F138920005774832623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Role of microtubules network in CYP genes expression</span></div><div class="casAuthors">Dvorak, Z.; Ulrichova, J.; Modriansky, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-552</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Superfamily of cytochrome P 450 enzymes (CYPs), a distinctive enzyme system by which human body defends itself against toxic compds., is the subject of a complex regulation process involving various mechanisms, on the levels of expression and activity.  Apart from physiol. factors, several pathophysiol. ones such as inflammation, infection, and stress affect CYP expression.  The aim of this review is to summarize the current knowledge on the role of microtubules network in the regulation of drug metabolizing CYPs.  Expts. on human and animal cell models revealed that microtubules disruption severely impaired basal and inducible expression of human CYP 1A1, 2B6, 2C8, 2C9, 2C19, and 3A4, and rat CYP 1A2, 2B1, 2B2, and 3A23.  Inhibition of aryl hydrocarbon receptor (AhR) and glucocorticoid receptor (GR) transcriptional activity by microtubules disarray was found to be responsible for the suppressed CYP enzymes expression.  However, the mechanism by which microtubules interfering agents (MIAs) inhibit GR and AhR transcriptional activities is not fully understood yet.  Several lines of evidence indicate that: (1) the cell cycle, G2/M phase in particular, has an influence on AhR and GR transcriptional activity, and (2) MIAs neg. modulate GR transcriptional activity via the activation of c-Jun-N-terminal kinase.  In conclusion, down-regulation of major CYP enzymes by microtubules disarray is intriguing from the mechanistic point of view and in relation to the cell differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogVGscOHp1kbVg90H21EOLACvtfcHk0ljbebMTSHJM6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1GrurrE&md5=b3cce0f18b5d2b612f8fd79cbfa96e60</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.2174%2F138920005774832623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920005774832623%26sid%3Dliteratum%253Aachs%26aulast%3DDvorak%26aufirst%3DZ.%26aulast%3DUlrichova%26aufirst%3DJ.%26aulast%3DModriansky%26aufirst%3DM.%26atitle%3DRole%2520of%2520microtubules%2520network%2520in%2520CYP%2520genes%2520expression%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D545%26epage%3D552%26doi%3D10.2174%2F138920005774832623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Dvorak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrzal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrichova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascussi, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modriansky, M.</span><span> </span><span class="NLM_article-title">Involvement of cytoskeleton in AhR-dependent CYP1A1 expression</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span><span class="refDoi"> DOI: 10.2174/138920006776359310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F138920006776359310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16611024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs12jt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=301-313&author=Z.+Dvorakauthor=R.+Vrzalauthor=J.+Ulrichovaauthor=J.+M.+Pascussiauthor=P.+Maurelauthor=M.+Modriansky&title=Involvement+of+cytoskeleton+in+AhR-dependent+CYP1A1+expression&doi=10.2174%2F138920006776359310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of cytoskeleton in AhR-dependent CYP1A1 expression</span></div><div class="casAuthors">Dvorak, Zdenek; Vrzal, Radim; Ulrichova, Jitka; Pascussi, Jean-Marc; Maurel, Patrick; Modriansky, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-313</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Cytochrome P 450 (CYP) 1A1 attracts attention mainly because of its role in prodn. of carcinogenic reactive metabolites from polycyclic arom. hydrocarbons such as benzo[a]pyrene, but recent developments indicate its apparent role in cell cycle progression.  Expression of the enzyme is subject to regulation by aryl hydrocarbon receptor (AhR).  It was shown that induction of CYP 1A1 in HepG2 cells and primary rat hepatocytes by tetrachloro-p-dibenzodioxin (TCDD) is diminished by colchicine and nocodazole.  Both compds. decrease CYP1A1 mRNA, protein, and activity levels in HepG2 cells and mRNA level in primary rat hepatocytes.  Neither compd. significantly affected [3H]-TCDD binding to AhR, thus their effect on AhR transcriptional activity proceeds via indirect means.  For colchicine and nocodazole are well-known microtubule interfering agents, we also assessed their effect on microtubule integrity in both cell types under investigation.  Both compds. disrupt cytoskeleton integrity with differential potency depending on cell type.  The obsd. suppression of AhR transcriptional activity by colchicine and nocodazole can be assocd. with G2/M cell cycle arrest in HepG2 cells, as demonstrated by Myt1 protein hyperphosphorylation and FACS anal.  However, in primary rat hepatocytes, cytoskeleton disruption is independent of cell cycle while displaying the same influence on AhR-dependent gene transcription.  In our view, this is evidence in favor of modulatory role of cytoskeleton in AhR-dependent expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH-hitz3CdtLVg90H21EOLACvtfcHk0ljbebMTSHJM6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs12jt7Y%253D&md5=007b75bdd94f64912825eb1bb6428bc0</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2174%2F138920006776359310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920006776359310%26sid%3Dliteratum%253Aachs%26aulast%3DDvorak%26aufirst%3DZ.%26aulast%3DVrzal%26aufirst%3DR.%26aulast%3DUlrichova%26aufirst%3DJ.%26aulast%3DPascussi%26aufirst%3DJ.%2BM.%26aulast%3DMaurel%26aufirst%3DP.%26aulast%3DModriansky%26aufirst%3DM.%26atitle%3DInvolvement%2520of%2520cytoskeleton%2520in%2520AhR-dependent%2520CYP1A1%2520expression%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2006%26volume%3D7%26spage%3D301%26epage%3D313%26doi%3D10.2174%2F138920006776359310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Lowry, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosebrough, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randall, R. J.</span><span> </span><span class="NLM_article-title">Protein measurement with the Folin phenol reagent</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2FS0021-9258%2819%2952451-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=14907713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADyaG38XhsVyrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=1951&pages=265-275&author=O.+H.+Lowryauthor=N.+J.+Rosebroughauthor=A.+L.+Farrauthor=R.+J.+Randall&title=Protein+measurement+with+the+Folin+phenol+reagent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Protein measurement with the Folin phenol reagent</span></div><div class="casAuthors">Lowry, Oliver H.; Rosebrough, Nira J.; Farr, A. Lewis; Randall, Rose J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1951</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">265-75</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">cf. C.A. 41, 1271h.  Proteins were detd. with the Folin phenol reagent after alk. Cu treatment.  The method is as sensitive as with Nessler reagent, yet requires no digestion.  It is 10-20 times more sensitive than detn. of the ultraviolet absorption at λ = 280 mμ and is more specific.  It is several fold more sensitive than the ninhydrin reaction and 100 times more sensitive than the biuret reaction.  Two major disadvantages are: the amt. of color varies with different proteins; the color is not strictly proportional to concn.  Few substances cause serious interference.  Uric acid, guanine, and xanthine react with Folin reagent.  The method is useful for following enzyme fractionation, detg. mixed tissue proteins, detn. of very small amts. of protein, or detg. highly dild. protein, or protein in colored solns. or in the presence of N-contg. material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHNRKGd34F8LVg90H21EOLACvtfcHk0ljURgeCEyaM8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG38XhsVyrsw%253D%253D&md5=19d36395fad7dd87661caa3d2b97640d</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2952451-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252952451-6%26sid%3Dliteratum%253Aachs%26aulast%3DLowry%26aufirst%3DO.%2BH.%26aulast%3DRosebrough%26aufirst%3DN.%2BJ.%26aulast%3DFarr%26aufirst%3DA.%2BL.%26aulast%3DRandall%26aufirst%3DR.%2BJ.%26atitle%3DProtein%2520measurement%2520with%2520the%2520Folin%2520phenol%2520reagent%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1951%26volume%3D193%26spage%3D265%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Arocho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Q.</span><span> </span><span class="NLM_article-title">Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts</span> <span class="citation_source-journal">Diagn. Mol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1097/00019606-200603000-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1097%2F00019606-200603000-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16531770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XislOlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=56-61&author=A.+Arochoauthor=B.+Chenauthor=M.+Ladanyiauthor=Q.+Pan&title=Validation+of+the+2-DeltaDeltaCt+calculation+as+an+alternate+method+of+data+analysis+for+quantitative+PCR+of+BCR-ABL+P210+transcripts&doi=10.1097%2F00019606-200603000-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of the 2-ΔΔCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts</span></div><div class="casAuthors">Arocho, Alaina; Chen, Beiyun; Ladanyi, Marc; Pan, Qiulu</div><div class="citationInfo"><span class="NLM_cas:title">Diagnostic Molecular Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-61</span>CODEN:
                <span class="NLM_cas:coden">DMPAES</span>;
        ISSN:<span class="NLM_cas:issn">1052-9551</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that is characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 and results in the formation of the Philadelphia (Ph1) chromosome and is present in most of CML patients.  The Ph1 chromosome forms a chimeric gene that encodes an abnormal P210 mRNA transcript in most CML patients.  Surveillance for minimal residual disease by detection of BCR/ABL transcripts is currently done mostly by quant. real-time reverse transcriptase polymerase chain reaction (RT-PCR).  Quantitation of BCR/ABL transcripts can monitor tumor load and the outcome of therapy.  Abs. quantification dets. the input copy no. of the transcript of interest, usually by plotting the amt. of PCR product onto a std. curve based on serial dilns. of the same product cloned in plasmids.  Relative quantification describes the change in expression of the target gene in the patient sample relative to that of a control transcript by using the 2-ΔΔCt calcn.  The results of real-time RT-PCR for BCR/ABL transcripts are often analyzed by using plasmid DNA std. curves.  In the present study, 79 BCR/ABL transcript-pos. samples from CML patients who were being monitored for minimal residual disease by real-time quant. RT-PCR were studied to det. whether the 2-ΔΔCt approach was equiv. to the plasmid std. curve method.  BCR/ABL P210 transcripts were quantitated using both the plasmid std. curve method and the 2-ΔΔCt calcn.  The comparison of both methods revealed a highly significant and linear correlation between the plasmid std. curve method and the 2-ΔΔCt calcn. (R2 = 0.98, P < 0.0001).  Furthermore, there was a redn. of prepn. time, contamination risk, and reagent usage.  The 2-ΔΔCt calcn. is a convenient alternative method to derive accurate quant. information from real time PCR assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3vfJNCCjj67Vg90H21EOLACvtfcHk0ljURgeCEyaM8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislOlurc%253D&md5=c90dfa61e8c39a3cb47e9964f6fa6b32</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1097%2F00019606-200603000-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00019606-200603000-00009%26sid%3Dliteratum%253Aachs%26aulast%3DArocho%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPan%26aufirst%3DQ.%26atitle%3DValidation%2520of%2520the%25202-DeltaDeltaCt%2520calculation%2520as%2520an%2520alternate%2520method%2520of%2520data%2520analysis%2520for%2520quantitative%2520PCR%2520of%2520BCR-ABL%2520P210%2520transcripts%26jtitle%3DDiagn.%2520Mol.%2520Pathol.%26date%3D2006%26volume%3D15%26spage%3D56%26epage%3D61%26doi%3D10.1097%2F00019606-200603000-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Smarakan  Sneha</span>, <span class="hlFld-ContribAuthor ">Simon C.  Baker</span>, <span class="hlFld-ContribAuthor ">Andrew  Green</span>, <span class="hlFld-ContribAuthor ">Sarah  Storr</span>, <span class="hlFld-ContribAuthor ">Radhika  Aiyappa</span>, <span class="hlFld-ContribAuthor ">Stewart  Martin</span>, <span class="hlFld-ContribAuthor ">Klaus  Pors</span>. </span><span class="cited-content_cbyCitation_article-title">Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies. </span><span class="cited-content_cbyCitation_journal-name">Biomedicines</span><span> <strong>2021,</strong> <em>9 </em>
                                    (3)
                                     , 290. <a href="https://doi.org/10.3390/biomedicines9030290" title="DOI URL">https://doi.org/10.3390/biomedicines9030290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biomedicines9030290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiomedicines9030290%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicines%26atitle%3DIntratumoural%252BCytochrome%252BP450%252BExpression%252Bin%252BBreast%252BCancer%25253A%252BImpact%252Bon%252BStandard%252Bof%252BCare%252BTreatment%252Band%252BNew%252BEfforts%252Bto%252BDevelop%252BTumour-Selective%252BTherapies%26aulast%3DSneha%26aufirst%3DSmarakan%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D3%26spage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yeo-Jung  Kwon</span>, <span class="hlFld-ContribAuthor ">Sangyun  Shin</span>, <span class="hlFld-ContribAuthor ">Young-Jin  Chun</span>. </span><span class="cited-content_cbyCitation_article-title">Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2021,</strong> <em>44 </em>
                                    (1)
                                     , 63-83. <a href="https://doi.org/10.1007/s12272-021-01306-w" title="DOI URL">https://doi.org/10.1007/s12272-021-01306-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-021-01306-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-021-01306-w%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DBiological%252Broles%252Bof%252Bcytochrome%252BP450%252B1A1%25252C%252B1A2%25252C%252Band%252B1B1%252Benzymes%26aulast%3DKwon%26aufirst%3DYeo-Jung%26date%3D2021%26date%3D2021%26volume%3D44%26issue%3D1%26spage%3D63%26epage%3D83" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mitra  Zarifi Khosroshahi</span>, <span class="hlFld-ContribAuthor ">Atziri  Corin Chavez Alvarez</span>, <span class="hlFld-ContribAuthor ">Mathieu  Gagné-Boulet</span>, <span class="hlFld-ContribAuthor ">René  C.-Gaudreault</span>, <span class="hlFld-ContribAuthor ">Stéphane  Gobeil</span>, <span class="hlFld-ContribAuthor ">Sébastien  Fortin</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of the time-dependent antiproliferative activity and liver microsome stability of 3 phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as promising CYP1A1-dependent antimicrotubule prodrugs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacy and Pharmacology</span><span> <strong>2020,</strong> <em>72 </em>
                                    (2)
                                     , 249-258. <a href="https://doi.org/10.1111/jphp.13198" title="DOI URL">https://doi.org/10.1111/jphp.13198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jphp.13198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjphp.13198%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacy%2520and%2520Pharmacology%26atitle%3DEvaluation%252Bof%252Bthe%252Btime-dependent%252Bantiproliferative%252Bactivity%252Band%252Bliver%252Bmicrosome%252Bstability%252Bof%252B3%252Bphenyl%252B4-%2525282-oxo-3-alkylimidazolidin-1-yl%252529benzenesulfonates%252Bas%252Bpromising%252BCYP1A1-dependent%252Bantimicrotubule%252Bprodrugs%26aulast%3DZarifi%2BKhosroshahi%26aufirst%3DMitra%26date%3D2020%26date%3D2019%26volume%3D72%26issue%3D2%26spage%3D249%26epage%3D258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Koki  Yamamoto</span>. </span><span class="cited-content_cbyCitation_article-title">Introduction. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 1-9. <a href="https://doi.org/10.1007/978-981-15-2965-8_1" title="DOI URL">https://doi.org/10.1007/978-981-15-2965-8_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-15-2965-8_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-15-2965-8_1%26sid%3Dliteratum%253Aachs%26atitle%3DIntroduction%26aulast%3DYamamoto%26aufirst%3DKoki%26date%3D2020%26date%3D2020%26spage%3D1%26epage%3D9%26pub%3DSpringer%2520Singapore%26atitle%3DStructure%2525E2%252580%252593Activity%252BRelationships%252Bfor%252BDevelopment%252Bof%252BNeurokinin-3%252BReceptor%252BAntagonists%26aulast%3DYamamoto%26aufirst%3DKoki%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nick Y.  Shin</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Ryss</span>, <span class="hlFld-ContribAuthor ">Xin  Zhang</span>, <span class="hlFld-ContribAuthor ">Scott J.  Miller</span>, <span class="hlFld-ContribAuthor ">Robert R.  Knowles</span>. </span><span class="cited-content_cbyCitation_article-title">Light
              -
              driven deracemization enabled by excited
              -
              state electron transfer. </span><span class="cited-content_cbyCitation_journal-name">Science</span><span> <strong>2019,</strong> <em>366 </em>
                                    (6463)
                                     , 364-369. <a href="https://doi.org/10.1126/science.aay2204" title="DOI URL">https://doi.org/10.1126/science.aay2204</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/science.aay2204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscience.aay2204%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%26atitle%3DLight%252B-%252Bdriven%252Bderacemization%252Benabled%252Bby%252Bexcited%252B-%252Bstate%252Belectron%252Btransfer%26aulast%3DShin%26aufirst%3DNick%2BY.%26date%3D2019%26date%3D2019%26volume%3D366%26issue%3D6463%26spage%3D364%26epage%3D369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhiwen  Cao</span>, <span class="hlFld-ContribAuthor ">Wen  Li</span>, <span class="hlFld-ContribAuthor ">Rui  Liu</span>, <span class="hlFld-ContribAuthor ">Xiang  Li</span>, <span class="hlFld-ContribAuthor ">Hui  Li</span>, <span class="hlFld-ContribAuthor ">Linlin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Chen</span>, <span class="hlFld-ContribAuthor ">Cheng  Lv</span>, <span class="hlFld-ContribAuthor ">Yuanyan  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">pH- and enzyme-triggered drug release as an important process in the design of anti-tumor drug delivery systems. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2019,</strong> <em>118 </em>, 109340. <a href="https://doi.org/10.1016/j.biopha.2019.109340" title="DOI URL">https://doi.org/10.1016/j.biopha.2019.109340</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2019.109340&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2019.109340%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DpH-%252Band%252Benzyme-triggered%252Bdrug%252Brelease%252Bas%252Ban%252Bimportant%252Bprocess%252Bin%252Bthe%252Bdesign%252Bof%252Banti-tumor%252Bdrug%252Bdelivery%252Bsystems%26aulast%3DCao%26aufirst%3DZhiwen%26date%3D2019%26volume%3D118%26spage%3D109340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Reza  Peymanfar</span>, <span class="hlFld-ContribAuthor ">Shahrzad  Javanshir</span>, <span class="hlFld-ContribAuthor ">Mohammad Reza  Naimi-Jamal</span>, <span class="hlFld-ContribAuthor ">Ahmad  Cheldavi</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation of a superior intense, lightweight, affordable, broadband microwave-absorbing nanocomposite by PUF/PANi. </span><span class="cited-content_cbyCitation_journal-name">Materials Research Express</span><span> <strong>2019,</strong> <em>6 </em>
                                    (8)
                                     , 0850e9. <a href="https://doi.org/10.1088/2053-1591/ab2793" title="DOI URL">https://doi.org/10.1088/2053-1591/ab2793</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1088/2053-1591/ab2793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1088%2F2053-1591%2Fab2793%26sid%3Dliteratum%253Aachs%26jtitle%3DMaterials%2520Research%2520Express%26atitle%3DPreparation%252Bof%252Ba%252Bsuperior%252Bintense%25252C%252Blightweight%25252C%252Baffordable%25252C%252Bbroadband%252Bmicrowave-absorbing%252Bnanocomposite%252Bby%252BPUF%25252FPANi%26aulast%3DPeymanfar%26aufirst%3DReza%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D8%26spage%3D0850e9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron G.  Bart</span>, <span class="hlFld-ContribAuthor ">Emily E.  Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Structures of human cytochrome P450 1A1 with bergamottin and erlotinib reveal active-site modifications for binding of diverse ligands. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biological Chemistry</span><span> <strong>2018,</strong> <em>293 </em>
                                    (50)
                                     , 19201-19210. <a href="https://doi.org/10.1074/jbc.RA118.005588" title="DOI URL">https://doi.org/10.1074/jbc.RA118.005588</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/jbc.RA118.005588&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fjbc.RA118.005588%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biological%2520Chemistry%26atitle%3DStructures%252Bof%252Bhuman%252Bcytochrome%252BP450%252B1A1%252Bwith%252Bbergamottin%252Band%252Berlotinib%252Breveal%252Bactive-site%252Bmodifications%252Bfor%252Bbinding%252Bof%252Bdiverse%252Bligands%26aulast%3DBart%26aufirst%3DAaron%2BG.%26date%3D2018%26volume%3D293%26issue%3D50%26spage%3D19201%26epage%3D19210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atziri Corin  Chavez Alvarez</span>, <span class="hlFld-ContribAuthor ">Mitra  Zarifi Khosroshahi</span>, <span class="hlFld-ContribAuthor ">Marie-France  Côté</span>, <span class="hlFld-ContribAuthor ">Mathieu  Gagné-Boulet</span>, <span class="hlFld-ContribAuthor ">Sébastien  Fortin</span>. </span><span class="cited-content_cbyCitation_article-title">4-(3-Alkyl-2-oxoimidazolidin-1-yl)-N-phenylbenzenesulfonamides as new antimitotic prodrugs activated by cytochrome P450 1A1 in breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (18)
                                     , 5045-5052. <a href="https://doi.org/10.1016/j.bmc.2018.09.001" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.09.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3D4-%2525283-Alkyl-2-oxoimidazolidin-1-yl%252529-N-phenylbenzenesulfonamides%252Bas%252Bnew%252Bantimitotic%252Bprodrugs%252Bactivated%252Bby%252Bcytochrome%252BP450%252B1A1%252Bin%252Bbreast%252Bcancer%252Bcells%26aulast%3DChavez%2BAlvarez%26aufirst%3DAtziri%2BCorin%26date%3D2018%26volume%3D26%26issue%3D18%26spage%3D5045%26epage%3D5052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of CYP1A1 inducers, including: 2,3,7,8-tetrachlorodibenzo-<i>p</i>-dioxin, benzo[<i>a</i>]pyrene, omeprazole, sunitinib, as well as two phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonate (PIB-SOs: <b>1</b> and <b>2</b>) derivatives acting as cytocidal antimicrotubules, as well as duocarmycin bioprecursor <b>3</b>, benzothiazole <b>4</b>, and aminoflavone <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0007.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaH, relevant alkyl iodide, THF; (ii) ClSO<sub>3</sub>H, CCl<sub>4</sub>; (iii) relevant phenol, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. PAIB-SO <b>67</b> has an antimicrotubule effect in sensitive MDA-MB-468 and MCF7 cells and are inactive in MDA-MB-231 cells. Effect of PAIB-SO <b>67</b> [50 nM, (c,f,i)] and its parental drug <b>1</b> [8 nM, (b,e,h)] on cytoskeletal integrity and cell cycle progression in sensitive MDA-MB-468 (a–c) and MCF7 (d–f) and insensitive MDA-MB-231 cells (g–i). Control groups (a, d, g) were incubated with vehicle only (0.5% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effect of subtoxic concentrations of known CYP1A1 inhibitors [(a) α-naphthoflavone, (b) resveratrol, (c) ketoconazole, (d) quercetin, (e) tacrine, and (f) capsaicin] and known CYP inhibitors devoid of anti-CYP1A1 activity [(g) aniline, (h) curcumin, (i) mefipristone, (j) pentachlorophenol, and (k) salicylamide] on the cytocidal activity of PAIB-SO <b>67</b> in sensitive MDA-MB-468 cells. The experiments were conducted in triplicates.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Conversion of inactive PAIB-SOs into potent PIB-SOs by CYP1A1. Oxidation of PAIB-SOs (a) <b>49</b>, (b) <b>67</b>, and (c) <b>63</b> to their parent PIB-SOs (<b>1</b> and <b>2</b>) by CYP1A1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Stability of PAIB-SO toward various CYPs. HPLC analysis of a control mixture containing (a) PAIB-SO <b>67</b> and its parent PIB-SO drug <b>1</b>, and the supernatant obtained after incubation of PAIB-SO <b>67</b> with (b) CYP1A2, (c) CYP1B1, (d) CYP3A4, and (e) human liver microsomes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/medium/jm-2017-00343u_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. In vitro and in vivo selectivity of PAIB-SOs toward human fibrosarcoma HT-1080 cells stably transfected with pCMV6-AC_Empty (HT-1080<sup>empty</sup>) and pCMV6-AC_CYP1A1 (HT-1080<sup><i>CYP1A1</i></sup>) plasmids. (a) Antiproliferative activity and selectivity ratios (HT-1080<sup>empty</sup>/HT-1080<sup><i>CYP1A1</i></sup>) of <b>1</b>, <b>2</b>, and the selected <b>49</b>, <b>67</b>, and <b>63</b> derivatives in HT-1080 wild-type, HT-1080<sup>empty</sup>, and HT-1080<sup><i>CYP1A1</i></sup> cells. (b) CYP1A1 expression in HT-1080, HT-1080<sup>empty</sup>, and HT-1080<sup><i>CYP1A1</i></sup> cells. (c) Effect of PAIB-SO <b>67</b> and <b>1</b> on HT-1080, HT-1080<sup>empty</sup>, and HT-1080<sup><i>CYP1A1</i></sup> tumor growth using the CAM assay, with the assessment of drug toxicity in the chick embryos. The <i>blue</i> bars represent the percentage of tumor-specific wet weight in tumor grafts treated with and without excipient. The <i>red</i> bars indicate the percentage of chick embryo mortality.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00343/20170616/images/large/jm-2017-00343u_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00343&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i102">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00310" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00310" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 67 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Torre, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferlay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lortet-Tieulent, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Global cancer statistics, 2012</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">108</span><span class="refDoi"> DOI: 10.3322/caac.21262</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.3322%2Fcaac.21262" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=25651787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2015&pages=87-108&author=L.+A.+Torreauthor=F.+Brayauthor=R.+L.+Siegelauthor=J.+Ferlayauthor=J.+Lortet-Tieulentauthor=A.+Jemal&title=Global+cancer+statistics%2C+2012&doi=10.3322%2Fcaac.21262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics, 2012</span></div><div class="casAuthors">Torre Lindsey A; Bray Freddie; Siegel Rebecca L; Ferlay Jacques; Lortet-Tieulent Joannie; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-108</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer constitutes an enormous burden on society in more and less economically developed countries alike.  The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development.  Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in 2012 worldwide.  Over the years, the burden has shifted to less developed countries, which currently account for about 57% of cases and 65% of cancer deaths worldwide.  Lung cancer is the leading cause of cancer death among males in both more and less developed countries, and has surpassed breast cancer as the leading cause of cancer death among females in more developed countries; breast cancer remains the leading cause of cancer death among females in less developed countries.  Other leading causes of cancer death in more developed countries include colorectal cancer among males and females and prostate cancer among males.  In less developed countries, liver and stomach cancer among males and cervical cancer among females are also leading causes of cancer death.  Although incidence rates for all cancers combined are nearly twice as high in more developed than in less developed countries in both males and females, mortality rates are only 8% to 15% higher in more developed countries.  This disparity reflects regional differences in the mix of cancers, which is affected by risk factors and detection practices, and/or the availability of treatment.  Risk factors associated with the leading causes of cancer death include tobacco use (lung, colorectal, stomach, and liver cancer), overweight/obesity and physical inactivity (breast and colorectal cancer), and infection (liver, stomach, and cervical cancer).  A substantial portion of cancer cases and deaths could be prevented by broadly applying effective prevention measures, such as tobacco control, vaccination, and the use of early detection tests.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS93OidvnAA79ts4TFFB11gfW6udTcc2eZCkt001k5FFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mris1Ggsg%253D%253D&md5=f008b208320b129e10c7c383193ff772</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21262%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DLortet-Tieulent%26aufirst%3DJ.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2015%26volume%3D65%26spage%3D87%26epage%3D108%26doi%3D10.3322%2Fcaac.21262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Torre, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span> </span><span class="NLM_article-title">Global cancer incidence and mortality rates and trends-an update</span> <span class="citation_source-journal">Cancer Epidemiol., Biomarkers Prev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span><span class="refDoi"> DOI: 10.1158/1055-9965.EPI-15-0578</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1158%2F1055-9965.EPI-15-0578" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=26667886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC28vpvVOlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=16-27&author=L.+A.+Torreauthor=R.+L.+Siegelauthor=E.+M.+Wardauthor=A.+Jemal&title=Global+cancer+incidence+and+mortality+rates+and+trends-an+update&doi=10.1158%2F1055-9965.EPI-15-0578"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Global Cancer Incidence and Mortality Rates and Trends--An Update</span></div><div class="casAuthors">Torre Lindsey A; Siegel Rebecca L; Jemal Ahmedin; Ward Elizabeth M</div><div class="citationInfo"><span class="NLM_cas:title">Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-27</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There are limited published data on recent cancer incidence and mortality trends worldwide.  We used the International Agency for Research on Cancer's CANCERMondial clearinghouse to present age-standardized cancer incidence and death rates for 2003-2007.  We also present trends in incidence through 2007 and mortality through 2012 for select countries from five continents.  High-income countries (HIC) continue to have the highest incidence rates for all sites, as well as for lung, colorectal, breast, and prostate cancer, although some low- and middle-income countries (LMIC) now count among those with the highest rates.  Mortality rates from these cancers are declining in many HICs while they are increasing in LMICs.  LMICs have the highest rates of stomach, liver, esophageal, and cervical cancer.  Although rates remain high in HICs, they are plateauing or decreasing for the most common cancers due to decreases in known risk factors, screening and early detection, and improved treatment (mortality only).  In contrast, rates in several LMICs are increasing for these cancers due to increases in smoking, excess body weight, and physical inactivity.  LMICs also have a disproportionate burden of infection-related cancers.  Applied cancer control measures are needed to reduce rates in HICs and arrest the growing burden in LMICs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTTu2rxqNRkftos8R3JUhXfW6udTcc2eZCkt001k5FFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28vpvVOlsw%253D%253D&md5=a700298a7a2bc2d381bb33ed9279df5b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1158%2F1055-9965.EPI-15-0578&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1055-9965.EPI-15-0578%26sid%3Dliteratum%253Aachs%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DWard%26aufirst%3DE.%2BM.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520incidence%2520and%2520mortality%2520rates%2520and%2520trends-an%2520update%26jtitle%3DCancer%2520Epidemiol.%252C%2520Biomarkers%2520Prev.%26date%3D2016%26volume%3D25%26spage%3D16%26epage%3D27%26doi%3D10.1158%2F1055-9965.EPI-15-0578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Siegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeSantis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virgo, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mariotto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gansler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedewa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cannady, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scoppa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hachey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jemal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, E.</span><span> </span><span class="NLM_article-title">Cancer treatment and survivorship statistics, 2012</span> <span class="citation_source-journal">Ca-Cancer J. Clin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">220</span><span class="NLM_x">–</span> <span class="NLM_lpage">241</span><span class="refDoi"> DOI: 10.3322/caac.21149</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.3322%2Fcaac.21149" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22700443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC38jhvFGrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=220-241&author=R.+Siegelauthor=C.+DeSantisauthor=K.+Virgoauthor=K.+Steinauthor=A.+Mariottoauthor=T.+Smithauthor=D.+Cooperauthor=T.+Ganslerauthor=C.+Lerroauthor=S.+Fedewaauthor=C.+Linauthor=C.+Leachauthor=R.+S.+Cannadyauthor=H.+Choauthor=S.+Scoppaauthor=M.+Hacheyauthor=R.+Kirchauthor=A.+Jemalauthor=E.+Ward&title=Cancer+treatment+and+survivorship+statistics%2C+2012&doi=10.3322%2Fcaac.21149"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer treatment and survivorship statistics, 2012</span></div><div class="casAuthors">Siegel Rebecca; DeSantis Carol; Virgo Katherine; Stein Kevin; Mariotto Angela; Smith Tenbroeck; Cooper Dexter; Gansler Ted; Lerro Catherine; Fedewa Stacey; Lin Chunchieh; Leach Corinne; Cannady Rachel Spillers; Cho Hyunsoon; Scoppa Steve; Hachey Mark; Kirch Rebecca; Jemal Ahmedin; Ward Elizabeth</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">220-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Although there has been considerable progress in reducing cancer incidence in the United States, the number of cancer survivors continues to increase due to the aging and growth of the population and improvements in survival rates.  As a result, it is increasingly important to understand the unique medical and psychosocial needs of survivors and be aware of resources that can assist patients, caregivers, and health care providers in navigating the various phases of cancer survivorship.  To highlight the challenges and opportunities to serve these survivors, the American Cancer Society and the National Cancer Institute estimated the prevalence of cancer survivors on January 1, 2012 and January 1, 2022, by cancer site.  Data from Surveillance, Epidemiology, and End Results (SEER) registries were used to describe median age and stage at diagnosis and survival; data from the National Cancer Data Base and the SEER-Medicare Database were used to describe patterns of cancer treatment.  An estimated 13.7 million Americans with a history of cancer were alive on January 1, 2012, and by January 1, 2022, that number will increase to nearly 18 million.  The 3 most prevalent cancers among males are prostate (43%), colorectal (9%), and melanoma of the skin (7%), and those among females are breast (41%), uterine corpus (8%), and colorectal (8%).  This article summarizes common cancer treatments, survival rates, and posttreatment concerns and introduces the new National Cancer Survivorship Resource Center, which has engaged more than 100 volunteer survivorship experts nationwide to develop tools for cancer survivors, caregivers, health care professionals, advocates, and policy makers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiAZAFyHc8fwWRJ3OJdH_qfW6udTcc2eYHt17_akfugrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jhvFGrtw%253D%253D&md5=2aeac577b945bdbf9c9248fae48b1df6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21149%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DDeSantis%26aufirst%3DC.%26aulast%3DVirgo%26aufirst%3DK.%26aulast%3DStein%26aufirst%3DK.%26aulast%3DMariotto%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DCooper%26aufirst%3DD.%26aulast%3DGansler%26aufirst%3DT.%26aulast%3DLerro%26aufirst%3DC.%26aulast%3DFedewa%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DC.%26aulast%3DLeach%26aufirst%3DC.%26aulast%3DCannady%26aufirst%3DR.%2BS.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DScoppa%26aufirst%3DS.%26aulast%3DHachey%26aufirst%3DM.%26aulast%3DKirch%26aufirst%3DR.%26aulast%3DJemal%26aufirst%3DA.%26aulast%3DWard%26aufirst%3DE.%26atitle%3DCancer%2520treatment%2520and%2520survivorship%2520statistics%252C%25202012%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2012%26volume%3D62%26spage%3D220%26epage%3D241%26doi%3D10.3322%2Fcaac.21149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Zanger, U. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, M.</span><span> </span><span class="NLM_article-title">Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">138</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2012.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.pharmthera.2012.12.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23333322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXislykt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2013&pages=103-141&author=U.+M.+Zangerauthor=M.+Schwab&title=Cytochrome+P450+enzymes+in+drug+metabolism%3A+regulation+of+gene+expression%2C+enzyme+activities%2C+and+impact+of+genetic+variation&doi=10.1016%2Fj.pharmthera.2012.12.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation</span></div><div class="casAuthors">Zanger, Ulrich M.; Schwab, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-141</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Cytochromes P 450 (CYP) are a major source of variability in drug pharmacokinetics and response.  Of 57 putatively functional human CYPs only about a dozen enzymes, belonging to the CYP1, 2, and 3 families, are responsible for the biotransformation of most foreign substances including 70-80% of all drugs in clin. use.  The highest expressed forms in liver are CYPs 3A4, 2C9, 2C8, 2E1, and 1A2, while 2A6, 2D6, 2B6, 2C19 and 3A5 are less abundant and CYPs 2J2, 1A1, and 1B1 are mainly expressed extrahepatically.  Expression of each CYP is influenced by a unique combination of mechanisms and factors including genetic polymorphisms, induction by xenobiotics, regulation by cytokines, hormones and during disease states, as well as sex, age, and others.  Multiallelic genetic polymorphisms, which strongly depend on ethnicity, play a major role for the function of CYPs 2D6, 2C19, 2C9, 2B6, 3A5 and 2A6, and lead to distinct pharmacogenetic phenotypes termed as poor, intermediate, extensive, and ultrarapid metabolizers.  For these CYPs, the evidence for clin. significance regarding adverse drug reactions (ADRs), drug efficacy and dose requirement is rapidly growing.  Polymorphisms in CYPs 1A1, 1A2, 2C8, 2E1, 2J2, and 3A4 are generally less predictive, but new data on CYP3A4 show that predictive variants exist and that addnl. variants in regulatory genes or in NADPH:cytochrome P 450 oxidoreductase (POR) can have an influence.  Here we review the recent progress on drug metab. activity profiles, interindividual variability and regulation of expression, and the functional and clin. impact of genetic variation in drug metabolizing P450s.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyfuepoWIAkLVg90H21EOLACvtfcHk0lgXgKx1_2QAyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXislykt7w%253D&md5=474dd89d1aae3c9d57ff2d33f176602e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2012.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2012.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DZanger%26aufirst%3DU.%2BM.%26aulast%3DSchwab%26aufirst%3DM.%26atitle%3DCytochrome%2520P450%2520enzymes%2520in%2520drug%2520metabolism%253A%2520regulation%2520of%2520gene%2520expression%252C%2520enzyme%2520activities%252C%2520and%2520impact%2520of%2520genetic%2520variation%26jtitle%3DPharmacol.%2520Ther.%26date%3D2013%26volume%3D138%26spage%3D103%26epage%3D141%26doi%3D10.1016%2Fj.pharmthera.2012.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Guengerich, F. P.</span><span> </span><span class="NLM_article-title">Cytochrome P450 enzymes in the generation of commercial products</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">359</span><span class="NLM_x">–</span> <span class="NLM_lpage">366</span><span class="refDoi"> DOI: 10.1038/nrd792</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnrd792" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=12120411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD38XktFSitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=359-366&author=F.+P.+Guengerich&title=Cytochrome+P450+enzymes+in+the+generation+of+commercial+products&doi=10.1038%2Fnrd792"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 enzymes in the generation of commercial products</span></div><div class="casAuthors">Guengerich, F. Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">359-366</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 enzymes are remarkably diverse oxygenation catalysts that are found throughout nature.  Although most of the interest in the pharmaceutical industry has focused on the role of cytochrome P450s in drug development, these enzymes also offer potential in the discovery not only of drugs, but also of other useful chems.  Potential applications range from the use of cytochrome P450s as drug targets, to the use of randomly generated mutants of cytochrome P450s to produce libraries of new chems. and drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMc-V9Gis5WLVg90H21EOLACvtfcHk0lgXgKx1_2QAyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktFSitbg%253D&md5=c39a8f0d7e43510ade7f2400766f4701</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd792&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd792%26sid%3Dliteratum%253Aachs%26aulast%3DGuengerich%26aufirst%3DF.%2BP.%26atitle%3DCytochrome%2520P450%2520enzymes%2520in%2520the%2520generation%2520of%2520commercial%2520products%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D359%26epage%3D366%26doi%3D10.1038%2Fnrd792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roychowdhury, A.</span><span> </span><span class="NLM_article-title">Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">3605</span><span class="NLM_x">–</span> <span class="NLM_lpage">3621</span><span class="refDoi"> DOI: 10.2174/092986712801323180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F092986712801323180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22680629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtF2itbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=3605-3621&author=S.+Kumarauthor=R.+Sharmaauthor=A.+Roychowdhury&title=Modulation+of+cytochrome-P450+inhibition+%28CYP%29+in+drug+discovery%3A+a+medicinal+chemistry+perspective&doi=10.2174%2F092986712801323180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of cytochrome-P450 inhibition (CYP) in drug discovery: a medicinal chemistry perspective</span></div><div class="casAuthors">Kumar, Sanjay; Sharma, Rajiv; Roychowdhury, Abhijit</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">3605-3621</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP450) has widely been implicated for drug-drug interactions (DDI) in the pharmaceutical industry.  Inhibition or induction of this enzyme family has led to withdrawal of multiple drugs from the market leading to major time and financial losses for the pharmaceutical industry.  CYP450 plays a prevailing role in the biotransformation of a large no. of structurally diverse drugs.  Few isoenzymes of the CYP enzyme family (CYP3A4, 2D6 and 2C9 family) are mainly involved in metab. of most of the drugs.  To avoid such interactions and potentially minimize DDI, major pharmaceutical organizations prefer to incorporate CYP enzyme screening at an early stage of their discovery program.  While this has been a prevalent practice in the pharmaceutical industry lately, there is very limited literature available reviewing the relationship between chemotypes and CYP isoforms.  This review will collate literature pertaining to CYP-inhibition modulation through physicochem. parameters and chem. modification and thus bring to focus commonly used trends by medicinal chemists world-wide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVIogYUZJywLVg90H21EOLACvtfcHk0lj_aEyunJpx-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtF2itbrF&md5=1f675ef0f7cd31a254b82d8b2eaac44b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.2174%2F092986712801323180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712801323180%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DRoychowdhury%26aufirst%3DA.%26atitle%3DModulation%2520of%2520cytochrome-P450%2520inhibition%2520%2528CYP%2529%2520in%2520drug%2520discovery%253A%2520a%2520medicinal%2520chemistry%2520perspective%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D3605%26epage%3D3621%26doi%3D10.2174%2F092986712801323180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Lynch, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, A.</span><span> </span><span class="NLM_article-title">The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects</span> <span class="citation_source-journal">Am. Fam. Physician</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=17708140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BD2svovFGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=391-396&author=T.+Lynchauthor=A.+Price&title=The+effect+of+cytochrome+P450+metabolism+on+drug+response%2C+interactions%2C+and+adverse+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects</span></div><div class="casAuthors">Lynch Tom; Price Amy</div><div class="citationInfo"><span class="NLM_cas:title">American family physician</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">391-6</span>
        ISSN:<span class="NLM_cas:issn">0002-838X</span>.
    </div><div class="casAbstract">Cytochrome P450 enzymes are essential for the metabolism of many medications.  Although this class has more than 50 enzymes, six of them metabolize 90 percent of drugs, with the two most significant enzymes being CYP3A4 and CYP2D6.  Genetic variability (polymorphism) in these enzymes may influence a patient's response to commonly prescribed drug classes, including beta blockers and antidepressants.  Cytochrome P450 enzymes can be inhibited or induced by drugs, resulting in clinically significant drug-drug interactions that can cause unanticipated adverse reactions or therapeutic failures.  Interactions with warfarin, antidepressants, antiepileptic drugs, and statins often involve the cytochrome P450 enzymes.  Knowledge of the most important drugs metabolized by cytochrome P450 enzymes, as well as the most potent inhibiting and inducing drugs, can help minimize the possibility of adverse drug reactions and interactions.  Although genotype tests can determine if a patient has a specific enzyme polymorphism, it has not been determined if routine use of these tests will improve outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQE6VB-Pf2cThe4jJGKT5N0fW6udTcc2eYn4TcTmsmMrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svovFGhtQ%253D%253D&md5=68832276c56c8fb5f2818fc25bcc637f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DT.%26aulast%3DPrice%26aufirst%3DA.%26atitle%3DThe%2520effect%2520of%2520cytochrome%2520P450%2520metabolism%2520on%2520drug%2520response%252C%2520interactions%252C%2520and%2520adverse%2520effects%26jtitle%3DAm.%2520Fam.%2520Physician%26date%3D2007%26volume%3D76%26spage%3D391%26epage%3D396" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Huttunen, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahonen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raunio, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rautio, J.</span><span> </span><span class="NLM_article-title">Cytochrome P450-activated prodrugs: targeted drug delivery</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2346</span><span class="NLM_x">–</span> <span class="NLM_lpage">2365</span><span class="refDoi"> DOI: 10.2174/092986708785909120</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F092986708785909120" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18855665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFCqsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2346-2365&author=K.+M.+Huttunenauthor=N.+Mahonenauthor=H.+Raunioauthor=J.+Rautio&title=Cytochrome+P450-activated+prodrugs%3A+targeted+drug+delivery&doi=10.2174%2F092986708785909120"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450-activated prodrugs: targeted drug delivery</span></div><div class="casAuthors">Huttunen, Kristiina M.; Mahonen, Niina; Raunio, Hannu; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2346-2365</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP) enzymes are a superfamily of heme contg. proteins that catalyze xenobiotic metab. phase I reactions.  Oxidn. reactions are the most common CYP-catalyzed reactions for both endogenous substrates and exogenous compds., including drugs, although CYP enzymes are capable also to catalyze redn. reactions.  Whereas the majority of clin. used drugs are inactivated by CYPs, several prodrugs are bioconverted to their active species by these enzymes.  Therefore, this mechanism could be exploited to a greater extend, e.g. by taking advantage of the different CYP enzymes to achieve targeted drug delivery, to improve efficacy or to decrease the unwanted adverse effects of existing and novel drug mols.  This review describes the potential of CYP enzymes in prodrug design and summarizes a wide variety of CYP-activated prodrug structures, which are on the market or under the development.  The bioactivation mechanisms of each CYP-activated prodrug structure are described and the specificity for the different forms of CYP enzymes is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqPjpymFFv2LVg90H21EOLACvtfcHk0lj_aEyunJpx-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFCqsb%252FO&md5=9e8392539ebdf2cb44b080129fbc5e6e</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F092986708785909120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785909120%26sid%3Dliteratum%253Aachs%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DMahonen%26aufirst%3DN.%26aulast%3DRaunio%26aufirst%3DH.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DCytochrome%2520P450-activated%2520prodrugs%253A%2520targeted%2520drug%2520delivery%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2346%26epage%3D2365%26doi%3D10.2174%2F092986708785909120" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Stella, V. J.</span><span> </span><span class="NLM_article-title">Prodrugs as therapeutics</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">277</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1517/13543776.14.3.277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1517%2F13543776.14.3.277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhslGiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=277-280&author=V.+J.+Stella&title=Prodrugs+as+therapeutics&doi=10.1517%2F13543776.14.3.277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs as therapeutics</span></div><div class="casAuthors">Stella, Valentino J.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-280</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review and discussion.  Prodrugs are bioreversible derivs. of drug mols. used to overcome some barriers to the utility of the parent drug mol.  These barriers include, but are not limited to, soly., permeability, stability, presystemic metab. and targeting limitations.  The patent literature shows a dramatic increase in nos. of prodrug patents (>2000% increase in 2002 compared to 1993), with claims for cancer treatment comprising 37% of these.  This increase is largely due to the rise from North American-based multinationals and some smaller drug delivery companies mirroring the overall trend.  In 2001 and 2002, 14% of all new approved chem. drugs were prodrugs.  It appears that prodrugs to overcome barriers to the delivery of problematic drug candidates are becoming an integral part of the drug discovery paradigm.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMwmFxtC_ygLVg90H21EOLACvtfcHk0lh_TcvQjXudHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhslGiur4%253D&md5=904bd948cc7c772097eac32cec40170a</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1517%2F13543776.14.3.277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.14.3.277%26sid%3Dliteratum%253Aachs%26aulast%3DStella%26aufirst%3DV.%2BJ.%26atitle%3DProdrugs%2520as%2520therapeutics%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2004%26volume%3D14%26spage%3D277%26epage%3D280%26doi%3D10.1517%2F13543776.14.3.277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Stella, V. J.; Borchardt, R. T.; Hageman, M. J.; Oliyai, R.; Maag, H.; Tilley, J.</span> <span class="citation_source-book">Prodrugs: Challenges and Rewards (Parts 1 and 2)</span>; <span class="NLM_publisher-name">AAPS Press</span>: <span class="NLM_publisher-loc">Arlington, VA</span>; <span class="NLM_publisher-name">Springer Science</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1007%2F978-0-387-49785-3" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=V.+J.+Stella&author=R.+T.+Borchardt&author=M.+J.+Hageman&author=R.+Oliyai&author=H.+Maag&author=J.+Tilley&title=Prodrugs%3A+Challenges+and+Rewards+%28Parts+1+and+2%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-49785-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-49785-3%26sid%3Dliteratum%253Aachs%26aulast%3DStella%26aufirst%3DV.%2BJ.%26btitle%3DProdrugs%253A%2520Challenges%2520and%2520Rewards%2520%2528Parts%25201%2520and%25202%2529%26pub%3DAAPS%2520Press%26pub%3DSpringer%2520Science%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Guise, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mowday, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashoorzadeh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia</span> <span class="citation_source-journal">Aizheng</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">80</span><span class="NLM_x">–</span> <span class="NLM_lpage">86</span><span class="refDoi"> DOI: 10.5732/cjc.012.10285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.5732%2Fcjc.012.10285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23845143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFaiu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=80-86&author=C.+P.+Guiseauthor=A.+M.+Mowdayauthor=A.+Ashoorzadehauthor=R.+Yuanauthor=W.+H.+Linauthor=D.+H.+Wuauthor=J.+B.+Smaillauthor=A.+V.+Pattersonauthor=K.+Ding&title=Bioreductive+prodrugs+as+cancer+therapeutics%3A+targeting+tumor+hypoxia&doi=10.5732%2Fcjc.012.10285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia</span></div><div class="casAuthors">Guise, Christopher P.; Mowday, Alexandra M.; Amir, Ashoorzadeh; Yuan, Ran; Lin, Wan-hua; Wu, Dong-hai; Smaill, Jeff B.; Patterson, Adam V.; Ding, Ke</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Journal of Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">80-86</span>CODEN:
                <span class="NLM_cas:coden">CJCHDJ</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Sun Yat-sen University Cancer Center</span>)
        </div><div class="casAbstract">A review.  Hypoxia, a state of low oxygen, is a common feature of solid tumors and is assocd. with disease progression as well as resistance to radiotherapy and certain chemotherapeutic drugs.  Hypoxic regions in tumors, therefore, represent attractive targets for cancer therapy.  To date, five distinct classes of bioreactive prodrugs have been developed to target hypoxic cells in solid tumors.  These hypoxia-activated prodrugs, including nitro compds., N-oxides, quinones and metal complexes, generally share a common mechanism of activation whereby they are reduced by intracellular oxidoreductases in an oxygen-sensitive manner to form cytotoxins.  Several examples including PR-104, TH-302, and EO9 are currently undergoing phase II and phase III clin. evaluation.  In this review, we discuss the nature of tumor hypoxia as a therapeutic target, focusing on the development of bioreductive prodrugs.  We also describe the current knowledge of how each prodrug class is activated and detail the clin. progress of leading examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnm_C8IXOkcLVg90H21EOLACvtfcHk0lh_TcvQjXudHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFaiu7%252FM&md5=68b99104d2f73798fb5878437760cd06</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.5732%2Fcjc.012.10285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5732%252Fcjc.012.10285%26sid%3Dliteratum%253Aachs%26aulast%3DGuise%26aufirst%3DC.%2BP.%26aulast%3DMowday%26aufirst%3DA.%2BM.%26aulast%3DAshoorzadeh%26aufirst%3DA.%26aulast%3DYuan%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.%2BH.%26aulast%3DWu%26aufirst%3DD.%2BH.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DPatterson%26aufirst%3DA.%2BV.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DBioreductive%2520prodrugs%2520as%2520cancer%2520therapeutics%253A%2520targeting%2520tumor%2520hypoxia%26jtitle%3DAizheng%26date%3D2014%26volume%3D33%26spage%3D80%26epage%3D86%26doi%3D10.5732%2Fcjc.012.10285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Rautio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpulainen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliyai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarvinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savolainen, J.</span><span> </span><span class="NLM_article-title">Prodrugs: design and clinical applications</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span><span class="refDoi"> DOI: 10.1038/nrd2468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnrd2468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18219308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=255-270&author=J.+Rautioauthor=H.+Kumpulainenauthor=T.+Heimbachauthor=R.+Oliyaiauthor=D.+Ohauthor=T.+Jarvinenauthor=J.+Savolainen&title=Prodrugs%3A+design+and+clinical+applications&doi=10.1038%2Fnrd2468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs: design and clinical applications</span></div><div class="casAuthors">Rautio, Jarkko; Kumpulainen, Hanna; Heimbach, Tycho; Oliyai, Reza; Oh, Dooman; Jaervinen, Tomi; Savolainen, Jouko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-270</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Prodrugs are bioreversible derivs. of drug mols. that undergo an enzymic and/or chem. transformation in vivo to release the active parent drug, which can then exert the desired pharmacol. effect.  In both drug discovery and development, prodrugs have become an established tool for improving physicochem., biopharmaceutical or pharmacokinetic properties of pharmacol. active agents.  About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend.  To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxnlEXYMLCVbVg90H21EOLACvtfcHk0lh_TcvQjXudHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D&md5=481a088ad2ee4da062779b5b28a33cbb</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd2468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2468%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DKumpulainen%26aufirst%3DH.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DOliyai%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DD.%26aulast%3DJarvinen%26aufirst%3DT.%26aulast%3DSavolainen%26aufirst%3DJ.%26atitle%3DProdrugs%253A%2520design%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D255%26epage%3D270%26doi%3D10.1038%2Fnrd2468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Huttunen, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raunio, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rautio, J.</span><span> </span><span class="NLM_article-title">Prodrugs-from serendipity to rational design</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">750</span><span class="NLM_x">–</span> <span class="NLM_lpage">771</span><span class="refDoi"> DOI: 10.1124/pr.110.003459</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1124%2Fpr.110.003459" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=21737530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtbrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=750-771&author=K.+M.+Huttunenauthor=H.+Raunioauthor=J.+Rautio&title=Prodrugs-from+serendipity+to+rational+design&doi=10.1124%2Fpr.110.003459"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs - from serendipity to rational design</span></div><div class="casAuthors">Huttunen, Kristiina M.; Raunio, Hannu; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">750-771</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The prodrug concept has been used to improve undesirable properties of drugs since the late 19th century, although it was only at the end of the 1950s that the actual term prodrug was introduced for the first time.  Prodrugs are inactive, bioreversible derivs. of active drug mols. that must undergo an enzymic and/or chem. transformation in vivo to release the active parent drug, which can then elicit its desired pharmacol. effect in the body.  In most cases, prodrugs are simple chem. derivs. that are only one or two chem. or enzymic steps away from the active parent drug.  However, some prodrugs lack an obvious carrier or promoiety but instead result from a mol. modification of the prodrug it- self, which generates a new active compd.  Numerous prodrugs designed to overcome formulation, delivery, and toxicity barriers to drug utilization have reached the market.  In fact, approx. 20% of all small mol. drugs approved during the period 2000 to 2008 were prodrugs.  Although the development of a prodrug can be very challenging, the prodrug approach represents a feasible way to improve the erratic properties of investigational drugs or drugs already on the market.  This review introduces in depth the rationale behind the use of the prodrug approach from past to present, and also considers the possible problems that can arise from inadequate activation of prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrULDT77jec3bVg90H21EOLACvtfcHk0ljqh8HQAYI22g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVyrtbrO&md5=5eafb63a714ed05cf60407ca588aa01a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.003459&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.003459%26sid%3Dliteratum%253Aachs%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DRaunio%26aufirst%3DH.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DProdrugs-from%2520serendipity%2520to%2520rational%2520design%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D750%26epage%3D771%26doi%3D10.1124%2Fpr.110.003459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">McFadyen, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, G. I.</span><span> </span><span class="NLM_article-title">Cytochrome P450 1B1: a novel anticancer therapeutic target</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">259</span><span class="NLM_x">–</span> <span class="NLM_lpage">263</span><span class="refDoi"> DOI: 10.1517/14796694.1.2.259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1517%2F14796694.1.2.259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16555997" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktlOmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=259-263&author=M.+C.+McFadyenauthor=G.+I.+Murray&title=Cytochrome+P450+1B1%3A+a+novel+anticancer+therapeutic+target&doi=10.1517%2F14796694.1.2.259"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 1B1: a novel anticancer therapeutic target</span></div><div class="casAuthors">McFadyen, Morag; Murray, Graeme I.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">259-263</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytochrome P 450 (CYP)1B1 is overexpressed in tumor cells and is also recognized as a biomarker of the tumor phenotype.  This review highlights the tremendous potential of this enzyme as a novel cancer therapeutic target.  The range of therapeutic strategies including immunotherapeutics, CYP1B1-activated prodrugs and CYP1B1 inhibitors, that are currently being developed to exploit the presence and activity of CYP1B1 in tumor cells is outlined.  The therapeutic strategy, which is at the most advanced stage of development, is a CYP1B1-based vaccine which has already successfully completed a Phase I clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9cwEq9as3qrVg90H21EOLACvtfcHk0ljqh8HQAYI22g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktlOmtbk%253D&md5=d600899104592d118ae8f73cc9f42b93</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1517%2F14796694.1.2.259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14796694.1.2.259%26sid%3Dliteratum%253Aachs%26aulast%3DMcFadyen%26aufirst%3DM.%2BC.%26aulast%3DMurray%26aufirst%3DG.%2BI.%26atitle%3DCytochrome%2520P450%25201B1%253A%2520a%2520novel%2520anticancer%2520therapeutic%2520target%26jtitle%3DFuture%2520Oncol.%26date%3D2005%26volume%3D1%26spage%3D259%26epage%3D263%26doi%3D10.1517%2F14796694.1.2.259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Potter, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruparelia, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ijaz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilsher, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanogho, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoang, T. T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanley, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burke, M. D.</span><span> </span><span class="NLM_article-title">DMU-212: A novel CYP1B1 activated anticancer prodrug</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">S117</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2002&pages=S117&author=G.+A.+Potterauthor=P.+C.+Butlerauthor=K.+C.+Rupareliaauthor=T.+Ijazauthor=N.+E.+Wilsherauthor=E.+Wanoghoauthor=H.+L.+Tanauthor=T.+T.+V.+Hoangauthor=L.+A.+Stanleyauthor=M.+D.+Burke&title=DMU-212%3A+A+novel+CYP1B1+activated+anticancer+prodrug"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPotter%26aufirst%3DG.%2BA.%26aulast%3DButler%26aufirst%3DP.%2BC.%26aulast%3DRuparelia%26aufirst%3DK.%2BC.%26aulast%3DIjaz%26aufirst%3DT.%26aulast%3DWilsher%26aufirst%3DN.%2BE.%26aulast%3DWanogho%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DH.%2BL.%26aulast%3DHoang%26aufirst%3DT.%2BT.%2BV.%26aulast%3DStanley%26aufirst%3DL.%2BA.%26aulast%3DBurke%26aufirst%3DM.%2BD.%26atitle%3DDMU-212%253A%2520A%2520novel%2520CYP1B1%2520activated%2520anticancer%2520prodrug%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2002%26volume%3D86%26spage%3DS117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. W.</span><span> </span><span class="NLM_article-title">CYP epoxygenase derived EETs: from cardiovascular protection to human cancer therapy</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">1454</span><span class="NLM_x">–</span> <span class="NLM_lpage">1469</span><span class="refDoi"> DOI: 10.2174/1568026611313120007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F1568026611313120007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23688135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1WntrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=1454-1469&author=C.+Chenauthor=D.+W.+Wang&title=CYP+epoxygenase+derived+EETs%3A+from+cardiovascular+protection+to+human+cancer+therapy&doi=10.2174%2F1568026611313120007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy</span></div><div class="casAuthors">Chen, Chen; Wang, Dao Wen</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1454-1469</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Arachidonic acids are converted to eicosanoid mediators by the distinct enzyme systems: cyclooxygenase, lipoxygenase and cytochrome P 450 (CYP) monooxygenase pathways ( ω/ω-1-hydroxylases and epoxygenases).  CYP2J2, CYP2C8 and CYP2C9 are the predominant epoxygenase isoforms abundantly expressed in the endothelium, myocardium, and kidney in human.  The primary epoxidn. products by epoxygenases are four regioisomers of cisepoxyeicosatrienoic acids (EETs): 5,6-, 8,9-, 11,12-, and 14,15-EETs.  Numerous studies demonstrated that the cardiovascular protective effects of CYP epoxygenases and EETs range from vasodilation, anti-hypertension, pro-angiogenesis, anti-atherosclerosis, and anti-inflammation to anti-injury caused by ischemia-reperfusion.  The roles of arachidonic acids and its metabolites in cancer biol. have recently attracted great attentions.  However, CYP epoxygenase derived EETs and cancer has received little attention.  It was demonstrated that CYP epoxygenases and EETs are significantly upregulated in human tumors and promote tumor progression and metastasis.  Addnl., specific inhibitors of CYP2J2, derived from terfenadine, exhibit strong anti-tumor activity in vitro and in vivo.  It is implicated that CYP2J2 may be a therapeutic target for treating human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkBhXAIWmmAbVg90H21EOLACvtfcHk0ljqh8HQAYI22g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1WntrrL&md5=cc1b4be6547a8632d3ea5a49cba53d0a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F1568026611313120007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026611313120007%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DD.%2BW.%26atitle%3DCYP%2520epoxygenase%2520derived%2520EETs%253A%2520from%2520cardiovascular%2520protection%2520to%2520human%2520cancer%2520therapy%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2013%26volume%3D13%26spage%3D1454%26epage%3D1469%26doi%3D10.2174%2F1568026611313120007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ortiz de Montellano, P. R.</span><span> </span><span class="NLM_article-title">Cytochrome P450-activated prodrugs</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">228</span><span class="refDoi"> DOI: 10.4155/fmc.12.197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.4155%2Ffmc.12.197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23360144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1aiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=213-228&author=P.+R.+Ortiz+de+Montellano&title=Cytochrome+P450-activated+prodrugs&doi=10.4155%2Ffmc.12.197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450-activated prodrugs</span></div><div class="casAuthors">Ortiz de Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-228</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  A prodrug is a compd. that has negligible, or lower, activity against a specified pharmacol. target than one of its major metabolites.  Prodrugs can be used to improve drug delivery or pharmacokinetics, to decrease toxicity, or to target the drug to specific cells or tissues.  Ester and phosphate hydrolysis are widely used in prodrug design because of their simplicity, but such approaches are relatively ineffective for targeting drugs to specific sites.  The activation of prodrugs by the cytochrome P 450 system provides a highly versatile approach to prodrug design that is particularly adaptable for targeting drug activation to the liver, to tumors or to hypoxic tissues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZGS2TH9y2VLVg90H21EOLACvtfcHk0ljZR2JbLKnP4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1aiurk%253D&md5=dbb23db4fb8703d63dc8aa1f1d0d9dc1</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.197%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DCytochrome%2520P450-activated%2520prodrugs%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2013%26volume%3D5%26spage%3D213%26epage%3D228%26doi%3D10.4155%2Ffmc.12.197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Nishida, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Montellano, P. R.</span><span> </span><span class="NLM_article-title">Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1124/mol.110.065045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1124%2Fmol.110.065045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20566689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFersbjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=497-502&author=C.+R.+Nishidaauthor=M.+Leeauthor=P.+R.+de+Montellano&title=Efficient+hypoxic+activation+of+the+anticancer+agent+AQ4N+by+CYP2S1+and+CYP2W1&doi=10.1124%2Fmol.110.065045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1</span></div><div class="casAuthors">Nishida, Clinton R.; Lee, Melody; Ortiz de Montellano, Paul R.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">497-502</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">AQ4N [1,4-bis{[2-(dimethylamino-N-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione], a prodrug with two dimethylamino N-oxide groups, is converted to the topoisomerase II inhibitor AQ4 [1,4-bis{[2-(dimethylamino)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione] by redn. of the N-oxides to dimethylamino substituents.  Earlier studies showed that several drug-metabolizing cytochrome P 450 enzymes can catalyze this reductive reaction under hypoxic conditions comparable with those in solid tumors.  CYP2S1 and CYP2W1, two extrahepatic P 450 enzymes identified from the human genome whose functions are unknown, are expressed in hypoxic tumor cells at much higher levels than in normal tissue.  Here, we demonstrate that CYP2S1, contrary to a published report (Mol Pharmacol 76:1031-1043, 2009), is efficiently reduced by NADPH-P 450 reductase.  Most importantly, both CYP2S1 and CYP2W1 are better catalysts for the reductive activation of AQ4N to AQ4 than all previously examd. P 450 enzymes.  The overexpression of CYP2S1 and CYP2W1 in tumor tissues, together with their high catalytic activities for AQ4N activation, suggests that they may be exploited for the localized activation of anticancer prodrugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn4p-3yzvt6bVg90H21EOLACvtfcHk0ljZR2JbLKnP4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFersbjO&md5=537f933a472173bc88f656f68593a0c5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1124%2Fmol.110.065045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.110.065045%26sid%3Dliteratum%253Aachs%26aulast%3DNishida%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DM.%26aulast%3Dde%2BMontellano%26aufirst%3DP.%2BR.%26atitle%3DEfficient%2520hypoxic%2520activation%2520of%2520the%2520anticancer%2520agent%2520AQ4N%2520by%2520CYP2S1%2520and%2520CYP2W1%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D78%26spage%3D497%26epage%3D502%26doi%3D10.1124%2Fmol.110.065045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rodriguez, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potter, D. A.</span><span> </span><span class="NLM_article-title">CYP1A1 regulates breast cancer proliferation and survival</span> <span class="citation_source-journal">Mol. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span><span class="refDoi"> DOI: 10.1158/1541-7786.MCR-12-0675</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1158%2F1541-7786.MCR-12-0675" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23576571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFenu7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=780-792&author=M.+Rodriguezauthor=D.+A.+Potter&title=CYP1A1+regulates+breast+cancer+proliferation+and+survival&doi=10.1158%2F1541-7786.MCR-12-0675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">CYP1A1 Regulates Breast Cancer Proliferation and Survival</span></div><div class="casAuthors">Rodriguez, Mariangellys; Potter, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">780-792</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Cytochrome P 450-1A1 (CYP1A1) is an extrahepatic phase I metabolizing enzyme whose expression is suppressed under physiol. conditions but can be induced by substrates via the aryl hydrocarbon receptor (AhR).  Recent studies have shown that the majority of breast cancer tumors constitutively express CYP1A1.  These findings led us to test the hypothesis that CYP1A1 promotes breast cancer progression by evaluating the effects of CYP1A1 knockdown on the proliferation and survival of the MCF7 and MDA-MB-231 lines.  Independently of estrogen receptor status, CYP1A1 knockdown decreased colony formation, decreased cell proliferation, blocked the cell cycle at G0-G1 assocd. with redn. of cyclin D1, and increased apoptosis assocd. with redn. of survivin.  CYP1A1 knockdown markedly increased phosphorylation of AMP-activated protein kinase (AMPK) and decreased phosphorylation of AKT, extracellular signal-regulated kinases 1 and 2 (ERK1/2), and 70-kDa ribosomal protein S6 kinase (P70S6K).  AMPK inhibition by compd. C partially abrogated the proapoptotic effects of CYP1A1 knockdown, suggesting that effects of CYP1A1 knockdown are mediated in part through AMPK signaling.  Consistent with CYP1A1 knockdown, pharmacol. redn. of CYP1A1 levels by the phytopolyphenol carnosol also correlated with impaired proliferation and induced AMPK phosphorylation.  These results indicate that redn. of basal CYP1A1 expression is crit. for inhibition of proliferation, which is not affected by α-naphthoflavone-mediated inhibition of CYP1A1 activity nor modulated by AhR silencing.  This study supports the notion that CYP1A1 promotes breast cancer proliferation and survival, at least in part, through suppression of AMPK signaling and that redn. of CYP1A1 levels is a potential strategy for breast cancer therapeutics.  Mol Cancer Res; 11(7); 780-92. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnj6PvXHmqh7Vg90H21EOLACvtfcHk0ljZR2JbLKnP4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFenu7zF&md5=44d8766ab0ad65a500180527b814a832</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-12-0675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-12-0675%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DM.%26aulast%3DPotter%26aufirst%3DD.%2BA.%26atitle%3DCYP1A1%2520regulates%2520breast%2520cancer%2520proliferation%2520and%2520survival%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2013%26volume%3D11%26spage%3D780%26epage%3D792%26doi%3D10.1158%2F1541-7786.MCR-12-0675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Pors, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiakos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searcey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, L. H.</span><span> </span><span class="NLM_article-title">Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity</span> <span class="citation_source-journal">Chem. Commun. (Cambridge, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">12062</span><span class="NLM_x">–</span> <span class="NLM_lpage">12064</span><span class="refDoi"> DOI: 10.1039/c1cc15638a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1039%2Fc1cc15638a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22002321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=12062-12064&author=K.+Porsauthor=P.+M.+Loadmanauthor=S.+D.+Shnyderauthor=M.+Sutherlandauthor=H.+M.+Sheldrakeauthor=M.+Guinoauthor=K.+Kiakosauthor=J.+A.+Hartleyauthor=M.+Searceyauthor=L.+H.+Patterson&title=Modification+of+the+duocarmycin+pharmacophore+enables+CYP1A1+targeting+for+biological+activity&doi=10.1039%2Fc1cc15638a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity</span></div><div class="casAuthors">Pors, Klaus; Loadman, Paul M.; Shnyder, Steven D.; Sutherland, Mark; Sheldrake, Helen M.; Guino, Meritxell; Kiakos, Konstantinos; Hartley, John A.; Searcey, Mark; Patterson, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">12062-12064</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The identification of an agent that is selectively activated by a cytochrome P 450 (CYP) has the potential for tissue specific dose intensification as a means of significantly improving its therapeutic value.  Towards this goal, we disclose evidence for the pathway of activation of a duocarmycin analog, ICT2700, which targets CYP1A1 for biol. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7hViB3S6PnbVg90H21EOLACvtfcHk0ljZR2JbLKnP4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtl2ntb7P&md5=85cf95f8b0edca5d63e0e22ea584b7c9</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc1cc15638a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1cc15638a%26sid%3Dliteratum%253Aachs%26aulast%3DPors%26aufirst%3DK.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DSutherland%26aufirst%3DM.%26aulast%3DSheldrake%26aufirst%3DH.%2BM.%26aulast%3DGuino%26aufirst%3DM.%26aulast%3DKiakos%26aufirst%3DK.%26aulast%3DHartley%26aufirst%3DJ.%2BA.%26aulast%3DSearcey%26aufirst%3DM.%26aulast%3DPatterson%26aufirst%3DL.%2BH.%26atitle%3DModification%2520of%2520the%2520duocarmycin%2520pharmacophore%2520enables%2520CYP1A1%2520targeting%2520for%2520biological%2520activity%26jtitle%3DChem.%2520Commun.%2520%2528Cambridge%252C%2520U.%2520K.%2529%26date%3D2011%26volume%3D47%26spage%3D12062%26epage%3D12064%26doi%3D10.1039%2Fc1cc15638a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Sheldrake, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travica, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elsalem, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illingworth, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cresswell, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuillon, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mkrtchian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searcey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingelman-Sundberg, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pors, K.</span><span> </span><span class="NLM_article-title">Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">6273</span><span class="NLM_x">–</span> <span class="NLM_lpage">6277</span><span class="refDoi"> DOI: 10.1021/jm4000209</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4000209" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=6273-6277&author=H.+M.+Sheldrakeauthor=S.+Travicaauthor=I.+Johanssonauthor=P.+M.+Loadmanauthor=M.+Sutherlandauthor=L.+Elsalemauthor=N.+Illingworthauthor=A.+J.+Cresswellauthor=T.+Reuillonauthor=S.+D.+Shnyderauthor=S.+Mkrtchianauthor=M.+Searceyauthor=M.+Ingelman-Sundbergauthor=L.+H.+Pattersonauthor=K.+Pors&title=Re-engineering+of+the+duocarmycin+structural+architecture+enables+bioprecursor+development+targeting+CYP1A1+and+CYP2W1+for+biological+activity&doi=10.1021%2Fjm4000209"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm4000209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4000209%26sid%3Dliteratum%253Aachs%26aulast%3DSheldrake%26aufirst%3DH.%2BM.%26aulast%3DTravica%26aufirst%3DS.%26aulast%3DJohansson%26aufirst%3DI.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DSutherland%26aufirst%3DM.%26aulast%3DElsalem%26aufirst%3DL.%26aulast%3DIllingworth%26aufirst%3DN.%26aulast%3DCresswell%26aufirst%3DA.%2BJ.%26aulast%3DReuillon%26aufirst%3DT.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DMkrtchian%26aufirst%3DS.%26aulast%3DSearcey%26aufirst%3DM.%26aulast%3DIngelman-Sundberg%26aufirst%3DM.%26aulast%3DPatterson%26aufirst%3DL.%2BH.%26aulast%3DPors%26aufirst%3DK.%26atitle%3DRe-engineering%2520of%2520the%2520duocarmycin%2520structural%2520architecture%2520enables%2520bioprecursor%2520development%2520targeting%2520CYP1A1%2520and%2520CYP2W1%2520for%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D6273%26epage%3D6277%26doi%3D10.1021%2Fjm4000209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Sutherland, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loadman, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laye, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheldrake, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Illingworth, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alandas, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Searcey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pors, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shnyder, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, L. H.</span><span> </span><span class="NLM_article-title">Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">37</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1158%2F1535-7163.MCT-12-0405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23033491" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntValug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=27-37&author=M.+Sutherlandauthor=J.+H.+Gillauthor=P.+M.+Loadmanauthor=J.+P.+Layeauthor=H.+M.+Sheldrakeauthor=N.+A.+Illingworthauthor=M.+N.+Alandasauthor=P.+A.+Cooperauthor=M.+Searceyauthor=K.+Porsauthor=S.+D.+Shnyderauthor=L.+H.+Patterson&title=Antitumor+activity+of+a+duocarmycin+analogue+rationalized+to+be+metabolically+activated+by+cytochrome+P450+1A1+in+human+transitional+cell+carcinoma+of+the+bladder&doi=10.1158%2F1535-7163.MCT-12-0405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder</span></div><div class="casAuthors">Sutherland, Mark; Gill, Jason H.; Loadman, Paul M.; Laye, Jonathan P.; Sheldrake, Helen M.; Illingworth, Nicola A.; Alandas, Mohammed N.; Cooper, Patricia A.; Searcey, Mark; Pors, Klaus; Shnyder, Steve D.; Patterson, Laurence H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-37</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We identify cytochrome P 450 1A1 (CYP1A1) as a target for tumor-selective drug development in bladder cancer and describe the characterization of ICT2700, designed to be metabolized from a prodrug to a potent cytotoxin selectively by CYP1A1.  Elevated CYP1A1 expression was shown in human bladder cancer relative to normal human tissues.  RT112 bladder cancer cells, endogenously expressing CYP1A1, were selectively chemosensitive to ICT2700, whereas EJ138 bladder cells that do not express CYP1A1 were significantly less responsive.  Introduction of CYP1A1 into EJ138 cells resulted in 75-fold increased chemosensitivity to ICT2700 relative to wild-type EJ138.  Negligible chemosensitivity was obsd. in ICT2700 in EJ138 cells expressing CYP1A2 or with exposure of EJ138 cells to CYP1B1- or CYP3A4-generated metabolites of ICT2700.  Chemosensitivity to ICT2700 was also negated in EJ138-CYP1A1 cells by the CYP1 inhibitor α-naphthoflavone.  Furthermore, ICT2700 did not induce expression of the AhR-regulated CYP1 family, indicating that constitutive CYP1A1 expression is sufficient for activation of ICT2700.  Consistent with the selective activity by CYP1A1 was a time and concn.-dependent increase in γ-H2AX protein expression, indicative of DNA damage, assocd. with the activation of ICT2700 in RT112 but not EJ138 cells.  In mice-bearing CYP1A1-pos. and neg. isogenic tumors, ICT2700 administration resulted in an antitumor response only in the CYP1A1-expressing tumor model.  This antitumor response was assocd. with detection of the CYP1A1-activated metabolite in tumors but not in the liver.  Our findings support the further development of ICT2700 as a tumor-selective treatment for human bladder cancers.  Mol Cancer Ther; 12(1); 27-37. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxYjJoCLDNXLVg90H21EOLACvtfcHk0lgEobnPJyRRkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntValug%253D%253D&md5=37b3d9b31e93f01da485bca19fe2a48e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0405%26sid%3Dliteratum%253Aachs%26aulast%3DSutherland%26aufirst%3DM.%26aulast%3DGill%26aufirst%3DJ.%2BH.%26aulast%3DLoadman%26aufirst%3DP.%2BM.%26aulast%3DLaye%26aufirst%3DJ.%2BP.%26aulast%3DSheldrake%26aufirst%3DH.%2BM.%26aulast%3DIllingworth%26aufirst%3DN.%2BA.%26aulast%3DAlandas%26aufirst%3DM.%2BN.%26aulast%3DCooper%26aufirst%3DP.%2BA.%26aulast%3DSearcey%26aufirst%3DM.%26aulast%3DPors%26aufirst%3DK.%26aulast%3DShnyder%26aufirst%3DS.%2BD.%26aulast%3DPatterson%26aufirst%3DL.%2BH.%26atitle%3DAntitumor%2520activity%2520of%2520a%2520duocarmycin%2520analogue%2520rationalized%2520to%2520be%2520metabolically%2520activated%2520by%2520cytochrome%2520P450%25201A1%2520in%2520human%2520transitional%2520cell%2520carcinoma%2520of%2520the%2520bladder%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D27%26epage%3D37%26doi%3D10.1158%2F1535-7163.MCT-12-0405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Androutsopoulos, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsatsakis, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spandidos, D. A.</span><span> </span><span class="NLM_article-title">Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="refDoi"> DOI: 10.1186/1471-2407-9-187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1186%2F1471-2407-9-187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=19531241" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvlt1SjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=187&author=V.+P.+Androutsopoulosauthor=A.+M.+Tsatsakisauthor=D.+A.+Spandidos&title=Cytochrome+P450+CYP1A1%3A+wider+roles+in+cancer+progression+and+prevention&doi=10.1186%2F1471-2407-9-187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention</span></div><div class="casAuthors">Androutsopoulos Vasilis P; Tsatsakis Aristidis M; Spandidos Demetrios A</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">187</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CYP1A1 is one of the main cytochrome P450 enzymes, examined extensively for its capacity to activate compounds with carcinogenic properties.  Continuous exposure to inhalation chemicals and environmental carcinogens is thought to increase the level of CYP1A1 expression in extrahepatic tissues, through the aryl hydrocarbon receptor (AhR).  Although the latter has long been recognized as a ligand-induced transcription factor, which is responsible for the xenobiotic activating pathway of several phase I and phase II metabolizing enzymes, recent evidence suggests that the AhR is involved in various cell signaling pathways critical to cell cycle regulation and normal homeostasis.  Disregulation of these pathways is implicated in tumor progression.  In addition, it is becoming increasingly evident that CYP1A1 plays an important role in the detoxication of environmental carcinogens, as well as in the metabolic activation of dietary compounds with cancer preventative activity.  Ultimately the contribution of CYP1A1 to cancer progression or prevention may depend on the balance of procarcinogen activation/detoxication and dietary natural product extrahepatic metabolism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ_xKAnLQ_73VMGsG_HTXYFfW6udTcc2eZFTfkxq_ymy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvlt1SjtA%253D%253D&md5=4ce7773732301c4d620307dc2ce8f441</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-9-187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-9-187%26sid%3Dliteratum%253Aachs%26aulast%3DAndroutsopoulos%26aufirst%3DV.%2BP.%26aulast%3DTsatsakis%26aufirst%3DA.%2BM.%26aulast%3DSpandidos%26aufirst%3DD.%2BA.%26atitle%3DCytochrome%2520P450%2520CYP1A1%253A%2520wider%2520roles%2520in%2520cancer%2520progression%2520and%2520prevention%26jtitle%3DBMC%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D187%26doi%3D10.1186%2F1471-2407-9-187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Nguyen, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradfield, C. A.</span><span> </span><span class="NLM_article-title">The search for endogenous activators of the aryl hydrocarbon receptor</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">102</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span><span class="refDoi"> DOI: 10.1021/tx7001965</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx7001965" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2008&pages=102-116&author=L.+P.+Nguyenauthor=C.+A.+Bradfield&title=The+search+for+endogenous+activators+of+the+aryl+hydrocarbon+receptor&doi=10.1021%2Ftx7001965"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Ftx7001965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx7001965%26sid%3Dliteratum%253Aachs%26aulast%3DNguyen%26aufirst%3DL.%2BP.%26aulast%3DBradfield%26aufirst%3DC.%2BA.%26atitle%3DThe%2520search%2520for%2520endogenous%2520activators%2520of%2520the%2520aryl%2520hydrocarbon%2520receptor%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2008%26volume%3D21%26spage%3D102%26epage%3D116%26doi%3D10.1021%2Ftx7001965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Shimada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii-Kuriyama, Y.</span><span> </span><span class="NLM_article-title">Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">6</span><span class="refDoi"> DOI: 10.1111/j.1349-7006.2004.tb03162.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1111%2Fj.1349-7006.2004.tb03162.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=14720319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhvFOrtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2004&pages=1-6&author=T.+Shimadaauthor=Y.+Fujii-Kuriyama&title=Metabolic+activation+of+polycyclic+aromatic+hydrocarbons+to+carcinogens+by+cytochromes+P450+1A1+and+1B1&doi=10.1111%2Fj.1349-7006.2004.tb03162.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1</span></div><div class="casAuthors">Shimada, Tsutomu; Fujii-Kuriyama, Yoshiaki</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Japanese Cancer Association</span>)
        </div><div class="casAbstract">A review.  Polycyclic arom. hydrocarbons (PAHs) are ubiquitously distributed environmental chems.  PAHs acquire carcinogenicity only after they were activated by xenobiotic-metabolizing enzymes to highly reactive metabolites capable of attacking cellular DNA.  Cytochrome P 450 (CYP) enzymes are central to the metabolic activation of these PAHs to epoxide intermediates, which are converted with the aid of epoxide hydrolase to the ultimate carcinogens, diol-epoxides.  Historically, CYP1A1 was believed to be the only enzyme that catalyzes activation of these procarcinogenic PAHs.  However, recent studies have established that CYP1B1, a newly identified member of the CYP1 family, plays a very important role in the metabolic activation of PAHs.  In CYP1B1 gene-knockout mice treated with 7,12-dimethylbenz[a]anthracene and dibenzo[a,l]pyrene, decreased rates of tumor formation were obsd., when compared to wild-type mice.  Significantly, gene expression of CYP1A1 and 1B1 is induced by PAHs and polyhalogenated hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-p-dioxin through the arylhydrocarbon receptor.  Differences in the susceptibility of individuals to the adverse action of PAHs may, in part, be due to differences in the levels of expression of CYP1A1 and 1B1 and to genetic variations in the CYP1A1 and 1B1 genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNa2KB5QQ18rVg90H21EOLACvtfcHk0ljaVnSGY_dCPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhvFOrtL8%253D&md5=b71f6b453d43b5aceaf8ea7c76d085b0</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2004.tb03162.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2004.tb03162.x%26sid%3Dliteratum%253Aachs%26aulast%3DShimada%26aufirst%3DT.%26aulast%3DFujii-Kuriyama%26aufirst%3DY.%26atitle%3DMetabolic%2520activation%2520of%2520polycyclic%2520aromatic%2520hydrocarbons%2520to%2520carcinogens%2520by%2520cytochromes%2520P450%25201A1%2520and%25201B1%26jtitle%3DCancer%2520Sci.%26date%3D2004%26volume%3D95%26spage%3D1%26epage%3D6%26doi%3D10.1111%2Fj.1349-7006.2004.tb03162.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Altmann, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gertsch, J.</span><span> </span><span class="NLM_article-title">Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents</span> <span class="citation_source-journal">Nat. Prod. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">357</span><span class="refDoi"> DOI: 10.1039/B515619J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1039%2FB515619J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=17390000" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Oqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2007&pages=327-357&author=K.+H.+Altmannauthor=J.+Gertsch&title=Anticancer+drugs+from+nature-natural+products+as+a+unique+source+of+new+microtubule-stabilizing+agents&doi=10.1039%2FB515619J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents</span></div><div class="casAuthors">Altmann, Karl-Heinz; Gertsch, Jurg</div><div class="citationInfo"><span class="NLM_cas:title">Natural Product Reports</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">327-357</span>CODEN:
                <span class="NLM_cas:coden">NPRRDF</span>;
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review on the current state of research in the area of microtubule-stabilizing agents from natural sources, with a primary focus on the biochem., biol., and pharmacol. assocd. with these compds.  A variety of natural products have been discovered over the last decade to inhibit human cancer cell proliferation through a taxol-like mechanism.  These compds. represent a whole new range of structurally diverse lead structures for anticancer drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcQVNENM_PALVg90H21EOLACvtfcHk0ljaVnSGY_dCPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Oqsro%253D&md5=4da4dab103a7fd80567920b602bdb8c2</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FB515619J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FB515619J%26sid%3Dliteratum%253Aachs%26aulast%3DAltmann%26aufirst%3DK.%2BH.%26aulast%3DGertsch%26aufirst%3DJ.%26atitle%3DAnticancer%2520drugs%2520from%2520nature-natural%2520products%2520as%2520a%2520unique%2520source%2520of%2520new%2520microtubule-stabilizing%2520agents%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2007%26volume%3D24%26spage%3D327%26epage%3D357%26doi%3D10.1039%2FB515619J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Maayah, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El Gendy, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kadi, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korashy, H. M.</span><span> </span><span class="NLM_article-title">Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation</span> <span class="citation_source-journal">Arch. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">847</span><span class="NLM_x">–</span> <span class="NLM_lpage">856</span><span class="refDoi"> DOI: 10.1007/s00204-012-0996-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1007%2Fs00204-012-0996-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=23288144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVGmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=847-856&author=Z.+H.+Maayahauthor=M.+A.+El+Gendyauthor=A.+O.+El-Kadiauthor=H.+M.+Korashy&title=Sunitinib%2C+a+tyrosine+kinase+inhibitor%2C+induces+cytochrome+P450+1A1+gene+in+human+breast+cancer+MCF7+cells+through+ligand-independent+aryl+hydrocarbon+receptor+activation&doi=10.1007%2Fs00204-012-0996-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation</span></div><div class="casAuthors">Maayah, Zaid H.; El Gendy, Mohamed A. M.; El-Kadi, Ayman O.; Korashy, Hesham M.</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">847-856</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Sunitinib (SUN) is a new multi-targeted oral tyrosine kinase inhibitor that has both anti-angiogenic and anti-tumor activities.  However, information reported in the literature on the effects of SUN on the constitutive expression of cytochrome P 450 1A1 (CYP1A1) gene in cells from mammalian species remains unclear.  Therefore, the main objectives of the current work were to investigate the potentiality of SUN to induce CYP1A1 gene expression in human breast cancer MCF7 cells and to explore the mol. mechanisms involved.  Our results showed that SUN induced the CYP1A1 mRNA, protein, and activity levels in a concn.-dependent manner in MCF7 cells.  The increase in CYP1A1 mRNA by SUN was completely blocked by the transcriptional inhibitor, actinomycin D; implying that SUN increased de novo RNA synthesis.  Furthermore, the ability of SUN to increase luciferase reporter gene expression suggests an aryl hydrocarbon receptor (AhR)-dependent transcriptional control and excludes the possibility of any posttranscriptional mechanisms.  In addn., blocking of AhR activation by resveratrol, a well-known AhR antagonist, prevented the SUN-induced CYP1A1 gene expression, further confirms the involvement of AhR.  Interestingly, this was assocd. with the inability of SUN to directly bind to and induce transformation of cytosolic AhR to its DNA-binding form in vitro, suggesting that the effect of SUN does not involve direct binding to AhR.  The current manuscript provides the first evidence for the ability of SUN to induce CYP1A1 gene expression in MCF7 cells through AhR ligand-independent mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc-m-DDKDjYrVg90H21EOLACvtfcHk0ljaVnSGY_dCPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVGmsg%253D%253D&md5=cedd024c06f1b8e01094d27e7d5b2ed2</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs00204-012-0996-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-012-0996-y%26sid%3Dliteratum%253Aachs%26aulast%3DMaayah%26aufirst%3DZ.%2BH.%26aulast%3DEl%2BGendy%26aufirst%3DM.%2BA.%26aulast%3DEl-Kadi%26aufirst%3DA.%2BO.%26aulast%3DKorashy%26aufirst%3DH.%2BM.%26atitle%3DSunitinib%252C%2520a%2520tyrosine%2520kinase%2520inhibitor%252C%2520induces%2520cytochrome%2520P450%25201A1%2520gene%2520in%2520human%2520breast%2520cancer%2520MCF7%2520cells%2520through%2520ligand-independent%2520aryl%2520hydrocarbon%2520receptor%2520activation%26jtitle%3DArch.%2520Toxicol.%26date%3D2013%26volume%3D87%26spage%3D847%26epage%3D856%26doi%3D10.1007%2Fs00204-012-0996-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Murray, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patimalla, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heys, S. D.</span><span> </span><span class="NLM_article-title">Profiling the expression of cytochrome P450 in breast cancer</span> <span class="citation_source-journal">Histopathology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">202</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span><span class="refDoi"> DOI: 10.1111/j.1365-2559.2010.03606.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1111%2Fj.1365-2559.2010.03606.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20716162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC3cjlsFGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2010&pages=202-211&author=G.+I.+Murrayauthor=S.+Patimallaauthor=K.+N.+Stewartauthor=I.+D.+Millerauthor=S.+D.+Heys&title=Profiling+the+expression+of+cytochrome+P450+in+breast+cancer&doi=10.1111%2Fj.1365-2559.2010.03606.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling the expression of cytochrome P450 in breast cancer</span></div><div class="casAuthors">Murray Graeme I; Patimalla Siva; Stewart Keith N; Miller Iain D; Heys Steven D</div><div class="citationInfo"><span class="NLM_cas:title">Histopathology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">202-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">AIMS:  The cytochrome P450s (P450) are key oxidative enzymes that metabolize many carcinogens and anticancer drugs.  Thus, these enzymes influence tumour development, tumour response to therapy and are putative tumour biomarkers.  The aim was to define the P450 expression profile in breast cancer and establish the significance of P450 expression in this tumour type.  METHODS AND RESULTS:  A tissue microarray containing 170 breast cancers of no special type was immunostained for a panel of 21 P450s.  The highest percentage of strong immunopositivity in breast cancers was seen for CYP4X1 (50.8%), CYP2S1 (37.5%) and CYP2U1 (32.2%), while CYP2J (98.6%) and CYP3A43 (70.7%) were the P450s that most frequently displayed no immunoreactivity.  CYP4V2 (P = 0.01), CYP4X1 (P = 0.01) and CYP4Z1 (P = 0.01) showed correlations with tumour grade.  CYP1B1 (P = 0.001), CYP3A5 (P = 0.001) and CYP51 (P = 0.005) showed the most significant correlations with oestrogen receptor status.  Correlations with survival were identified for CYP2S1 (P = 0.03), CYP3A4 (P = 0.025), CYP4V2 (P = 0.026) and CYP26A1 (P = 0.03), although none of these P450s was an independent marker of prognosis.  CONCLUSIONS:  This study has defined the expression profile of cytochrome P450s in breast cancer and may offer their potential application as biomarkers to aid decisions regarding optimal adjuvant hormonal therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT0ZpvUgyuFaDAyhZbj3lKdfW6udTcc2eaiqkl5vH-MFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjlsFGnsg%253D%253D&md5=96f08d44d30348e8511e91145b731b75</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2559.2010.03606.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2559.2010.03606.x%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DG.%2BI.%26aulast%3DPatimalla%26aufirst%3DS.%26aulast%3DStewart%26aufirst%3DK.%2BN.%26aulast%3DMiller%26aufirst%3DI.%2BD.%26aulast%3DHeys%26aufirst%3DS.%2BD.%26atitle%3DProfiling%2520the%2520expression%2520of%2520cytochrome%2520P450%2520in%2520breast%2520cancer%26jtitle%3DHistopathology%26date%3D2010%26volume%3D57%26spage%3D202%26epage%3D211%26doi%3D10.1111%2Fj.1365-2559.2010.03606.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Vinothini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagini, S.</span><span> </span><span class="NLM_article-title">Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NFkappaB signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast</span> <span class="citation_source-journal">Clin. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">411</span><span class="NLM_x">, </span> <span class="NLM_fpage">368</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.1016/j.cca.2009.11.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.cca.2009.11.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=19995559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCmsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=411&publication_year=2010&pages=368-374&author=G.+Vinothiniauthor=S.+Nagini&title=Correlation+of+xenobiotic-metabolizing+enzymes%2C+oxidative+stress+and+NFkappaB+signaling+with+histological+grade+and+menopausal+status+in+patients+with+adenocarcinoma+of+the+breast&doi=10.1016%2Fj.cca.2009.11.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Correlation of xenobiotic-metabolizing enzymes, oxidative stress and NFκB signaling with histological grade and menopausal status in patients with adenocarcinoma of the breast</span></div><div class="casAuthors">Vinothini, Govindarajah; Nagini, Siddavaram</div><div class="citationInfo"><span class="NLM_cas:title">Clinica Chimica Acta</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">411</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">368-374</span>CODEN:
                <span class="NLM_cas:coden">CCATAR</span>;
        ISSN:<span class="NLM_cas:issn">0009-8981</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Adenocarcinoma of the breast is the most common cancer worldwide and accounts for the highest morbidity and mortality.  The increasing global incidence of breast cancer emphasizes the need to understand the mol. mechanisms of breast tumorigenesis.  The present study was designed to correlate changes in xenobiotic-metabolizing enzymes (XME), oxidative stress and NFκB signaling with histol. grading and menopausal status in breast cancer patients.  Sixty breast cancer patients histol. categorized as grades I, II and III, and as pre- and postmenopausal were chosen for the study.  We analyzed phase I and phase II XME activities as well as the expression of the CYP isoforms CYP1A1 and CYP1B1, oxidative stress markers, and the expression of NFκB family members in tumor and adjacent tissues by immunohistochem. localization and Western blot analyses.  The breast tumors analyzed in the present study were characterized by increased activities of xenobiotic-metabolizing enzymes and enhanced oxidative damage to lipids, proteins, and DNA assocd. with variations in the expression of NFκB family members.  The magnitude of the changes was however more pronounced in premenopausal patients and in grade III breast tumors.  The present study delineates the correlation between XME-mediated oxidative stress and NFκB signaling that leads to the development of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkxCVRl-2LHrVg90H21EOLACvtfcHk0ljEKnLIY4MmzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCmsLw%253D&md5=a77c7062bb92b91ac51109a2ec80220f</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.cca.2009.11.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cca.2009.11.034%26sid%3Dliteratum%253Aachs%26aulast%3DVinothini%26aufirst%3DG.%26aulast%3DNagini%26aufirst%3DS.%26atitle%3DCorrelation%2520of%2520xenobiotic-metabolizing%2520enzymes%252C%2520oxidative%2520stress%2520and%2520NFkappaB%2520signaling%2520with%2520histological%2520grade%2520and%2520menopausal%2520status%2520in%2520patients%2520with%2520adenocarcinoma%2520of%2520the%2520breast%26jtitle%3DClin.%2520Chim.%2520Acta%26date%3D2010%26volume%3D411%26spage%3D368%26epage%3D374%26doi%3D10.1016%2Fj.cca.2009.11.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">McLean, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soto, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jimenez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pommier, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brantley, E.</span><span> </span><span class="NLM_article-title">Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">1665</span><span class="NLM_x">–</span> <span class="NLM_lpage">1674</span><span class="refDoi"> DOI: 10.1002/ijc.23244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1002%2Fijc.23244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18059023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXivVahsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2008&pages=1665-1674&author=L.+McLeanauthor=U.+Sotoauthor=K.+Agamaauthor=J.+Francisauthor=R.+Jimenezauthor=Y.+Pommierauthor=L.+Sowersauthor=E.+Brantley&title=Aminoflavone+induces+oxidative+DNA+damage+and+reactive+oxidative+species-mediated+apoptosis+in+breast+cancer+cells&doi=10.1002%2Fijc.23244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells</span></div><div class="casAuthors">McLean, Lancelot; Soto, Ubaldo; Agama, Keli; Francis, Jawad; Jimenez, Randi; Pommier, Yves; Sowers, Lawrence; Brantley, Eileen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1665-1674</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Aminoflavone (5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methylchromen-4-one; AF; NSC 686288), a novel anticancer candidate agent, is undergoing clin. evaluation.  AF induces DNA-protein cross-links (DPCs), γ-H2AX phosphorylation, aryl hydrocarbon receptor (AhR) signaling, apoptosis and its own metab. via cytochrome P 4501A1 and 1A2 (CYP1A1/1A2) activation in sensitive estrogen receptor pos. (ER+) MCF7 breast cancer cells.  Estrogen receptor neg. (ER-) breast cancer is typically more aggressive with a poorer prognosis.  In this investigation, we evaluated the ability of AF to induce reactive oxygen species (ROS) formation, oxidative DNA damage and apoptosis in ER- MDA-MB-468 breast cancer cells.  The antioxidant, N-acetyl-L-cysteine (NAC), attenuated the cytotoxic effects of AF in MDA-MB-468 cells; an effect is also obsd. in ER+ T47D breast cancer cells.  Nonmalignant MCF10A breast epithelial cells were resistant to the cytotoxic effects of AF.  AF increased intracellular ROS, an effect blocked by NAC and the CYP1A1/1A2 inhibitor, α-Naphthoflavone (α-NF).  AF induced oxidative DNA damage as evidenced by increased 8-oxo-7,8-dihydroguanine (8-oxodG) levels and DPC formation in these cells.  AF caused S-phase arrest corresponding to an increase in p21(waf1/cip1) protein expression.  AF induced caspase 3, 8 and 9 activation, caspase-dependent apoptotic body formation and poly [ADP-ribose] polymerase (PARP) cleavage.  Pretreatment with the pan-caspase inhibitor, benzyloxy-carbonyl-Val-Ala-DL-Asp(OMe)-fluoromethylketone inhibited apoptosis and partially inhibited ROS formation and oxidative DNA damage.  Pretreatment with NAC attenuated AF-induced apoptotic body formation and caspase 3 activation.  These studies suggest AF inhibits the growth of breast cancer cells in part, by inducing ROS prodn., oxidative DNA damage and apoptosis and has the potential to treat hormone-independent breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNPnwbDX4L-rVg90H21EOLACvtfcHk0ljEKnLIY4MmzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXivVahsLk%253D&md5=cd4aa5fadc5db6d67df076100c7be329</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fijc.23244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.23244%26sid%3Dliteratum%253Aachs%26aulast%3DMcLean%26aufirst%3DL.%26aulast%3DSoto%26aufirst%3DU.%26aulast%3DAgama%26aufirst%3DK.%26aulast%3DFrancis%26aufirst%3DJ.%26aulast%3DJimenez%26aufirst%3DR.%26aulast%3DPommier%26aufirst%3DY.%26aulast%3DSowers%26aufirst%3DL.%26aulast%3DBrantley%26aufirst%3DE.%26atitle%3DAminoflavone%2520induces%2520oxidative%2520DNA%2520damage%2520and%2520reactive%2520oxidative%2520species-mediated%2520apoptosis%2520in%2520breast%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2008%26volume%3D122%26spage%3D1665%26epage%3D1674%26doi%3D10.1002%2Fijc.23244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Hose, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollingshead, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monks, A.</span><span> </span><span class="NLM_article-title">Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1265</span><span class="NLM_x">–</span> <span class="NLM_lpage">1272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=14707267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFSk" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=1265-1272&author=C.+D.+Hoseauthor=M.+Hollingsheadauthor=E.+A.+Sausvilleauthor=A.+Monks&title=Induction+of+CYP1A1+in+tumor+cells+by+the+antitumor+agent+2-%5B4-amino-3-methylphenyl%5D-5-fluoro-benzothiazole%3A+a+potential+surrogate+marker+for+patient+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: A potential surrogate marker for patient sensitivity</span></div><div class="casAuthors">Hose, Curtis D.; Hollingshead, Melinda; Sausville, Edward A.; Monks, Anne</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1265-1272</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A candidate antitumor agent, 2-(4-amino-3-methylphenyl)-5-fluoro-benzothiazole (5F-203), like its non-fluorinated parent compd. (DF-203), has a unique cytotoxicity pattern in the National Cancer Institute in vitro anticancer drug screen.  These compds. show selective toxicity for a subset of cell types including estrogen receptor pos. breast cancer and certain renal and ovarian cancer cell lines.  Metabolic activation of these benzothiazoles seems to be mediated through the CYP1 family of cytochrome P450s.  In an effort to characterize the involvement of CYP1A1 and CYP1B1 in the unique toxicity response of 5F-203, constitutive and 5F-203-induced gene expression patterns were measured in 60 cell lines of the National Cancer Institute drug screen using TaqMan real-time PCR.  The patterns of CYP1A1 and CYP1B1 gene expression in the 60 cell lines were correlated with the toxicity pattern of 5F-203 and DF-203.  There was significant correlation between drug sensitivity and induced CYP1A1 (R = 0.752, P < 0.001), but not constitutive CYP1A1 mRNA expression.  CYP1A1 protein expression was found to mirror the corresponding gene expression, indicating that gene expression changes were concordant with function.  Treatment of sensitive cell lines with 10 μM resveratrol, an inhibitor of CYP1A1 induction, in combination with either 1 or 10 μM 5F-203 showed an ablation of the obsd. CYP1A1, but not CYP1B1 mRNA induction in parallel with a decreased sensitivity to 5F-203.  Fine needle aspirates were obtained from a variety of human tumor xenografts, and treated ex vivo with 1 μM 5F-203 for 24 h.  In these samples, induction of CYP1A1 by 5F-203 correlated with in vitro sensitivity (R = 0.711, P < 0.05), and corresponded to in vivo sensitivity in human tumor xenografts.  These data are concordant with the idea that toxicity of 5F-203 requires activation by CYP1A1, and therefore induction of CYP1A1 mRNA in response to 5F-203 treatments ex vivo may provide a possible surrogate marker for detn. of drug-sensitive tumors in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Bm6TZpLeRrVg90H21EOLACvtfcHk0ljEKnLIY4MmzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFSk&md5=e868510342b8124a7da2b73f00ce6de9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHose%26aufirst%3DC.%2BD.%26aulast%3DHollingshead%26aufirst%3DM.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26aulast%3DMonks%26aufirst%3DA.%26atitle%3DInduction%2520of%2520CYP1A1%2520in%2520tumor%2520cells%2520by%2520the%2520antitumor%2520agent%25202-%255B4-amino-3-methylphenyl%255D-5-fluoro-benzothiazole%253A%2520a%2520potential%2520surrogate%2520marker%2520for%2520patient%2520sensitivity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2003%26volume%3D2%26spage%3D1265%26epage%3D1272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwell, A. D.</span><span> </span><span class="NLM_article-title">The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">210</span><span class="refDoi"> DOI: 10.2174/0929867013373714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F0929867013373714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=11172675" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhtVSgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2001&pages=203-210&author=T.+D.+Bradshawauthor=M.+F.+Stevensauthor=A.+D.+Westwell&title=The+discovery+of+the+potent+and+selective+antitumour+agent+2-%284-amino-3-methylphenyl%29benzothiazole+%28DF+203%29+and+related+compounds&doi=10.2174%2F0929867013373714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery of the potent and selective antitumour agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) and related compounds</span></div><div class="casAuthors">Bradshaw, T. D.; Stevens, M. F. G.; Westwell, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-210</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers</span>)
        </div><div class="casAbstract">A review with 14 refs.  The development of a series of potent and selective antitumor agents, the 2-(4-aminophenyl)benzothiazoles, is described.  The original lead compd. in this series, CJM 126, exhibits nanomolar in vitro activity against certain human breast cancer cell lines.  Structure-activity relation studies within this simple antitumor benzothiazole pharmacophore revealed that 2-(4-aminophenyl) benzothiazoles bearing a 3'- Me, 3'-bromo, 3'-iodo or 3'-chloro substituent are esp. potent, extending the spectrum of in vitro antitumor activity to ovarian, lung, renal and colon carcinoma cell lines with a remarkable selectivity profile (NCI anal.).  Other interesting features of this series include the highly unusual transient biphasic dose response relation and possible unique mechanism of action (NCI COMPARE anal.).  2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) has been selected as the lead compd. in this series on the basis of superior in vivo results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx9w0zxmLgGbVg90H21EOLACvtfcHk0lgqewgD5a3dig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhtVSgtrc%253D&md5=cb79d5da405114a2367cf50c26417fcc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2174%2F0929867013373714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867013373714%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DStevens%26aufirst%3DM.%2BF.%26aulast%3DWestwell%26aufirst%3DA.%2BD.%26atitle%3DThe%2520discovery%2520of%2520the%2520potent%2520and%2520selective%2520antitumour%2520agent%25202-%25284-amino-3-methylphenyl%2529benzothiazole%2520%2528DF%2520203%2529%2520and%2520related%2520compounds%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2001%26volume%3D8%26spage%3D203%26epage%3D210%26doi%3D10.2174%2F0929867013373714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwell, A. D.</span><span> </span><span class="NLM_article-title">The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1009</span><span class="NLM_x">–</span> <span class="NLM_lpage">1021</span><span class="refDoi"> DOI: 10.2174/0929867043455530</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F0929867043455530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=15078163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFGjs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=1009-1021&author=T.+D.+Bradshawauthor=A.+D.+Westwell&title=The+development+of+the+antitumour+benzothiazole+prodrug%2C+Phortress%2C+as+a+clinical+candidate&doi=10.2174%2F0929867043455530"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The development of the antitumour benzothiazole prodrug, phortress, as a clinical candidate</span></div><div class="casAuthors">Bradshaw, T. D.; Westwell, A. D.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1009-1021</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">This review traces the development of a series of potent and selective antitumor benzothiazoles from the discovery of the initial lead compd., 2-(4-amino-3-methylphenyl)benzothiazole (DF 203) in 1995 to the identification of a clin. candidate, Phortress, scheduled to enter Phase 1 trials in Q1 2004 under the auspices of Cancer Research U.K.  Advances in the authors' understanding of the mechanism of action of this unique series of agents are described and can be summarized as follows: selective uptake into sensitive cells followed by Arylhydrocarbon Receptor (AhR) binding and translocation into the nucleus, induction of the cytochrome P 450 isoform (CYP) 1A1, conversion of the drug into an electrophilic reactive intermediate and formation of extensive DNA adducts resulting in cell death.  The authors' understanding of this mechanistic scenario has played a crucial role in the drug development process, most notably in the synthesis of fluorinated DF 203 analogs to thwart deactivating oxidative metab. (5F 203) and water-sol. prodrug design for parenteral administration.  Aspects of mechanism of action studies, in vitro and in vivo screening, synthetic chem. and pharmacokinetics are reviewed here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdjQPzfUjzIbVg90H21EOLACvtfcHk0lgqewgD5a3dig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFGjs7o%253D&md5=6e9498925bf7d40abbdb3aa6f0774eaf</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2174%2F0929867043455530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867043455530%26sid%3Dliteratum%253Aachs%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DWestwell%26aufirst%3DA.%2BD.%26atitle%3DThe%2520development%2520of%2520the%2520antitumour%2520benzothiazole%2520prodrug%252C%2520Phortress%252C%2520as%2520a%2520clinical%2520candidate%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2004%26volume%3D11%26spage%3D1009%26epage%3D1021%26doi%3D10.2174%2F0929867043455530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span> </span><span class="NLM_article-title">Inhibitors and prodrugs targeting CYP1: a novel approach in cancer prevention and therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">519</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.2174/09298673113206660277</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F09298673113206660277" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=24083611" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC2cXisFyis7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=519-552&author=J.+Cuiauthor=S.+Li&title=Inhibitors+and+prodrugs+targeting+CYP1%3A+a+novel+approach+in+cancer+prevention+and+therapy&doi=10.2174%2F09298673113206660277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors and Prodrugs Targeting CYP1: A Novel Approach in Cancer Prevention and Therapy</span></div><div class="casAuthors">Cui, Jiahua; Li, Shaoshun</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">519-552</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Since Human CYP1 enzymes catalyze the metabolic activation of procarcinogens and deactivation of certain anticancer drugs, the inhibition of these enzymes has been considered as an effective approach for chemoprevention and treatment of CYP1-mediated drug resistance.  Recent knowledge relating to the enhanced expression of CYP1B1 in tumors also provided certain advantages in cancer therapy by the activation of prodrugs only in tumor cells.  This review concs. on the characterized CYP1 inhibitors and CYP1-activated anticancer prodrugs.  The mechanism for enzyme inhibition and activation of prodrugs, the cancer preventive/therapeutic potential of these chems. and their related SARs are highlighted.  According to their structural features, CYP1 inhibitors are divided into the following categories: flavonoids, trans-stilbenes, coumarins, terpenoids, alkaloids, quinones, isothiocyanates and synthetic aroms.  In the same way, CYP1-activated prodrugs are categorized into four groups: benzothiazoles, flavonoids, stilbenes and alkylating agents.  Almost all of these inhibitors and prodrugs are planar mols. with one arom. ring and some have similarity with identified CYP1 substrates.  CYP1 inhibitors could effectively block the procarcinogen-induced tumor initiation in animal models and benefit us with chemoprevention.  The advent of Phortress and aminoflavone as clin. candidates shows promising perspectives in developing CYP1-mediated prodrugs as chemotherapeutic drugs that are specifically activated in tumors.  All of these preclin. and clin. studies indicate that inhibitors and prodrugs target CYP1 are promising anticancer strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNaK3qEukohrVg90H21EOLACvtfcHk0lgqewgD5a3dig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXisFyis7g%253D&md5=d8f45c83c1c3f1d69b5d54856f4b9ceb</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F09298673113206660277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113206660277%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DInhibitors%2520and%2520prodrugs%2520targeting%2520CYP1%253A%2520a%2520novel%2520approach%2520in%2520cancer%2520prevention%2520and%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2014%26volume%3D21%26spage%3D519%26epage%3D552%26doi%3D10.2174%2F09298673113206660277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Kuffel, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pobst, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaufmann, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span> </span><span class="NLM_article-title">Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span><span class="refDoi"> DOI: 10.1124/mol.62.1.143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1124%2Fmol.62.1.143" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=143-153&author=M.+J.+Kuffelauthor=J.+C.+Schroederauthor=L.+J.+Pobstauthor=S.+Naylorauthor=J.+M.+Reidauthor=S.+H.+Kaufmannauthor=M.+M.+Ames&title=Activation+of+the+antitumor+agent+aminoflavone+%28NSC+686288%29+is+mediated+by+induction+of+tumor+cell+cytochrome+P450+1A1%2F1A2&doi=10.1124%2Fmol.62.1.143"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fmol.62.1.143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.62.1.143%26sid%3Dliteratum%253Aachs%26aulast%3DKuffel%26aufirst%3DM.%2BJ.%26aulast%3DSchroeder%26aufirst%3DJ.%2BC.%26aulast%3DPobst%26aufirst%3DL.%2BJ.%26aulast%3DNaylor%26aufirst%3DS.%26aulast%3DReid%26aufirst%3DJ.%2BM.%26aulast%3DKaufmann%26aufirst%3DS.%2BH.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26atitle%3DActivation%2520of%2520the%2520antitumor%2520agent%2520aminoflavone%2520%2528NSC%2520686288%2529%2520is%2520mediated%2520by%2520induction%2520of%2520tumor%2520cell%2520cytochrome%2520P450%25201A1%252F1A2%26jtitle%3DMol.%2520Pharmacol.%26date%3D2002%26volume%3D62%26spage%3D143%26epage%3D153%26doi%3D10.1124%2Fmol.62.1.143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Haas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harth, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruning, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamann, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justenhoven, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brauch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, H. P.</span><span> </span><span class="NLM_article-title">Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">1785</span><span class="NLM_x">–</span> <span class="NLM_lpage">1791</span><span class="refDoi"> DOI: 10.1002/ijc.21915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1002%2Fijc.21915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16721811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD28Xps1Sns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2006&pages=1785-1791&author=S.+Haasauthor=C.+Pierlauthor=V.+Harthauthor=B.+Peschauthor=S.+Rabsteinauthor=T.+Bruningauthor=Y.+Koauthor=U.+Hamannauthor=C.+Justenhovenauthor=H.+Brauchauthor=H.+P.+Fischer&title=Expression+of+xenobiotic+and+steroid+hormone+metabolizing+enzymes+in+human+breast+carcinomas&doi=10.1002%2Fijc.21915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas</span></div><div class="casAuthors">Haas, Susanne; Pierl, Christiane; Harth, Volker; Pesch, Beate; Rabstein, Sylvia; Bruening, Thomas; Ko, Yon; Hamann, Ute; Justenhoven, Christina; Brauch, Hiltrud; Fischer, Hans-Peter</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1785-1791</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The potential to metabolize endogenous and exogenous substances may influence breast cancer development and tumor growth.  Therefore, the authors investigated the protein expression of Glutathione S-transferase (GST) isoforms and cytochrome P 450 (CYP) known to be involved in the metab. of steroid hormones and endogenous as well as exogenous carcinogens in breast cancer tissue to obtain new information on their possible role in tumor progression.  Expression of GST pi, mu, alpha and CYP1A1/2, 1A2, 3A4/5, 1B1, 2E1 was assessed by immunohisto-chem. for primary breast carcinomas of 393 patients from the German GENICA breast cancer collection.  The percentages of pos. tumors were 50.1 and 44.5% for GST mu and CYP2E1, and ranged from 13 to 24.7% for CYP1A2, GST pi, CYP1A1/2, CYP3A4/5, CYP1B1.  GST alpha was expressed in 1.8% of tumors.  The authors obsd. the following assocns. between strong protein expression and histopathol. characteristics: GST expression was assocd. with a better tumor differentiation (GST mu, p = 0.018) and with reduced lymph node metastasis (GST pi, p = 0.02).  In addn., GST mu expression was assocd. with a pos. estrogen receptor and progesterone receptor status (p < 0.001).  CYP3A4/5 expression was assocd. with a pos. nodal status (p = 0.018).  Expression of CYP1B1 was assocd. with poor tumor differentiation (p = 0.049).  Our results demonstrate that the majority of breast carcinomas expressed xenobiotic and drug metabolizing enzymes.  They particularly suggest that GST mu and pi expression may indicate a better prognosis and that strong CYP3A4/5 and CYP1B1 expression may be key features of non-favorable prognosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRo025xvmHJbVg90H21EOLACvtfcHk0lje69q1GMaH6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xps1Sns70%253D&md5=263d70c71205fd9b43a8c77566e1a7d4</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fijc.21915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21915%26sid%3Dliteratum%253Aachs%26aulast%3DHaas%26aufirst%3DS.%26aulast%3DPierl%26aufirst%3DC.%26aulast%3DHarth%26aufirst%3DV.%26aulast%3DPesch%26aufirst%3DB.%26aulast%3DRabstein%26aufirst%3DS.%26aulast%3DBruning%26aufirst%3DT.%26aulast%3DKo%26aufirst%3DY.%26aulast%3DHamann%26aufirst%3DU.%26aulast%3DJustenhoven%26aufirst%3DC.%26aulast%3DBrauch%26aufirst%3DH.%26aulast%3DFischer%26aufirst%3DH.%2BP.%26atitle%3DExpression%2520of%2520xenobiotic%2520and%2520steroid%2520hormone%2520metabolizing%2520enzymes%2520in%2520human%2520breast%2520carcinomas%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D119%26spage%3D1785%26epage%3D1791%26doi%3D10.1002%2Fijc.21915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petitclerc, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotra, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C.-Gaudreault, R.</span><span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4559</span><span class="NLM_x">–</span> <span class="NLM_lpage">4580</span><span class="refDoi"> DOI: 10.1021/jm200488a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200488a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnsVSjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4559-4580&author=S.+Fortinauthor=L.+Weiauthor=E.+Moreauauthor=J.+Lacroixauthor=M.-F.+C%C3%B4t%C3%A9author=E.+Petitclercauthor=L.+P.+Kotraauthor=R.+C.-Gaudreault&title=Design%2C+synthesis%2C+biological+evaluation%2C+and+structure-activity+relationships+of+substituted+phenyl+4-%282-oxoimidazolidin-1-yl%29benzenesulfonates+as+new+tubulin+inhibitors+mimicking+combretastatin+A-4&doi=10.1021%2Fjm200488a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Biological Evaluation, and Structure-Activity Relationships of Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl)benzenesulfonates as New Tubulin Inhibitors Mimicking Combretastatin A-4</span></div><div class="casAuthors">Fortin, Sebastien; Wei, Lianhu; Moreau, Emmanuel; Lacroix, Jacques; Cote, Marie-France; Petitclerc, Eric; Kotra, Lakshmi P.; C.-Gaudreault, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4559-4580</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Sixty-one Ph 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PIB-SOs), e.g. I [R = 4-Me2N; 2-Et; 3-Cl; 3,5-(MeO)2; 3,4,5-(MeO)3; 3-Me-4-H2N; 4-I], and 13 of their tetrahydro-2-oxopyrimidin-1(2H)-yl analogs (PPB-SOs), e.g. II [R = 2-Et, 3,4,5-(MeO)3], were prepd. and biol. evaluated.  The antiproliferative activities of PIB-SOs on 16 cancer cell lines are in the nanomolar range and unaffected in cancer cells resistant to colchicine, paclitaxel, and vinblastine or overexpressing the P-glycoprotein.  None of the PPB-SOs exhibit significant antiproliferative activity.  PIB-SOs block the cell cycle progression in the G2/M phase and bind to the colchicine-binding site on β-tubulin leading to cytoskeleton disruption and cell death.  Chick chorioallantoic membrane tumor assays show that compds. I [R = 3-Cl; 3,5-(MeO)2; 3,4,5-(MeO)3], efficiently block angiogenesis and tumor growth at least at similar levels as combretastatin A-4 (CA-4) and exhibit low to very low toxicity on the chick embryos.  PIB-SOs were subjected to CoMFA and CoMSIA analyses to establish quant. structure-activity relationships.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGdFVEICwzpbVg90H21EOLACvtfcHk0lje69q1GMaH6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnsVSjs7c%253D&md5=8de94a7636a14fcfac8c339e906cdac4</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm200488a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200488a%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DLacroix%26aufirst%3DJ.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DM.-F.%26aulast%3DPetitclerc%26aufirst%3DE.%26aulast%3DKotra%26aufirst%3DL.%2BP.%26aulast%3DC.-Gaudreault%26aufirst%3DR.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520structure-activity%2520relationships%2520of%2520substituted%2520phenyl%25204-%25282-oxoimidazolidin-1-yl%2529benzenesulfonates%2520as%2520new%2520tubulin%2520inhibitors%2520mimicking%2520combretastatin%2520A-4%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4559%26epage%3D4580%26doi%3D10.1021%2Fjm200488a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotra, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C.-Gaudreault, R.</span><span> </span><span class="NLM_article-title">Novel cytocidal substituted phenyl 4-(2-oxoimidazolidin-1-yl) benzenesulfonates and benzenesulfonamides with affinity to the colchicine-binding site: is the phenyl 2-imidazolidinone moiety a new haptophore for the design of new antimitotics?</span> <span class="citation_source-journal">Open J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">9</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.4236/ojmc.2015.51002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.4236%2Fojmc.2015.51002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFymtrvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=9-22&author=S.+Fortinauthor=L.+Weiauthor=L.+P.+Kotraauthor=R.+C.-Gaudreault&title=Novel+cytocidal+substituted+phenyl+4-%282-oxoimidazolidin-1-yl%29+benzenesulfonates+and+benzenesulfonamides+with+affinity+to+the+colchicine-binding+site%3A+is+the+phenyl+2-imidazolidinone+moiety+a+new+haptophore+for+the+design+of+new+antimitotics%3F&doi=10.4236%2Fojmc.2015.51002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel cytocidal substituted phenyl 4-(2-oxoimidazolidin-1-yl) benzenesulfonates and benzenesulfonamides with affinity to the colchicine-binding site: is the phenyl 2-imidazolidinone moiety a new haptophore for the design of new antimitotics?</span></div><div class="casAuthors">Fortin, Sebastien; Wei, Lianhu; Kotra, Lakshmi P.; C.-Gaudreault, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Open Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9-22</span>CODEN:
                <span class="NLM_cas:coden">OJMCAD</span>;
        ISSN:<span class="NLM_cas:issn">2164-313X</span>.
    
            (<span class="NLM_cas:orgname">Scientific Research Publishing, Inc.</span>)
        </div><div class="casAbstract">Ph 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PIB-SOs) and Ph 4-(2-oxoimidazolidin- 1-yl)benzenesulfonamides (PIB-SAs) are new, potent combretastatin A-4 (CA-4) analogs designed on the basis of their common Ph 2-imidazolidone moiety.  This Ph 2-imidazolidone group is a bioisosteric equiv. of the trimethoxyphenyl group also found in colchicine, podophyllotoxin and several other ligands of the colchicine-binding site (C-BS).  In this study, we investigate the interactions involved in the binding of PIB-SO and PIB-SA into the C-BS.  We describe three distinct pockets (I, II, and III) as key structural elements involved in the interactions between the C-BS and PIB-SOs as well as PIB-SAs.  We show that PIB-SOs and PIB-SAs adopt 4 and 3 distinct binding conformations, resp., within the C-BS.  The binding conformations I and IV are common to most PIB-SOs and PIB-SAs exhibiting high affinity for the C-BS and high cytocidal potency.  In addn., binding conformation I is the main conformation adopted by PIB-SOs, PIB-SAs, T138067, ABT-751, colchicine and CA-4.  We also observe that the sulfonate and the sulfonamide moieties of PIB-SOs and PIB-SAs are bioisosteric equiv.  Interestingly, we further find that a large portion of the Ph 2-imidazolidinone moiety in these analogs does not bind to pocket I unlike the trimethoxyphenyl moiety found in several antimicrotubule agents such as colchicine, CA-4 and podophyllotoxin, suggesting that the Ph 2-imidazolidinone group may represent a new haptophoric moiety useful for the design of new C-BS inhibitors mimicking the tropolone and the methoxylated phenolic moieties of colchicine and CA-4, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDIdN43sCtdLVg90H21EOLACvtfcHk0lje69q1GMaH6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFymtrvN&md5=e8d3c850fa6c892b4c204c3e643b753d</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.4236%2Fojmc.2015.51002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4236%252Fojmc.2015.51002%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DKotra%26aufirst%3DL.%2BP.%26aulast%3DC.-Gaudreault%26aufirst%3DR.%26atitle%3DNovel%2520cytocidal%2520substituted%2520phenyl%25204-%25282-oxoimidazolidin-1-yl%2529%2520benzenesulfonates%2520and%2520benzenesulfonamides%2520with%2520affinity%2520to%2520the%2520colchicine-binding%2520site%253A%2520is%2520the%2520phenyl%25202-imidazolidinone%2520moiety%2520a%2520new%2520haptophore%2520for%2520the%2520design%2520of%2520new%2520antimitotics%253F%26jtitle%3DOpen%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D5%26spage%3D9%26epage%3D22%26doi%3D10.4236%2Fojmc.2015.51002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Fletcher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullins, R. D.</span><span> </span><span class="NLM_article-title">Cell mechanics and the cytoskeleton</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">463</span><span class="NLM_x">, </span> <span class="NLM_fpage">485</span><span class="NLM_x">–</span> <span class="NLM_lpage">492</span><span class="refDoi"> DOI: 10.1038/nature08908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnature08908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20110992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Slu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=463&publication_year=2010&pages=485-492&author=D.+A.+Fletcherauthor=R.+D.+Mullins&title=Cell+mechanics+and+the+cytoskeleton&doi=10.1038%2Fnature08908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Cell mechanics and the cytoskeleton</span></div><div class="casAuthors">Fletcher, Daniel A.; Mullins, R. Dyche</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">463</span>
        (<span class="NLM_cas:issue">7280</span>),
    <span class="NLM_cas:pages">485-492</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The ability of a eukaryotic cell to resist deformation, to transport intracellular cargo and to change shape during movement depends on the cytoskeleton, an interconnected network of filamentous polymers and regulatory proteins.  Recent work has demonstrated that both internal and external phys. forces can act through the cytoskeleton to affect local mech. properties and cellular behavior.  Attention is now focused on how cytoskeletal networks generate, transmit and respond to mech. signals over both short and long timescales.  An important insight emerging from this work is that long-lived cytoskeletal structures may act as epigenetic determinants of cell shape, function and fate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9ixndytG2bLVg90H21EOLACvtfcHk0ljIKAsI8-d7Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Slu7o%253D&md5=aa99ea3ac26664afad09ac8ba4963080</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnature08908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08908%26sid%3Dliteratum%253Aachs%26aulast%3DFletcher%26aufirst%3DD.%2BA.%26aulast%3DMullins%26aufirst%3DR.%2BD.%26atitle%3DCell%2520mechanics%2520and%2520the%2520cytoskeleton%26jtitle%3DNature%26date%3D2010%26volume%3D463%26spage%3D485%26epage%3D492%26doi%3D10.1038%2Fnature08908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Hall, A.</span><span> </span><span class="NLM_article-title">The cytoskeleton and cancer</span> <span class="citation_source-journal">Cancer Metastasis Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span><span class="refDoi"> DOI: 10.1007/s10555-008-9166-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1007%2Fs10555-008-9166-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=19153674" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BD1M3hslSntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=5-14&author=A.+Hall&title=The+cytoskeleton+and+cancer&doi=10.1007%2Fs10555-008-9166-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The cytoskeleton and cancer</span></div><div class="casAuthors">Hall Alan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer metastasis reviews</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">5-14</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer is a disease in which many of the characteristics of normal cell behavior are lost or perturbed.  Uncontrolled cell proliferation and inappropriate cell survival are common features of all cancers, but in addition defects in cellular morphogenesis that lead to tissue disruption, the acquisition of inappropriate migratory and invasive characteristics and the generation of genomic instability through defects in mitosis also accompany progression of the disease.  This volume is focused on the actin and microtubule cytoskeletons, key players that underpin these cellular processes.  Actin and tubulin form highly versatile, dynamic polymers that are capable of organizing cytoplasmic organelles and intracellular compartments, defining cell polarity and generating both pushing and contractile forces.  In the cell cycle, these two cytoskeletal structures drive chromosomal separation and cell division.  During morphogenesis, they determine cell shape and polarity, and promote stable cell-cell and cell-matrix adhesions through their interactions with cadherins and integrins, respectively.  Finally, during cell migration they generate protrusive forces at the front and retraction forces at the rear.  These are all aspects of cell behavior than often go awry in cancer.  This volume brings together those interested in understanding the contribution of the actin and microtubule cytoskeletons to the cell biology of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgWNHWmc0hKNTiMd2aNQVUfW6udTcc2ebX6_91Fzu6XLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3hslSntw%253D%253D&md5=3cf3fa56373a36e883fee0812d3cc0cc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2Fs10555-008-9166-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10555-008-9166-3%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DA.%26atitle%3DThe%2520cytoskeleton%2520and%2520cancer%26jtitle%3DCancer%2520Metastasis%2520Rev.%26date%3D2009%26volume%3D28%26spage%3D5%26epage%3D14%26doi%3D10.1007%2Fs10555-008-9166-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Zhou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannakakou, P.</span><span> </span><span class="NLM_article-title">Targeting microtubules for cancer chemotherapy</span> <span class="citation_source-journal">Curr. Med. Chem.: Anti-Cancer Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.2174/1568011053352569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F1568011053352569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=15720262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=65-71&author=J.+Zhouauthor=P.+Giannakakou&title=Targeting+microtubules+for+cancer+chemotherapy&doi=10.2174%2F1568011053352569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting microtubules for cancer chemotherapy</span></div><div class="casAuthors">Zhou, Jun; Giannakakou, Paraskevi</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-71</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Chem. compds. that interfere with microtubules such as the vinca alkaloids and taxanes are important chemotherapeutic agents for the treatment of cancer.  As knowledge of microtubule-targeting drugs increases, the mechanism underlying the anticancer activity of these agents may mainly lie in their inhibitory effects on spindle microtubule dynamics, rather than in their effects on microtubule polymer mass.  There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell cycle progression at mitosis and eventually leading to apoptotic cell death.  The effectiveness of microtubule-targeting drugs for cancer therapy has been impaired by various side effects, notably neurol. and hematol. toxicities.  Drug resistance is another notorious factor that thwarts the effectiveness of these agents, as with many other cancer chemotherapeutics.  Several new microtubule-targeting agents have shown potent activity against the proliferation of various cancer cells, including cells that display resistance to the existing microtubule-targeting drugs.  Continued investigation of the mechanisms of action of microtubule-targeting drugs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance may provide more effective therapeutic options for cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqI0IucAUr4V7Vg90H21EOLACvtfcHk0ljIKAsI8-d7Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhvFKlsA%253D%253D&md5=e5d34ca2c4d4adf0e6975989da8aaee8</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.2174%2F1568011053352569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011053352569%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DGiannakakou%26aufirst%3DP.%26atitle%3DTargeting%2520microtubules%2520for%2520cancer%2520chemotherapy%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2005%26volume%3D5%26spage%3D65%26epage%3D71%26doi%3D10.2174%2F1568011053352569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Dumontet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, M. A.</span><span> </span><span class="NLM_article-title">Microtubule-binding agents: a dynamic field of cancer therapeutics</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">803</span><span class="refDoi"> DOI: 10.1038/nrd3253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnrd3253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20885410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=790-803&author=C.+Dumontetauthor=M.+A.+Jordan&title=Microtubule-binding+agents%3A+a+dynamic+field+of+cancer+therapeutics&doi=10.1038%2Fnrd3253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding agents: a dynamic field of cancer therapeutics</span></div><div class="casAuthors">Dumontet, Charles; Jordan, Mary Ann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">790-803</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Microtubules are dynamic filamentous cytoskeletal proteins composed of tubulin and are an important therapeutic target in tumor cells.  Agents that bind to microtubules have been part of the pharmacopoeia of anticancer therapy for decades and until the advent of targeted therapy, microtubules were the only alternative to DNA as a therapeutic target in cancer.  The screening of a range of botanical species and marine organisms has yielded promising new antitubulin agents with novel properties.  In the current search for novel microtubule-binding agents, enhanced tumor specificity, reduced neurotoxicity and insensitivity to chemoresistance mechanisms are the three main objectives.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ43DyXjdN7rVg90H21EOLACvtfcHk0lhZOAw2aO4MGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1akur%252FI&md5=9fc6fd966859785605936ecbe6dca44e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrd3253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3253%26sid%3Dliteratum%253Aachs%26aulast%3DDumontet%26aufirst%3DC.%26aulast%3DJordan%26aufirst%3DM.%2BA.%26atitle%3DMicrotubule-binding%2520agents%253A%2520a%2520dynamic%2520field%2520of%2520cancer%2520therapeutics%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D790%26epage%3D803%26doi%3D10.1038%2Fnrd3253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Microtubules as a target for anticancer drugs</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">265</span><span class="refDoi"> DOI: 10.1038/nrc1317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fnrc1317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=15057285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=253-265&author=M.+A.+Jordanauthor=L.+Wilson&title=Microtubules+as+a+target+for+anticancer+drugs&doi=10.1038%2Fnrc1317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubules as a target for anticancer drugs</span></div><div class="casAuthors">Jordan, Mary Ann; Wilson, Leslie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">253-265</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Highly dynamic mitotic-spindle microtubules are among the most successful targets for anticancer therapy.  Microtubule-targeted drugs, including paclitaxel and Vinca alkaloids, were previously considered to work primarily by increasing or decreasing the cellular microtubule mass.  Although these effects might have a role in their chemotherapeutic actions, we now know that at lower concns., microtubule-targeted drugs can suppress microtubule dynamics without changing microtubule mass; this action leads to mitotic block and apoptosis.  In addn. to the expanding array of chem. diverse antimitotic agents, some microtubule-targeted drugs can act as vascular-targeting agents, rapidly depolymg. microtubules of newly formed vasculature to shut down the blood supply to tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJbrFnzwqjbVg90H21EOLACvtfcHk0lhZOAw2aO4MGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gmt74%253D&md5=bbbf212e03ffe6763098fc41f21a8158</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrc1317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1317%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMicrotubules%2520as%2520a%2520target%2520for%2520anticancer%2520drugs%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2004%26volume%3D4%26spage%3D253%26epage%3D265%26doi%3D10.1038%2Fnrc1317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreau, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacroix, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petitclerc, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotra, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">C.-Gaudreault, R.</span><span> </span><span class="NLM_article-title">Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5327</span><span class="NLM_x">–</span> <span class="NLM_lpage">5342</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2011.08.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.ejmech.2011.08.034" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=5327-5342&author=S.+Fortinauthor=L.+Weiauthor=E.+Moreauauthor=J.+Lacroixauthor=M.+F.+Coteauthor=E.+Petitclercauthor=L.+P.+Kotraauthor=R.+C.-Gaudreault&title=Substituted+phenyl+4-%282-oxoimidazolidin-1-yl%29benzenesulfonamides+as+antimitotics.+Antiproliferative%2C+antiangiogenic+and+antitumoral+activity%2C+and+quantitative+structure-activity+relationships&doi=10.1016%2Fj.ejmech.2011.08.034"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.08.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.08.034%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DL.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DLacroix%26aufirst%3DJ.%26aulast%3DCote%26aufirst%3DM.%2BF.%26aulast%3DPetitclerc%26aufirst%3DE.%26aulast%3DKotra%26aufirst%3DL.%2BP.%26aulast%3DC.-Gaudreault%26aufirst%3DR.%26atitle%3DSubstituted%2520phenyl%25204-%25282-oxoimidazolidin-1-yl%2529benzenesulfonamides%2520as%2520antimitotics.%2520Antiproliferative%252C%2520antiangiogenic%2520and%2520antitumoral%2520activity%252C%2520and%2520quantitative%2520structure-activity%2520relationships%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D5327%26epage%3D5342%26doi%3D10.1016%2Fj.ejmech.2011.08.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span>NCI-60 Human Tumor Cell Line Screen, <span class="NLM_publisher-name">Developmental Therapeutics Program, National Cancer Institute (NCI/NIH)</span>: <span class="NLM_publisher-loc">Bethesda, MD</span>, Aug 26,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span><a href="https://dtp.cancer.gov/discovery_development/nci-60/default.htm" class="extLink">https://dtp.cancer.gov/discovery_development/nci-60/default.htm</a> (accessed February 17, 2016).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=NCI-60+Human+Tumor+Cell+Line+Screen%2C+Developmental+Therapeutics+Program%2C+National+Cancer+Institute+%28NCI%2FNIH%29%3A+Bethesda%2C+MD%2C+Aug+26%2C+2015%3B+https%3A%2F%2Fdtp.cancer.gov%2Fdiscovery_development%2Fnci-60%2Fdefault.htm+%28accessed+February+17%2C+2016%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DNCI-60%2520Human%2520Tumor%2520Cell%2520Line%2520Screen%26pub%3DDevelopmental%2520Therapeutics%2520Program%252C%2520National%2520Cancer%2520Institute%2520%2528NCI%252FNIH%2529%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Subik, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strzepek, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costello, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonfiglio, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, P.</span><span> </span><span class="NLM_article-title">The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines</span> <span class="citation_source-journal">Breast Cancer (Auckl)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1177%2F117822341000400004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=20697531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC3cjjs1Wguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2010&pages=35-41&author=K.+Subikauthor=J.+F.+Leeauthor=L.+Baxterauthor=T.+Strzepekauthor=D.+Costelloauthor=P.+Crowleyauthor=L.+Xingauthor=M.+C.+Hungauthor=T.+Bonfiglioauthor=D.+G.+Hicksauthor=P.+Tang&title=The+expression+patterns+of+ER%2C+PR%2C+HER2%2C+CK5%2F6%2C+EGFR%2C+Ki-67+and+AR+by+immunohistochemical+analysis+in+breast+cancer+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines</span></div><div class="casAuthors">Subik Kristina; Lee Jin-Feng; Baxter Laurie; Strzepek Tamera; Costello Dawn; Crowley Patti; Xing Lianping; Hung Mien-Chie; Bonfiglio Thomas; Hicks David G; Tang Ping</div><div class="citationInfo"><span class="NLM_cas:title">Breast cancer : basic and clinical research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">35-41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The molecular classification for breast carcinomas has been used in clinical studies with a simple surrogate panel of immunohistochemistry (IHC) markers.  The objective of this current project was to study the molecular classification of commonly used breast cancer cell lines by IHC analysis.  Seventeen breast cancer cell lines were harvested, fixed in formalin and made into cell blocks.  IHC analyses were performed on each cell block with antibodies to estrogen receptor (ER), progesterone receptor (PR), HER2, EGFR, CK5/6, Ki-67 and androgen receptor (AR).  Among the 17 cell lines, MCF-7 and ZR-75-1 fell to Luminal A subtype; BT-474 to Luminal B subtype; SKBR-3, MDA-MD-435 and AU 565 to HER2 over-expression subtype; MDA-MB-231, MCF-12A, HBL 101, HS 598 T, MCF-10A, MCF-10F, BT-20, 468 and BT-483 to basal subtype.  MDA-MB-453 belonged to Unclassified subtype.  Since each subtype defined by this IHC-based molecular classification does show a distinct clinical outcome, attention should be paid when choosing a cell line for any study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYiuOaYnyGMPh3YQQtAhNufW6udTcc2ebaTdTYLieSNbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjjs1Wguw%253D%253D&md5=d443eb5bfd9c90667fefd356b1c1a191</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1177%2F117822341000400004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F117822341000400004%26sid%3Dliteratum%253Aachs%26aulast%3DSubik%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DJ.%2BF.%26aulast%3DBaxter%26aufirst%3DL.%26aulast%3DStrzepek%26aufirst%3DT.%26aulast%3DCostello%26aufirst%3DD.%26aulast%3DCrowley%26aufirst%3DP.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DBonfiglio%26aufirst%3DT.%26aulast%3DHicks%26aufirst%3DD.%2BG.%26aulast%3DTang%26aufirst%3DP.%26atitle%3DThe%2520expression%2520patterns%2520of%2520ER%252C%2520PR%252C%2520HER2%252C%2520CK5%252F6%252C%2520EGFR%252C%2520Ki-67%2520and%2520AR%2520by%2520immunohistochemical%2520analysis%2520in%2520breast%2520cancer%2520cell%2520lines%26jtitle%3DBreast%2520Cancer%2520%2528Auckl%2529%26date%3D2010%26volume%3D4%26spage%3D35%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Elsherbiny, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kadi, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brocks, D. R.</span><span> </span><span class="NLM_article-title">The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole</span> <span class="citation_source-journal">J. Pharm. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.18433/J3SG66</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.18433%2FJ3SG66" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18445370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ClsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2008&pages=147-159&author=M.+E.+Elsherbinyauthor=A.+O.+El-Kadiauthor=D.+R.+Brocks&title=The+metabolism+of+amiodarone+by+various+CYP+isoenzymes+of+human+and+rat%2C+and+the+inhibitory+influence+of+ketoconazole&doi=10.18433%2FJ3SG66"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole</span></div><div class="casAuthors">Elsherbiny, Marwa E.; El-Kadi, Ayman O. S.; Brocks, Dion R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy & Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">147-159</span>CODEN:
                <span class="NLM_cas:coden">JPPSFY</span>;
        ISSN:<span class="NLM_cas:issn">1482-1826</span>.
    
            (<span class="NLM_cas:orgname">Canadian Society for Pharmaceutical Sciences</span>)
        </div><div class="casAbstract">To evaluate the metab. of amiodarone (AM) to desethylamiodarone (DEA) by selected human and rat cytochrome P 450, and the inhibitory effect of ketoconazole (KTZ).  Some important CYP isoenzymes (rat CYP1A1, 1A2, 2C6, 2C11, 2D1, 2D2, and 3A1 and human CYP1A1, 1A2, 2D6 and 3A4) were spiked with various concns. of AM to det. the relative kinetic parameters for formation of DEA in the presence and absence of various concns. of KTZ.  The formation of DEA was obsd. when AM was exposed to each of the CYP tested, although the rates were varied.  Human CYP1A1 followed by 3A4 had the highest intrinsic clearance (CLint) for DEA formation whereas in rat, CYP2D1 followed by CYP2C11 had the highest CLint.  Human and rat CYP1A2 seemed to have the lowest CLint.  At high concns. of AM and KTZ, near those expected in vivo, significant inhibition of all isoforms except for rat CYP1A2 was obsd.  At lower concn. ranges of both drugs, the inhibitory const. was detd.  At these levels, KTZ was found to potently inhibit human CYP1A1 and 3A4 and rat 2D2 and 1A1.  Human CYP1A1 and 3A4 and rat CYP2D1 and 2C11 were most efficient in converting AM to DEA.  For DEA formation, the in vivo administration of KTZ could inhibit other CYP isoforms besides CYP3A in human and rat.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolP7FYnhCLl7Vg90H21EOLACvtfcHk0liEsdGbySDifA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ClsLnE&md5=03c5e4e247ccde0e30d818bc0e6ad379</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.18433%2FJ3SG66&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18433%252FJ3SG66%26sid%3Dliteratum%253Aachs%26aulast%3DElsherbiny%26aufirst%3DM.%2BE.%26aulast%3DEl-Kadi%26aufirst%3DA.%2BO.%26aulast%3DBrocks%26aufirst%3DD.%2BR.%26atitle%3DThe%2520metabolism%2520of%2520amiodarone%2520by%2520various%2520CYP%2520isoenzymes%2520of%2520human%2520and%2520rat%252C%2520and%2520the%2520inhibitory%2520influence%2520of%2520ketoconazole%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D11%26spage%3D147%26epage%3D159%26doi%3D10.18433%2FJ3SG66" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Beedanagari, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebenek, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hankinson, O.</span><span> </span><span class="NLM_article-title">Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes</span> <span class="citation_source-journal">Toxicol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">61</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span><span class="refDoi"> DOI: 10.1093/toxsci/kfp079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1093%2Ftoxsci%2Fkfp079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=19376845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFKktLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2009&pages=61-67&author=S.+R.+Beedanagariauthor=I.+Bebenekauthor=P.+Buiauthor=O.+Hankinson&title=Resveratrol+inhibits+dioxin-induced+expression+of+human+CYP1A1+and+CYP1B1+by+inhibiting+recruitment+of+the+aryl+hydrocarbon+receptor+complex+and+RNA+polymerase+II+to+the+regulatory+regions+of+the+corresponding+genes&doi=10.1093%2Ftoxsci%2Fkfp079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Resveratrol Inhibits Dioxin-Induced Expression of Human CYP1A1 and CYP1B1 by Inhibiting Recruitment of the Aryl Hydrocarbon Receptor Complex and RNA Polymerase II to the Regulatory Regions of the Corresponding Genes</span></div><div class="casAuthors">Beedanagari, Sudheer R.; Bebenek, Ilona; Bui, Peter; Hankinson, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">61-67</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-6080</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The CYP1A family of cytochrome P450s (CYPs), comprising CYP1A1, CYP1A2, and CYP1B1, plays a role in bioactivation of several procarcinogens to carcinogenic derivs., and also in detoxification of several xenobiotic compds.  Resveratrol (3,4,5-trihydroxystelbine) is a naturally occurring compd. that has been shown in a no. of studies to inhibit the induction of CYP1A1 and CYP1B1 by dioxin (2,3,7,8-tetrachloro-dibenzo-p-dioxin), but the mechanism(s) of resveratrol inhibition is controversial.  In the current study, 100nM dioxin treatment for 24, 48, and 72 h induced CYP1A1, CYP1A2, and CYP1B1 mRNA levels in the human breast cancer cell line MCF-7, and CYP1A1 and CYP1A2 mRNA levels in the human hepatocellular carcinoma cell line, HepG2.  Simultaneous treatment with 10μM resveratrol significantly inhibited dioxin-induced mRNA expression levels of these genes in both cell lines.  Our studies are novel in that we used the chromatin immunopptn. assay to assay dioxin-induced recruitment of the aryl hydrocarbon receptor (AHR), and aryl hydrocarbon nuclear translocator (ARNT) to the enhancer regions and recruitment of RNA polymerase II to the promoter regions, of the CYP1A1 and CYP1B1 genes in their natural chromosomal settings.  These recruitments were significantly inhibited in cells cotreated with resveratrol.  Our studies thus indicate that resveratrol inhibits dioxin induction of the CYP1 family members either by directly or indirectly inhibiting the recruitment of the transcription factors AHR and ARNT to the xenobiotic response elements of the corresponding genes.  The reduced transcriptional factor binding at their enhancers then results in reduced pol II recruitment at the promoters of these genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr33EQ9RtRUK7Vg90H21EOLACvtfcHk0liEsdGbySDifA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFKktLk%253D&md5=cc33d83dc51a512103fbed6ce38b3224</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfp079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfp079%26sid%3Dliteratum%253Aachs%26aulast%3DBeedanagari%26aufirst%3DS.%2BR.%26aulast%3DBebenek%26aufirst%3DI.%26aulast%3DBui%26aufirst%3DP.%26aulast%3DHankinson%26aufirst%3DO.%26atitle%3DResveratrol%2520inhibits%2520dioxin-induced%2520expression%2520of%2520human%2520CYP1A1%2520and%2520CYP1B1%2520by%2520inhibiting%2520recruitment%2520of%2520the%2520aryl%2520hydrocarbon%2520receptor%2520complex%2520and%2520RNA%2520polymerase%2520II%2520to%2520the%2520regulatory%2520regions%2520of%2520the%2520corresponding%2520genes%26jtitle%3DToxicol.%2520Sci.%26date%3D2009%26volume%3D110%26spage%3D61%26epage%3D67%26doi%3D10.1093%2Ftoxsci%2Fkfp079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Chen, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurh, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Na, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surh, Y. J.</span><span> </span><span class="NLM_article-title">Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2013</span><span class="refDoi"> DOI: 10.1093/carcin/bgh183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1093%2Fcarcin%2Fbgh183" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2004&pages=2005-2013&author=Z.+H.+Chenauthor=Y.+J.+Hurhauthor=H.+K.+Naauthor=J.+H.+Kimauthor=Y.+J.+Chunauthor=D.+H.+Kimauthor=K.+S.+Kangauthor=M.+H.+Choauthor=Y.+J.+Surh&title=Resveratrol+inhibits+TCDD-induced+expression+of+CYP1A1+and+CYP1B1+and+catechol+estrogen-mediated+oxidative+DNA+damage+in+cultured+human+mammary+epithelial+cells&doi=10.1093%2Fcarcin%2Fbgh183"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgh183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgh183%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DZ.%2BH.%26aulast%3DHurh%26aufirst%3DY.%2BJ.%26aulast%3DNa%26aufirst%3DH.%2BK.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DChun%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DKang%26aufirst%3DK.%2BS.%26aulast%3DCho%26aufirst%3DM.%2BH.%26aulast%3DSurh%26aufirst%3DY.%2BJ.%26atitle%3DResveratrol%2520inhibits%2520TCDD-induced%2520expression%2520of%2520CYP1A1%2520and%2520CYP1B1%2520and%2520catechol%2520estrogen-mediated%2520oxidative%2520DNA%2520damage%2520in%2520cultured%2520human%2520mammary%2520epithelial%2520cells%26jtitle%3DCarcinogenesis%26date%3D2004%26volume%3D25%26spage%3D2005%26epage%3D2013%26doi%3D10.1093%2Fcarcin%2Fbgh183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Pelkonen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turpeinen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakkola, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honkakoski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hukkanen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raunio, H.</span><span> </span><span class="NLM_article-title">Inhibition and induction of human cytochrome P450 enzymes: current status</span> <span class="citation_source-journal">Arch. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">667</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span><span class="refDoi"> DOI: 10.1007/s00204-008-0332-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1007%2Fs00204-008-0332-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18618097" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ehtLfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=667-715&author=O.+Pelkonenauthor=M.+Turpeinenauthor=J.+Hakkolaauthor=P.+Honkakoskiauthor=J.+Hukkanenauthor=H.+Raunio&title=Inhibition+and+induction+of+human+cytochrome+P450+enzymes%3A+current+status&doi=10.1007%2Fs00204-008-0332-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition and induction of human cytochrome P450 enzymes: current status</span></div><div class="casAuthors">Pelkonen, Olavi; Turpeinen, Miia; Hakkola, Jukka; Honkakoshi, Paavo; Hukkanen, Janne; Raunio, Hannu</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">667-715</span>CODEN:
                <span class="NLM_cas:coden">ARTODN</span>;
        ISSN:<span class="NLM_cas:issn">0340-5761</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  The variability of drug metab., esp. that of the most important phase I enzymes or cytochrome P 450 (CYP) enzymes, is an important complicating factor in many areas of pharmacol. and toxicol., in drug development, preclin. toxicity studies, clin. trials, drug therapy, environmental exposures, and risk assessment.  With these frequently enormous consequences in mind, predictive and pre-emption measures have been a top priority in both pharmacol. and toxicol.  This means the development of predictive in vitro approaches.  Sound prediction is always based on a firm background of basic research on the phenomena of inhibition and induction and their underlying mechanisms; consequently, the description of these aspects is the purpose of this review.  Here, the authors cover both inhibition and induction of CYP isoforms, always keeping in mind the basic mechanisms on which to build predictive and preventive in vitro approaches.  Just because validation is an essential part of any in vitro/in vivo extrapolation scenario, the authors also cover necessary in vivo research and findings in order to provide a proper view to justify in vitro approaches and observations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRVX_0TMOx8rVg90H21EOLACvtfcHk0liEsdGbySDifA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ehtLfL&md5=d5e7527e1dfd964e3d5be002a0fe0273</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1007%2Fs00204-008-0332-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00204-008-0332-8%26sid%3Dliteratum%253Aachs%26aulast%3DPelkonen%26aufirst%3DO.%26aulast%3DTurpeinen%26aufirst%3DM.%26aulast%3DHakkola%26aufirst%3DJ.%26aulast%3DHonkakoski%26aufirst%3DP.%26aulast%3DHukkanen%26aufirst%3DJ.%26aulast%3DRaunio%26aufirst%3DH.%26atitle%3DInhibition%2520and%2520induction%2520of%2520human%2520cytochrome%2520P450%2520enzymes%253A%2520current%2520status%26jtitle%3DArch.%2520Toxicol.%26date%3D2008%26volume%3D82%26spage%3D667%26epage%3D715%26doi%3D10.1007%2Fs00204-008-0332-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Ciolino, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daschner, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, G. C.</span><span> </span><span class="NLM_article-title">Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span><span class="refDoi"> DOI: 10.1016/S0006-2952(98)00143-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2FS0006-2952%2898%2900143-9" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1998&pages=197-206&author=H.+P.+Ciolinoauthor=P.+J.+Daschnerauthor=T.+T.+Wangauthor=G.+C.+Yeh&title=Effect+of+curcumin+on+the+aryl+hydrocarbon+receptor+and+cytochrome+P450+1A1+in+MCF-7+human+breast+carcinoma+cells&doi=10.1016%2FS0006-2952%2898%2900143-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2898%2900143-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252898%252900143-9%26sid%3Dliteratum%253Aachs%26aulast%3DCiolino%26aufirst%3DH.%2BP.%26aulast%3DDaschner%26aufirst%3DP.%2BJ.%26aulast%3DWang%26aufirst%3DT.%2BT.%26aulast%3DYeh%26aufirst%3DG.%2BC.%26atitle%3DEffect%2520of%2520curcumin%2520on%2520the%2520aryl%2520hydrocarbon%2520receptor%2520and%2520cytochrome%2520P450%25201A1%2520in%2520MCF-7%2520human%2520breast%2520carcinoma%2520cells%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1998%26volume%3D56%26spage%3D197%26epage%3D206%26doi%3D10.1016%2FS0006-2952%2898%2900143-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Navas, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chana, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herradon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Segner, H.</span><span> </span><span class="NLM_article-title">Induction of cytochrome P4501A (CYP1A) by clotrimazole, a non-planar aromatic compound. Computational studies on structural features of clotrimazole and related imidazole derivatives</span> <span class="citation_source-journal">Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">–</span> <span class="NLM_lpage">714</span><span class="refDoi"> DOI: 10.1016/j.lfs.2004.09.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.lfs.2004.09.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=699-714&author=J.+M.+Navasauthor=A.+Chanaauthor=B.+Herradonauthor=H.+Segner&title=Induction+of+cytochrome+P4501A+%28CYP1A%29+by+clotrimazole%2C+a+non-planar+aromatic+compound.+Computational+studies+on+structural+features+of+clotrimazole+and+related+imidazole+derivatives&doi=10.1016%2Fj.lfs.2004.09.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2004.09.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2004.09.015%26sid%3Dliteratum%253Aachs%26aulast%3DNavas%26aufirst%3DJ.%2BM.%26aulast%3DChana%26aufirst%3DA.%26aulast%3DHerradon%26aufirst%3DB.%26aulast%3DSegner%26aufirst%3DH.%26atitle%3DInduction%2520of%2520cytochrome%2520P4501A%2520%2528CYP1A%2529%2520by%2520clotrimazole%252C%2520a%2520non-planar%2520aromatic%2520compound.%2520Computational%2520studies%2520on%2520structural%2520features%2520of%2520clotrimazole%2520and%2520related%2520imidazole%2520derivatives%26jtitle%3DLife%2520Sci.%26date%3D2004%26volume%3D76%26spage%3D699%26epage%3D714%26doi%3D10.1016%2Fj.lfs.2004.09.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Casper, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quesne, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirota, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jolivet, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milgrom, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savouret, J. F.</span><span> </span><span class="NLM_article-title">Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">790</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1999&pages=784-790&author=R.+F.+Casperauthor=M.+Quesneauthor=I.+M.+Rogersauthor=T.+Shirotaauthor=A.+Jolivetauthor=E.+Milgromauthor=J.+F.+Savouret&title=Resveratrol+has+antagonist+activity+on+the+aryl+hydrocarbon+receptor%3A+implications+for+prevention+of+dioxin+toxicity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCasper%26aufirst%3DR.%2BF.%26aulast%3DQuesne%26aufirst%3DM.%26aulast%3DRogers%26aufirst%3DI.%2BM.%26aulast%3DShirota%26aufirst%3DT.%26aulast%3DJolivet%26aufirst%3DA.%26aulast%3DMilgrom%26aufirst%3DE.%26aulast%3DSavouret%26aufirst%3DJ.%2BF.%26atitle%3DResveratrol%2520has%2520antagonist%2520activity%2520on%2520the%2520aryl%2520hydrocarbon%2520receptor%253A%2520implications%2520for%2520prevention%2520of%2520dioxin%2520toxicity%26jtitle%3DMol.%2520Pharmacol.%26date%3D1999%26volume%3D56%26spage%3D784%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Bjornsson, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callaghan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einolf, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grimm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miwa, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLeod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snikeris, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tweedie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vega, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrighton, S. A.</span><span> </span><span class="NLM_article-title">The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">815</span><span class="NLM_x">–</span> <span class="NLM_lpage">832</span><span class="refDoi"> DOI: 10.1124/dmd.31.7.815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1124%2Fdmd.31.7.815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=12814957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltFalu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2003&pages=815-832&author=T.+D.+Bjornssonauthor=J.+T.+Callaghanauthor=H.+J.+Einolfauthor=V.+Fischerauthor=L.+Ganauthor=S.+Grimmauthor=J.+Kaoauthor=S.+P.+Kingauthor=G.+Miwaauthor=L.+Niauthor=G.+Kumarauthor=J.+McLeodauthor=R.+S.+Obachauthor=S.+Robertsauthor=A.+Roeauthor=A.+Shahauthor=F.+Snikerisauthor=J.+T.+Sullivanauthor=D.+Tweedieauthor=J.+M.+Vegaauthor=J.+Walshauthor=S.+A.+Wrighton&title=The+conduct+of+in+vitro+and+in+vivo+drug-drug+interaction+studies%3A+a+Pharmaceutical+Research+and+Manufacturers+of+America+%28PhRMA%29+perspective&doi=10.1124%2Fdmd.31.7.815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective</span></div><div class="casAuthors">Bjornsson, Thorir D.; Callaghan, John T.; Einolf, Heidi J.; Fischer, Volker; Gan, Lawrence; Grimm, Scott; Kao, John; King, S. Peter; Miwa, Gerald; Ni, Lan; Kumar, Gondi; McLeod, James; Obach, R. Scott; Roberts, Stanley; Roe, Amy; Shah, Anita; Snikeris, Fred; Sullivan, John T.; Tweedie, Donald; Vega, Jose M.; Walsh, John; Wrighton, Steven A.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">815-832</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies.  There is a common desire by regulatory authorities and by industry sponsors to harmonize approaches, to allow for a better assessment of the significance of findings across different studies and drugs.  There is also a growing consensus for the standardization of cytochrome P 450 (P 450) probe substrates, inhibitors and inducers and for the development of classification systems to improve the communication of risk to health care providers and to patients.  While existing guidances cover mainly P 450-mediated drug interactions, the importance of other mechanisms, such as transporters, has been recognized more recently, and should also be addressed.  This article was prepd. by the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Metab. and Clin. Pharmacol. Tech. Working Groups and represents the current industry position.  The intent is to define a minimal best practice for in vitro and in vivo pharmacokinetic drug-drug interaction studies targeted to development (not discovery support) and to define a data package that can be expected by regulatory agencies in compd. registration dossiers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogi0LDV4FgLVg90H21EOLACvtfcHk0ljBxizXQdPUQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltFalu70%253D&md5=2a41b5f54f65504448656ac7f7409aea</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1124%2Fdmd.31.7.815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.31.7.815%26sid%3Dliteratum%253Aachs%26aulast%3DBjornsson%26aufirst%3DT.%2BD.%26aulast%3DCallaghan%26aufirst%3DJ.%2BT.%26aulast%3DEinolf%26aufirst%3DH.%2BJ.%26aulast%3DFischer%26aufirst%3DV.%26aulast%3DGan%26aufirst%3DL.%26aulast%3DGrimm%26aufirst%3DS.%26aulast%3DKao%26aufirst%3DJ.%26aulast%3DKing%26aufirst%3DS.%2BP.%26aulast%3DMiwa%26aufirst%3DG.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DKumar%26aufirst%3DG.%26aulast%3DMcLeod%26aufirst%3DJ.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DRoberts%26aufirst%3DS.%26aulast%3DRoe%26aufirst%3DA.%26aulast%3DShah%26aufirst%3DA.%26aulast%3DSnikeris%26aufirst%3DF.%26aulast%3DSullivan%26aufirst%3DJ.%2BT.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DVega%26aufirst%3DJ.%2BM.%26aulast%3DWalsh%26aufirst%3DJ.%26aulast%3DWrighton%26aufirst%3DS.%2BA.%26atitle%3DThe%2520conduct%2520of%2520in%2520vitro%2520and%2520in%2520vivo%2520drug-drug%2520interaction%2520studies%253A%2520a%2520Pharmaceutical%2520Research%2520and%2520Manufacturers%2520of%2520America%2520%2528PhRMA%2529%2520perspective%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2003%26volume%3D31%26spage%3D815%26epage%3D832%26doi%3D10.1124%2Fdmd.31.7.815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span> </span><span class="NLM_article-title">The conduct of drug metabolism studies considered good practice (II): in vitro experiments</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">822</span><span class="NLM_x">–</span> <span class="NLM_lpage">829</span><span class="refDoi"> DOI: 10.2174/138920007782798207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F138920007782798207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=18220563" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVahtrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=822-829&author=L.+Jiaauthor=X.+Liu&title=The+conduct+of+drug+metabolism+studies+considered+good+practice+%28II%29%3A+in+vitro+experiments&doi=10.2174%2F138920007782798207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">The conduct of drug metabolism studies considered good practice (II): in vitro experiments</span></div><div class="casAuthors">Jia, Lee; Liu, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">822-829</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In vitro drug metab. studies, which are inexpensive and readily carried out, serve as an adequate screening mechanism to characterize drug metabolites, elucidate their pathways, and make suggestions for further in vivo testing.  This publication is a sequel to part I in a series and aims at providing a general framework to guide designs and protocols of the in vitro drug metab. studies considered good practice in an efficient manner such that it would help researchers avoid common pitfalls and misleading results.  The in vitro models include hepatic and non-hepatic microsomes, cDNA-expressed recombinant human CYPs expressed in insect cells or human B lymphoblastoid, chem. P 450 inhibitors, S9 fraction, hepatocytes and liver slices.  Important conditions for conducting the in vitro drug metab. studies using these models are stated, including relevant concns. of enzymes, co-factors, inhibitors and test drugs; time of incubation and sampling in order to establish kinetics of reactions; appropriate control settings, buffer selection and method validation.  Sep. in vitro data should be logically integrated to explain results from animal and human studies and to provide insights into the nature and consequences of in vivo drug metab.  This article offers tech. information and data and addresses scientific rationales and practical skills related to in vitro evaluation of drug metab. to meet regulatory requirements for drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGoXIA8orbI7Vg90H21EOLACvtfcHk0lg05GukH-jn4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVahtrrP&md5=d4d3c90782386a82d8978b7a71bf78b1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.2174%2F138920007782798207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920007782798207%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DThe%2520conduct%2520of%2520drug%2520metabolism%2520studies%2520considered%2520good%2520practice%2520%2528II%2529%253A%2520in%2520vitro%2520experiments%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2007%26volume%3D8%26spage%3D822%26epage%3D829%26doi%3D10.2174%2F138920007782798207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Fortin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brasseur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asselin, É.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bérubé, G.</span><span> </span><span class="NLM_article-title">New platinum(II) complexes conjugate at position 7α of 17β-acetyl-testosterone as new combi-molecules against prostate cancer: Design, synthesis, structure-activity relationships and biological evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">433</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.08.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.ejmech.2013.08.011" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=433-443&author=S.+Fortinauthor=K.+Brasseurauthor=N.+Morinauthor=%C3%89.+Asselinauthor=G.+B%C3%A9rub%C3%A9&title=New+platinum%28II%29+complexes+conjugate+at+position+7%CE%B1+of+17%CE%B2-acetyl-testosterone+as+new+combi-molecules+against+prostate+cancer%3A+Design%2C+synthesis%2C+structure-activity+relationships+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2013.08.011"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.08.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.08.011%26sid%3Dliteratum%253Aachs%26aulast%3DFortin%26aufirst%3DS.%26aulast%3DBrasseur%26aufirst%3DK.%26aulast%3DMorin%26aufirst%3DN.%26aulast%3DAsselin%26aufirst%3D%25C3%2589.%26aulast%3DB%25C3%25A9rub%25C3%25A9%26aufirst%3DG.%26atitle%3DNew%2520platinum%2528II%2529%2520complexes%2520conjugate%2520at%2520position%25207%25CE%25B1%2520of%252017%25CE%25B2-acetyl-testosterone%2520as%2520new%2520combi-molecules%2520against%2520prostate%2520cancer%253A%2520Design%252C%2520synthesis%252C%2520structure-activity%2520relationships%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D433%26epage%3D443%26doi%3D10.1016%2Fj.ejmech.2013.08.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Pauty, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Côté, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodrigue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velic, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masson, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortin, S.</span><span> </span><span class="NLM_article-title">Investigation of the DNA damage response to SFOM-0046, a new small-molecule drug inducing DNA double-strand breaks</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">23302</span><span class="refDoi"> DOI: 10.1038/srep23302</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fsrep23302" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=27001483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC28XkvVersrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=23302&author=J.+Pautyauthor=M.-F.+C%C3%B4t%C3%A9author=A.+Rodrigueauthor=D.+Velicauthor=J.-Y.+Massonauthor=S.+Fortin&title=Investigation+of+the+DNA+damage+response+to+SFOM-0046%2C+a+new+small-molecule+drug+inducing+DNA+double-strand+breaks&doi=10.1038%2Fsrep23302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of the DNA damage response to SFOM-0046, a new small-molecule drug inducing DNA double-strand breaks</span></div><div class="casAuthors">Pauty, Joris; Cote, Marie-France; Rodrigue, Amelie; Velic, Denis; Masson, Jean-Yves; Fortin, Sebastien</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">23302</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">2-Ethylphenyl 4-(3-ethylureido)benzenesulfonate (SFOM-0046) is a novel anticancer agent that arrests cell cycle in S-phase and causes DNA replication stress leading to the phosphorylation of H2AX into γ-H2AX.  First, using the M21, HT29, HT-1080 and HeLa cell lines, we confirmed that S-phase cell cycle arrest and γ-H2AX foci induction by SFOM-0046 is a general mechanism occurring in diverse cancer cell lines.  In addn. to γ-H2AX, SFOM-0046 activates preferentially ATR-Chk1 in M21 and HT29 cells while both ATR-Chk1 and ATM-Chk2 pathways are activated in HCT116 cells.  Co-localization of SFOM-0046-induced 53BP1 foci with γ-H2AX foci validates that the DNA damage generated corresponds to double-strand-breaks (DSBs).  Consistent with an S-phase arrest, SFOM-0046 treatment induces RAD51 foci formation but not DNA-PKcs foci, confirming that homologous recombination is the major DSB repair pathway targeted by the drug.  Furthermore, using isogenic HCT116 p53+/+ and HCT116 p53-/- cells, we showed that p53 plays a key role in the survival mechanism to SFOM-0046.  Finally, SFOM-0046 exhibits a dose-dependent antitumor activity on human fibrosarcoma HT-1080 tumors grafted onto chick chorioallantoic membranes without showing embryo toxicity even at high doses.  Altogether, our results highlight SFOM-0046 as a very promising drug that induces a replication stress response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKEPZ_bC4lubVg90H21EOLACvtfcHk0lg05GukH-jn4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XkvVersrg%253D&md5=0c8c76bf9f1480d3dc4343ea21184401</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fsrep23302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep23302%26sid%3Dliteratum%253Aachs%26aulast%3DPauty%26aufirst%3DJ.%26aulast%3DC%25C3%25B4t%25C3%25A9%26aufirst%3DM.-F.%26aulast%3DRodrigue%26aufirst%3DA.%26aulast%3DVelic%26aufirst%3DD.%26aulast%3DMasson%26aufirst%3DJ.-Y.%26aulast%3DFortin%26aufirst%3DS.%26atitle%3DInvestigation%2520of%2520the%2520DNA%2520damage%2520response%2520to%2520SFOM-0046%252C%2520a%2520new%2520small-molecule%2520drug%2520inducing%2520DNA%2520double-strand%2520breaks%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D23302%26doi%3D10.1038%2Fsrep23302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Mahato, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, K.</span><span> </span><span class="NLM_article-title">Prodrugs for improving tumor targetability and efficiency</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">–</span> <span class="NLM_lpage">670</span><span class="refDoi"> DOI: 10.1016/j.addr.2011.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2Fj.addr.2011.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=21333700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC3MXoslalurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=659-670&author=R.+Mahatoauthor=W.+Taiauthor=K.+Cheng&title=Prodrugs+for+improving+tumor+targetability+and+efficiency&doi=10.1016%2Fj.addr.2011.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs for improving tumor targetability and efficiency</span></div><div class="casAuthors">Mahato, Rubi; Tai, Wanyi; Cheng, Kun</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">659-670</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As the mainstay in the treatment of various cancers for several decades, chemotherapy is successful but still faces challenges including non-selectivity and high toxicity.  Improving the selectivity is therefore a crit. step to improve the therapeutic efficacy of chemotherapy.  Prodrug is one of the most promising approaches to increase the selectivity and efficacy of a chemotherapy drug.  The classical prodrug approach is to improve the pharmaceutical properties (soly., stability, permeability, irritation, distribution, etc.) via a simple chem. modification.  This review will focus on various targeted prodrug designs that were developed to increase the selectivity of chemotherapy drugs.  Various tumor-targeting ligands, transporter-assocd. ligands, and polymers can be incorporated in a prodrug to enhance the tumor uptake.  Prodrugs can also be activated by enzymes that are specifically expressed at a higher level in tumors, leading to a selective anti-tumor effect.  This can be achieved by conjugating the enzyme to a tumor-specific antibody, or delivering a vector expressing the enzyme into tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHPTqCpofgqrVg90H21EOLACvtfcHk0lg05GukH-jn4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXoslalurg%253D&md5=4ab69987ce95c6ab2ecb1601f8a3e17c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2011.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2011.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DMahato%26aufirst%3DR.%26aulast%3DTai%26aufirst%3DW.%26aulast%3DCheng%26aufirst%3DK.%26atitle%3DProdrugs%2520for%2520improving%2520tumor%2520targetability%2520and%2520efficiency%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D659%26epage%3D670%26doi%3D10.1016%2Fj.addr.2011.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Loaiza-Perez, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenney, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boswell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollingshead, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alley, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hose, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciolino, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trepel, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vistica, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sausville, E. A.</span><span> </span><span class="NLM_article-title">Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">715</span><span class="NLM_x">–</span> <span class="NLM_lpage">725</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=15210858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVajs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=715-725&author=A.+I.+Loaiza-Perezauthor=S.+Kenneyauthor=J.+Boswellauthor=M.+Hollingsheadauthor=M.+C.+Alleyauthor=C.+Hoseauthor=H.+P.+Ciolinoauthor=G.+C.+Yehauthor=J.+B.+Trepelauthor=D.+T.+Visticaauthor=E.+A.+Sausville&title=Aryl+hydrocarbon+receptor+activation+of+an+antitumor+aminoflavone%3A+basis+of+selective+toxicity+for+MCF-7+breast+tumor+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells</span></div><div class="casAuthors">Loaiza-Perez, Andrea I.; Kenney, Susan; Boswell, Jamie; Hollingshead, Melinda; Alley, Michael C.; Hose, Curtis; Ciolino, Henry P.; Yeh, Grace C.; Trepel, Jane B.; Vistica, David T.; Sausville, Edward A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">715-725</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aminoflavone (4H-1-benzopyran-4-one, 5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl; NSC 686288) demonstrates differential antiproliferative activity in the National Cancer Institute's anticancer drug screen.  We demonstrate here that MCF-7 human breast cancer cells are sensitive to aminoflavone both in vitro and when grown in vivo as xenografts in athymic mice.  As previous work has indicated that aminoflavone requires metabolic activation by cytochrome P 450 1A1 (CYP1A1), we investigated the effect of aminoflavone on CYP1A1 expression and on the aryl hydrocarbon receptor (AhR), a transcriptional regulator of CYP1A1.  In aminoflavone-sensitive but not aminoflavone-resistant cells, the drug caused a 100-fold induction of CYP1A1 mRNA and a corresponding increase in ethoxyresorufin-O-deethylase activity.  An AhR-deficient variant of the MCF-7 breast carcinoma, AHR100, with diminished CYP1A1 inducibility, exhibits cellular resistance to aminoflavone and is refractory to CYP1A1 mRNA induction by the drug.  The increase in CYP1A1 mRNA in the aminoflavone-sensitive MCF-7 breast tumor cell results from transcriptional activation of xenobiotic-responsive element (XRE)-controlled transcription.  Aminoflavone treatment causes a translocation of the AhR from the cytoplasm to the nucleus with subsequent formation of AhR-XRE protein DNA complexes.  In contrast to the aminoflavone-sensitive MCF-7 cells, the resistant cell lines (MDA-MB-435, PC-3, and AHR100) demonstrated constitutive nuclear localization of AhR.  Addnl., aminoflavone failed to induce ethoxyresorufin-O-deethylase activity, CYP1A1 transcription, AhR-XRE complex formation, and apoptosis in aminoflavone-resistant cells.  These results suggest that the cytotoxicity of aminoflavone in a sensitive breast tumor cell line is the result of the engagement of AhR-mediated signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBxtJjXbIVRLVg90H21EOLACvtfcHk0lgTv-CIKhCGrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVajs7Y%253D&md5=14a3ca764db9af562945d2d305630d69</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLoaiza-Perez%26aufirst%3DA.%2BI.%26aulast%3DKenney%26aufirst%3DS.%26aulast%3DBoswell%26aufirst%3DJ.%26aulast%3DHollingshead%26aufirst%3DM.%26aulast%3DAlley%26aufirst%3DM.%2BC.%26aulast%3DHose%26aufirst%3DC.%26aulast%3DCiolino%26aufirst%3DH.%2BP.%26aulast%3DYeh%26aufirst%3DG.%2BC.%26aulast%3DTrepel%26aufirst%3DJ.%2BB.%26aulast%3DVistica%26aufirst%3DD.%2BT.%26aulast%3DSausville%26aufirst%3DE.%2BA.%26atitle%3DAryl%2520hydrocarbon%2520receptor%2520activation%2520of%2520an%2520antitumor%2520aminoflavone%253A%2520basis%2520of%2520selective%2520toxicity%2520for%2520MCF-7%2520breast%2520tumor%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D715%26epage%3D725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Leong, C. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaskell, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heydon, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bibby, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Double, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, M. F.</span><span> </span><span class="NLM_article-title">Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">88</span><span class="NLM_x">, </span> <span class="NLM_fpage">470</span><span class="NLM_x">–</span> <span class="NLM_lpage">477</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6600719</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1038%2Fsj.bjc.6600719" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=12569393" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=470-477&author=C.+O.+Leongauthor=M.+Gaskellauthor=E.+A.+Martinauthor=R.+T.+Heydonauthor=P.+B.+Farmerauthor=M.+C.+Bibbyauthor=P.+A.+Cooperauthor=J.+A.+Doubleauthor=T.+D.+Bradshawauthor=M.+F.+Stevens&title=Antitumour+2-%284-aminophenyl%29benzothiazoles+generate+DNA+adducts+in+sensitive+tumour+cells+in+vitro+and+in+vivo&doi=10.1038%2Fsj.bjc.6600719"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo</span></div><div class="casAuthors">Leong, C-O.; Gaskell, M.; Martin, E. A.; Heydon, R. T.; Farmer, P. B.; Bibby, M. C.; Cooper, P. A.; Double, J. A.; Bradshaw, T. D.; Stevens, M. F. G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">470-477</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">2-(4-Aminophenyl)benzothiazoles represent a potent and highly selective class of antitumor agent.  In vitro, sensitive carcinoma cells deplete 2-(4-aminophenyl)benzothiazoles from nutrient media; cytochrome P 450 1A1 activity, crit. for execution of antitumor activity, and protein expression are powerfully induced. 2-(4-Amino-3-methylphenyl)benzothiazole-derived covalent binding to cytochrome P 450 1A1 is reduced by glutathione, suggesting 1A1-dependent prodn. of a reactive electrophilic species.  In vitro, 2-(4-aminophenyl)benzothiazole-generated DNA adducts form in sensitive tumor cells only.  At concns. >100 nM, adducts were detected in DNA of MCF-7 cells treated with 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203).  5F 203 (1 μM) led to the formation of one major and a no. of minor adducts.  However, treatment of cells with 10 μM 5F 203 resulted in the emergence of a new dominant adduct.  Adducts accumulated steadily within DNA of MCF-7 cells exposed to 1 μM 5F 203 between 2 and 24 h.  Concns. of the lysylamide prodrug of 5F 203 (Phortress) ≥100 nM generated adducts in the DNA of sensitive MCF-7 and IGROV-1 ovarian cells.  At 1 μM, one major Phortress-derived DNA adduct was detected in these two sensitive phenotypes; 10 μM Phortress led to the emergence of an addnl. major adduct detected in the DNA of MCF-7 cells.  Inherently resistant MDA-MB-435 breast carcinoma cells incurred no DNA damage upon exposure to Phortress (≤10 μM, 24 h).  In vivo, DNA adducts accumulated within sensitive ovarian IGROV-1 and breast MCF-7 xenografts 24 h after treatment of mice with Phortress (20 mg kg-1).  Moreover, Phortress-derived DNA adduct generation distinguished sensitive MCF-7 tumors from inherently resistant MDA-MB-435 xenografts implanted in opposite flanks of the same mouse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQQ-QrsA4eBLVg90H21EOLACvtfcHk0lgTv-CIKhCGrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKmuw%253D%253D&md5=b24f741cf9b0ea7ce29055c4a437cf19</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600719&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600719%26sid%3Dliteratum%253Aachs%26aulast%3DLeong%26aufirst%3DC.%2BO.%26aulast%3DGaskell%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DE.%2BA.%26aulast%3DHeydon%26aufirst%3DR.%2BT.%26aulast%3DFarmer%26aufirst%3DP.%2BB.%26aulast%3DBibby%26aufirst%3DM.%2BC.%26aulast%3DCooper%26aufirst%3DP.%2BA.%26aulast%3DDouble%26aufirst%3DJ.%2BA.%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DStevens%26aufirst%3DM.%2BF.%26atitle%3DAntitumour%25202-%25284-aminophenyl%2529benzothiazoles%2520generate%2520DNA%2520adducts%2520in%2520sensitive%2520tumour%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D470%26epage%3D477%26doi%3D10.1038%2Fsj.bjc.6600719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Callero, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loaiza-Perez, A. I.</span><span> </span><span class="NLM_article-title">The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone</span> <span class="citation_source-journal">Int. J. Breast Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">923250</span><span class="refDoi"> DOI: 10.4061/2011/923250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.4061%2F2011%2F923250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22295239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A280%3ADC%252BC387ptlymtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=923250&author=M.+A.+Calleroauthor=A.+I.+Loaiza-Perez&title=The+role+of+aryl+hydrocarbon+receptor+and+crosstalk+with+estrogen+receptor+in+response+of+breast+cancer+cells+to+the+novel+antitumor+agents+benzothiazoles+and+aminoflavone&doi=10.4061%2F2011%2F923250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone</span></div><div class="casAuthors">Callero Mariana A; Loaiza-Perez Andrea I</div><div class="citationInfo"><span class="NLM_cas:title">International journal of breast cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">923250</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Many estrogen-receptor- (ER-) expressing breast cancers become refractory to ER-based therapies.  New antitumor drugs like aminoflavone (AF) and benzothiazoles (Bzs) have been developed and have exquisite antitumor activity in ER+MCF-7 and T47D cells and in a MCF-7 nude mouse model.  ER(-) breast cancer cells like MDA-MB-231 are less susceptible.  We previously found in MCF-7 cells that these drugs activate the aryl hydrocarbon receptor (AhR) via translocation to the nucleus, induction of AhR-specific DNA binding activity, and expression of CYP1A1, whose transcription is controlled by the AhR-ARNT transcription factor.  CYP1A1 metabolizes AF and Bz to a species which directly or after further metabolism damages DNA.  In contrast an AhR-deficient variant of MCF-7 or cells with predominantly nuclear AhR expression, such as MDA-MB 231, are resistant.  Thus, these drugs, unlike other neoplastic agents, require AhR-mediated signaling to cause DNA damage.  This is a new treatment strategy for breast cancers with intact AhR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQY89M2DydDN7mQt-ICR3qNfW6udTcc2eayO2jpYOSHu7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387ptlymtQ%253D%253D&md5=276bba155eb5d7c0324860b614c8592c</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.4061%2F2011%2F923250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4061%252F2011%252F923250%26sid%3Dliteratum%253Aachs%26aulast%3DCallero%26aufirst%3DM.%2BA.%26aulast%3DLoaiza-Perez%26aufirst%3DA.%2BI.%26atitle%3DThe%2520role%2520of%2520aryl%2520hydrocarbon%2520receptor%2520and%2520crosstalk%2520with%2520estrogen%2520receptor%2520in%2520response%2520of%2520breast%2520cancer%2520cells%2520to%2520the%2520novel%2520antitumor%2520agents%2520benzothiazoles%2520and%2520aminoflavone%26jtitle%3DInt.%2520J.%2520Breast%2520Cancer%26date%3D2011%26volume%3D2011%26spage%3D923250%26doi%3D10.4061%2F2011%2F923250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Callero, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suarez, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzani, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Itkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loaiza-Perez, A. I.</span><span> </span><span class="NLM_article-title">Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.3892/ijo.2012.1427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.3892%2Fijo.2012.1427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=22485252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BC38Xptl2lsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2012&pages=125-134&author=M.+A.+Calleroauthor=G.+V.+Suarezauthor=G.+Luzzaniauthor=B.+Itkinauthor=B.+Nguyenauthor=A.+I.+Loaiza-Perez&title=Aryl+hydrocarbon+receptor+activation+by+aminoflavone%3A+new+molecular+target+for+renal+cancer+treatment&doi=10.3892%2Fijo.2012.1427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment</span></div><div class="casAuthors">Callero, Mariana A.; Suarez, Guadalupe V.; Luzzani, Gabriela; Itkin, Boris; Nguyen, Binh; Loaiza-Perez, Andrea I.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Aminoflavone (AF; NSC 686288, AFP464, NSC710464) is a new anticancer drug that has recently entered phase II clin. trials.  It has demonstrated antiproliferative effects in MCF-7 human breast cancer cells mediated by the aryl hydrocarbon receptor (AhR).  AF also exhibits noteworthy evidence of antitumor activity in vitro and in vivo against neoplastic cells of renal origin.  AF treatment of sensitive renal cells, in contrast to resistant cells, promotes the induction of CYP1A1, the covalent binding of AF-reactive intermediates and apoptosis.  Based on this evidence, the aim of this study was to evaluate the role of AhR, the main transcriptional regulator of CYP1A1, in the antiproliferative effects of AF in human renal cancer cells.  AF-cytoxicity in human renal cell lines and a renal cancer cell strain was assessed by MTS assay in the presence or absence of an Ahr inhibitor.  Drug-induced AhR nuclear translocation was evaluated by western blotting of AhR in cytosolic and nuclear fractions and by measuring xenobiotic response element-driven luciferase activity.  Apoptosis induced by the drug was evaluated by 4,6-diamidino-2-phenylindole and acridine orange/ethidium bromide staining and by measuring phosphorylated P53 (p-P53) and P21 levels, caspase 3 activation and poly(ADP-ribose) polymerase cleavage.  AF inhibited cell growth in a dose-dependent manner in TK-10, Caki-1, SN12-C and A498 human renal cells but not in ACHN cells.  The antiproliferative effect of AF was abrogated by pre-incubation of TK-10, Caki-1 and SN12-C cells with the AhR antagonist, α-naphthoflavone.  AF treatment also induced apoptosis in TK-10, Caki-1 and SN12-C cells, which was not obsd. in ACHN cells.  AF induced time-dependent AhR nuclear translocation and AhR transcriptional activity in sensitive renal cancer cell lines.  A renal cell strain derived from a human papillary tumor also showed sensitivity to AF, as well as AhR pathway activation and drug-induced apoptosis.  AhR translocation could be included as a marker of sensitivity to AF in sensitive renal tumor cells of different histol. origin, in ongoing phase II clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6EVkR9xO0nLVg90H21EOLACvtfcHk0li665tjvFedmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xptl2lsLk%253D&md5=4e855f044c41cbd081a2091db7afefde</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3892%2Fijo.2012.1427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2012.1427%26sid%3Dliteratum%253Aachs%26aulast%3DCallero%26aufirst%3DM.%2BA.%26aulast%3DSuarez%26aufirst%3DG.%2BV.%26aulast%3DLuzzani%26aufirst%3DG.%26aulast%3DItkin%26aufirst%3DB.%26aulast%3DNguyen%26aufirst%3DB.%26aulast%3DLoaiza-Perez%26aufirst%3DA.%2BI.%26atitle%3DAryl%2520hydrocarbon%2520receptor%2520activation%2520by%2520aminoflavone%253A%2520new%2520molecular%2520target%2520for%2520renal%2520cancer%2520treatment%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2012%26volume%3D41%26spage%3D125%26epage%3D134%26doi%3D10.3892%2Fijo.2012.1427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Seckl, M.; Cresti, N.; Boddy, A.; Phillips, R.; Chapman, F.; Schmid, P.; Calvert, H.; Robson, L.; Plummer, R.</span><span> </span><span class="NLM_article-title">A Cancer Research UK phase I trial of Phortress (novel antitumour benzothiazole) given intravenously in consecutive 21 day cycles with treatment on day 1 of each cycle</span>. 8th NCRI Cancer Conference, November 4–7, 2013, BT Convention Center, Liverpool,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span><div class="note"><p class="first last">Poster Session B, Diagnosis and Therapy</p></div>,  <a href="http://conference.ncri.org.uk/abstracts/2012/abstracts/LB79.html" class="extLink">http://conference.ncri.org.uk/abstracts/2012/abstracts/LB79.html</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=M.+Seckl&author=N.+Cresti&author=A.+Boddy&author=R.+Phillips&author=F.+Chapman&author=P.+Schmid&author=H.+Calvert&author=L.+Robson&author=R.+Plummer&title=A+Cancer+Research+UK+phase+I+trial+of+Phortress+%28novel+antitumour+benzothiazole%29+given+intravenously+in+consecutive+21+day+cycles+with+treatment+on+day+1+of+each+cycle"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSeckl%26aufirst%3DM.%26atitle%3DA%2520Cancer%2520Research%2520UK%2520phase%2520I%2520trial%2520of%2520Phortress%2520%2528novel%2520antitumour%2520benzothiazole%2529%2520given%2520intravenously%2520in%2520consecutive%252021%2520day%2520cycles%2520with%2520treatment%2520on%2520day%25201%2520of%2520each%2520cycle%26jtitle%3D8th%2520NCRI%2520Cancer%2520Conference%252C%2520November%25204%25E2%2580%25937%252C%25202013%252C%2520BT%2520Convention%2520Center%252C%2520Liverpool%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Dvorak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrichova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modriansky, M.</span><span> </span><span class="NLM_article-title">Role of microtubules network in CYP genes expression</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">545</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span><span class="refDoi"> DOI: 10.2174/138920005774832623</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F138920005774832623" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16379668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1GrurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=545-552&author=Z.+Dvorakauthor=J.+Ulrichovaauthor=M.+Modriansky&title=Role+of+microtubules+network+in+CYP+genes+expression&doi=10.2174%2F138920005774832623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Role of microtubules network in CYP genes expression</span></div><div class="casAuthors">Dvorak, Z.; Ulrichova, J.; Modriansky, M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">545-552</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Superfamily of cytochrome P 450 enzymes (CYPs), a distinctive enzyme system by which human body defends itself against toxic compds., is the subject of a complex regulation process involving various mechanisms, on the levels of expression and activity.  Apart from physiol. factors, several pathophysiol. ones such as inflammation, infection, and stress affect CYP expression.  The aim of this review is to summarize the current knowledge on the role of microtubules network in the regulation of drug metabolizing CYPs.  Expts. on human and animal cell models revealed that microtubules disruption severely impaired basal and inducible expression of human CYP 1A1, 2B6, 2C8, 2C9, 2C19, and 3A4, and rat CYP 1A2, 2B1, 2B2, and 3A23.  Inhibition of aryl hydrocarbon receptor (AhR) and glucocorticoid receptor (GR) transcriptional activity by microtubules disarray was found to be responsible for the suppressed CYP enzymes expression.  However, the mechanism by which microtubules interfering agents (MIAs) inhibit GR and AhR transcriptional activities is not fully understood yet.  Several lines of evidence indicate that: (1) the cell cycle, G2/M phase in particular, has an influence on AhR and GR transcriptional activity, and (2) MIAs neg. modulate GR transcriptional activity via the activation of c-Jun-N-terminal kinase.  In conclusion, down-regulation of major CYP enzymes by microtubules disarray is intriguing from the mechanistic point of view and in relation to the cell differentiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogVGscOHp1kbVg90H21EOLACvtfcHk0li665tjvFedmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1GrurrE&md5=b3cce0f18b5d2b612f8fd79cbfa96e60</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.2174%2F138920005774832623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920005774832623%26sid%3Dliteratum%253Aachs%26aulast%3DDvorak%26aufirst%3DZ.%26aulast%3DUlrichova%26aufirst%3DJ.%26aulast%3DModriansky%26aufirst%3DM.%26atitle%3DRole%2520of%2520microtubules%2520network%2520in%2520CYP%2520genes%2520expression%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D545%26epage%3D552%26doi%3D10.2174%2F138920005774832623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Dvorak, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vrzal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrichova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascussi, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modriansky, M.</span><span> </span><span class="NLM_article-title">Involvement of cytoskeleton in AhR-dependent CYP1A1 expression</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">301</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span><span class="refDoi"> DOI: 10.2174/138920006776359310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.2174%2F138920006776359310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16611024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD28Xjs12jt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=301-313&author=Z.+Dvorakauthor=R.+Vrzalauthor=J.+Ulrichovaauthor=J.+M.+Pascussiauthor=P.+Maurelauthor=M.+Modriansky&title=Involvement+of+cytoskeleton+in+AhR-dependent+CYP1A1+expression&doi=10.2174%2F138920006776359310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of cytoskeleton in AhR-dependent CYP1A1 expression</span></div><div class="casAuthors">Dvorak, Zdenek; Vrzal, Radim; Ulrichova, Jitka; Pascussi, Jean-Marc; Maurel, Patrick; Modriansky, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">301-313</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Cytochrome P 450 (CYP) 1A1 attracts attention mainly because of its role in prodn. of carcinogenic reactive metabolites from polycyclic arom. hydrocarbons such as benzo[a]pyrene, but recent developments indicate its apparent role in cell cycle progression.  Expression of the enzyme is subject to regulation by aryl hydrocarbon receptor (AhR).  It was shown that induction of CYP 1A1 in HepG2 cells and primary rat hepatocytes by tetrachloro-p-dibenzodioxin (TCDD) is diminished by colchicine and nocodazole.  Both compds. decrease CYP1A1 mRNA, protein, and activity levels in HepG2 cells and mRNA level in primary rat hepatocytes.  Neither compd. significantly affected [3H]-TCDD binding to AhR, thus their effect on AhR transcriptional activity proceeds via indirect means.  For colchicine and nocodazole are well-known microtubule interfering agents, we also assessed their effect on microtubule integrity in both cell types under investigation.  Both compds. disrupt cytoskeleton integrity with differential potency depending on cell type.  The obsd. suppression of AhR transcriptional activity by colchicine and nocodazole can be assocd. with G2/M cell cycle arrest in HepG2 cells, as demonstrated by Myt1 protein hyperphosphorylation and FACS anal.  However, in primary rat hepatocytes, cytoskeleton disruption is independent of cell cycle while displaying the same influence on AhR-dependent gene transcription.  In our view, this is evidence in favor of modulatory role of cytoskeleton in AhR-dependent expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH-hitz3CdtLVg90H21EOLACvtfcHk0lghxWvGus7dRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xjs12jt7Y%253D&md5=007b75bdd94f64912825eb1bb6428bc0</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2174%2F138920006776359310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920006776359310%26sid%3Dliteratum%253Aachs%26aulast%3DDvorak%26aufirst%3DZ.%26aulast%3DVrzal%26aufirst%3DR.%26aulast%3DUlrichova%26aufirst%3DJ.%26aulast%3DPascussi%26aufirst%3DJ.%2BM.%26aulast%3DMaurel%26aufirst%3DP.%26aulast%3DModriansky%26aufirst%3DM.%26atitle%3DInvolvement%2520of%2520cytoskeleton%2520in%2520AhR-dependent%2520CYP1A1%2520expression%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2006%26volume%3D7%26spage%3D301%26epage%3D313%26doi%3D10.2174%2F138920006776359310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Lowry, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosebrough, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farr, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Randall, R. J.</span><span> </span><span class="NLM_article-title">Protein measurement with the Folin phenol reagent</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">193</span><span class="NLM_x">, </span> <span class="NLM_fpage">265</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1016%2FS0021-9258%2819%2952451-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=14907713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADyaG38XhsVyrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=193&publication_year=1951&pages=265-275&author=O.+H.+Lowryauthor=N.+J.+Rosebroughauthor=A.+L.+Farrauthor=R.+J.+Randall&title=Protein+measurement+with+the+Folin+phenol+reagent"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Protein measurement with the Folin phenol reagent</span></div><div class="casAuthors">Lowry, Oliver H.; Rosebrough, Nira J.; Farr, A. Lewis; Randall, Rose J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1951</span>),
    <span class="NLM_cas:volume">193</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">265-75</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">cf. C.A. 41, 1271h.  Proteins were detd. with the Folin phenol reagent after alk. Cu treatment.  The method is as sensitive as with Nessler reagent, yet requires no digestion.  It is 10-20 times more sensitive than detn. of the ultraviolet absorption at λ = 280 mμ and is more specific.  It is several fold more sensitive than the ninhydrin reaction and 100 times more sensitive than the biuret reaction.  Two major disadvantages are: the amt. of color varies with different proteins; the color is not strictly proportional to concn.  Few substances cause serious interference.  Uric acid, guanine, and xanthine react with Folin reagent.  The method is useful for following enzyme fractionation, detg. mixed tissue proteins, detn. of very small amts. of protein, or detg. highly dild. protein, or protein in colored solns. or in the presence of N-contg. material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHNRKGd34F8LVg90H21EOLACvtfcHk0lghxWvGus7dRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG38XhsVyrsw%253D%253D&md5=19d36395fad7dd87661caa3d2b97640d</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2819%2952451-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252819%252952451-6%26sid%3Dliteratum%253Aachs%26aulast%3DLowry%26aufirst%3DO.%2BH.%26aulast%3DRosebrough%26aufirst%3DN.%2BJ.%26aulast%3DFarr%26aufirst%3DA.%2BL.%26aulast%3DRandall%26aufirst%3DR.%2BJ.%26atitle%3DProtein%2520measurement%2520with%2520the%2520Folin%2520phenol%2520reagent%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1951%26volume%3D193%26spage%3D265%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Arocho, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Q.</span><span> </span><span class="NLM_article-title">Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts</span> <span class="citation_source-journal">Diagn. Mol. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">61</span><span class="refDoi"> DOI: 10.1097/00019606-200603000-00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=10.1097%2F00019606-200603000-00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=16531770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;key=1%3ACAS%3A528%3ADC%252BD28XislOlurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2006&pages=56-61&author=A.+Arochoauthor=B.+Chenauthor=M.+Ladanyiauthor=Q.+Pan&title=Validation+of+the+2-DeltaDeltaCt+calculation+as+an+alternate+method+of+data+analysis+for+quantitative+PCR+of+BCR-ABL+P210+transcripts&doi=10.1097%2F00019606-200603000-00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of the 2-ΔΔCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts</span></div><div class="casAuthors">Arocho, Alaina; Chen, Beiyun; Ladanyi, Marc; Pan, Qiulu</div><div class="citationInfo"><span class="NLM_cas:title">Diagnostic Molecular Pathology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">56-61</span>CODEN:
                <span class="NLM_cas:coden">DMPAES</span>;
        ISSN:<span class="NLM_cas:issn">1052-9551</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that is characterized by the presence of a reciprocal translocation between chromosomes 9 and 22 and results in the formation of the Philadelphia (Ph1) chromosome and is present in most of CML patients.  The Ph1 chromosome forms a chimeric gene that encodes an abnormal P210 mRNA transcript in most CML patients.  Surveillance for minimal residual disease by detection of BCR/ABL transcripts is currently done mostly by quant. real-time reverse transcriptase polymerase chain reaction (RT-PCR).  Quantitation of BCR/ABL transcripts can monitor tumor load and the outcome of therapy.  Abs. quantification dets. the input copy no. of the transcript of interest, usually by plotting the amt. of PCR product onto a std. curve based on serial dilns. of the same product cloned in plasmids.  Relative quantification describes the change in expression of the target gene in the patient sample relative to that of a control transcript by using the 2-ΔΔCt calcn.  The results of real-time RT-PCR for BCR/ABL transcripts are often analyzed by using plasmid DNA std. curves.  In the present study, 79 BCR/ABL transcript-pos. samples from CML patients who were being monitored for minimal residual disease by real-time quant. RT-PCR were studied to det. whether the 2-ΔΔCt approach was equiv. to the plasmid std. curve method.  BCR/ABL P210 transcripts were quantitated using both the plasmid std. curve method and the 2-ΔΔCt calcn.  The comparison of both methods revealed a highly significant and linear correlation between the plasmid std. curve method and the 2-ΔΔCt calcn. (R2 = 0.98, P < 0.0001).  Furthermore, there was a redn. of prepn. time, contamination risk, and reagent usage.  The 2-ΔΔCt calcn. is a convenient alternative method to derive accurate quant. information from real time PCR assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3vfJNCCjj67Vg90H21EOLACvtfcHk0lghxWvGus7dRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislOlurc%253D&md5=c90dfa61e8c39a3cb47e9964f6fa6b32</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1097%2F00019606-200603000-00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00019606-200603000-00009%26sid%3Dliteratum%253Aachs%26aulast%3DArocho%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DPan%26aufirst%3DQ.%26atitle%3DValidation%2520of%2520the%25202-DeltaDeltaCt%2520calculation%2520as%2520an%2520alternate%2520method%2520of%2520data%2520analysis%2520for%2520quantitative%2520PCR%2520of%2520BCR-ABL%2520P210%2520transcripts%26jtitle%3DDiagn.%2520Mol.%2520Pathol.%26date%3D2006%26volume%3D15%26spage%3D56%26epage%3D61%26doi%3D10.1097%2F00019606-200603000-00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i98"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00343">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_70417"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00343">10.1021/acs.jmedchem.7b00343</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Induction of CYP1A1 by PAIB-SO <b>67</b> in MCF7 and MDA-MB-231 cells (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00343/suppl_file/jm7b00343_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00343/suppl_file/jm7b00343_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00343/suppl_file/jm7b00343_si_001.pdf">jm7b00343_si_001.pdf (147.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00343/suppl_file/jm7b00343_si_002.csv">jm7b00343_si_002.csv (4.86 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00343&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00343%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00343" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67993800b9162521","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
